Report of the International Narcotics Control Board for 2019. by unknown
INTERNATIONAL NARCOTICS CONTROL BOARD
Report 
2019
UNITED NATIONS
EMBARGO
Observe release date: 
Not to be published or broadcast before 
Thursday, 27 February 2020, at 1100 hours (CET)
CAUTION
  
   
 
 
 
Reports  published  by  the  International  Narcotics  Control  Board  for  2019 
  The Report  of  the  International  Narcotics  Control  Board  for  2019 (E/INCB/2019/1)  is 
supplemented  by  the  following  reports:
Narcotic  Drugs:  Estimated  World  Requirements  for  2020  —  Statistics  for  2018
(E/INCB/2019/2)
Psychotropic  Substances:  Statistics  for  2018  —  Assessments  of  Annual  Medical  and  Scientific 
Requirements  for  Substances  in  Schedules  II,  III  and  IV  of  the  Convention  on  Psychotropic  Sub- 
stances  of  1971 (E/INCB/2019/3)
Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psy- 
chotropic Substances: Report of the International Narcotics Control Board for 2019 on the Imple- 
mentation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs 
and  Psychotropic  Substances  of  1988 (E/INCB/2019/4)
  The  updated  lists  of  substances  under  international  control,  comprising  narcotic  drugs,  psy- 
chotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and 
psychotropic  substances,  are  contained  in  the  latest  editions  of  the  annexes  to  the  statistical  forms
(“Yellow  List”,  “Green  List”  and  “Red  List”),  which  are  also  issued  by  the  Board.
Contacting  the  International  Narcotics  Control  Board
 The secretariat of the Board may be reached at the following address:
 Vienna International Centre
 Room E-1339
 P.O. Box 500
 1400 Vienna
 Austria
 In addition, the following may be used to contact the secretariat:
 Telephone: (+43-1) 26060
 Fax: (+43-1) 26060-5867 or 26060-5868
 Email: incb.secretariat@un.org
 The text of the present report is also available on the website of the Board (www.incb.org).
UNITED NATIONS
Vienna, 2020
INTERNATIONAL NARCOTICS CONTROL BOARD
Report
of the International Narcotics Control Board  
for 2019
E/INCB/2019/1
UNITED NATIONS PUBLICATION
Sales No. E.20.XI.4 
ISBN: 978-92-1-148341-3
eISBN: 978-92-1-004853-8
ISSN 0257-3717
© United Nations: International Narcotics Control Board, January 2020. All rights reserved worldwide.
Publishing production: English, Publishing and Library Section, United Nations Office at Vienna.
iii
Foreword 
The thematic chapter of the INCB annual report for 2019 focuses on improving prevention and treat-
ment services for young people. The year 2019 marked the thirtieth anniversary of the Convention 
on the Rights of the Child. In article 33 of that Convention, States parties committed to taking 
measures to protect children from the illicit use of narcotic drugs and psychotropic substances and 
prevent the use of children in the illicit production and trafficking of drugs. Sadly, substance use and 
the associated health consequences are greatest among young people, especially those between the 
ages of 18 and 25. The Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol 
and the 1971 Convention on Psychotropic Substances set out requirements for parties to take all prac-
ticable measures to prevent and treat drug dependence. That obligation was reaffirmed in the United 
Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 and 
in numerous resolutions and declarations of the Commission on Narcotic Drugs, the Economic and 
Social Council and the General Assembly in its special sessions on the world drug problem. This 
year’s thematic chapter is aimed at improving understanding of the complexity of the problem and 
provides a way forward for Member States and civil society to promote the safe and healthy devel-
opment of children, young people, families and communities through the effective prevention and 
treatment of drug use. It is our shared duty to safeguard the well-being of young people.
INCB is committed to continuing to support Member States in achieving the health and welfare aims 
of the three drug control conventions and Sustainable Development Goal 3, on health and well-being. 
At its 126th session, in November 2019, the Board held an open dialogue with Member States to dis-
cuss their experiences in implementing measures to forge the way ahead as presented in the INCB 
report on availability of 2018.1 Challenges remain: we see overprescription of controlled medicines in 
some countries on the one hand, and the ongoing lack of availability in very many countries and 
regions on the other. Despite the overall global increase in the availability of controlled medicines for 
consumption, global inequity and imbalance remain evident, which has serious health consequences 
for patients and their families. The present report contains a number of recommendations to address 
this imbalance, for example, with regard to the availability of affordable medicines containing con-
trolled substances, raising awareness among health personnel and patients and their families, and 
curbing promotional activities by the pharmaceutical industry for high-cost formulations, including 
synthetic opioids. INCB is also supporting efforts to improve the availability of controlled substances 
for medical and scientific purposes through the International Import and Export Authorization System 
(I2ES), which is increasingly being used by Member States and which is facilitating international trade 
in narcotic drugs and psychotropic substances, and INCB Learning, through which 237 officials from 
88 countries and territories have received training. That training is resulting in improved reporting 
to the Board, which should in turn lead to improved access to hospitals and doctors and to the med-
icines that patients need. 
Drug abuse, illicit manufacture, trafficking and the continued emergence of new psychoactive sub-
stances, non-medical synthetic opioids and non-scheduled precursors and their impact on public 
health are among the challenges highlighted in the global issues and regional analysis contained in 
chapter III. Of special concern is the growing trend in manufacture, trafficking and use of metham-
phetamine in many parts of the world. INCB is working to assist Governments in addressing these 
challenges through a number of initiatives. 
1 Progress in ensuring adequate access to internationally controlled substances for medical and scientific purposes (E/
INCB/2018/1/Supp.1).
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Our long-standing project to carry out activities mandated by article 12 of the 1988 Convention 
monitors the international trade in precursor chemicals in order to prevent illicit manufacture and 
supports international cooperation in precursor control through the Board’s Pre-Export Notification 
Online (PEN Online) system and the Precursors Incident Communication System (PICS) system. 
A detailed analysis of the challenges faced in addressing designer precursors and pre-precursors is 
covered in the Board’s report on precursors for 2019.2 In November 2019, INCB decided to pro-
pose the international control of methyl alpha-phenylacetoacetate, a pre-precursor used in the illicit 
manufacture of amphetamine and methamphetamine. The Board’s Project Ion, the Project Ion 
Incident Communication System (IONICS) platform and the global Operational Partnerships to 
Interdict Opioids’ Illicit Distribution and Sales (OPIOIDS) project are assisting national authorities 
in addressing the emergence of new psychoactive substances and non-medical synthetic opioids in 
order to safeguard public health.
Human rights are inalienable and can never be relinquished. In our examination of the global issue 
of human rights, in chapter III, we note with great concern the continued reports of grave human 
rights violations perpetrated in the name of drug control. The conventions provide States with the 
possibility of applying alternative measures to conviction, punishment and incarceration, including 
education, rehabilitation or social reintegration. If the drug control measures adopted by States vio-
late internationally recognized human rights standards, they also violate the international drug con-
trol conventions. INCB once again calls for a halt to extrajudicial responses to drug-related offences 
and urges States that retain capital punishment for drug-related offences to consider its abolition. 
INCB remains concerned at the legislative developments permitting the use of cannabis for “rec-
reational” uses. Not only are these developments in contravention of the drug control conventions 
and the commitments made by States parties, the consequences for health and well-being, in par-
ticular of young people, are of serious concern. 
We remain in dialogue with all countries for the full implementation of the three drug control con-
ventions and to achieve their aims of safeguarding health and welfare. To that end, we count on 
the continued cooperation of Governments in meeting their reporting obligations to INCB, accept-
ing INCB missions and participating in and supporting INCB activities and projects. Without the 
cooperation of Governments, the Board would be unable to fulfil its mandate of ensuring that the 
three international drug control conventions are implemented in accordance with the objectives 
and requirements that were established by States parties when they signed the conventions. 
We stand at a challenging point in drug control. Much has been achieved, yet more remains to be 
done. States need to ensure that national policy and practice are directed towards full implemen-
tation of the three conventions, which enjoy almost universal adherence and to which Member 
States recently reaffirmed their commitment at the thirtieth special session of the General Assembly, 
on the world drug problem, held in 2016, and in the 2019 Ministerial Declaration adopted at the 
sixty-second session of the Commission on Narcotic Drugs. This year, the Board was pleased to 
welcome Palau as the newest State party to the United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988. 
2 Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report 
of the International Narcotics Control Board for 2019 on the Implementation of Article 12 of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2019/4).
vThe community of nations faces many challenges that have severe implications for the health and 
well-being of people. By fully implementing the drug control conventions, Member States, civil soci-
ety and the international community as a whole can build upon the significant improvements 
achieved over the past years. I urge you to carefully study the Board’s recommendations set out in 
this report and to implement them in good faith. INCB remains committed to monitoring and pro-
moting compliance with the drug control treaties and to supporting Member States as they imple-
ment their drug control obligations, for the benefit of all. 
Cornelis P. de Joncheere
President
International Narcotics Control Board
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Explanatory notes
Data reported later than 1 November 2019 could not be taken into consideration in the prepara-
tion of this report.
The designations employed and the presentation of the material in this publication do not imply 
the expression of any opinion whatsoever on the part of the Secretariat of the United Nations con-
cerning the legal status of any country, territory, city or area or of its authorities, or concerning the 
delimitation of its frontiers or boundaries.
Countries and areas are referred to by the names that were in official use at the time the relevant 
data were collected.
References to dollars ($) are to United States dollars, unless otherwise stated.
The following abbreviations have been used in this report:
ASEAN Association of Southeast Asian Nations
CARICC Central Asian Regional Information and Coordination Centre
CBD cannabidiol 
CICAD Inter-American Drug Abuse Control Commission of the Organization of American States
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
Europol European Union Agency for Law Enforcement Cooperation 
GBL gamma-butyrolactone
GHB gamma-hydroxybutyric acid
I2ES International Import and Export Authorization System
ICRC International Committee of the Red Cross
INCB International Narcotics Control Board 
INTERPOL International Criminal Police Organization
IONICS Project Ion Incident Communication System
LSD lysergic acid diethylamide
MDMA 3,4-methylenedioxymethamphetamine
OAS Organization of American States
OECD Organization for Economic Cooperation and Development
OPIOIDS global Operational Partnerships to Interdict Opioids’ Illicit Distribution and Sales project
OSCE Organization for Security and Cooperation in Europe
PEN Online Pre-Export Notification Online system
PICP Pacific Islands Chiefs of Police
PICS Precursors Incident Communication System
SCO Shanghai Cooperation Organization
xS-DDD defined daily doses for statistical purposes
SENAPRED National Secretariat for Drug Care and Prevention of Brazil
THC tetrahydrocannabinol
UNAIDS Joint United Nations Programme on HIV/AIDS
UNAMA United Nations Assistance Mission in Afghanistan
UNESCO United Nations Educational, Scientific and Cultural Organization
UNIOGBIS United Nations Integrated Peacebuilding Office in Guinea-Bissau
UNODC United Nations Office on Drugs and Crime
UPU Universal Postal Union
WCO World Customs Organization
WHO World Health Organization
1Chapter I. 
Improving substance use prevention and 
treatment services for young people
1. According to the UNODC World Drug Report 2018, 
it is estimated that over 31 million people who use drugs 
suffer from drug use disorders, and many of them are 
young people.3 Drug use has a significant economic and 
social impact for countries, families and communities, in 
particular the impact it has on the future opportunities 
of young people.4 The situation calls for renewed efforts 
to support the prevention of substance use and the treat-
ment of drug use disorders, including services aimed at 
reducing the adverse health consequences of drug use. 
Through the outcome document of the thirtieth special 
session of the General Assembly, entitled “Our joint com-
mitment to effectively addressing and countering the 
world drug problem” and Sustainable Development Goal 
1 (reducing poverty), Goal 3 (good health and well-be-
ing), Goal 4 (quality education) and Goal 10 (reducing 
inequality), among other Sustainable Development Goals, 
Member States have reaffirmed their commitment to 
3 The United Nations uses the terms “youth” and “young people” 
interchangeably and defines “youth” as meaning those persons aged 15–24, 
without prejudice to other definitions used by Member States and other 
entities. Although the age of initiation of drug use tends to correspond to 
that age group, it is important to start prevention interventions early in life, 
including at the prenatal stage and in early and middle childhood. 
4 For the purposes of the present report, the term “the prevention of 
the use of psychoactive substances” refers to efforts to avoid or delay the 
initiation of the use of psychoactive substances, or, if use has started, to 
avert the development of substance use disorders (harmful substance use 
or dependence). The much broader aim of prevention is the healthy and 
safe development of children and youth so that they can realize their tal-
ents and potential and become contributing members of their commu-
nity and society. Effective prevention significantly contributes to the 
positive engagement of children, youth and adults with their families, 
schools, workplace and community. “Treatment” is defined as the man-
agement of substance use disorders of individuals in order to reduce their 
drug use and cravings for drug use, treat co-morbidity, improve the 
health, well-being and social functioning of the affected individual, and 
prevent future harms by decreasing the risk of complications and relapse. 
adopting a balanced and health-centred approach to sub-
stance use prevention and treatment.
2. Article 38 of the Single Convention on Narcotic 
Drugs of 19615 underscores the importance of measures 
to prevent and treat drug dependence. That article, as 
contained in the 1961 Convention as amended by the 
1972 Protocol,6 and article 20 of the Convention on 
Psychotropic Substances of 19717 both state that the par-
ties shall give special attention to and take all practicable 
measures for the prevention of abuse of drugs and for the 
early identification, treatment, education, aftercare, reha-
bilitation and social reintegration of the persons involved 
and shall coordinate their efforts to those ends.
3. Further, the conventions also state that parties shall 
as far as possible promote the training of personnel in 
the treatment, aftercare, rehabilitation and social reinte-
gration of abusers of psychotropic substances, as well as 
assist persons whose work so requires to gain an under-
standing of the problems of abuse of drugs.
4. The drafters of the conventions, however, did not pre-
scribe particular approaches or methods to achieve those 
objectives, particularly in consideration of the different 
conditions in the diverse countries. They may have also 
considered that over the course of time there would be 
scientific advances that would enhance understanding of 
the problem of drug dependence, accompanied by the 
development of new methods to prevent and treat this 
problem. The conventions leave it to Governments to 
5 United Nations, Treaty Series, vol. 520, No. 7515.
6 Ibid., vol. 976, No. 14152. 
7 Ibid., vol. 1019, No. 14956. 
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identify the “practicable measures” to be developed to 
prevent and treat drug dependence, but they also under-
score the importance of having trained personnel in the 
area of prevention and treatment, who would receive fur-
ther training as new knowledge and skills become 
available. 
5. At the time of the drafting of the conventions, there 
was only limited scientific research on the physiological 
and psychological effects of psychoactive substance use 
on young people and on the most effective methods for 
the prevention and treatment of such use among young 
people. However, over the past 40 years, that knowledge 
base has grown considerably. Prevention strategies based 
on that scientific evidence indicate the effective ways to 
work with families, schools and communities and to 
implement treatment approaches specifically designed for 
the needs of adolescent substance users. Those preven-
tion strategies ensure that children and young people, 
especially the most marginalized and poor, have oppor-
tunities to grow and stay healthy and safe into adulthood 
and old age. 
6. Apart from the international drug control conven-
tions, the importance of protecting children from drug 
use and dependence is also reiterated in article 33 of the 
Convention on the Rights of the Child,8 in which States 
parties undertake to “take all appropriate measures, 
including legislative, administrative, social and educa-
tional measures, to protect children from the illicit use of 
narcotic drugs and psychotropic substances as defined in 
the relevant international treaties, and to prevent the use 
of children in the illicit production and trafficking of such 
substances”.
7. In addition, the need to address drug use and depen-
dence, in particular among young people, has been the 
subject of numerous resolutions and declarations of the 
Commission on Narcotic Drugs, the Economic and Social 
Council, and the General Assembly in its special sessions 
on the world drug problem held in 1998 and 2016. 
8. Chapter I of the INCB annual report for 20099 
focused on prevention, summarizing the accumulated sci-
entific advances in prevention for young people and made 
the following recommendations:
•  Governments should establish a clear focal point 
for primary prevention, develop a national drug 
control strategy and a public health framework, 
and build capacity for collaboration and working 
8 Ibid., vol. 1577, No. 27531. 
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together with organizations and institutions to 
achieve prevention aims.
•  Governments should establish mechanisms to 
improve understanding of drug use and the fac-
tors that influence drug use, build and disseminate 
knowledge of best practices, evaluate their efforts 
and develop the primary prevention workforce.
•  UNODC should collaborate with others to 
develop standards against which Governments 
may measure their efforts in primary prevention. 
Specifically, UNODC should collaborate with the 
United Nations Children’s Fund, the International 
Labour Organization, UNESCO, WHO, relevant 
non-governmental organizations and the private 
sector to develop, promote and disseminate 
resources to help Governments strengthen the 
quality of their primary prevention work.
9. More recently, in the INCB annual report for 2017,10 
chapter I (Treatment, rehabilitation and social reintegra-
tion for drug use disorders: essential components of drug 
demand reduction) addressed the treatment needs of spe-
cial populations including adolescents. In that chapter, the 
many challenges in addressing those needs were noted, 
and it was underscored that there was a need for more 
research on the effects that medications used in the treat-
ment of adults had on children and adolescents and for 
more research on effective psychosocial interventions for 
adolescents.
10. The present chapter of the annual report for 2019 
focuses on the use of psychoactive substances among 
young people and on improving the implementation of 
evidence-based prevention and treatment services, and it 
builds on and expands the findings and recommendations 
of the INCB annual reports for 2009 and 2017. In the 
10 years since the publication of the INCB annual report 
for 2009, Governments have made progress in the imple-
mentation of prevention programmes, but only recently 
has it been recognized that the results of science and their 
application to policy and practice could make a significant 
difference in the worldwide response to substance use. 
11. A series of UNODC publications on drug preven-
tion, treatment, care and rehabilitation respond to the 
need to support Member States in meeting their commit-
ments to “promote, develop, review or strengthen effec-
tive, comprehensive, integrated drug demand reduction 
programmes, based on scientific evidence and covering a 
range of measures, including primary prevention, early 
10 E/INCB/2017/1.
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intervention, treatment, care, rehabilitation, social reinte-
gration and related support services”.11 Some of those 
publications discussed, in particular, the issues of inter-
ventions and services targeting children and youth, 
including the UNODC International Standards on Drug 
Use Prevention, first published in 2013 and revised jointly 
with WHO in 2018; the International Standards for the 
Treatment of Drug Use Disorders of 2017; and Booklet 10: 
Education Sector Responses to the Use of Alcohol, Tobacco 
and Drugs of the Good Policy and Practice in Health 
Education Series, published by UNESCO, WHO and 
UNODC in 2017. Those publications reflect the current 
state of the research and evidence in these fields, but they 
will need to be updated as future, additional evidence 
becomes available. 
12. While there is often widespread awareness and con-
cern among policymakers and the public about substance 
use, in particular substance use among young people, 
there may not be an awareness of the evidence-based pre-
vention and treatment strategies currently available to 
intervene effectively at any point to prevent the initiation 
and progression of substance use, and of the kind of treat-
ment that can be implemented for those who need it. 
These effective strategies, which are the result of more 
than 30 years of research and field testing, are currently 
being implemented in various parts of the world. It is 
important for government experts and civil society to rec-
ognize these strategies and develop policies incorporat-
ing the most effective ways to support and deliver 
evidence-based substance use prevention and treatment 
services for young people. 
13. In many countries, great attention has been given 
to the issue of substance use among young people, and 
that attention can lead to the impression among young 
people themselves that substance use is normal – that is, 
that “everyone is doing it”. For example, the recent adop-
tion of legislation supporting medical use – and recently, 
non-medical or “recreational” use – of cannabis in some 
countries, the decriminalization of cannabis use in some 
other countries and the easy access to a number of psy-
choactive substances may decrease the perceived risk 
among young people regarding the social, emotional or 
physical consequences of substance use.12 There is 
11 Political Declaration and Plan of Action on International Coopera-
tion towards an Integrated and Balanced Strategy to Counter the World 
Drug Problem (See Official Records of the Economic and Social Council, 
2009, Supplement No. 8 (E/2009/28), chap. I, sect. C).
12 Charlotte Skoglund and others, “Public opinion on alcohol 
 consumption and intoxication at Swedish professional football events”, 
Substance Abuse Treatment and Prevention Policy, vol. 12, No. 21 
(May 2017); Tina Van Havere and others, “Drug use and nightlife: more 
than just dance music”, Substance Abuse Treatment and Prevention Policy, 
vol. 6, No. 18 (July 2011). 
evidence that such misperceptions can lead to the initia-
tion of use among young people.13 Governments and soci-
ety have learned from the history of tobacco use how 
important it is to protect children and young people from 
initiating use of these psychoactive substances through 
the implementation of evidence-based prevention inter-
ventions and policies. 
14. In spite of the concerns, available research shows 
that worldwide, substance use among the general popu-
lation is not actually as prevalent as it may seem at first 
glance. For example, the international epidemiological 
data available show that among young people (under the 
age of 24), the majority (over 80 per cent) do not use any 
controlled substance.14 Nevertheless, there is also evi-
dence that some young people are made particularly vul-
nerable due to poverty and extreme social conditions. 
Evidence-based drug prevention and treatment targeting 
youth have a demonstrated effect on substance use and 
substance use disorders, their health and social conse-
quences, as well as on aggressiveness, youth violence and 
– in the case of family skills training – child maltreatment. 
Therefore, there is a strong mandate for evidence-based 
prevention and treatment under several targets of the 
Sustainable Development Goals, most notably target 3.5, 
on strengthening the prevention and treatment of sub-
stance abuse, but also target 3.3, on ending the epidemic 
of AIDS and combating hepatitis, target 3.4, which 
includes promoting mental health and well-being, target 
16.1, on significantly reducing all forms of violence, and 
target 16.2, on ending all forms of violence against chil-
dren. In addition, evidence-based substance use preven-
tion and treatment contribute to the reduction of poverty 
(Sustainable Development Goal 1) and the reduction of 
gender inequality and socioeconomic inequality (Goals 5 
and 10), as well as contributing to making cities safe and 
resilient (Goal 11).
15. The INCB annual reports for 2009 and 2017 
addressed the scientific advances made to date in the pre-
vention and treatment of substance use disorders. The 
present chapter provides an update on those advances and 
the resulting improved understanding of use of psycho-
active substances, the nature and extent of use among 
young people, how initial use during adolescence can lead 
to substance use dependency and disorders and, in 
13 Sarah-Jeanne Salvy and others, “Proximal and distal social influ-
ence on alcohol consumption and marijuana use among middle school 
adolescents”, Drug and Alcohol Dependence, vol. 144 (November 2014), 
pp. 93–101; Megan S. Schuler and others, “Relative influence of perceived 
peer and family substance use on adolescent alcohol, cigarette, and mari-
juana use across middle and high school”, Addictive Behaviors, vol. 88 
(January 2019), pp. 99–105.
14 World Drug Report 2018 (United Nations publication, Sales No. 
E.18.XI.9).
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particular, the effective prevention and treatment strate-
gies identified by science to address drug use and drug 
use disorders among young people.
16. Several important areas should be noted:
•  Improved international epidemiological data that 
heighten concerns about, and advance our under-
standing of, substance use among adolescents and 
young adults, specifically those aged 15–24
•  The defining of the field of prevention science and 
the potential for its practical application
•  The reconceptualization of the aetiology of sub-
stance use and vulnerability to progression from 
substance use to substance use disorders
•  The reframing of substance use prevention within 
a public health context to incorporate prevention 
interventions that address the level of risk and vul-
nerability (i.e., universal, selected and indicated 
interventions) and the treatment needs of young 
people, who require an array of services that dif-
fer from those needed by adults
•  The UNODC-WHO International Standards on 
Drug Use Prevention (revised 2nd ed., 2018) and 
the International Standards for the Treatment of 
Drug Use Disorders (2017), mentioned above, 
which summarize the research literature and pre-
sent evidence-based prevention and treatment 
principles and strategies, including the compo-
nents of a national drug prevention and treatment 
service system
Epidemiology of psychoactive substance 
use by young people 
17. There are considerable differences from region to 
region in the trends and patterns of substance use, in gen-
eral and for young people in particular, that are related 
to different issues and different cultural and social cir-
cumstances. For example, there is a higher prevalence of 
use of amphetamine-type stimulants in Asia, while in 
Latin America coca paste and cocaine are widely used in 
addition to cannabis. Similarly, between North America 
and Europe there are significant differences in the pat-
terns of substance use. 
18. The most recent available epidemiological data on 
substance use among young people (aged 15–24 years) 
are provided in the UNODC World Drug Report 2018, 
which contains in its booklet 4, on drugs and age, key 
findings pertaining to young people:
•  Substance use and associated health consequences 
are highest among young people (in particular 
those aged 18–25).
•  Global estimates of substance use among young 
people under the age of 18 are difficult to obtain 
due to the limited number of surveys carried out 
in some regions, and due to the different ways of 
measuring prevalence and categories for age 
groups used in the various surveys available.
•  In general, it has been found that males have 
higher rates of use than do females, although it 
has been noted that the gender difference has been 
narrowing in some regions.
•  Cannabis is widely used by young people. Based 
on data from 130 countries, the UNODC global 
estimate of cannabis use in 2016 was that 13.8 mil-
lion, or 5.6 per cent of young people aged 15–16, 
had used cannabis at least once in the year prior 
to the survey. In Oceania, the past-year prevalence 
rate for that age group was 11.4 per cent; in the 
Americas, 11.6 per cent; in Africa, 6.6 per cent; in 
Europe, 13.9 per cent; and in Asia, 2.7 per cent.
•  Although collecting and harmonizing data on the 
cause of death for different countries is challeng-
ing, the WHO Global Health Estimates 2015 show 
that while deaths of young people aged 15–29 
from all causes accounted for only 4.8 per cent of 
all deaths in 2015, that age group accounted for 
23.1 per cent of all deaths attributed to drug use 
disorders that year.15
•  Owing to the pharmacology of these psychoactive 
substances and the physiology of the developing 
brains of young people, use eventually comes to 
be driven by the desire for the effects of the psy-
choactive substance, regardless of the social and 
psychological factors that had originally played a 
role in initiation and early use.
•  The paths that lead young people to substance use 
disorders are complex. Many factors play a role in 
the progression from substance use to substance 
use disorder. Although many who initiate use of 
psychoactive substances eventually discontinue 
15 WHO, Global Health Estimates 2015: Deaths by Cause, Age and 
Sex and by Country and Region, 2000–2015 (Geneva, 2016).
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use, those who are most vulnerable because of 
physiological, social, emotional and developmen-
tal factors may progress to the use of multiple sub-
stances and/or an increased frequency of use. 
•  Many young people are involved in the drug sup-
ply chain, among other reasons, due to poverty 
and a lack of opportunities for social and eco-
nomic advancement. Such involvement puts them 
at risk of further involvement in criminal behav-
iours, violence, incarceration and premature death. 
19. The age of onset of substance use is of greatest global 
concern because research shows that the earlier the age 
of onset, the greater the likelihood of developing sub-
stance use disorders due to the effects of these substances 
on the developing brain.16 Degenhart and others17 have 
presented comparisons of age of onset of use for alcohol, 
tobacco, cannabis and cocaine for the 17 countries that 
participated in the World Mental Health Survey Initiative. 
The authors show that the median age of onset of use for 
these substances is similar in those countries: 16–19 years 
for alcohol and tobacco, 18–19 years for cannabis and 
21–24 years for cocaine. The information suggests that 
children and adolescents should be targeted long before 
they reach the age of first use, by means of evidence-based 
prevention interventions and policies. 
20. Longitudinal studies that have followed children 
into adulthood indicate that the earlier the age of onset 
for alcohol, tobacco and cannabis use, the greater the like-
lihood of use of drugs such as opiates and cocaine.18 
Epidemiological and laboratory research has explored this 
relationship and has shown that genetic, biological and 
societal factors are associated with this progression.19 
16 Ibid. 
17 Louisa Degenhardt and others, “Toward a global view of alcohol, 
tobacco, cannabis, and cocaine use: findings from the WHO World Men-
tal Health Surveys”, PLoS Medicine, vol. 5, No. 7 (July 2008). 
18 Denise Kandel, “Stages in adolescent involvement in drug 
use”, Science, vol. 190, No. 4217 (November 1975), pp. 912–914. Michael 
T. Lynskey and others, “Escalation of drug use in early-onset cannabis 
users vs. co-twin controls”, Journal of the American Medical Association, 
vol. 289, No. 4 (January 2003), pp. 427–433. 
19 Arpana Agrawal, Carol A. Prescott and Kenneth S. Kendler, 
“Forms of cannabis and cocaine: a twin study”, American Journal of 
 Medical Genetics, Part B Neuropsychiatric Genetics, vol. 129B, No. 1 
(May 2004), pp. 125–128; Denise Kandel and Eric Kandel, “The gateway 
hypothesis of substance abuse: developmental, biological and societal 
perspectives”, Acta Paediatrica, vol. 104, No. 2 (February 2015), pp. 130–
137; Stephen Nkansah-Amankra and Mark Minelli, “‘Gateway hypothe-
sis’ and early drug use: additional findings from tracking a population-
based sample of adolescents to adulthood”, Preventive Medicine Reports, 
vol. 4 (May 2016), pp. 134–141; and Michael M. Vanyukov and others, 
“Common liability to addiction and ‘gateway hypothesis’”: theoretical, 
empirical and evolutionary perspective, Drug and Alcohol Dependence, 
vol. 123, Suppl. 1 (June 2012), pp. S3–S17. 
21. Research indicates that adolescents begin use of alco-
hol, tobacco and cannabis due to their positive perceptions 
of availability and the social approval or the normative 
nature of substance use, and their lack of awareness of the 
risks associated with substance use.20 Effective prevention 
interventions address the misconceptions held by adoles-
cents. Interventions that change their misperceptions, in 
particular their perception of the normative nature of sub-
stance use, are associated with positive outcomes.21
22. Young people from families with high socioeconomic 
status try cannabis (episodic experimentation) more often 
than young people from lower socioeconomic status. 
However, the risk of developing cannabis use disorders is 
more closely associated with a lower socioeconomic status, 
lower academic achievement and early school leaving. That 
is because young people from families with high socioeco-
nomic status dispose of greater sociocultural resources to 
master and regulate their consumption.22
23. The strong evidence of the link between alcohol and 
tobacco use and the use of other psychoactive substances 
that are the primary concern of the international conven-
tions underlines the need to also address the use of 
tobacco and alcohol in the implementation of pro-
grammes for preventing substance use.
24. The impact on children of their parents’ substance 
use can be significant and may result in long-term emo-
tional and physical morbidity among children that will 
manifest itself in early adulthood. These effects include 
the direct health effects of maternal substance use, 
20 Lloyd D. Johnston and others, Monitoring the Future National Sur­
vey Results on Drug Use, 1975–2012, vol. I: Secondary School Students 
(Ann Arbor, Institute for Social Research, University of Michigan, 2013); 
Katherine M. Keyes and others, “The social norms of birth cohorts and 
adolescent marijuana use in the United States, 1976–2007”, Addiction, vol. 
106, No. 10 (October 2011), pp. 1790–1800; and Yvonne M. Terry-McElrath 
and others, “Risk is still relevant: time-varying associations between per-
ceived risk and marijuana use among US 12th grade students from 1991 
to 2016”, Addictive Behaviors, vol. 74 (November 2017), pp. 13–19.
21 Kenneth W. Griffin and Gilbert J. Botvin, “Evidence-based inter-
ventions for preventing substance use disorders in adolescents”, Child and 
Adolescent Psychiatric Clinics of North America, vol. 19, No. 3 (July 2010), 
pp. 505–526; Li C. Liu, Brian R. Flay and Aban Aya Investigators, “Evalu-
ating mediation in longitudinal multivariate data: mediation effects for 
the Aban Aya Youth Project Drug Prevention Program”, Prevention 
 Science, vol. 10, No. 3 (September 2009), pp. 197–207; and Catherine J. 
Lillehoj, Linda Trudeau and Richard Spoth, “Longitudinal modeling of 
adolescent normative beliefs and substance initiation”, Journal of Alcohol 
and Drug Education, vol. 49, No. 2 (June 2005). 
22 François Beck, Romain Guignard and Jean-Baptiste Richard, 
“ Actualités épidémiologiques du cannabis”, La Revue du Practicien, 
vol. 63, No. 10 (December 2013), pp. 1420–1424.
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including low birthweight, fetal alcohol syndrome,23 
 respiratory problems due to second-hand smoke,24 
increased child abuse and neglect,25 other health issues26 
and long-term developmental issues,27 as well as the 
increased possibility of substance use among children.28 
These effects are far-reaching and have both social and 
economic implications in all countries.29 Therefore, for 
these age groups – infancy through late adolescence – it 
is important to address not only the effects of the child’s 
or adolescent’s own substance use but also the effects of 
parental/family use, which can affect both children and 
adolescents who use substances and those who do not. 
Understanding the progression from 
use  to abuse
25. Epidemiological research in the 1970s paved the way 
for understanding the determinants of the initiation of 
substance use and the progression to deeper involvement 
with substances. Two studies, published in 1992 and 1993, 
summarized those findings. The first study, by authors 
23 Sylvia Roozen and others, “Worldwide prevalence of fetal alcohol 
spectrum disorders: a systematic literature review including meta-
analysis”, Alcoholism: Clinical and Experimental    Research, vol. 40, No. 1 
(June 2016), pp. 18–32; and Thitinart Sithisarn, Don T. Granger and 
 Henrietta S. Bada, “Consequences of prenatal substance use”, Inter­
national Journal of Adolescent Medicine and Health, vol. 24, No. 2 
( December 2012), pp. 105–112.
24 United States, Department of Health and Human Services, The 
Health Consequences of Involuntary Exposure to Tobacco Smoke: A  Report 
of the Surgeon General (Atlanta, Georgia, 2006).
25 Brad Donohue and others, “Contribution of illicit/non prescribed 
marijuana and hard-drug use to child abuse and neglect potential while 
considering social desirability”, British Journal of Social Work, vol. 49, 
No. 1 (January 2019), pp. 77–95. 
26 Tessa L. Crume and others, “Cannabis use during the perinatal 
period in a State with legalized recreational and medical marijuana: the 
association between maternal characteristics, breastfeeding patterns, and 
neonatal outcome”, Journal of Pediatrics, vol. 197 (June 2018), pp. 90–96.
27 Peter A. Fried, “Conceptual issues in behavioral teratology and 
their application in determining long-term sequelae of prenatal mari-
huana exposure”, Journal of Child Psychology and Psychiatry, vol. 43, No. 1 
(March 2002), pp. 81–102. 
28 Pamela C. Griesler and others, “Nonmedical prescription opioid 
use by parents and adolescents in the US”, Pediatrics, vol. 143, No. 3 
(March 2019); Kimberly L. Henry, “Fathers’ alcohol and cannabis use dis-
order and early onset of drug use by their children”, Journal of Studies of 
Alcohol and Drugs, vol. 78, No. 3 (May 2017), pp. 458–462; and Shulamith 
Straussner and Christine Fewell, “A review of recent literature on the 
impact of parental substance use disorders on children and provision of 
effective services”, Current Opinion in Psychiatry, vol. 31, No. 4 (July 
2018), pp. 363–367. 
29 Henrick Harwood, Douglas Fountain and Gina Livermore, The 
Economic Costs of Alcohol and Drug Abuse in the United States, 1992 
(Rockville, Maryland, National Institute on Drug Abuse and National 
Institute on Alcohol Abuse and Alcoholism, 1998). 
Hawkins and others (1992),30 outlined the risk factors 
associated with the initiation of substance use; those risk 
factors included both contextual factors (e.g., laws and 
norms favourable to substance use behaviours, availabil-
ity of substances, extreme economic deprivation and 
neighbourhood disorganization) and individual and 
interpersonal factors (e.g., physiological measures, family 
history of substance use, attitudes toward substance use, 
poor/inconsistent family management, family conflict and 
a low level of family bonding). The second study, by 
Glantz and Pickens,31 indicated that while contextual fac-
tors played a significant role in the initiation of substance 
use, it was the individual and interpersonal factors, in 
particular the physiological, neurological and genetic fac-
tors, that were found to have a greater influence on the 
progression to substance abuse. 
26. Two more recent studies reached the conclusion that 
genetic factors constitute a significant part of a person’s 
vulnerability to dependence, including the effects of the 
environment on gene expression and function.32 For 
example, a recent study found that use of cannabis and 
alcohol appeared to be influenced by common genetic 
factors.33 Certain genetic profiles play an important role 
in an individual’s vulnerability to substance use and pro-
gression to dependence. Prevention interventions 
designed specifically for individuals who are genetically 
predisposed to vulnerability to drug use have been shown 
to be effective in altering those individuals’ substance use 
trajectories and improving their life outcomes.34
27. Research has shown that the initiation of use of 
some substances does not always lead to substance 
abuse.35 There is evidence that individuals are more likely 
to spontaneously desist from use of substances such as 
alcohol, cocaine, heroin and amphetamines, which may 
have more immediate negative physical and 
30 David J. Hawkins, Richard F. Catalano and Janet Y. Miller, “Risk 
and protective factors for alcohol and other drug problems in adolescence 
and early adulthood: implications for substance abuse prevention”, 
 Psychological Bulletin, vol. 112, No. 1 (July 1992), pp. 64–105.
31 Meyer D. Glantz and Roy W. Pickens, “Vulnerability to drug abuse: 
introduction and overview”, in Vulnerability to Drug Abuse, Meyer D. 
Glantz and Roy W. Pickens, eds. (Washington, D.C., American 
 Psychological Association, 1993), pp. 1–14.
32 Carolyn E. Sartor and others, “Common genetic contributions to 
alcohol and cannabis use and dependence symptomatology”, Alcoholism: 
Clinical and Experimental Research, vol. 34, No. 3 (March 2010), 
pp. 545–554.
33 Ibid.
34 Gene H. Brody and others, “Differential sensitivity to prevention 
programming: a dopaminergic polymorphism-enhanced prevention 
 effect on protective parenting and adolescent substance use”. Health 
 Psychology, vol. 33, No. 2 (February 2014), pp. 182–191.
35 Jerald G. Bachman and others, The Decline of Substance Use in 
Young Adulthood: Changes in Social Activities, Roles, and Beliefs (East 
 Sussex, United Kingdom, Psychology Press, 2014).
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psychological effects than do tobacco or cannabis.36 
Theoretically, at any one time, in the same geographical 
area, there can be four distinct groups involved in sub-
stance use:37 
•  Resolute non-users, who are committed to not 
using any psychoactive substance
•  Vulnerable non-users, who may not be currently 
using any psychoactive substance but who may, for 
psychological, social or emotional reasons, initiate use
•  Early initiators, who may have initiated use of one or 
more psychoactive substances and may or may not 
be experiencing negative consequences of such use
•  Users at an advanced stage of substance use, who 
have progressed beyond the initiation of substance 
use with or without health or social consequences
28. These observations arising from the above-mentioned 
studies would suggest that there is a need for an array of 
integrated prevention and treatment services within com-
munities to address the specific needs of the population.
36 G. Bischof and others, “Factors influencing remission from alcohol 
dependence without formal help in a representative population sample”, 
Addiction, vol. 96, No. 9 (September 2001), pp. 1327–1336 and Linda C. 
Sobell Timothy P. Ellingstad and Mark B. Sobell, “Natural recovery from 
alcohol and drug problems: methodological review of the research with 
suggestions for future directions”, Addiction, vol. 95, No. 5 (May 2002), 
pp. 749–764.
37 William D. Crano and others, “The at-risk adolescent marijuana 
nonuser: expanding the standard distinction”, Prevention Science, vol. 9, 
No. 2 (June 2008), pp. 129–137.
29. Most children and adolescents fall within one of the 
first three groups. As noted below, each of these groups 
requires specific forms of evidence-based prevention and 
treatment interventions.
30. All human beings share the same developmental 
age-related benchmarks for becoming healthy, productive 
members of society. The attainment of those benchmarks 
can be enhanced or hampered by individual characteris-
tics, as well as by the influence of proximal agents such 
as parents, family and school, and by distant agents such 
as economic and social conditions, media, social media 
and national policies. Research conducted on genetic, 
physical and environmental factors and their interactions 
in order to determine the vulnerabilities to substance use 
and other such behaviours has led to a reconceptualiza-
tion of risk and protective factors that has the potential 
to refine prevention and treatment delivery and imple-
mentation systems for children and adolescents.38 
31. Figure I shows this new perspective in simplified 
form. The figure helps to elucidate the concept of vulner-
ability and assists a further understanding of risk and pro-
tection as the interface between the physical, psychological 
and genetic make-up of an individual and by the influ-
ences on that individual’s physical, cognitive, emotional 
and social development: parents and family, school, faith-
based organizations, peers, workplace and close-knit ver-
sus more distant communities.
38 Zili Sloboda, Meyer D. Glantz and Ralph E. Tarter, “Revisiting the 
concepts of risk and protective factors for understanding the etiology and 
development of substance use and substance use disorders: implications 
for prevention”, Substance Use and Misuse, vol. 47, Nos. 8 and 9 (June 
2012), pp. 1–19.
Source: Zili Sloboda, “School-based prevention: evolution of evidence-based strategies”, in Adolescent Substance Abuse: Evidence­Based Approaches 
to Prevention and Treatment, Carl G. Leukefeld and Thomas P. Gullotta, eds. (New York, Springer, 2018).
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Figure I. Vulnerability model
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32. The framework shown in figure I illustrates the fac-
tors involved in human motivation and change processes. 
It shows how the various environmental levels and per-
sonal characteristics interact in the decision-making that 
takes place before substance use and the performance of 
other problem behaviours. 
33. Genetics and other biological factors play a signifi-
cant role in the achievement of developmental bench-
marks, that is, the goal of each stage of development, from 
infancy to early adulthood, including intellectual ability, 
language development, cognitive, emotional and psycho-
logical functioning, and the attainment of social compe-
tency skills.
34. The extent to which developmental benchmarks are 
achieved determines our level of vulnerability to influ-
ences from our environment. Our vulnerability liability 
may vary over our lifespan. However, children who do 
not achieve early developmental benchmarks, for a vari-
ety of reasons, are most likely to fail in the achievement 
of later benchmarks and, as a result, face problems in 
adulthood.
35. Environmental factors can either lessen or enhance 
that vulnerability. The risk of substance use increases 
because of environmental experiences, such as adverse 
childhood experiences, that are associated with height-
ened stress or adversity. The environmental influences are 
viewed as being at two major levels: those in close prox-
imity to the individual – the micro-level environments, 
which include parents and family, school and peers – and 
those that are more distant – the macro-level environ-
ments, which include both our physical and social set-
ting, including the Internet and social media. The broader 
community environment and the need to respect the rule 
of law and other societal norms also influences the vul-
nerability of young people. An example is that of mar-
ginalized urban areas where criminal organizations, 
frequently associated with drug trafficking, dominate the 
territory and the authorities are unable to assert their 
control, provide citizens with access to even basic health 
and social services or give young people the assistance 
necessary to develop their potential.
36. Although the Internet and social media offer new 
ways to deliver preventive education, they have also cre-
ated increased opportunities for both the marketing and 
the social transmission of risky products and behaviour 
and have thus contributed to an increased exposure to 
substance use by normalizing use and presenting users’ 
experiences in a positive light. For example, some YouTube 
bloggers and influencers disseminate information about 
new substances and new ways of administrating them; 
they emphasize the so-called “positive” effects and down-
play the negative consequences of substance use, and as a 
way of defending their choices, they provide young peo-
ple with extensive but not necessarily factual information 
on substance use. 
37. The two levels of influence – the micro- and 
macro-level environments – do not operate independently 
as they influence our behaviour: they also affect one 
another. For instance, family stability and even parenting 
behaviours can be challenged when one or both caregiv-
ers are unemployed for long periods of time.39
38. It is the interface where the micro- and macro-level 
environments interact with the individual that shapes 
cognitive and emotional development, as well as beliefs, 
attitudes and behaviours that serve to socialize human 
beings to become productive members of their commu-
nities. These interfacial connections can either be posi-
tive (protective) or negative (risky). They also provide 
opportunities for interventions to improve or enhance 
positive growth. So, it is possible for vulnerable children 
who receive positive parenting to overcome the challenges 
they face, while similarly vulnerable children who are 
neglected by their parents are less likely to be as 
successful.40
39. Cultural factors and context play a role as well. If a 
culture strongly discourages substance use, the rate of 
substance use may be lower. However, if substance use is 
an integral part of a culture’s rituals or celebrations, there 
may be few disincentives to prevent a person from start-
ing and continuing substance use, unless restrictions are 
built into those cultural rituals. Cultural definitions of 
roles, in particular gender roles, may also inhibit or 
underscore the use of substances. 
40. We can draw examples of these processes from our 
own experiences. Think about a child living in poverty 
39 Geert Dom and others, “The impact of the 2008 economic crisis on 
substance use patterns in the countries of the European Union”, Inter­
national Journal of Environmental Research and Public Health, vol. 13, 
No. 1 (January 2016); Mark A. Bellis and others, “National household 
survey of adverse childhood experiences and their relationship with resil-
ience to health-harming behaviors in England”, BMC Medicine, vol. 12, 
No. 72 (May 2014); Dieter Henkel, “Unemployment and substance use: a 
review of the literature (1990–2011)”, Current Drug Abuse Reviews, vol. 4, 
No. 1 (2011), pp. 4–27; Heta Moustgaard, Mauricio Avendano and Pekka 
 Martikainen, “Parental unemployment and offspring psychotropic 
 medication purchases: a longitudinal fixed-effects analysis of 138,644 
adolescents”, American Journal of Epidemiology, vol. 187, No. 9 ( September 
2018), pp. 1880–1888 and University of Oxford, “ Unemployment triggers 
increase in child neglect, according to new  research”, 3 November 2017.
40 Karl G. Hill and others, “Person-environment interaction in the 
prediction of alcohol abuse and alcohol dependence in adulthood”, Drug 
and Alcohol Dependence, vol. 110, Nos. 1 and 2 (July 2010), pp. 62–69.
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and whose parents are absent – because of incarceration 
or dependence, or because they are working two or three 
jobs. Now think about a child in this situation but who 
has a grandparent or other caring, supportive adult who 
can help her meet her developmental benchmarks. Or 
think about this child entering a school where she feels 
safe and accepted. Such a child is more likely to develop 
pro-social attitudes and engage in pro-social and healthy 
behaviours because of that bonding or attachment pro-
cess. Feelings of belonging and being supported are key 
to human development. Now let us think about this girl 
without a safe and supportive family member or school 
environment. What if there were a street gang that filled 
her need for a sense of belonging? And what if that gang 
trafficked drugs or engaged in criminal behaviour?
41. These are not hypothetical situations; they are drawn 
from real life. Evidence-based prevention interventions 
are designed to help parents and families in stress to focus 
on positive parenting to help their children. They are 
designed to help schools create safe and positive environ-
ments where children, as well as school staff, can enjoy 
an effective learning environment.
The vulnerability model and prevention 
interventions
42. Figure I also serves to guide the development of pre-
vention approaches as shown in figure II. It suggests that 
the socialization process (i.e., learning the culture, atti-
tudes, beliefs, language and behaviour of the society within 
which we live) also acts as the process of prevention where 
key socialization agents (e.g., parents and other family 
members, teachers, laws and regulations) are helped to 
improve their socialization skills, such as by improving par-
enting or teaching skills, or modify the social and physi-
cal settings to make it more difficult to engage in negative 
behaviours. Thus, through evidence-based prevention 
interventions, the family, school and community environ-
ments can become positive forces in raising a child to resist 
engaging in substance use or other risky behaviours. The 
stars in figure II indicate opportunities for prevention 
interventions.
43. As can be seen in the model in figure II, it is “intent”, 
shown in the figure, that has been found to predict the 
initiation of substance use and has become the target of 
effective interventions, particularly for children and 
young people in their early teens prior to the “at-risk” 
years. Theories of human behaviour inform us that inten-
tions are based on beliefs and attitudes, knowledge, social 
and cognitive competencies, and skills related to any 
behaviour. Effective prevention interventions are those 
that address these mediating factors to alter or change the 
behaviour of those on a negative life course by promot-
ing positive developmental outcomes and reducing neg-
ative behaviours and, for those who have no intention of 
using psychoactive substances, to reinforce those positive 
factors. 
International Standards on Drug Use 
Prevention and other evidence-based 
prevention resources
44. Research progress has led to a number of products 
designed to help prevention planners identify evidence- 
based prevention interventions that match the 
Figure II. Prevention intervention points
Source: Zili Sloboda, Universal Prevention Curriculum for Substance Use.
Note: Stars indicate points of intervention.
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characteristics and meet the needs of their communities. 
The most notable is the UNODC-WHO International 
Standards on Drug Use Prevention (2nd ed., 2018). This 
guide outlines the key content, structures and delivery 
strategies that have been found to be consistent across 
interventions. Figure III summarizes the content of the 
Standards document.
45. Figure III identifies the settings in which the inter-
ventions take place (family, school, community, work-
place and health sector, as listed in the left column), and 
interventions are organized according to the age group 
being targeted (prenatal and infancy, early childhood, 
middle childhood, early adolescence, adolescence and 
adulthood, as listed across the top). 
46. Examples of programmes focusing on the micro-
level environment are those that include family and par-
enting skills. Such programmes provide support for 
treatment, prenatal medical care, and support for hous-
ing and other needs. The Triple P–Positive Parenting 
Program41 is another family support and parenting skills 
41 Matthew R. Sanders, “Development, evaluation and multinational 
dissemination of the Triple P-Positive Parenting Program”, Annual  Review 
of Clinical Psychology, vol. 8 (April 2012), pp. 345–379.
programme that includes a system of parenting pro-
grammes that operate on a tiered continuum of increas-
ing strength and intensity. A third example of an effective 
family intervention is the “Strengthening Family Program 
10–14” programme.42 This programme has components 
for parents only, for children only, and for parents and 
children together, focused on parenting skills and family 
bonding, and is delivered over the course of seven weeks.
47. Examples of school-based, evidence-based preven-
tion policies and interventions include school curricula 
such as LifeSkills Training43 and Unplugged.44 Both of 
these programmes target personal and social skills, 
including decision-making skills, goal-setting skills and 
42 Richard Spoth and others, “Research on the strengthening families 
program for parents and youth 10–14: long-term effects, mechanisms, 
translation to public health, PROSPER partnership scale up”, in Hand­
book of Adolescent Drug Prevention: Research, Intervention, Strategies, and 
Practices (Washington, D.C., American Psychological Association, 2015), 
pp. 267–292.
43 Gilbert J. Botvin and others, “Preventing illicit drug use in adoles-
cents: long-term follow-up data from a randomized control trial of a 
school population”, Addictive Behaviors, vol. 25, No. 5 (September– 
October 2000), pp. 769–774.
44 Federica D. Vigna-Taglianti and others, “‘Unplugged,’ a European 
school-based program for substance use prevention among adolescents: 
overview of results from the EU-Dap trial”, New Directions for Youth 
 Development, vol. 2014, No. 141 (April 2014), pp. 67–82. 
Figure III.  Summary table of evidence-based strategies identified in the UNODC-WHO 
International Standards on Drug Use Prevention (2nd ed., 2018)
Source: UNODC and WHO.
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analytical skills to assess information on psychoactive 
substances and violence. These skills are designed so that 
students understand and resist pro-drug influences and 
make decisions not to use any psychoactive substance. To 
reinforce this decision, the programmes address misper-
ceptions regarding normative beliefs about psychoactive 
substances, reinforce intentions not to use substances, and 
provide opportunities to practise refusal skills with their 
classmates within a variety of simulated real situations 
that they face or may face in the future. Another very 
effective programme that enhances the classroom climate 
and enhances bonding in the school setting is the Good 
Behaviour Game.45
48. Examples of evidence-based policies are those that 
target the accessibility and use of psychoactive substances, 
such as school policies regarding use on school property. 
The following are the keys to a successful policy: the 
choice of persons involved in developing the policy; hav-
ing clearly stated responses to infractions, not only for 
students but also for school staff, that are not punitive 
(i.e., leading to suspension, expulsion, or firing) but sup-
portive (through referrals for further evaluation and 
counselling); and making school staff, students, parents 
and other key stakeholders aware of the policies and their 
enforcement.
49. Effective environment-based regulatory approaches 
include limiting access to medications with psychoac-
tive qualities by requiring a prescription from a licensed 
health practitioner and reducing accessibility to tobacco, 
alcohol and, where appropriate, cannabis for children 
and adolescents. Other regulations found to be effective 
when enforced include banning the smoking of ciga-
rettes in public places, limiting the amount of alcohol 
served in a bar, tavern or restaurant, and limiting access 
to substances that are precursors for the manufacture of 
some illicit drugs such as benzyl methyl ketone, ephed-
rine and pseudo ephedrine, which are used in making 
methamphetamines.
50. The Standards also include research on approaches 
found to be ineffective and, in some cases, iatrogenic. 
Such approaches include testing for drug use in schools, 
testing in workplaces without the support of evidence-based 
substance use policies, and programmes that focus on 
scare tactics or provide only information without further 
addressing the elements for evidence-based interventions 
mentioned above. 
45 Nicholas S. Ialongo and others, “Proximal impact of two first-
grade preventive interventions on the early risk behaviors for later 
 substance abuse, depression, and antisocial behavior”, American Journal 
of Community Psychology, vol. 27, No. 5 (October 1999), pp. 599–641.
Advances in evidence-based treatment 
approaches for young people
51. The history of research on treatment is longer than 
that on prevention. The present section focuses on prog-
ress made over the past 45 years in understanding the 
treatment needs of substance users of all ages, in partic-
ular for young people. Because the brain is still develop-
ing throughout adolescence into early adulthood, and as 
psychoactive substances impact brain functioning, ado-
lescents experience a more rapid transition from initia-
tion of substance use to dependence compared with 
adults, whose brain development is more complete. 
Therefore, the treatment of adolescents needs to be dif-
ferent from that of adults. Winters and others (2011)46 
state that this observation was made as early as 1952. By 
the 1980s, the acknowledged differences in substance use 
patterns and consequences, as well as developmental 
issues, gave support to exploring specialized treatment 
options for adolescents.
52. Epidemiological data on the use of psychoactive 
substances by adolescents indicate that their substance 
use experiences as addressed in treatment will differ from 
those of adults. For instance, adolescents are more likely 
to use inhalants and cannabis and binge drink. In addi-
tion, as Izenwasser (2005)47 and others have found, the 
effects of use of these substances (in particular, alcohol 
and nicotine) are more extreme for adolescents than for 
adults, particularly for males. Adolescents have higher 
rates of binge use than do adults and have lower prob-
lem recognition, are more focused on short-term impli-
cations of use and have higher rates of diagnosed 
co-morbid psychiatric problems as compared with 
adults.48 Treatment for adolescents may therefore be 
challenging.
53. The UNODC-WHO International Standards for the 
Treatment of Drug Use Disorders make specific recom-
mendations regarding the treatment of adolescents. Those 
recommendations include focusing on psychosocial/
behavioural approaches to treatment, while involving the 
46 Ken C. Winters, Adrian M. Botzet and Tamara Fahnhorst, 
“ Advances in adolescent substance abuse treatment”, Current Psychiatry 
Reports, vol. 13, No. 5 (October 2011), pp. 416–421.
47 Sari Izenwasser, “Differential effects of psychoactive drugs in ado-
lescents and adults”, Critical Reviews of Neurobiology, vol. 17, No. 2 
(2005), pp. 51–68.
48 Sandra A. Brown and others, “Treatment of adolescent alcohol-
related problems”, in Recent Developments in Alcoholism, vol. 17, Marc 
Galanter, ed. (New York, Springer, 2005), pp. 327–348; and Margo 
 Gardner and Laurence Steinberg, “Peer influence on risk taking, risk 
 preference, and risky decision making in adolescence and adulthood: an 
experimental study”, Developmental Psychology, vol. 41, No. 4 (July 2005), 
pp. 625–635.
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family and taking into account other social aspects of the 
child’s or adolescent’s life in the treatment process. 
Treatment must take into consideration the cognitive 
development and life experiences of children and adoles-
cents and for that reason may vary according to the age 
and developmental level of the child or adolescent. The 
lack of developmentally appropriate knowledge and skills 
and the potential adolescent propensity towards risk-taking 
and sensitivity to peer pressure also require special 
accommodation in treatment. 
54. Although more research is needed in this field, it 
has been found that children and adolescents may expe-
rience less motivation to adhere to treatment than do 
adults and will think about issues in more concrete terms, 
be less introspective and be less likely to engage in 
“talking” therapies. These special features of treatment for 
children and adolescents are related to the aetiological 
model discussed above, suggesting that treatment must 
take into consideration the child/adolescent substance 
users’ interface with their micro- and macro-level envi-
ronments and their specific vulnerabilities that may be 
associated with not only the initiation of substance use 
but also its progression. 
55. Key treatment components that have been found to 
contribute to positive outcomes for adolescents include the 
following: involvement, whenever safe, of the adolescent’s 
family in the treatment process, even in therapeutic com-
munities; use of a motivational approach that focuses on 
minimizing the adverse public health and social conse-
quences of drug abuse; psychosocial treatment approaches 
combined with individualized treatment approaches to 
address special needs such as mental health issues; life 
skills training and cognitive behavioural interventions; 
motivational enhancement therapy; family-based thera-
pies, from brief strategic family therapy to multi-systemic 
family therapy; and basic education.49
56. Winters and others (2011)50 suggest combining 
these evidence-based treatment interventions for young 
people within the context of the five treatment levels sug-
gested by the American Society of Addiction Medicine 
49 Emily K. Lichvar and others, “Residential treatment of adolescents 
with substance use disorders: evidence-based approaches and best prac-
tice recommendations”, in Adolescent Substance Abuse: Evidence­Based 
Approaches to Prevention and Treatment, 2nd ed., Carl G. Leukefeld and 
Thomas P. Gullotta, eds. (New York, Springer, 2018), pp. 191–214. 
National Institute on Drug Abuse, “Principles of adolescent substance use 
disorder treatment: a research guide”, NIH Publication No. 14-7953 
(Rockville, Maryland, 2014); and UNODC and WHO, International 
Standards for the Treatment of Drug Use Disorders: Draft for Field Testing 
(Vienna, 2017). 
50 Winters, Botzet and Fahnhorst, “Advances in adolescent substance 
abuse treatment”. 
(2001),51 which include: (a) early intervention services 
(consisting of educational or brief intervention 
approaches); (b) outpatient treatment lasting up to six 
hours per week, depending on the progress being made 
through the treatment plan; (c) intensive daily outpatient 
treatment for up to 20 hours per week, for two months 
up to one year; (d) residential/inpatient treatment for one 
month up to one year; and (e) medically managed inten-
sive inpatient treatment limited to adolescents whose sub-
stance use and related problems are severe enough to 
require 24 hours of primary medical care until stabiliza-
tion is achieved.
57. The need for screening assessments to determine the 
special needs of substance-using adolescents has long 
been recognized, and several such instruments have been 
developed and validated. The National Institute on Drug 
Abuse of the United States supports two such tools: the 
Brief Screener for Alcohol, Tobacco and Other Drugs 
(BSATD) and the Screening to Brief Intervention (S2BI). 
These two-minute screeners, among others, are recom-
mended for use by health-care providers to determine 
whether an adolescent needs a treatment intervention. If 
a child or adolescent is referred for treatment, it is incum-
bent on the treatment facility to screen for at least three 
risk factors: intoxication, evidence of self-harm and evi-
dence of harm to others. If those factors are noted, the 
child/adolescent may need to be referred to an inpatient 
facility for observation and appropriate treatment.52 
Recent research has shown that brief interventions have 
been successful for adolescents in preventing their pro-
gression from use to problematic use.53
Implications for policy development 
worldwide: conclusions and 
recommendations
58. Prevention of drug use, treatment of drug depen-
dence and rehabilitation and social reintegration of the 
persons involved is one of the key provisions of inter-
national drug control systems. The main goal of the inter-
national drug control conventions is to protect people’s 
health from harm caused by the non-medical use of 
51 D. Mee-Lee and others, ASAMPPC­2R: ASAM Patient Placement 
Criteria for the Treatment of Substance­Related Disorders, 2nd revised ed. 
(Chevy Chase, Maryland, American Society of Addiction Medicine, 
2001).
52 UNODC and WHO, International Standards for the Treatment of 
Drug Use Disorders.
53 Lilia D’Souza-Li and Sion K. Harris, “The future of screening, brief 
intervention, and referral to treatment in adolescent primary care: 
 research directions and dissemination challenges”, Current Opinion in 
 Pediatrics, vol. 28, No. 4 (August 2016), pp. 434–440.
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controlled substances while ensuring the availability of 
those substances for medical and scientific purposes. Drug 
use prevention and the treatment of drug dependence, 
especially among young people, are key elements to achieve 
that goal by ensuring that young people can achieve healthy 
development and become productive members of society. 
59. The UNODC-WHO International Standards on 
Drug Use Prevention (2nd ed., 2018) summarize the sci-
entific evidence demonstrating the effectiveness of drug 
use prevention efforts. In many documents and resolu-
tions, such as the outcome document of the thirtieth 
special session of the General Assembly, on the world 
drug problem, Governments have recognized the 
International Standards as a useful tool for promoting 
evidence-based prevention. The International Standards 
on Drug Use Prevention, together with the UNODC-
WHO International Standards for the Treatment of Drug 
Use Disorders (2017), are unique documents as they 
 provide not only summaries regarding the components 
of evidence-based prevention interventions and policies 
and treatment for substance use but also comprehensive 
models of national systems of care that provide for 
 financial and multi-ministerial collaborative support for 
programming at the local level, support for the delivery 
of comprehensive prevention interventions that are 
 evidence-based, and an ongoing data collection system 
that monitors service delivery and provides feedback for 
updating the national care system and allows for the 
inclusion of rigorously evaluated new interventions and 
policies. Youth services such as juvenile detention, 
 education and family services should be incorporated into 
such a broader national care system.
60. The Board recommends the use of those two 
above-mentioned sets of international standards when 
implementing programmes for the prevention of drug use 
and the treatment of drug dependence among young 
 people. In addition to preventing drug use, it has been 
established that evidence-based prevention strategies also 
prevent many other risky behaviours, promoting the healthy 
and safe development of children and young people. 
Understanding the issue
61. A first priority for countries is the development of 
national epidemiological data systems to inform their 
policies on the prevention and treatment of psychoactive 
substance use among young people. Although some 
countries have data systems that do more than simply 
monitor substance use through school and/or population 
(e.g., household) surveys, only a few countries have sur-
veillance systems in place.
Developing professional expertise
62. A second priority is the development of professional 
expertise in the field of substance use prevention and 
treatment, which should include national training and 
credentialing systems for prevention and treatment pro-
fessionals engaged in decision-making/planning and 
implementation, and research with a special focus on the 
needs of young people. In many jurisdictions, credential-
ing is currently available for treatment and prevention 
professionals but not necessarily required. Like for other 
professions, it is important that the underlying science, 
knowledge, skills, competencies and ethical standards be 
internationally accepted by means of an international pro-
fessional organization or organizations that maintain this 
base and propose updates for improved services and ser-
vice delivery on the basis of rigorous research regarding 
the biological, neurological, psychological and sociologi-
cal aspects of substance use. The Board recommends that 
Governments build, with the assistance of UNODC and 
WHO, the expertise of prevention and treatment profes-
sionals in delivering evidence-based interventions effec-
tively, in order to achieve positive outcomes.
Early start and broad prevention strategies
63. Substance use and dependence are caused by vari-
ous factors, and they tend to start in adolescence, but cur-
rent research demonstrates that vulnerability to drug use 
may originate in what happened earlier in an individual’s 
development, during childhood and early adolescence. 
For that reason, intervention should start at an early age 
and not be delayed until the age of first use. There are 
interventions that can and should be delivered at the spe-
cific stages of pregnancy, infancy, childhood and middle 
childhood, supporting mothers, parents and schools to 
promote the healthy development of children, as these 
interventions have been shown to be effective in prevent-
ing substance use and other risky behaviours during 
adolescence.
Multiple approaches
64. A variety of factors (mainly genetic and environ-
mental) determine vulnerability to substance use and 
dependence, and, to address these problems effectively, it 
is necessary to adopt a wide range of interventions and 
not one single approach. Various environments and set-
tings such as family, school, the workplace, the commu-
nity, media and leisure activities need to be considered 
in the development of substance use prevention pro-
grammes. Also, different approaches may be required for 
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different populations. For example, vulnerable popula-
tions, such as children with a substance-dependent par-
ent, homeless and street children, children in custodial 
settings, orphans and abandoned children, migrants and 
refugee children and children exploited for sex work, 
need specific, targeted interventions that are different 
from those used with other children. Prevention should 
include strategies for the population at large (universal 
prevention), for groups that are particularly at risk (selec-
tive prevention) and for individuals that are particularly 
at risk (indicated prevention).
65. For the most vulnerable and youth engaged in 
 substance use behaviours, it is necessary to adopt a wide 
network of outreach and basic social assistance services 
that have a strong emphasis on screening and assessment. 
These youth must be provided with a range of effective 
substance use disorder treatment interventions on the 
continuum of care that allows them to engage with  family, 
schools, the workplace and the community, with the 
intention of building a network of support.
Family 
66. The setting that is most influential for the develop-
ment of children and adolescents is the family, and pre-
vention approaches focusing on family have been found 
to be particularly effective. Family skills training focus-
ing on supporting parents and helping families to work 
better have been found to be more effective. In these pro-
grammes, parents are encouraged to raise their children 
in a warm and responsive manner and to become involved 
in their children’s lives and learn how to communicate 
effectively with their children and use constant monitor-
ing and the enforcement of rules and limits. Drug-specific 
content in these programmes pertains to the parents’ own 
substance use and, depending on the developmental stage 
of the child in question, to the expectations that the par-
ents have about the child’s substance use and how to com-
municate about drug issues. Such interventions achieve 
positive preventive outcomes for both boys and girls in 
the short and long run with regard to substance use and 
other problem behaviour.
School and education 
67. In drug prevention, the school setting (including pre-
school and elementary school, for which age-appropriate 
activities are delivered) serves as an access path for mea-
sures promoting knowledge and personal and social skills 
of individuals to attenuate individual risk factors of sub-
stance use. Research has shown that programmes that only 
provide information about the danger of drugs and pro-
grammes that only use lecturing as a way to deliver sub-
stance use prevention have been found to be associated 
with no effectiveness or even adverse effects. Programmes 
that work are those that focus on the development of per-
sonal and social skills, discuss the normative nature of use 
and reflect on the expectations and perception of risk, 
using a set of interactive sessions (not just a one-time 
event) with well-trained facilitators. The aim is to improve 
several personal or social skills, such as self-awareness, 
creative thinking, relationship skills, problem-solving, 
decision-making, coping with stress and emotions, and to 
improve school bonding and academic achievements. The 
evidence available suggests that developing individual 
social skills is the most effective form of school-level inter-
vention for the prevention of early substance use. The pre-
sentation of information on drugs that is aimed at 
generating fear is ineffective among young people. Aside 
from implementing individual-oriented interventions, pre-
ventive effects can also be achieved by targeting the gen-
eral climate and drug-specific rules of schools. 
68. Schools also serve as a potential point for screening 
and assessment of children and adolescents. A well-
trained school nurse, school psychologist or even an edu-
cator can administer a screening instrument to assist in 
making a referral to substance use disorder treatment 
when appropriate. In addition, it is critical that young 
persons in a treatment programme continue to engage in 
the process of education to the extent possible.
Community 
69. Together with the family, the community can pro-
vide a preventive developmental context by setting clear 
standards and values with regard to the use of drugs, and 
by providing opportunities for adolescents to learn skills, 
contribute to community life and be recognized for their 
contribution. Tight bonds with the family and the com-
munity in general motivate young people to adopt healthy 
standards of behaviour. Community interventions – both 
prevention and treatment interventions – work better 
when combined and consistent with school and family 
interventions and messages. 
Environment policies, such as those commonly 
implemented for alcohol and tobacco use
70. The first use of alcohol and nicotine at a young age 
is related to later initiation of cannabis use; thus, the pre-
vention of alcohol and tobacco use is also relevant for the 
prevention of substance use. 
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Leisure, sports and entertainment venues 
71. The effectiveness of specific drug prevention efforts 
in leisure settings – for example, peer education pro-
grammes at festivals or activities in sports clubs, includ-
ing the promotion of physical activities – has not yet been 
studied in depth. Sports clubs have been described as 
both a setting with great potential for promoting good 
health and a risk environment for substance use, but 
effectiveness studies are not available. Furthermore, pro-
viding low-resource intensive leisure activities to children 
and young people is a popular non-drug-specific preven-
tion intervention, but these activities have not been 
empirically studied with regard to their effect in attenu-
ating substance use or risk factors of substance use. 
Health sector
72. The community health sector can prevent progres-
sion to substance use disorders (when it is in touch with 
individuals already using drugs) by providing brief inter-
ventions. In the few, short and structured sessions of these 
interventions, trained health or social workers first iden-
tify whether there is a problem of substance use and then 
provide basic counselling or referral to additional 
treatment. 
Media 
73. In addition to the factors of availability and afford-
ability, some societal norms favourable to substance use 
create an additional risk factor. As described above, 
affordability and availability may be influenced by enforce-
ment of laws and regulations. In addition, children, ado-
lescents and young adults face norms of substance use 
informally through the approval or disapproval expressed 
by peers, parents, teachers, neighbours and other com-
munity members. Media campaigns are one way to influ-
ence those informal social norms. Accordingly, one 
frequently used component of State and community pro-
grammes is to conduct awareness campaigns or expand 
media coverage in order to increase awareness of and 
focus on drug-related issues. More research is needed on 
the effectiveness of mass media campaigns and the use of 
social media because the available evidence is very 
limited.
Treatment for young people
74. Young people have unique substance use patterns 
and treatment needs that are different than those for 
adults. Any use of psychoactive substances by young peo-
ple is cause for concern, even if they are merely experi-
menting, as substance use exposes them to more risk 
behaviour and increases the risk and severity of later sub-
stance use disorders. Evidence-based treatment is benefi-
cial for young people who use substances even if they are 
not suffering from diagnosable substance use disorders.
75. The Board recommends that Governments refer to 
the recommendations contained in chapter I of its annual 
report for 2017, entitled “Treatment, rehabilitation and 
social reintegration for drug use disorders: essential com-
ponents of drug demand reduction”, and, more broadly, 
to the UNODC-WHO International Standards for the 
Treatment of Drug Use Disorders (2017).
The way forward 
76. The scientific evidence reviewed and presented in 
this section illustrates that effective and feasible interven-
tions and policies are available for drug prevention and 
treatment. However, the gaps in both evidence and effec-
tiveness research underline the fact that more evaluation 
of impact is needed. Reaching groups that have height-
ened vulnerability remains a challenge, while the ques-
tion of how to adapt interventions developed in optimal 
conditions to real-life, local contexts has not yet been fully 
answered. Many activities labelled as drug prevention or 
drug treatment are not evidence-based; their coverage is 
limited, and their quality is unknown at best. 
77. In summary, countries need to move away from a 
model in which the prevention of substance use and the 
treatment of substance use disorders are delivered by 
well-intentioned individuals who are delivering interven-
tions in an isolated manner. Interventions should be 
based on the specific situation and should systematically 
employ and expand the use of evidence-based tools, sup-
porting practitioners and policymakers in developing 
their knowledge, skills and competencies and building a 
critical mass of genuine prevention and treatment spe-
cialists capable of promoting the safe and healthy devel-
opment of children, young people, families and 
communities through the effective prevention of sub-
stance use and treatment of substance use disorders.
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Chapter II.
Functioning of the international drug 
control system
offences, and they provide a legal basis for certain investi-
gative techniques such as controlled deliveries, for extradi-
tion and for mutual legal assistance between parties. The 
conventions provide that criminal justice responses to sus-
pected drug-related crime should be consistent with the 
principle of proportionality and, accordingly, that crimes 
of lesser gravity may be subject to lesser penalties and 
crimes committed by people who use drugs may be dealt 
with through alternative measures to conviction or pun-
ishment, including measures of treatment, education, after-
care, rehabilitation and social reintegration.
81. States parties to the drug control conventions are 
also required to develop strategies aimed at prevention 
and frameworks for the treatment and rehabilitation of 
people affected by drug dependence.
Status of adherence to the international 
drug control treaties
82. As at 1 November 2019, the 1961 Convention as 
amended by the 1972 Protocol had been ratified or 
acceded to by 186 States, with only 10 States yet to 
become parties. Of these, two were in Africa (Equatorial 
Guinea and South Sudan), one in Asia (Timor-Leste) and 
seven in Oceania (Cook Islands, Kiribati, Nauru, Niue, 
Samoa, Tuvalu and Vanuatu). Chad has ratified the 1961 
Convention in its unamended form.
83. The number of States parties to the 1971 Convention 
has remained unchanged, at 184, over the period under 
review, with 13 States currently not parties to that 
Convention.
A.  Promoting the consistent 
application of the international 
drug control treaties
78. The international legal drug control framework con-
sists of the Single Convention on Narcotic Drugs of 1961 
as amended by the 1972 Protocol, the Convention on 
Psychotropic Substances of 1971 and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988.54 Those conventions are 
among the most widely ratified international instruments, 
with near universal adherence.
79. Together, the international drug control conven-
tions establish the legal framework for the licit trade in 
narcotic drugs, psychotropic substances and precursor 
chemicals. They do this by requiring States parties to cre-
ate administrative structures responsible for monitoring 
the production and manufacture of and trade in sub-
stances scheduled under the conventions and by estab-
lishing an obligation for States parties to report to the 
Board on their expected licit requirements, actual con-
sumption, international trade and seizures. Through that 
reporting mechanism, the conventions foster the avail-
ability of controlled substances for medical, scientific or 
industrial use while preventing their diversion into illicit 
channels. One of the hallmarks of the drug control frame-
work is that it limits the production, manufacture, export, 
import and distribution of, trade in and possession of 
drugs exclusively to medical and scientific purposes.
80. The conventions contain the obligation for States par-
ties to make certain drug-related behaviours punishable 
54 United Nations, Treaty Series, vol. 1582, No. 27627. 
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84. In August 2019, Palau acceded to the 1988 
Convention, becoming the 191st party to the Convention, 
which has been ratified by 190 States and the European 
Union. As is the case with the 1961 Convention and the 
1971 Convention, most of the non-parties to the 1988 
Convention are in Oceania (Kiribati, Papua New Guinea, 
Solomon Islands and Tuvalu). Three non-parties are in 
Africa (Equatorial Guinea, Somalia and South Sudan).
85. INCB continues to actively engage all States hav-
ing yet to accede to one or more of the international 
drug control conventions to do so without delay and to 
ensure their comprehensive implementation into 
national law. The Board reiterates that universal ratifi-
cation of the drug control conventions is imperative for 
strengthening the international legal drug control 
framework and in ensuring that traffickers do not tar-
get non-parties due to actual or perceived weaknesses 
in the scope of control of scheduled substances.
B.  Ensuring the implementation of 
the provisions of the 
international drug control 
treaties
86. The fundamental goal of the international drug con-
trol system is assuring the health and welfare of human-
kind. That goal is to be achieved through two, twin 
actions: ensuring the availability of internationally con-
trolled substances for medical and scientific purposes 
and, in the case of precursor chemicals, also ensuring 
their legitimate industrial use; and preventing the diver-
sion of controlled substances into illicit channels.
87. To monitor compliance with the international drug 
control treaties, the Board examines action taken by 
Governments to implement the treaty provisions aimed 
at achieving the overall goals of the conventions. Over 
the years, the treaty provisions have been supplemented 
with additional control measures adopted by the Economic 
and Social Council and the Commission on Narcotic 
Drugs to enhance their effectiveness. In the present sec-
tion, the Board highlights action that needs to be taken 
to implement the international drug control system, 
describes problems encountered in that regard and pro-
vides specific recommendations on how to deal with 
those problems.
1.  Preventing the diversion of 
controlled substances
(a) Legislative and administrative basis
88. Governments have to ensure that national legisla-
tion complies with the provisions of the international 
drug control treaties. They also have the obligation to 
amend lists of the substances controlled at the national 
level when a substance is included in a schedule of an 
international drug control treaty or transferred from one 
schedule to another. Inadequate legislation or implemen-
tation mechanisms at the national level or delays in bring-
ing lists of substances controlled at the national level into 
line with the schedules of the international drug control 
treaties will result in inadequate national controls being 
applied to substances under international control and 
may lead to the diversion of substances into illicit chan-
nels. The Board is therefore pleased to note that, as in 
previous years, Governments have continued to furnish 
information to the Board on legislative or administrative 
measures taken to ensure compliance with the provisions 
of the international drug control treaties. At the same 
time, the Board is concerned that some Governments 
have introduced or are planning to introduce legislative 
measures in contravention of the requirements of the 
international drug control treaties. The Board would like 
to remind Governments that in General Assembly 
 resolution S-30/1, entitled “Our joint commitment to 
effectively addressing and countering the world drug 
problem”, adopted by the Assembly on 19 April 2016, 
Member States reaffirmed their commitment to the 
goals and objectives of the three international drug 
 control conventions. 
89. In March 2019, at its sixty-second session, the 
Commission on Narcotic Drugs, by its decisions 62/1, 
62/2, 62/3 and 62/4, included four new substances in 
Schedule I of the 1961 Convention as amended, namely 
parafluorobutyrylfentanyl, orthofluorofentanyl, methoxy-
acetylfentanyl and cyclopropylfentanyl. In accordance 
with article 3, paragraph 7, of the 1961 Convention as 
amended, that decision was communicated by the 
Secretary-General to all Governments, WHO and the 
Board on 23 May 2019 and became effective with respect 
to each party upon receipt of that notification. The Board 
welcomes the efforts made by Governments that have 
already put those substances under control and urges 
all other Governments to amend the lists of substances 
controlled at the national level accordingly and to apply 
to those substances all control measures required under 
the 1961 Convention as amended.
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90. The Commission also decided to include five new 
substances in the schedules of the 1971 Convention. 
Pursuant to its decisions 62/5, 62/6, 62/7, 62/8 and 62/9, 
ADB-FUBINACA, FUB-AMB (MMB-FUBINACA, AMB-
FUBINACA), CUMYL-4CN-BINACA, ADB-CHMINACA 
(MAB-CHMINACA) and N-ethylnorpentylone (ephylone) 
were added to Schedule II of the 1971 Convention. In 
accordance with article 2, paragraph 7, of the 1971 
Convention, those decisions of the Commission were 
 communicated by the Secretary-General to all Governments, 
WHO and the Board on 23 May 2019 and became fully 
effective with respect to each party on 19 November 2019. 
The Board welcomes the efforts made by Governments 
that have already put those substances under control and 
urges all other Governments to amend their lists of 
 substances controlled at the national level accordingly, to 
apply to those substances the control measures required 
under the 1971 Convention, as well as in the relevant 
 resolutions of the Commission and the Council, and to 
inform the Board accordingly. 
91. By its decisions 62/10, 62/11, 62/12, the Commission 
added “3,4-MDP-2-P methyl glycidate” (“PMK glycidate”) 
(all stereoisomers), 3,4-MDP-2-P methyl glycidic acid 
(“PMK glycidic acid”) (all stereoisomers) and 
alpha-phenylacetoacetamide (APAA) (including its optical 
isomers) to Table I of the 1988 Convention. In accordance 
with article 12, paragraph 6, of the 1988 Convention, those 
decisions of the Commission were communicated by the 
Secretary-General to all States and other entities which are 
or which are entitled to become parties to the Convention, 
and those decisions became fully effective with respect to 
each party on 19 November 2019. Furthermore, the 
Commission also considered hydriodic acid and decided 
(decision 62/13) not to include it in the tables of the 1988 
Convention. The Board welcomes the efforts made by 
Governments that have already amended their lists of 
chemicals controlled at the national level and encourages 
Governments to use the PEN Online system for ship-
ments of these chemicals in international trade, provide 
for seizures when there is evidence of illicit use, and 
cooperate to that end with each other and with the Board 
in a timely manner.
92. In accordance with Economic and Social Council 
resolutions 1985/15, 1987/30 and 1993/38, Governments 
are required to introduce an import authorization require-
ment for zolpidem, a substance that was included in 
Schedule IV of the 1971 Convention in 2001. In response 
to the request made by the Board in its annual reports 
for 2012 and 2013 and a circular letter sent in 2016, a 
number of Governments have provided the requisite 
information. As of 1 November 2019, relevant informa-
tion was available for 134 countries and territories. Of 
those, 127 countries and territories have introduced an 
import authorization requirement, and one country (the 
United States of America) requires a pre-import declara-
tion. Three countries and one territory (Cabo Verde, New 
Zealand, Vanuatu and Gibraltar) do not require an import 
authorization for zolpidem. Imports of zolpidem into 
Azerbaijan are prohibited, and Ethiopia does not import 
the substance. At the same time, information on the con-
trol of zolpidem remains unknown for 72 countries and 
territories. The Board therefore again urges the 
Governments of countries and territories that have not 
yet done so to supply it with information on the con-
trol status of zolpidem as soon as possible. 
(b)  Prevention of diversion from 
international trade
Estimates and assessments of annual 
requirements for internationally controlled 
substances
93. The system of estimates and assessments of annual 
licit requirements for narcotic drugs and psychotropic 
substances is the cornerstone of the international drug 
control system. It enables both exporting and importing 
countries to ensure that trade in those substances stays 
within the limits determined by the Governments of 
importing countries and that diversion of controlled sub-
stances from international trade is effectively prevented. 
For narcotic drugs, such a system is mandatory under the 
1961 Convention, and the estimates furnished by 
Governments need to be confirmed by the Board before 
becoming the basis for calculating the limits on manu-
facture and import. 
94. The system of assessments of annual requirements 
for psychotropic substances was adopted by the Economic 
and Social Council in its resolutions 1981/7, 1991/44, 
1993/38 and 1996/30, and the system of annual legitimate 
requirements for selected precursors was adopted by the 
Commission on Narcotic Drugs in its resolution 49/3, to 
help Governments to prevent attempts by traffickers to 
divert internationally controlled substances into illicit 
channels. The assessments of annual legitimate require-
ments for psychotropic substances and annual legitimate 
requirements for selected precursors help Governments 
to identify unusual transactions. The diversion of drugs 
and precursors has been prevented in many cases when 
the exporting country declined to authorize the export of 
the substance because the quantities of the substance to 
be exported would have exceeded the quantities required 
in the importing country.
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95. The Board regularly investigates cases involving pos-
sible non-compliance by Governments with the system of 
estimates or assessments, given that non-compliance 
could facilitate the diversion of controlled substances 
from licit international trade into illicit channels. In that 
connection, the Board provides information, support and 
guidance to Governments on the working of the system 
for estimates or assessments, as necessary.
96. Governments are obliged to comply with the lim-
its on imports and exports of narcotic drugs provided for 
under articles 21 and 31 of the 1961 Convention. Article 
21 stipulates, inter alia, that the total of the quantities of 
each drug manufactured and imported by any country or 
territory in a given year is not to exceed the sum of the 
following: the quantity consumed for medical and scien-
tific purposes; the quantity used, within the limits of the 
relevant estimates, for the manufacture of other drugs, 
preparations or substances; the quantity exported; the 
quantity added to the stock for the purpose of bringing 
that stock up to the level specified in the relevant esti-
mate; and the quantity acquired within the limit of the 
relevant estimate for special purposes. Article 31 requires 
all exporting countries to limit the export of narcotic 
drugs to any country or territory to quantities that fall 
within the limits of the total of the estimates of the 
importing country or territory, with the addition of the 
amounts intended for re-export.
97. As in previous years, the Board finds that, in gen-
eral, the system of imports and exports continues to be 
respected and works well. In 2019, a total of nine coun-
tries were contacted regarding possible excess imports or 
excess exports identified with regard to international 
trade in narcotic drugs that had been carried out during 
the year. As at 1 November 2019, five of those countries 
had responded. One of those confirmed that excess 
exports had occurred and was reminded of the need to 
ensure full compliance with the relevant treaty provi-
sions. Two other countries reported that the drug had 
been exported to another country and subsequently 
re-exported by that country, while the last two countries 
advised that the initial reports had been incorrect and 
submitted amended statistics. The Board continues to 
pursue the matter with those countries that have not 
responded.
98. The provision of timely and accurate estimates of 
narcotic drug requirements is an essential step for 
ensuring the supply of those drugs. Underestimation 
can contribute to many problems, including shortages. 
Overestimation, on the other hand, may result in wast-
age and carries with it an increased risk of diversion of 
those drugs into illicit channels. The Board therefore 
calls upon Governments to ensure that submitted esti-
mates on requirements for narcotic drugs accurately 
reflect the actual level of narcotic drugs needed in their 
country for the calendar year.
99. Pursuant to Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of annual domestic 
medical and scientific requirements for psychotropic sub-
stances listed in Schedules II, III and IV of the 1971 
Convention. The assessments received are communicated 
to all States and territories to assist the competent author-
ities of exporting countries when approving exports of 
psychotropic substances. As at 1 November 2019, the 
Governments of all countries and territories, except for 
South Sudan, for which assessments were established by 
the Board in 2011, had submitted at least one assessment 
of their annual medical requirements for psychotropic 
substances.
100. The Board recommends that Governments review 
and update the assessments of their annual medical and 
scientific requirements for psychotropic substances at 
least every three years. However, 44 Governments have 
not submitted a revision of their legitimate requirements 
for psychotropic substances for three years or more. The 
assessments valid for those countries and territories may 
therefore no longer reflect their actual medical and 
 scientific requirements for psychotropic substances. 
101. When assessments are lower than the actual legit-
imate requirements, the importation of psychotropic sub-
stances needed for medical or scientific purposes may be 
delayed. When assessments are significantly higher than 
legitimate needs, the risk of psychotropic substances 
being diverted into illicit channels may be increased.
102. As in previous years, the system of assessments of 
annual requirements for psychotropic substances contin-
ues to function well and is respected by most countries 
and territories. In 2018, the authorities of 20 countries 
issued import authorizations for substances for which 
they had not established any such assessments or for 
quantities that significantly exceeded their assessments. 
Only two countries were identified as having exported 
psychotropic substances in quantities exceeding the rele-
vant assessment. 
103. The Commission on Narcotic Drugs, in its resolu-
tion 49/3, entitled “Strengthening systems for the control 
of precursor chemicals used in the illicit manufacture of 
synthetic drugs”, requested Member States to provide the 
Board, on a voluntary basis, with annual legitimate 
requirements for imports of four precursors of 
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amphetamine-type stimulants and, to the extent possible, 
preparations containing those substances. As at 1 November 
2019, 169 Governments had provided an estimate for at 
least one of those substances, thus providing the compe-
tent authorities of exporting countries with an indication 
of the legitimate requirements of importing countries and 
thereby preventing diversion attempts.
Requirement for import and export 
authorizations
104. The universal application of the requirement for 
import and export authorizations laid down in the 1961 
and 1971 Conventions is key to preventing the diversion 
of drugs into the illicit market. Such authorizations are 
required for transactions involving any of the substances 
controlled under the 1961 Convention or listed in 
Schedules I and II of the 1971 Convention. 
105. Competent national authorities are required by 
those Conventions to issue import authorizations for 
transactions involving the importation of such substances 
into their country. The competent national authorities of 
exporting countries must verify the authenticity of such 
import authorizations before issuing the export authori-
zations required to allow shipments containing the sub-
stances to leave their country.
106. The 1971 Convention does not require import and 
export authorizations for trade in the psychotropic sub-
stances listed in its Schedules III and IV. However, in view 
of the widespread diversion of those substances from licit 
international trade during the 1970s and 1980s, the 
Economic and Social Council, in its resolutions 1985/15, 
1987/30 and 1993/38, requested Governments to extend 
the system of import and export authorizations to cover 
those psychotropic substances as well.
107. Most countries and territories have already intro-
duced an import and export authorization requirement 
for psychotropic substances listed in Schedules III and IV 
of the 1971 Convention, in accordance with the 
above-mentioned Economic and Social Council resolu-
tions. As at 1 November 2019, specific information had 
been made available to the Board by 206 countries and 
territories, showing that all major importing and export-
ing countries now require import and export authoriza-
tions for all psychotropic substances in Schedules III and 
IV of the 1971 Convention. Twice a year, the Board dis-
seminates to all Governments a table showing the import 
authorization requirements for substances in Schedules 
III and IV pursuant to the relevant Economic and Social 
Council resolutions. That table is also published in the 
secure area of the Board’s website, which is accessible only 
to specifically authorized government officials, so that the 
competent national authorities of exporting countries 
may be informed as soon as possible of changes in import 
authorization requirements in importing countries. The 
Board urges the Governments of the few remaining 
States in which national legislation and/or regulations 
do not yet require import and export authorizations for 
all psychotropic substances, regardless of whether they 
are States parties to the 1971 Convention, to extend such 
controls to all substances in Schedules III and IV of the 
1971 Convention as soon as possible, and to inform the 
Board in that regard.
108. While the 1988 Convention does not have a 
requirement for import and export authorizations for 
trade in substances listed in Tables I and II of that 
Convention, Governments that do not apply some system 
of control over exports and imports of precursors are not 
fully complying with their treaty obligation to effectively 
contribute to the prevention of diversion. Under the 
Convention, countries are also requested to provide 
advance notification of planned shipments to the author-
ities of the importing Government with a view to pre-
venting the diversion of those substances (see para. 128 
below regarding pre-export notifications for precursor 
chemicals).
International electronic import and export 
authorization system for narcotic drugs and 
psychotropic substances
109. Pursuant to article 31 of the 1961 Convention as 
amended, article 12 of the 1971 Convention and relevant 
resolutions of the Economic and Social Council, interna-
tional trade in narcotic drugs and psychotropic sub-
stances requires both import and export authorizations. 
Given the growing volume of licit trade in internation-
ally controlled substances, which leads to an increasing 
workload for competent national authorities, it is essen-
tial to modernize the import and export authorization 
system in order to reduce the risk of diversion while con-
tinuing to ensure the adequate availability of and access 
to those substances. 
110. As part of its endeavours to harness technological 
progress for the effective and efficient implementation of 
the import and export authorization regime for licit inter-
national trade in narcotic drugs and psychotropic sub-
stances, the Board has spearheaded efforts to develop an 
electronic tool, I2ES, to facilitate and expedite the work 
of competent national authorities and to reduce the risks 
of diversion of narcotic drugs and psychotropic 
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substances. I2ES is an innovative, web-based application 
that was developed by the Board in cooperation with 
UNODC and with the support of Member States. I2ES 
was designed to promote paperless trade in internation-
ally controlled substances by facilitating the online 
exchange of import and export authorizations and enables 
Governments to generate electronically import and export 
authorizations for licit imports and exports of narcotic 
drugs and psychotropic substances, to exchange those 
authorizations in real time and to verify instantly the 
legitimacy of individual transactions while ensuring full 
compliance with the requirements of the international 
drug control conventions.
111. In March 2019, a user-group meeting was held on 
the margins of the sixty-second session of the Commission 
on Narcotic Drugs to gather feedback on I2ES. More than 
25 officials from 19 countries participated in that meet-
ing. The meeting afforded government officials of partic-
ipating countries a valuable opportunity to exchange 
ideas on bringing about the fuller implementation of I2ES 
and to provide feedback to INCB and the information 
technology service of UNODC to guide future action and 
the further development of the system. The user group 
emphasized the importance of sharing the experiences of 
competent national authorities from different parts of the 
world with other users and potential users as a way of 
promoting greater usage of the system.
112. Available to all Governments free of charge, I2ES 
serves as a safe and secure platform for generating and 
exchanging import and export authorizations between 
trading countries, and its user-friendly interface helps 
competent national authorities to reduce errors in data 
entry and save time and communication costs. 
113. The estimates of requirements of narcotic drugs 
and the assessments of psychotropic substances estab-
lished by States parties and endorsed by the Board are 
automatically synchronized with I2ES. After an import 
authorization has been approved, the system calculates in 
real time the remaining balance of the estimates or assess-
ments available to the importing country. Trading part-
ners registered with the platform can access that 
information at any time. Authorities of the trading coun-
tries can also use the system to securely communicate 
and exchange information directly with their counter-
parts if a transaction request requires further 
clarification.
114. Unlike paper-based systems, in which authoriza-
tions can be further processed only after their physical 
delivery and receipt, the online exchange of import and 
export authorizations using I2ES enables the 
instantaneous transfer of data between trading countries, 
thus facilitating a much faster approval process. To pro-
vide a fully electronic and paperless international trade 
system, the Board established the possibility for 
Governments to use electronic signatures along with the 
import and export authorizations processed through the 
system.
115. In the outcome document of the thirtieth special 
session of the General Assembly, entitled “Our joint com-
mitment to effectively addressing and countering the 
world drug problem”,55 Heads of State and Government 
recommended expediting the process of issuing import 
and export authorizations for licit international trade on 
narcotic drugs and psychotropic substances by using I2ES.
116. Through its resolutions 55/6, 57/10, 58/10 and 
61/5, the Commission on Narcotic Drugs set out actions 
to further the establishment of an import and export 
authorization system, and invited the secretariat of INCB 
to administer and monitor I2ES and report on the prog-
ress made on its implementation. 
117. As at 1 November 2019, nearly five years after the 
launch of I2ES, the Board notes that 66 Governments 
have registered with I2ES, of which 50 Governments have 
an active administrator account, an increase of 20 per 
cent compared with last year, at 1 November 2018. More 
than one fifth of those countries entered data in the sys-
tem in 2019.
118. In order to encourage the adoption of I2ES among 
Member States, INCB carried out multiple activities in 
2019 to: (a) raise awareness of the system; and (b) improve 
the technical capabilities of competent national 
authorities. 
119. In June, an on-site training session took place in 
Quito, during an INCB Learning workshop, in which 
I2ES was presented to eight countries56 of the Latin 
America and the Caribbean region. In July, the system 
was also introduced to officials representing 13 countries 
of Central, Eastern and South-Eastern Europe, the 
Caucasus and Central Asia during a workshop on prohi-
bitions, licensing and other quantitative restrictions on 
international trade, hosted in Vienna by the World Trade 
Organization.
120. Recognizing the limitations making it impossible 
to physically reach all countries worldwide that require 
55 General Assembly resolution S-30/1, annex.
56 Argentina, Brazil, Chile, Colombia, Costa Rica, the Dominican 
Republic, Ecuador and Peru.
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technical expertise on I2ES, and being aware of the pos-
sibilities of new communication technologies for deploy-
ing training in a fast and convenient manner, the Board, 
through its secretariat, conducted seven webinars for 
more than 16 countries57 in Africa, the Americas, Asia 
and Europe. Further Member States have expressed an 
interest in training activities of that type, and accordingly, 
more online training sessions are planned. 
121. The efforts carried out by the Board can be rein-
forced and complemented only with the continuous com-
mitment of Member States in supporting the adoption of 
I2ES as the unequivocal choice of a digital international 
trade system for controlled substances. At its sixty-first 
session, the Commission on Narcotic Drugs, in its reso-
lution 61/5, invited Member States to maintain that com-
mitment and invited them to consider what further 
measures should be adopted for the continuing adminis-
tration and further development of I2ES.
122. A multilingual user interface would ease the adop-
tion of I2ES in countries and regions where English is 
not a widespread language. The possibility of adding 
nationally controlled substances in the import authoriza-
tions processed via I2ES would enable competent national 
authorities to comply with domestic legal obligations and 
avoid the burden at the operational level of running two 
parallel systems, one for nationally controlled substances 
and another for internationally controlled substances. In 
addition, the trading data stored in I2ES could be 
exported for post-processing purposes, which would help 
competent authorities to expedite reporting to INCB on 
substances controlled under the international drug con-
trol treaties.
123. At the same time, know-how at the operational 
level and commitment to use I2ES at the decision-making 
level continue to be significant barriers to be overcome. 
The Board reiterates its commitment to working hand in 
hand with Member States on activities that encourage 
the wider adoption of the system and greater user 
engagement.
124. The Board encourages all Member States to con-
tact its secretariat to discuss challenges they face in imple-
menting the system and jointly develop strategies setting 
out the concrete steps to achieve a road map that inte-
grates I2ES into nationwide governmental procedures and 
policies for supervising the control of narcotic drugs and 
psychotropic substances.
57 Afghanistan, Argentina, Brazil, Chile, Colombia, Costa Rica, the 
Dominican Republic, Ecuador, Estonia, Indonesia, Kenya, Panama, 
Paraguay, Peru, Qatar and the United Arab Emirates.
125. The Board also invites Member States that are 
already using I2ES to share their experiences and exper-
tise with the Board and other Governments, in particu-
lar, their trading partners that are not currently using the 
platform. Member States are invited to express their views 
on I2ES in regional meetings for drug control and health 
monitoring and engage with their counterparts to facili-
tate an active cooperation that expands adoption of the 
system.
126. It is essential for Governments and the Board to 
continue their cooperation to implement I2ES in order 
to fully realize the benefits of the platform and facilitate 
the more rapid trade of internationally controlled 
substances.
127. INCB encourages Governments that have not 
done so yet to request the assistance of the INCB sec-
retariat to implement and integrate I2ES in their 
national systems, including through the provision of 
guidance on first steps and additional training. The 
Board also invites Governments that actively use I2ES 
to engage with their trading partners that do not use 
I2ES, with the assistance of the INCB secretariat if 
required, to facilitate the adoption of the platform. 
Lastly, the Board encourages Member States to provide 
additional support, including extrabudgetary resources, 
to expand the functionalities of I2ES and hasten the 
adoption of the platform.
Pre-export notifications for precursor chemicals
128. To assist importing and exporting Governments in 
communicating with each other in real time as regards 
international trade in precursors and to provide alerts 
about any suspicious transactions, in 2006, the Board 
established a secure web-based tool, PEN Online. As at 
1 November 2019, two additional countries, Angola and 
North Macedonia, had registered with PEN Online, 
bringing the total number of registered countries and ter-
ritories to 164. INCB urges the remaining Governments 
that have not yet registered with the PEN Online sys-
tem to do so as soon as possible and calls upon 
Governments to use PEN Online actively and systemat-
ically. The Board stands ready to assist Governments in 
that regard.
129. To prevent the diversion of precursors, article 12, 
paragraph 10 (a), of the 1988 Convention allows the 
Governments of importing countries to make it manda-
tory for exporting countries to inform them of any 
planned export of precursors to their territory. Since the 
last issue of the annual report of the Board, no additional 
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Government has officially requested to be pre-notified, 
thus leaving the number of Governments that have 
invoked that provision unchanged at 113. The Board 
encourages those Governments that have not formally 
requested pre-export notifications to invoke article 12, 
paragraph 10 (a), of the 1988 Convention.
130. INCB, in its efforts to support Governments in the 
prevention and investigation of cases of diversion and 
trafficking of precursors, pre-precursors and other sub-
stances not yet under international control, has developed 
several online platforms, tools and projects to facilitate 
the real-time exchange of information between 
Governments. The two initiatives of the Board focusing 
on precursors used in the illicit manufacture of synthetic 
drugs and on chemicals related to the illicit manufacture 
of cocaine and heroin, namely Project Prism and Project 
Cohesion, respectively, have also contributed to prevent-
ing the diversion of controlled substances from interna-
tional trade and national distribution channels and to 
closing knowledge gaps during time-bound operations. 
The Board’s new Global Rapid Interdiction of Dangerous 
Substances (GRIDS) programme consolidates those suc-
cessful operational initiatives under Project Ion (2013) 
and the global OPIOIDS project (2017). GRIDS and the 
Board’s ongoing public-private partnerships support gov-
ernment activities aimed at preventing the diversion of, 
and trafficking in, fentanyl-related substances and other 
dangerous substances of abuse not yet under international 
control.
(c)  Effectiveness of the control measures 
aimed at preventing the diversion 
of controlled substances from 
international trade 
131. The system of control measures laid down in the 
1961 Convention provides for the monitoring of interna-
tional trade in narcotic drugs to prevent the diversion of 
such drugs into illicit channels. Similarly, as a result of the 
almost universal implementation of the control measures 
stipulated in the 1971 Convention and the relevant 
Economic and Social Council resolutions, there have been 
no identified cases involving the diversion of psychotropic 
substances from international trade into illicit channels in 
recent years. In addition, the 1988 Convention requires 
parties to prevent the diversion of precursor chemicals 
from international trade to the illicit manufacture of nar-
cotic drugs and psychotropic substances. The Board has 
also developed various systems to monitor compliance 
with that aspect of the 1988 Convention and to facilitate 
cooperation between Governments to that end. 
132. Discrepancies in government reports on interna-
tional trade in narcotic drugs and psychotropic sub-
stances are regularly investigated with the competent 
authorities of the relevant countries to ensure that no 
diversion of narcotic drugs and psychotropic substances 
from licit international trade takes place. Those investi-
gations may reveal shortcomings in the implementation 
of control measures for narcotic drugs and psychotropic 
substances, including the failure of companies to comply 
with national drug control provisions.
133. Since May 2019, investigations regarding discrep-
ancies for 2018 related to the trade in narcotic drugs have 
been initiated with 56 countries. As at 1 November 2019, 
replies had been received from 33 countries. The responses 
indicated that the discrepancies had been caused by cler-
ical and technical errors in preparing the reports, report-
ing on exports or imports of preparations listed in 
Schedule III of the 1961 Convention without indicating 
it on the form, or inadvertent reporting of transit coun-
tries as trading partners. In some cases, countries con-
firmed the quantities reported by them, resulting in the 
initiation of follow-up investigations with their trading 
partners. Reminder letters will be sent to the countries 
that did not reply.
134. Similarly, with regard to international trade in psy-
chotropic substances, investigations into 293 discrepan-
cies related to 2018 data were initiated with 66 countries. 
As at 1 November 2019, 24 countries had provided replies 
relating to those discrepancies, leading to the resolution 
of 29 of those discrepancies. In all cases in which the data 
provided were confirmed by the responding countries, 
follow-up actions with the counterpart countries were ini-
tiated as required. All the responses received indicated 
that the discrepancies had been caused by clerical or tech-
nical errors: in most cases, either the failure to convert 
amounts into anhydrous base or “overlapping”, i.e., an 
export in a given year being received by the importing 
country only at the beginning of the following year. None 
of the cases investigated indicated a possible diversion of 
psychotropic substances from international trade.
135. With regard to precursors, the 1988 Convention 
requires parties to prevent the diversion of precursors 
from international trade to the illicit manufacture of nar-
cotic drugs and psychotropic substances. In line with the 
provisions of article 12 of the 1988 Convention, which 
have been complemented by a number of General 
Assembly, Economic and Social Council and Commission 
on Narcotic Drugs resolutions, many Governments have 
adopted and implemented measures that have contrib-
uted to the effective monitoring of the movement of sub-
stances listed in Tables I and II of that Convention and 
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to limiting cases of diversion from licit international 
trade. As a result, Governments are facing new challenges, 
including the emergence of non-scheduled chemicals and 
diversion of substances listed in Tables I and II from 
domestic distribution channels. To assist the timely pre-
vention of precursors diversion, voluntary public-private 
partnerships based on shared goals and responsibility 
and formalized through agreements have an increasingly 
important role to play. More information on the 
public-private partnerships initiative in preventing diver-
sion of precursor chemicals is contained in the report of 
the Board on the implementation of article 12 of the 1988 
Convention.58 
(d)  Prevention of diversion of precursors 
from domestic distribution channels
136. In recent years, the Board has observed a shift in 
the diversion of precursors from international to domes-
tic trade between users located on territory within the 
same national borders. Diversion of precursors from 
domestic distribution channels remains a major source of 
substances listed in Tables I and II of the 1988 Convention 
that are used for illicit drug manufacture, as the control 
measures applied by Governments to domestic trade in 
and distribution of chemical substances vary from one 
country to another and often fall short of those used in 
international trade.
137. INCB, in its efforts to support Governments in the 
prevention and investigation of cases of diversion of pre-
cursors, has developed several online platforms, tools and 
projects to facilitate real-time exchange of information 
between Governments. The two initiatives of the Board 
focusing on precursors used in the illicit manufacture of 
synthetic drugs and on chemicals related to illicit cocaine 
and heroin manufacture, namely Project Prism and 
Project Cohesion, respectively, have also contributed to 
preventing the diversion of controlled substances from 
international trade and from domestic distribution chan-
nels and to closing knowledge gaps during time-bound 
operations. 
138. Detailed analysis of the latest trends and develop-
ments in legitimate international trade and in trafficking 
in precursor chemicals under international control, as 
well as their non-scheduled substitutes and alternatives, 
can be found in the report of the Board for 2019 on the 
implementation of article 12 of the 1988 Convention. 
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2.  Ensuring the availability of 
internationally controlled 
substances for medical and 
scientific purposes
139. In line with its mandate to ensure the availability 
of internationally controlled substances for medical and 
scientific purposes, the Board carries out various activi-
ties related to narcotic drugs and psychotropic substances. 
The Board monitors action taken by Governments, inter-
national organizations and other bodies to support the 
availability and rational use of controlled substances for 
medical and scientific purposes and provides, through its 
secretariat, technical support and guidance to Governments 
in their implementation of the provisions of the interna-
tional drug control treaties.
140. The lack of availability of controlled narcotic drugs 
and psychotropic substances for legitimate medical use 
continues to represent a pressing public health problem 
in many regions of the world, a situation that has often 
been falsely attributed to the control requirements of the 
international drug control framework. In many States, 
access to and the availability of controlled medicines have 
been hindered by the lack of capacity and training of 
national officials, weak and underresourced health-care 
systems, a lack of know-how for accurately evaluating the 
needs of the population, inadequate regulation and too 
few and insufficiently trained health-care professionals. 
The Board has provided information and recommenda-
tions on the availability of controlled substances for med-
ical purposes in the supplement to its annual report for 
2018.59
141. The Board renews its call to Governments to 
 foster access to and the availability of narcotic drugs and 
psychotropic substances for medical use through 
improved access to health services and effective systems 
of administrative controls that regulate the production, 
manufacture, import and export of such drugs and 
 substances, keeping in mind that States themselves must 
adequately evaluate their domestic requirements and 
report them to INCB.
142. Governments need to address capacity and 
resource constraints in health-care services, especially in 
the field of pain management, including by increasing 
the availability and know-how of health-care profession-
als, such as doctors, nurses, pharmacists and regulators. 
Medical practitioners should be adequately trained in 
the prescription of medicines to those who genuinely 
59 E/INCB/2018/1/Supp.1.
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need them and should be able to prescribe medicines 
without fear of sanction or prosecution.
143. INCB continues to analyse the availability of pain 
relief medicines on the basis of the consumption of the 
main opioid analgesics (codeine, fentanyl, hydrocodone, 
hydromorphone, morphine and oxycodone), expressed in 
defined daily doses for statistical purposes (S-DDD).60
144. Countries reporting the highest average consump-
tion of opioids for pain management in the period 2016–
2018 were the United States (27,641 S-DDD), Germany 
(24,983 S-DDD), Austria (20,452 S-DDD), Canada 
(16,617 S-DDD) and Belgium (15,910 S-DDD).
145. A comparison of the trends in the consumption of 
individual substances is provided in figures IV and V. It 
is evident that there was an exponential increase in the 
consumption of fentanyl over the 20-year period 1999–
2018. Compared with fentanyl, the consumption of oxy-
codone was at a lower level; however, it was increasing 
and, in 2009, it replaced morphine as the second most 
consumed opioid, reaching an all-time high of 45,717 
S-DDD in 2018. The trend in the use of morphine, how-
ever, remained relatively stable after the late 1990s. In 
2018, consumption of morphine increased slightly 
60 The list of defined daily doses for statistical purposes (S-DDD) and 
an explanation of that concept are contained in the notes to tables 
XIV.1.a-i, XIV.2 and XIV.3 of the technical report of the Board for 2019 on 
narcotic drugs (E/INCB/2019/2).
compared with the level of 2017, from 29,061 to 29,142 
S-DDD. Hydrocodone consumption increased for some 
years but recently started to decline. Hydromorphone 
consumption decreased after 2014, reaching in 2018 a 
level of 14,160 S-DDD, the lowest level since 2002. The 
United States accounted for 99.2 per cent of hydrocodone 
consumption, whereas the consumption of fentanyl was 
not concentrated in one country. Although the consump-
tion of fentanyl decreased globally in 2017, especially in 
North America, there were significant increases in vari-
ous countries in all other regions.
146. Regional analysis confirms the disparity in the con-
sumption of opioid analgesics (see figures VI and VII). 
The reported consumption of countries in North America, 
Oceania and Western Europe resulted in regional aver-
ages of over 7,000 S-DDD (17,436, 7918 and 12,335 
S-DDD, respectively). The analysis in figures VI and VII 
of the 20-year trend shows in 2017 and 2018 a sharp 
decrease in consumption, expressed in defined daily doses 
for statistical purposes, in North America, the region with 
highest consumption of opioids for pain management in 
the world. This decrease was driven mainly by the 
United States. In Oceania, consumption, which had been 
declining since 2012, was reported to have increased in 
2017, to 9,065 S-DDD. In 2018, however, the declining 
trend continued, reaching 7,918 S-DDD. The general 
upward trend in consumption is evident in South-Eastern 
Europe and Western Europe.
Figure IV. Consumption of codeine, fentanyl, 
hydrocodone, hydromorphone, morphine and 
oxycodone, expressed in S-DDD, 1999–2018 
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Figure V. Consumption of codeine, 
hydrocodone, hydromorphone, morphine and 
oxycodone, (excluding fentanyl), expressed in 
S-DDD, 1999–2018
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147. Average consumption well below those values was 
reported in other regions. A long-term trend of increased 
consumption was reported in all regions except Africa 
and South Asia. 
148. Figures VIII and IX show for 2018 the average 
consumption of opioid analgesics, expressed in defined 
daily doses for statistical purposes, in all regions (see fig-
ure VIII) and in all regions except North America, 
Western Europe and Oceania (see figure IX), where the 
average consumption of analgesics is most concentrated. 
This analysis highlights once again the prominence of fen-
tanyl in various regions of the world. Oxycodone con-
sumption is more concentrated in North America, 
Figure VI. Average consumption of opioids for 
pain management in regions with the highest 
consumption, expressed in S-DDD, 1999–2018
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Figure VII. Average consumption of opioids for 
pain management in the regions with the 
lowest consumption, expressed in S-DDD, 
1999–2018 
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Figure VIII. Average consumption of codeine, 
fentanyl, morphine, pethidine and other 
opioids, by region, expressed in S-DDD, 2018 
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Figure IX. Average consumption in selected 
regions of codeine, fentanyl, morphine, 
pethidine and other opioids, expressed in 
S-DDD, 2018
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Western Europe and Oceania, although it is also con-
sumed in other regions, such as West Asia, Central 
America and the Caribbean, and South-Eastern Europe. 
The share of morphine is less prominent in most regions, 
the exceptions being Africa, Central America and the 
Caribbean, and South America. 
149. To supplement and increase the effectiveness of the 
action mentioned above, in 2016, the Board launched a 
project called INCB Learning. The project provides assis-
tance to Member States in their efforts to achieve full 
compliance with the provisions of the international drug 
control treaties. One of the objectives of the project is to 
ensure the appropriate availability of internationally con-
trolled substances, while preventing their abuse and 
diversion into illicit channels. Several regional training 
seminars were conducted in 2019 (see paras. 215–230 
below for details). 
3.  Patterns and trends in the 
production, manufacture, 
consumption, use and stocks of 
narcotic drugs and psychotropic 
substances during 2018 
Narcotic drugs 
150. After a sharp increase in 2017, the stocks and pro-
duction of opium decreased in 2018, thus resuming the 
overall downward trend of the previous 20 years and fur-
ther signalling the eventual elimination of opium from 
the international market for opiate raw materials. 
However, use and imports increased in 2018.
151. Overall, the use of poppy straw and concentrate of 
poppy straw derived from the morphine-rich variety of 
poppy straw decreased in 2018 compared with 2017. With 
fewer than 400 tons in 2018, the global manufacture of 
morphine followed the trend initiated in 2017, contrary to 
the situation of the previous 10 years, when the global 
annual manufacture of morphine was always above 
400 tons. More than 80 per cent of the global manufacture 
of 388.2 tons in 2018 was converted into other narcotic 
drugs or substances not covered by the 1961 Convention 
as amended. Of the remaining amount, some 8 per cent 
was used mainly for palliative care purposes and the rest 
for preparations listed in Schedule III of the Convention.
152. There continued to be very significant differences in 
consumption levels among countries (see figure X). In 
2018, 79 per cent of the world’s population, living mainly 
in low- and middle-income countries, consumed only 
13 per cent of the total amount of morphine used for the 
management of pain and suffering, that is, 1 per cent of 
the morphine manufactured worldwide. While this rep-
resents an improvement over 2014, when 80 per cent of 
the world’s population consumed only 9.5 per cent of the 
morphine used for that purpose, the disparity in the con-
sumption of narcotic drugs for palliative care continues to 
be a matter of concern.
153. The use of poppy straw rich in thebaine increased 
in 2018, while that of concentrate of poppy straw rich in 
thebaine decreased. At 127.7 tons, the global manufac-
ture of thebaine remained high but considerably below 
the record level of 156 tons in 2016. The demand for med-
icines derived from thebaine may have been affected by 
the restrictions on prescription drugs imposed in the 
United States, which is the main market, in response to 
the abuse of such drugs and the high number of over-
dose deaths caused by them. Nonetheless, the data con-
tinued to indicate a high level of demand. 
154. With regard to semi-synthetic opioids, the global 
manufacture of oxycodone and hydrocodone decreased 
in 2018, while the manufacture of other such opioids 
remained relatively stable.
155. With regard to synthetic opioids, the global man-
ufacture of fentanyl continued to fluctuate, with a 
Note: The percentages in parentheses refer to the share in the world’s 
population of all countries that submitted data on morphine 
consumption. 
Figure X. Morphine: distribution of 
consumption, 2018
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substantive decrease to 1.9 tons in 2018 (see figure XI). 
However, the manufacture of all fentanyl analogues 
(alfentanil, remifentanil and sufentanil) increased. There 
was no report of manufacturing of dextropropoxyphene 
in 2018, while that of ketobemidone was reported after 
a gap of some years in the manufacture of that substance. 
Diphenoxylate continued to be manufactured in much 
smaller quantities than in the past. The manufacture of 
tilidine decreased further in 2018, reaching a record low 
of 27 tons. The manufacture of pethidine and trimeper-
idine continued to fluctuate, increasing in 2018 after hav-
ing decreased in 2017. The manufacture of methadone 
remained relatively stable in 2018.
156. The licit use of cannabis has increased consider-
ably since 2000. Before 2000, the licit use of cannabis was 
restricted to scientific research and reported only by the 
United States. Since 2000, however, more and more coun-
tries have started to use cannabis and cannabis extracts 
for medical purposes, as well as for scientific research. In 
2000, the total licit production of cannabis was 1.4 tons, 
while it had increased to 289.5 tons in 2018. Since the 
licit cultivation of cannabis for medical and scientific pur-
poses has increased considerably in recent years, and the 
yield and manufacturing processes are not standardized, 
some data are being clarified with the relevant 
Governments to ensure consistency.
157. Peru has been the only country that exports coca 
leaf for the global market since 2000. Its exports amounted 
to 127.8 tons in 2018. The United States was the leading 
importing country, with 148.3 tons of coca leaf, and 
accounted for nearly 100 per cent of global imports.
158. The other major licit producer of coca leaf, the 
Plurinational State of Bolivia, accounted for 92 per cent 
of global production. The cultivation of coca bush for 
the chewing of coca leaf and the consumption and use 
of coca leaf in its natural state for cultural and  medicinal 
purposes, such as infusions, are allowed in that country 
in accordance with the reservation that it entered in 2013 
when it reacceded to the 1961 Convention as amended.
159. The licit manufacture of cocaine continued to fluc-
tuate, as it has done for more than 20 years. In 2018, the 
global manufacture of cocaine decreased by more than 
half compared with 2017. However, the licit consumption 
of cocaine, which had been stable for 20 years, nearly 
doubled in 2018 compared with 2017, reaching a record 
high of 394.1 kg. 
160. A detailed analysis of the patterns and trends in 
the production, manufacture, consumption, use and 
stocks of narcotic drugs is contained in the technical 
report of the Board for 2019 on narcotic drugs.61
Psychotropic substances
161. The controls on psychotropic substances expanded 
to six new substances at the end of 2018 with the addi-
tion of five synthetic cannabinoids (AB-CHMINACA, 
5F-MDMB-PINACA (5F-ADB), AB-PINACA, UR-144 
and 5F-PB-22) and of 4-fluoroamphetamine (4-FA), 
bringing the total number of psychotropic substances 
under international control to 144. As with other recently 
controlled synthetic cannabinoids and cathinones, the 
licit market activity of these substances is extremely lim-
ited, with manufacture and trade not exceeding one gram 
and intended for standard setting or forensic purposes.
162. As in previous years, benzodiazepines accounted 
for most of the manufacture of, trade in and consump-
tion of internationally controlled psychotropics in 2018. 
Overall, the major manufacturers of benzodiazepines 
continued to be Italy, India, China, Brazil and Germany, 
accounting for more than 90 per cent of total global man-
ufacture (see figure XII). During 2018, the most traded 
benzodiazepines worldwide were diazepam, midazolam, 
alprazolam, clonazepam and lorazepam, in descending 
order. The total global manufacture of benzodiazepines 
61 E/INCB/2019/2.
Figure XI. Fentanyl: global manufacture, 
consumption and stocks,a 1999–2018
 0
1
2
3
4
5
6
99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18
Stocks Manufacture Consumption
Year
Tons
a Stocks as at 31 December of each year.
30  INCB REPORT 2019
increased by 24 per cent compared with 2017, amount-
ing to 199 tons. 
163. More than 100 countries reported the consump-
tion of at least one benzodiazepine, representing a signif-
icant increase compared with 2017, when 82 countries 
reported such consumption. Europe and the Americas 
had the highest rate of countries reporting the consump-
tion of benzodiazepines, followed by Asia, Oceania and 
Africa. Alprazolam has been the most consumed benzo-
diazepine for the past five years, with more than 70 coun-
tries reporting its consumption in 2018. In 2018, 
11 countries reported consumption higher than 10 S-DDD 
per 1,000 inhabitants per day, while 25 countries reported 
the consumption of more than two S-DDD per 1,000 
inhabitants per day. The consumption of diazepam, a sub-
stance included on the WHO Model List of Essential 
Medicines, was reported by 92 countries in 2018, with 
countries in Europe and the Americas having the high-
est levels of reported consumption.
164. Phenobarbital, a substance included on the WHO 
Model List of Essential Medicines for treating epilepsy, is 
one of the most traded internationally controlled psycho-
tropic substances, with more than 161 countries report-
ing imports of the substance in 2018. China is the lead 
manufacturing country of phenobarbital, having pro-
duced 154 tons in 2018, followed by India and Hungary, 
at 87.2 tons and 32.3 tons, respectively.
165. Phenobarbital, which is widely traded, along with 
some benzodiazepines, is one of the most consumed 
internationally controlled psychotropic substances. 
Nonetheless, regional disparities regarding the consump-
tion of phenobarbital have persisted over the past five 
years, with Europe and the Americas reporting the high-
est levels of consumption (see figure XIII). Some of the 
disparities may be attributed to the lack of consumption 
data from countries that report imports of the 
substance.
166. The manufacture of methylphenidate dropped 
from 70.6 tons in 2017 to 62.7 tons in 2018, while imports 
of the substance rose from 32.5 tons to 42.9 tons over the 
same period. The decrease is due to a drop in manufac-
ture in Switzerland, the United Kingdom of Great Britain 
and Northern Ireland and the United States. More than 
120 countries reported importing methylphenidate in 
2018, a new high since the substance has been under 
international control. Overall, the market activity of 
methylphenidate has seen a steady rise over the past 
10  years, with total global imports in 2018 being more 
than twice those of 2009 (see figure XIV).
167. Along with the increase in the manufacture of, 
trade in and stocks of methylphenidate in the past 
10  years, global consumption levels of the substance 
have also risen and consumption was reported by 67 
countries in 2018. Some of the highest levels of con-
sumption were reported in northern Europe, with 
Iceland reporting a consumption of 29 S-DDD per 1,000 
inhabitants per day. High levels of consumption were 
also reported in North America and other parts of 
Figure XII. Benzodiazepines with significant 
presence on the licit market: share of global 
manufacture by country, 2018 
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Figure XIII. Phenobarbital: total global 
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Europe. Total consumption of methylphenidate of all 
reporting countries has risen since 2014 and has been 
more than 115 S-DDD per 1,000 inhabitants per day 
since 2016. 
168. A detailed analysis of the patterns and trends in 
the production, manufacture, consumption, use and 
stocks of psychotropic substances is contained in the 
technical report of the Board for 2019 on psychotropic 
substances.62
Supply of and demand for opiate raw 
materials
169. The Board, in fulfilment of the functions assigned 
to it under the 1961 Convention as amended and the rel-
evant resolutions of the Economic and Social Council and 
the Commission on Narcotic Drugs, regularly examines 
issues affecting the supply of and the demand for opiates 
for licit requirements and endeavours to ensure a stand-
ing balance between that supply and demand. 
170. The Board analyses the data provided by Governments 
on opiate raw materials and opiates manufactured from 
those raw materials to establish the status of the supply of 
and the demand for opiate raw materials globally. In addi-
tion, the Board analyses information on the use of those 
raw materials, estimated consumption for licit use and 
62 E/INCB/2019/3.
stocks at the global level. A detailed analysis of the current 
situation as it pertains to the supply of and the demand 
for opiate raw materials is contained in the technical report 
of the Board for 2019 on narcotic drugs.
171. The combined total area of cultivation of opium 
poppy rich in morphine and opium poppy rich in the-
baine increased by a significant 32 per cent in 2018, com-
pared with 2017. Over the same period, however, the 
production of opiate raw materials rich in morphine and 
opium raw materials rich in thebaine showed an increase 
of only 8 per cent and 0.4 per cent, respectively. 
Morphine
172. The total actual harvested area of opium rich in 
morphine increased from 44,024 ha in 2017 to 60,418 ha 
in 2018. Compared with 2017, the actual harvested area 
increased by 90 per cent in Turkey, 15 per cent in France 
and 1 per cent in Spain, while it decreased by 74 per cent 
in Hungary, 46 per cent in India and 7 per cent in 
Australia. India is the only opium-producing country 
included in the present analysis. Australia and Spain were 
the only two countries that cultivated opium poppy rich 
in codeine in 2018. The harvested area with this variety 
increased considerably in Australia, from 960 ha in 2017 
to 2,683 ha in 2018. In Spain, the harvested area of opium 
poppy rich in codeine was 1,990 ha in 2018, which was 
slightly lower than in 2017, when it reached 2,001 ha. 
173. The global production of morphine-rich opiate raw 
materials in the main producing countries increased to 
304 tons in morphine equivalent in 2018, compared with 
282 tons in 2017. Turkey was the largest producer, with 
102 tons in morphine equivalent, followed by Australia, 
France, Spain, India and Hungary. The production in Turkey 
in 2018 increased by 85 per cent compared with 2017, 
mostly because of the increase in the harvested area of 
opium poppy rich in morphine. Australia, France, Turkey 
and Spain accounted for 88 per cent of global production 
in 2018. 
174. At the end of 2018, the global stock of opiate raw 
materials rich in morphine, which includes poppy straw, 
concentrate of poppy straw and opium, amounted to 
564 tons in morphine equivalent, a decrease from 650 tons 
at the end of 2017. Those stocks were considered to be suf-
ficient to cover 18 months of expected global demand by 
manufacturers, on the basis of advance data for the level 
of demand in 2019 (see figure XV). In 2018, Turkey con-
tinued to be the country with the largest stocks of opiate 
raw materials rich in morphine, with 161 tons in morphine 
equivalent, mainly in the form of poppy straw and 
Figure XIV. Methylphenidate: global 
manufacture, imports and stocks, 2009–2018 
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concentrate of poppy straw, followed by Spain (78 tons), 
France (73 tons), India (58 tons, all in the form of opium), 
Australia (57 tons), the United Kingdom (54 tons), the 
United States (43 tons), Slovakia (21 tons), Japan (18 tons) 
and Belgium (7 tons). Together, those 10 countries 
accounted for 99.8 per cent of the global stock of opiate 
raw materials rich in morphine. The remaining stocks were 
held in other producing countries and in countries import-
ing opiate raw materials. 
175. At the end of 2018, global stocks of opiates based 
on morphine-rich raw materials, mainly in the form of 
codeine and morphine, amounted to 484 tons in mor-
phine equivalent. This was considered sufficient to cover 
global demand for about 19 months. On the basis of data 
reported by Governments, it appears that total stocks of 
both opiates and opiate raw materials are amply sufficient 
to cover demand for medical and scientific purposes.
176. From 2009 to 2016, the global production of opi-
ate raw materials rich in morphine exceeded global 
demand, with a resulting increase in stocks, with some 
fluctuations. However, since 2017, production has been 
lower than demand. The production amount in 2018 con-
tinued to be lower than demand, which again led to a 
decrease in stocks (to 564 tons in morphine equivalent) 
at the end of the year. 
Thebaine
177. The total actual harvested area of opium poppy 
rich in thebaine decreased slightly from 2017 to 2018, 
from 9,819 ha to 9,755 ha. The area decreased by 77 per 
cent in France but increased by 56 per cent in Australia 
and 1.4 per cent in Spain. Hungary stopped cultivating 
this variety in 2018.
178. In 2018, the global production of opiate raw mate-
rials rich in thebaine was 230 tons in thebaine equiva-
lent, of which Australia accounted for about 90 per cent, 
followed by Spain (4 per cent), France (3 per cent) and 
India (2 per cent). The remaining 1 per cent was held by 
other countries. The production of opium poppy rich in 
thebaine was almost equivalent to that of 2017. 
179. Stocks of opiate raw materials rich in thebaine, 
namely, poppy straw, concentrate of poppy straw and 
opium, decreased to 235 tons in thebaine equivalent at 
the end of 2018, from 244 tons at the end of 2017. Those 
stocks are considered sufficient to cover the expected 
global demand by manufacturers for about 18 months 
(see figure XVI). 
180. The global stock of thebaine-based opiates (oxyco-
done, thebaine and a small quantity of oxymorphone) 
amounted to 248 tons in thebaine equivalent at the end 
Figure XV. Production of and demand for 
opiate raw materials rich in morphine, in 
morphine equivalent, 2015–2020
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Figure XVI. Production of and demand for 
opiate raw materials rich in thebaine, in 
thebaine equivalent, 2015–2020
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of 2018, compared with 269 tons at the end of 2017. 
Stocks were considered sufficient to cover the global 
demand of thebaine-based opiates for medical and scien-
tific purposes for more than two years.
181. The global production of opiate raw materials rich 
in thebaine in 2018 (230 tons) was almost equivalent to 
that of 2017 (229 tons). On the other hand, the demand 
for this variety declined from 190 tons in 2017 to 144 tons 
in 2018. While it was expected that this would increase the 
quantity of stock at the end of 2018, according to the data 
submitted by countries, the stock level at the end of 2018 
was 235 tons, compared with 244 tons at the end of 2017. 
The stock at the end of 2018 was considered sufficient to 
cover the global demand for 18 months.
Noscapine 
182. Even though noscapine is not under international 
control, a significant amount of morphine can be extracted 
from opium poppy rich in noscapine. Cultivation of 
noscapine-rich opium poppy plants for the purpose of 
opiate production was reported by France in 2018. France 
harvested 2,053 ha of opium poppy rich in noscapine in 
2018 and produced noscapine-rich poppy straw with a 
gross weight of 1,173 tons. 
C.  Governments’ cooperation with 
the Board
1.  Provision of information by 
Governments to the Board
183. In accordance with its mandate, the Board pub-
lishes its annual report and the report of the Board on 
the implementation of article 12 of the 1988 Convention. 
It also publishes technical reports that provide 
Governments with an analysis of statistical information 
on the manufacture, consumption, utilization and stocks 
of and trade in internationally controlled substances, 
together with an analysis of estimates and assessments of 
requirements for those substances.
184. The Board’s reports and technical publications are 
produced on the basis of information that parties to the 
international drug control treaties are obligated to sub-
mit. In addition, pursuant to resolutions of the Economic 
and Social Council and the Commission on Narcotic 
Drugs, Governments voluntarily provide information in 
order to facilitate an accurate and comprehensive 
evaluation of the functioning of the international drug 
and precursor control system.
185. The data and other information received from 
Governments enable the Board to monitor licit activities 
involving narcotic drugs, psychotropic substances and 
precursor chemicals and to evaluate treaty compliance 
and the overall functioning of the international drug con-
trol system. On the basis of its analysis, the Board makes 
recommendations to improve the workings of the system 
with a view to ensuring the availability of narcotic drugs 
and psychotropic substances for medical and scientific 
needs, while at the same time preventing their diversion 
from licit into illicit channels and preventing the diver-
sion of precursors to illicit drug manufacture.
2.  Submission of statistical 
information
186. Governments have an obligation to furnish to the 
Board the annual and quarterly statistical reports required 
by the international drug control conventions.
(a) Narcotic drugs
187. As at 1 November 2019, the Board had received 
annual statistics reports from 173 States (both parties and 
non-parties) and territories on the production, manufac-
ture, consumption, stocks and seizures of narcotic drugs 
covering the calendar year 2018 (form C), or about 81 per 
cent of those requested. That number was higher than in 
2018 (when 167 reports pertaining to 2017 were received) 
and higher than in 2017 (when 149 reports pertaining to 
2016 were received). The Board notes with  satisfaction 
that the submission rate for annual  statistics has con-
tinuously increased over the past two years.
188. A total of 97 Governments (46 per cent) submit-
ted their data on time, that is, by the deadline of 30 June 
2019, which was fewer than in 2018 but more than in 
2017 (114 countries in 2018, and 89 countries in 2017). 
As at 1 November 2019, 40 Governments (19 per cent) 
— that is, 35 countries and 5 territories — had not sub-
mitted their annual statistics for 2018. It is expected that 
several additional countries and territories will be sub-
mitting the data over the coming months. Most countries 
and territories that have not submitted their reports are 
in Africa, the Caribbean, Asia and Oceania, which could 
be indicative of a lack of capacity in the drug control 
administrations of some countries in those regions.
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189. Almost all countries that produced, manufactured, 
imported, exported or consumed large amounts of narcotic 
drugs submitted annual statistics. In its annual report for 
2016, INCB highlighted the importance of accurate and 
timely reporting for the effectiveness and efficiency of the 
operation of the international drug control system and the 
significant impact that the availability of reliable data had 
on the ability of the Board to accurately monitor the world 
situation. The Board, however, remains very concerned 
about the quality of some of the data provided, especially 
those from some of the major producing and manufactur-
ing countries, as they indicate deficiencies in national 
mechanisms for regulating and monitoring internationally 
controlled substances. The Board urges Governments to 
enhance their national mechanisms to monitor the culti-
vation, production and manufacture of and trade in con-
trolled substances. This may be achieved, in part, by 
improving and developing national data-collection sys-
tems, training staff of the competent national authorities 
and ensuring close  cooperation with companies licensed 
to deal with internationally controlled substances.
190. As at 1 November 2019, the complete set of four 
quarterly statistics of imports and exports of narcotic 
drugs for 2018 (form A) had been received from 
171 Governments (153 countries and 18 territories), or 
about 80 per cent of the 213 Governments requested. In 
addition, 11 Governments (about 5 per cent) had submit-
ted at least one quarterly report. A total of 30 countries 
(about 14 per cent) had failed to submit any quarterly 
statistics for 2018.
(b) Psychotropic substances
191. As at 1 November 2019, annual statistical reports 
for 2018 on psychotropic substances (form P) had been 
submitted to the Board in accordance with article 16 of 
the 1971 Convention by 184 countries and territories. Of 
197 countries and territories subject to the reporting 
requirements of the Convention, 178 (90 per cent) sub-
mitted their annual statistical report for 2018. Furthermore, 
of the 13 countries not subject to the reporting require-
ments of the Convention, 6 (46 per cent) submitted their 
annual statistical report for 2018. In addition, 111 
Governments voluntarily submitted all four quarterly sta-
tistical reports on imports and exports of substances 
listed in Schedule II of the 1971 Convention for 2018, as 
requested by the Economic and Social Council in its res-
olution 1981/7, and a further 45 Governments submitted 
at least one quarterly report for 2018. The Board notes 
with satisfaction the significantly improved rate of 
 submission of the annual statistical reports for 2018 on 
psychotropic substances and the number of non-party 
countries and territories that have submitted an annual 
report.
192. While the majority of Governments regularly sub-
mit their mandatory and voluntary statistical reports, the 
cooperation of some has not been satisfactory. In 2019, 
about 86 per cent of the countries that submitted form P 
for 2018 did so by the deadline of 30 June 2019. Among 
those that failed to submit form P by the deadline were 
major manufacturing, importing and exporting countries 
such as Australia, Belgium, Brazil, Canada, China, 
Denmark, France, India, Japan, Luxembourg and Spain.
193. The Board notes with concern that the number of 
countries and territories that have not furnished form P 
continues to be highest in Africa, followed by Oceania, 
and Central America and the Caribbean. A total of 18 
countries and territories in Africa63 (32 per cent of those 
in that region) failed to furnish form P for 2018. Likewise, 
23 per cent of the countries and territories in Oceania64 
and 16 per cent of those in Central America and the 
Caribbean failed to do so. Form P for 2018 was furnished 
by all countries and territories in Europe and by all coun-
tries in North America except one. In Central America 
and the Caribbean, 2 countries and 2 territories out of 29 
failed to submit form P in 2018.65 In South America, one 
country failed to furnish form P for 2018.66 In Asia, two 
countries did not furnish form P for 2018.67
194. The Economic and Social Council, in its resolutions 
1985/15 and 1987/30, requested Governments to provide 
the Board with details on trade (data broken down by 
countries of origin and destination) in substances listed in 
Schedules III and IV of the 1971 Convention in their 
annual statistical reports on psychotropic substances. As at 
1 November 2019, complete details on such trade had been 
submitted by 166 Governments (90 per cent of all submis-
sions of form P for 2018), which is a much higher submis-
sion rate than in 2018. The remaining 18 Governments 
submitted blank forms or forms containing incomplete 
trade data for 2018. 
195. The Board notes with appreciation that a number 
of countries have already submitted consumption data for 
psychotropic substances on a voluntary basis in accor-
dance with Commission on Narcotic Drugs resolution 
63 Ascension Island, Cameroon, Central African Republic, Chad, 
Comoros, Congo, Côte d’Ivoire, Djibouti, Equatorial Guinea, Eritrea, 
Ethiopia, Gambia, Guinea-Bissau, Libya, Sao Tome and Principe, Somalia, 
South Sudan and Tristan da Cunha.
64 Cook Islands, Nauru, Samoa, Tuvalu and Vanuatu. 
65 Antigua and Barbuda, Aruba, British Virgin Islands and Cuba. 
66 Bolivarian Republic of Venezuela.
67 Cambodia and Turkmenistan. 
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54/6. Thus, for 2018, a total of 99 countries and territo-
ries submitted data on the consumption of some or all 
psychotropic substances, which is more than for 2017. 
The Board appreciates the cooperation of the 
Governments concerned and calls upon all Governments 
to report on the consumption of psychotropic  substances 
on an annual basis pursuant to Commission resolution 
54/6, as such data are essential for an improved 
 evaluation of the availability of psychotropic substances 
for medical and scientific purposes. 
196. The Board notes with appreciation that reports on 
seizures of psychotropic substances were furnished by the 
Governments of Kuwait and India, as well as notifications 
of seizures of internationally controlled licit substances 
smuggled through the mail, including those ordered over 
the Internet, furnished by the Governments of Estonia, 
Latvia, Lithuania and Norway pursuant to Commission 
on Narcotic Drugs resolution 50/11. The Board acknow-
ledges the interdiction efforts of the Governments 
 concerned and calls upon all Governments to furnish 
regularly to the Board information on seizures of 
 psychotropic substances ordered over the Internet and 
delivered through the mail, pursuant to Commission on 
Narcotic Drugs resolution 50/11. 
(c) Precursors
197. In accordance with article 12 of the 1988 
Convention, parties are obliged to furnish information on 
substances frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances. That infor-
mation, provided on form D, assists the Board in moni-
toring and identifying trends in trafficking in precursors 
and the illicit manufacture of drugs. It also enables the 
Board to provide Governments with recommendations 
concerning remedial action and policies, as necessary.
198. As at 1 November 2019, a total of 123 Governments 
had submitted form D for 2018. However, there contin-
ued to be a number of Governments that submitted blank 
forms or forms containing incomplete information. 
199. Of the Governments that provided data on form 
D for 2018, 71 reported the mandatory information on 
seizures of substances in Table I or Table II of the 1988 
Convention, and 49 reported seizures of non-scheduled 
substances. As in previous years, most Governments did 
not provide details on the methods of diversion and illicit 
manufacture.
200. Pursuant to Economic and Social Council resolu-
tion 1995/20, Governments are also requested to provide 
information regarding their licit trade in substances listed 
in Table I and Table II of the 1988 Convention on a vol-
untary and confidential basis. As at 1 November 2019, 
112 Governments had provided such information for 
2018 to the Board, and 106 had furnished data on licit 
uses of and/or requirements for one or more of the sub-
stances in Table I and Table II of the 1988 Convention.
201. Complementing PEN Online, as well as the aggre-
gated seizure data received annually from Governments 
through form D, PICS has, since early 2012, provided a 
secure online platform for sharing information in real 
time on chemical-related incidents such as seizures, ship-
ments stopped in transit, diversion attempts and the dis-
mantling of illicit laboratories. PICS has provided leads 
for national authorities to initiate backtracking investiga-
tions and, on several occasions, the timely communica-
tion of details of precursor incidents has led to further 
seizures or has prevented diversion attempts. The useful-
ness of PICS, however, depends largely on the timeliness 
of the information provided so that it can facilitate imme-
diate follow-up and cooperation to identify those respon-
sible for the diversion of and trafficking in precursors. 
202. As at 1 November 2019, PICS had registered users 
from more than 270 agencies in 117 countries and terri-
tories who had shared information about more than 2,700 
incidents. During the reporting period, more than 320 
new incidents were communicated through PICS.
3.  Submission of estimates and 
assessments
(a) Narcotic drugs
203. Under the 1961 Convention, parties and non-parties 
are requested to provide the Board each year with esti-
mates of their requirements for narcotic drugs for the fol-
lowing year. As at 1 November 2019, a total of 180 States 
and territories, 84 per cent of those required, had sub-
mitted estimates of their requirements for narcotic drugs 
for 2020 for confirmation by the Board, an increase over 
2019, when 175 Governments submitted estimates. 
Confirmed estimates are valid until 31 December of each 
year and need to be revised annually by Governments. 
204. As in previous years and in line with the provisions 
of article 12, paragraph 3, the Board established estimates 
for those countries and territories that had not submitted 
their estimates on time in accordance with article 12 of the 
1961 Convention to ensure that these narcotic drugs, many 
of which are essential in medical practice, can be imported. 
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About 90 Governments adjusted their estimates through-
out the year through the submission of supplementary esti-
mates to the Board. Special provisions of the Convention 
may be used to ensure access to narcotic drugs during 
acute emergencies. 
(b) Psychotropic substances
205. As at 1 November 2019, the Governments of all 
countries except South Sudan and all territories had sub-
mitted to the Board at least one assessment of their 
annual medical and scientific requirements for psycho-
tropic substances. In accordance with Economic and 
Social Council resolution 1996/30, the Board established 
the assessments of requirements for South Sudan in 2011 
to enable that country to import psychotropic substances 
for medical purposes without undue delay.
206. In line with Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of their annual medi-
cal and scientific requirements for psychotropic sub-
stances listed in Schedules II, III and IV of the 1971 
Convention. Assessments for psychotropic substances 
remain in force until Governments modify them to reflect 
changes in national requirements. To facilitate the sub-
mission of such modifications by competent national 
authorities, the Board created a form, entitled “Supplement 
to form B/P”, which has been made available to all 
Governments in the six official languages of the United 
Nations since October 2014 and can be accessed on the 
website of INCB. As at 1 November 2019, almost all coun-
tries were using it. The Board recommends that 
Governments review and update the assessments of 
their annual medical and scientific requirements for 
psychotropic substances at least once every three years. 
207. Between 1 November 2018 and 1 November 2019, 
a total of 81 countries and 7 territories submitted fully 
revised assessments of their requirements for psycho-
tropic substances, and a further 81 Governments submit-
ted modifications to their assessments for one or more 
substances. As at 1 November 2019, Governments of 36 
countries and 4 territories had not submitted any revi-
sion of their legitimate requirements for psychotropic 
substances for over three years.
(c) Precursors
208. In its resolution 49/3, entitled “Strengthening sys-
tems for the control of precursor chemicals used in the 
illicit manufacture of synthetic drugs”, the Commission on 
Narcotic Drugs requested Member States to provide the 
Board with annual legitimate requirements for imports of 
four precursors of amphetamine-type stimulants – 
ephedrine, pseudoephedrine, 3,4-methylenedioxyphenyl-2- 
propanone (3,4-MDP-2-P), and 1-phenyl-2-propanone 
(P-2-P) – and, to the extent possible, preparations con-
taining those substances that could be easily used or 
recovered by readily applicable means. The estimates help 
Governments to assess the legitimacy of shipments and 
to identify any excesses in pre-export notifications for 
those substances.
209. Although those estimates are provided to the 
Board on a voluntary basis, as at 1 November 2019, 
169 Governments had provided an estimate of their 
annual legitimate requirement for at least one of the 
above-mentioned substances. During the reporting 
period, more than 95 Governments reconfirmed or 
updated their annual legitimate requirements for at least 
one substance. 
210. Governments provide estimates of annual legiti-
mate requirements for precursors on form D and can 
update them at any time throughout the year. The latest 
annual legitimate requirements, as submitted by countries 
and territories, are regularly updated and published on 
the Board’s website. They are also accessible to registered 
users through PEN Online. 
4.  Improving the quality of information 
provided to the Board
211. The regular submission of comprehensive and reli-
able statistical data from Governments to the Board is 
vital for the proper overall functioning of the interna-
tional drug control system and the analysis of global 
trends. Good-quality data also provide essential informa-
tion that is necessary to uncover diversions of controlled 
substances for illicit purposes. 
212. Incomplete submissions, data gaps and other prob-
lems encountered by Governments in furnishing ade-
quate statistics and/or estimates and assessments to the 
Board are often an indication of deficiencies in their 
national control mechanisms and/or health-care systems. 
Such deficiencies may reflect problems in the implemen-
tation of treaty provisions, for instance gaps in national 
legislation, shortcomings in administrative regulations or 
a lack of training for staff of competent national 
authorities.
213. The Board strongly recommends that Governments 
strengthen national mechanisms to monitor the 
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cultivation, production and manufacture of and trade in 
controlled substances. This may be achieved, in part, by 
improving and developing national data-collection sys-
tems, training staff of the competent national authorities 
and ensuring that companies licensed to deal with inter-
nationally controlled substances fulfil the legal require-
ments associated with their licences.
214. The Board invites all Governments concerned to 
identify the causes of deficiencies in reporting statistics 
and/or estimates and assessments to the Board and to 
inform the Board accordingly with a view to resolving 
problems and ensuring adequate and timely reporting. 
To assist Governments, the Board has developed tools 
and kits, as well as several sets of guidelines, for use by 
competent national authorities. They are available on its 
website free of charge and include training materials and 
the Guide on Estimating Requirements for Substances 
under International Control. Governments are invited to 
make full use of those tools in their efforts to comply 
with the international drug control treaties.
INCB Learning: building capacity to ensure 
adequate access to controlled medicines 
and to improve reporting performance
215. The Board is grateful for the contributions made 
to INCB Learning68 by the Governments of Australia, 
Belgium, France, the Russian Federation, Thailand and 
the United States. 
216. The importance of capacity-building for ensuring 
the adequate availability of internationally controlled sub-
stances for medical and scientific purposes while prevent-
ing diversion and abuse was recognized by the international 
community in the outcome document of the thirtieth 
special session of the General Assembly, entitled “Our 
joint commitment to effectively addressing and counter-
ing the world drug problem”. That commitment was reit-
erated by Member States through the adoption, in March 
2019, of Commission on Narcotic Drugs resolution 62/5, 
entitled “Enhancing the capacity of Member States to ade-
quately estimate and assess the need for internationally 
controlled substances for medical and scientific purposes”. 
In that resolution, the Commission encourages the Board 
to continue implementing capacity-building and training 
activities for competent national authorities through the 
INCB Learning global project. 
68 Further information on INCB Learning is available at www.incb.
org/incb/en/learning.html.
217. Aimed at supporting the efforts of Governments 
to fulfil their responsibilities under the international drug 
control conventions, INCB Learning has been providing 
regional training seminars for officials of competent 
national authorities since 2016. 
218. By building capacities to ensure adequate access 
to controlled substances, INCB Learning is assisting 
Member States in their efforts to achieve Sustainable 
Development Goal 3 (Ensuring healthy lives and 
 promoting well-being for all at all ages). INCB Learning 
addresses the barriers to adequate availability of the 
indispensable narcotic and psychotropic substances 
required for medical treatments, in particular by pro-
viding training on adequately estimating and assessing 
the need for internationally controlled substances for 
medical and scientific purposes. 
219. In the first semester of 2019, two regional training 
seminars were held to strengthen the capacity of 
Governments to accurately estimate their requirements 
for controlled substances and to manage their licit trade 
in those substances.
220. A follow-up workshop for El Salvador, Guatemala 
and Honduras took place in Vienna in January 2019. Nine 
officials from the competent national authorities of the 
three countries participated in bilateral consultations and 
sessions dedicated to the importance of ensuring ade-
quate availability of narcotic drugs and psychotropic sub-
stances for medical and scientific purposes and received 
a briefing from the UNODC Laboratory and Scientific 
Section, including an explanatory visit of the UNODC 
laboratory. The seminar took place in the framework of 
an extended initiative to support the subregion of Central 
America and the Caribbean.
221. A second regional training seminar took place in 
Quito from 3 to 6 June 2019 for 43 officials of the com-
petent national authorities of Argentina, Brazil, Chile, 
Colombia, Costa Rica, the Dominican Republic, Ecuador 
and Peru. Specialized training was provided to the newly 
established INCB Learning focal point units on treaty 
requirements regarding the regulatory control and mon-
itoring of licit trade in narcotic drugs, psychotropic sub-
stances and precursor chemicals. The seminar provided 
training on the responsibilities of Governments under the 
conventions and raised awareness of the importance of 
timely and adequate reporting. 
222. On 7 June 2019, a national awareness-raising work-
shop on the availability of narcotic drugs and psychotro-
pic substances for medical and scientific purposes was 
jointly organized by INCB and the Ministry of Foreign 
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Affairs and Human Mobility of Ecuador. The workshop, 
hosted by the Ministry, brought together about 60 par-
ticipants from several national authorities, international 
organizations, civil society and the private sector to dis-
cuss the importance of ensuring access to medicines con-
taining substances under international control. The 
training seminar and the workshop in Ecuador were held 
in cooperation with WHO and UNODC.
223. The eight regional training seminars conducted 
between April 2016 and November 2019 resulted in the 
training of 237 officials from 88 countries and territories 
that are home to more than half the world’s 
population.
224. At the time of finalizing the annual report, prepa-
rations were underway for a training seminar for Russian-
speaking countries, to be held in Moscow in December 2019. 
The activity includes a regional workshop to raise aware-
ness of the importance of access to controlled substances 
for medical and scientific purposes, hosted at the Ministry 
of Foreign Affairs of the Russian Federation.
Impact of INCB Learning 
225. The Board welcomes the accession of Palau to the 
1988 Convention on 14 August 2019, confirming the 
commitment of Palau to participating in regional and 
international efforts to combat drug abuse and illicit 
trafficking. The Board takes this opportunity to urge the 
other countries in Oceania that participated in the 
awareness-raising workshop conducted under the INCB 
Learning initiative held in Australia in November 2017 
that have not yet ratified any of the international drug 
control treaties to identify specific obstacles that may have 
impeded their accession to the respective international 
drug control treaties and to take practical steps to ensure 
that they become a party to those conventions at the ear-
liest opportunity. The regional training seminar attended 
by officials from Palau and other countries in Oceania 
addressed the importance of ratifying the three interna-
tional drug control conventions, which have almost uni-
versal adherence, except in Oceania, the subregion with 
the largest number of countries that have not yet rati-
fied those treaties. As part of the follow-up conducted 
by the secretariat of the Board, training materials and 
further guidance on the steps required for treaty acces-
sion were shared with participants and other Government 
representatives. 
226. The impact of INCB Learning training sessions 
in Africa is evidenced by the improved reporting per-
formance of several participating countries. That 
includes the submission by one country of estimates and 
assessments for narcotic drugs and psychotropic sub-
stances for the first time, in 2018, after seven years of 
non-submission, another country providing estimates 
for narcotic drugs in October 2018 after a four-year gap, 
the resubmission by another country of more complete 
and accurate estimates for narcotic drugs for 2019, and 
the submission by one country of an updated assessment 
of requirements for psychotropic substances. One coun-
try submitted, in 2019, its assessment of requirements 
for psychotropic substances for the first time in 10 years, 
as well as, for the first time ever, its full annual statis-
tics for psychotropic substances. Two countries submit-
ted quarterly trade statistics for narcotic drugs for the 
first time, in 2019, after six years of not providing sub-
missions, which suggests an increase in their licit trade 
monitoring capacity. 
227. A preliminary analysis, done on 6 September 2019, 
of submissions of estimates for narcotic drugs of the eight 
countries that had benefited from the INCB Learning 
capacity-building training seminar held in Quito in June 
2019 shows that all eight countries had submitted their 
estimates for narcotic drugs for 2020 by that date. Three 
of those eight submissions of estimates were submitted by 
the submission deadline set at 30 June. One country sub-
mitted annual estimates for narcotic drugs (form B) before 
the deadline for the first time in nine years, considerably 
improving the timeliness of its submission of estimates. 
Following the training seminar in Quito, updated assess-
ments for psychotropic substances were received from four 
countries at the time of the analysis of 6 September 2019. 
Seven of the eight countries furnished annual statistics for 
narcotic drugs, and all eight countries submitted annual 
statistics for psychotropic substances. 
228. Available data suggest there have been some 
improvements in the quality of estimates for narcotic 
drugs submitted by countries participating in the Quito 
workshop of June 2019. For example, one country revised 
its estimated consumption of narcotic drugs, a key step 
in ensuring adequate availability of narcotic drugs for 
medical purposes. In that case, follow-up contacts with 
another country’s competent national authority facilitated 
clarifications before the submission of estimates.
229. Through INCB Learning, INCB has developed 
e-learning modules to support Governments in adequately 
estimating and assessing their needs for internationally 
controlled substances. The e-learning modules, covering 
narcotic drugs, psychotropic substances and precursors, 
are available upon registration to officials of competent 
national authorities at no cost. There is no limitation on 
the number of staff of competent national authorities that 
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can be registered by Governments. On 17 October 2019, 
INCB sent a circular to all Governments inviting them to 
register the staff of their competent national authorities to 
use the modules. As at 1 November 2019, the authorities 
of 28 countries and territories had requested access to the 
e-learning modules for 125 officials of their competent 
authorities. The Board urges all Governments to register 
pertinent officials of their competent national authorities 
to benefit from the e-learning modules and provide feed-
back and suggestions for areas in which the development 
of further training is needed. 
230. With a view to facilitating the implementation of 
Commission on Narcotic Drugs resolution 62/5, the 
Board invites Governments to consider actively 
 supporting INCB Learning by participating in its 
 activities and providing the resources required to ensure 
the project’s continuation and expansion.
D.  Evaluation of overall treaty 
compliance
1.  New developments with regard to 
overall treaty compliance in 
selected countries 
231. As part of its treaty monitoring functions, the 
Board continuously reviews implementation of the inter-
national drug control conventions by States parties. The 
Board examines developments in the drug control field 
in States parties in order to identify areas which may 
require increased dialogue or possible remedial actions. 
When shortcomings are noted, the Board, through close 
collaboration with Governments, identifies and recom-
mends specific good practices and measures that can be 
implemented with a view to improving compliance with 
the international drug control treaties.
232. States parties to the international drug control con-
ventions have substantial levels of discretion when engag-
ing in domestic drug policy actions. Although the 
legislative and policy choices made in implementing the 
treaty obligations can vary widely, the Board notes that 
these policy choices should adhere to the provisions of 
the treaties. Namely, the States parties must limit the use 
of narcotic drugs and psychotropic substances exclusively 
to medical and scientific purposes and adopt policies that 
respect human rights and safeguard the health of 
humanity.
233. In 2019, the Board reviewed drug control develop-
ments in Georgia, New Zealand, Nigeria, the Philippines 
and Sri Lanka and examined measures taken in those 
countries through the prism of dialogue, which include 
correspondence and meetings with government represen-
tatives and their submission of statistical data. As a result 
of this review process, the Board looks forward to con-
tinued exchange of information, the conduct of country 
missions and the enhanced participation of States parties 
in INCB projects and initiatives.
(a) Georgia
234. During the reporting period, the Board continued 
to follow the developments in Georgia regarding drug 
control. In particular, the Board engaged in close dia-
logue with the Government of Georgia on the judgment 
of the Constitutional Court of Georgia of 30 July 2018, 
in which the Court ruled that the imposition of admin-
istrative punishment for non-medical use of cannabis 
was unconstitutional, as, according to the Constitutional 
Court, it would violate the right of the person to “free 
development”. 
235. A meeting was held with representatives of the 
Government of Georgia on the margins of the sixty- second 
session of the Commission on Narcotic Drugs, where 
they informed the Board that until 2011 the drug policy 
of Georgia had been heavily focused on supply reduction 
and law enforcement and that since 2012 there had been 
a shift towards a balanced approach with a focus on 
health and welfare, including the treatment and rehabil-
itation of drug users. In 2013, the Inter-agency 
Coordinating Council for Combating Drug Abuse 
approved a national drug strategy and action plan which 
took a comprehensive approach to drug policy, including: 
(a) supply reduction measures, (b) demand reduction 
measures, as well as measures aimed at minimizing the 
adverse public health and social consequences of drug 
abuse, (c) activities to overcome stigmatization and dis-
crimination, (d) the promotion of coordination and inter-
national cooperation, and (e) facilitation of research and 
analysis. The current action plan to implement that strat-
egy covers the period 2019–2020.
236. A judgment by the Constitutional Court of Georgia 
issued in 2015 removed imprisonment as a punishment 
for the possession of up to 70 grams of cannabis but kept 
other administrative penalties such as fines. The subse-
quent judgment of the Constitutional Court of Georgia, 
issued on 30 July 2018, removed any penalties, including 
administrative fines, for non-prescribed use of cannabis. 
The Government of Georgia stressed to the Board that 
the latest judgment of the Constitutional Court was 
related to the consumption or possession of “small” 
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amounts of cannabis for personal consumption in “pri-
vate”, and according to the current legislation that would 
amount to 5 grams. 
237. The Ministry of Internal Affairs of Georgia took the 
lead in developing implementing legislation that followed 
that judgment, which was adopted in October 2018. It 
defined “private” as a private dwelling or home. However, 
it was noted that even in “private” circumstances, the con-
sumption of cannabis was prohibited in the presence of 
minors. The law also prohibited any consumption of can-
nabis in public places, public transport, the workplace and 
schools and other educational facilities and adjacent ter-
ritories, and a breach of those prohibitions would consti-
tute a punishable offence. The law also prohibited the 
consumption of cannabis by persons under 21 years of 
age. Cultivation of cannabis even in “private” places 
remained prohibited and was a punishable offence.
238. The Government also informed the effective work 
of the Inter-agency Coordinating Council for Combating 
Drug Abuse, which included the implementation of 
recent reforms in the area of drug treatment and rehabil-
itation, including the introduction of treatment pro-
grammes in the penitentiary services, an increase in 
beneficiaries in drug abuse prevention and treatment pro-
grammes, the increased length of rehabilitation pro-
grammes for drug users and the adoption of national 
treatment and rehabilitation standards, with the involve-
ment of all relevant agencies.
239. The Board will continue to monitor drug control 
developments in Georgia and engage in a dialogue with 
the Government to support the full implementation of 
the international drug control treaties.
(b) New Zealand
240. Over the period under review, the Board has con-
tinued to monitor drug control developments in New 
Zealand and engage with the Government on matters 
related to the implementation of its legal obligations as a 
State party to the three international drug control 
conventions.
241. The Board notes that in December 2018, the 
Misuse of Drugs (Medicinal Cannabis) Amendment Act 
came into effect, with specific regulations on medicinal 
cannabis products expected within a year. As it has done 
with other countries that have legalized the use of can-
nabis for medical purposes, in accordance with the 1961 
Convention as amended, the Board has emphasized that 
in order to be consistent with the Convention, any 
regulatory programme must respect the conditions estab-
lished in articles 23 and 28 of the Convention. 
242. In addition, a Government cabinet decision in New 
Zealand has led to expectations that there will be a bind-
ing public referendum on the regulation of cannabis for 
personal use. The referendum will be part of the national 
general election in 2020.
243. The New Zealand Ministry of Justice and Cabinet 
released a document detailing information about propos-
als for the binding referendum on non-medical cannabis 
and the legislative implications. Only one option for a 
regulatory framework will be selected and presented for 
public vote in the referendum. According to the 
Government of New Zealand, regulating cannabis is sup-
posed to provide safe and legal access to the substance 
and control the harmful aspects of cannabis use through-
out the whole supply chain. 
244. In its exchanges with States parties to the interna-
tional drug control conventions, including New Zealand, 
the Board has reiterated that any and all legislative or reg-
ulatory measures aimed at the legalization of cannabis for 
non-medical purposes are inconsistent with the provi-
sions of the 1961 Convention as amended, in particular 
article 4 (c), which requires States parties to limit the use 
of narcotic drugs exclusively to medical and scientific 
purposes, and article 3, paragraph 1 (a)(i), of the 1988 
Convention, which creates the obligation for States to 
establish as criminal offences, when committed intention-
ally, “the production, manufacture, extraction, prepara-
tion, offering for sale, distribution, sale, delivery on any 
terms whatsoever, brokerage, dispatch, dispatch in tran-
sit, transport, importation or exportation of any narcotic 
drug or psychotropic substance contrary to the provisions 
of the 1961 Convention, the 1961 Convention as amended 
or the 1971 Convention”. 
245. The Board will continue to monitor policy and 
legal developments in New Zealand pertaining to drug 
control and encourages the Government of New Zealand 
to continue its constructive dialogue with the Board to 
ensure consistency with the drug control conventions.
(c) Nigeria
246. The Board takes note of the importance of the first-
ever national drug use survey in Nigeria, the National 
Survey on Drug Use and Health, the results of which were 
published in January 2019, in particular the survey’s role 
in promoting evidence-based drug policy development 
and effective implementation of the drug control 
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conventions. The comprehensive examination of drug use 
and health in Nigeria revealed that the prevalence of past-
year drug use in Nigeria is more than twice the global 
average of 5.6 per cent, and is estimated at 14.4 per cent 
of people aged 15–64. The findings of the national sur-
vey are discussed in detail in chapter III of the present 
report.
247. The UNODC report Drug Use in Nigeria 2018, cov-
ering the findings of the National Survey on Drug Use 
and Health of Nigeria, notes that the country is address-
ing issues regarding access to and control of narcotics and 
psychotropic substances for medical and scientific pur-
poses. As part of the national efforts to remove barriers 
and impediments to the availability of life-saving medi-
cations, Nigeria has published its National Policy for 
Controlled Medicines, including the National Guidelines 
for Quantification of Narcotic Medicines and National 
Guidelines for Estimation of Psychotropic Substances and 
Precursors.
248. The Board commends Nigeria on its cooperation 
with international partners to develop evidence-based 
approaches to drug control. In line with the international 
drug control conventions, the Board will continue to 
monitor the outcomes of the efforts of Nigeria to fulfil its 
obligations under the international drug control treaties, 
which will also promote attainment of Sustainable 
Development Goal 3, which will help ensure healthy lives 
and promote well-being for all Nigerians.
(d) Philippines
249. The Board continued to closely monitor the ongo-
ing developments in the Philippines related to drug con-
trol. During the current reporting period, the Philippines 
continued the implementation of its anti-drug strategy, 
with police operations at the centre of national efforts, 
which have been accompanied by more reports of extra-
judicial targeting of people suspected of drug-related 
activity.
250. INCB reiterates that acts taken to prevent drug 
abuse and trafficking must be carried out adopting 
humane, health-based approaches that respect human 
rights and the rule of law. Drug trafficking can never jus-
tify human rights violations or excuse extrajudicial 
actions. That long-standing position of the Board is based 
on the underlying aim of the international drug control 
conventions of ensuring public health and welfare while 
preventing the diversion of controlled substances into 
illicit channels, a position which is also consistent with 
human rights instruments.
251. During the reporting period, the Board took note 
of Human Rights Council decision 41/2 of 11 July 2019 
on the promotion and protection of human rights in the 
Philippines, specifically with respect to the country’s cam-
paign against drug trafficking and use. In its decision, the 
Council urged the Government of the Philippines to take 
all necessary measures to prevent extrajudicial killings 
and enforced disappearances, to carry out impartial inves-
tigations and to hold perpetrators accountable, in accor-
dance with international norms and standards, including 
on due process and the rule of law.
252. On 17 March 2019, the decision of the Philippines 
to withdraw from the Statute of the International Criminal 
Court officially took effect. Previously, in 2018, the 
Prosecutor of the International Criminal Court opened a 
preliminary examination of the country situation based 
on a review of communications and reports document-
ing alleged crimes as part of the nationwide anti-drug 
campaign, including thousands of extrajudicial killings. 
The International Criminal Court continues to have juris-
diction over crimes under the Rome Statute that occurred 
in the Philippines during the period when it was a State 
party to the Statute.
253. The Board calls on the Government of the 
Philippines to issue an immediate and unequivocal con-
demnation and denunciation of extrajudicial actions 
against individuals suspected of involvement in the illicit 
drug trade or of drug use, to put an immediate stop to 
such actions and to ensure that the perpetrators of such 
acts are brought to justice in full observance of due pro-
cess and the rule of law.
254. The Board has been active in trying to secure an 
effective dialogue with the Government of the Philippines. 
The Board has suggested a country mission to the 
Philippines with a view to a closer examination of 
drug- related developments in the country, which the 
Government has accepted in principle. However, there has 
been no progress in obtaining acceptance of the Board’s 
suggested mission dates over the past several years. The 
Board has also, on several occasions, invited representa-
tives of the Government to attend a session of the Board 
for consultations. At the time of finalizing the present 
report, the Government of the Philippines has not yet com-
municated its acceptance of that invitation by the Board. 
(e) Sri Lanka
255. In July 2018, the Government of Sri Lanka 
announced that it would resume the use of the death pen-
alty for drug-related offences and would execute drug 
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dealers who were on death row. Although Sri Lanka has 
not enforced the death penalty for decades, courts have 
continued to hand out death sentences for serious 
offences, including murder, rape and certain drug offences. 
In June 2019, the President announced that he had signed 
the death warrants ordering the execution of four drug 
offenders. If Sri Lanka carries out these executions, it 
would end a moratorium on death sentences that has 
been in effect since 1976.
256. Several members of the international community 
and international and local human rights groups called 
on the Government of Sri Lanka to reconsider plans to 
implement the death penalty and to maintain the coun-
try’s de facto moratorium on the implementation of cap-
ital punishment including for drug-related crimes.
257. While acknowledging the challenges faced by Sri 
Lanka regarding drug trafficking and abuse, the Board 
wishes to reiterate its repeatedly expressed concerns with 
respect to the imposition of the death penalty for drug- 
related offences by States parties to the international drug 
control conventions in the light of the relevant inter-
national conventions and protocols and resolutions of the 
General Assembly, the Economic and Social Council and 
United Nations bodies pertaining to the death penalty. In 
this context, the Board wishes to note that, as discussed 
in its annual report for 2017, although the determination 
of sanctions applicable to drug-related crime remains the 
prerogative of States parties to the conventions, the Board 
 continues to encourage States that retain capital punish-
ment for drug-related offences to commute death sen-
tences that have already been handed down and to 
consider the abolition of the death penalty for drug-related 
offences.
2. Country missions
258. The Board periodically undertakes country mis-
sions to monitor compliance with the international drug 
control treaties and promote effective implementation of 
those treaties. 
259. During these country missions, the Board  discusses 
with relevant national authorities of the countries  hosting 
the mission the legislative, institutional and practical 
measures implemented at the national level in the areas 
of licit manufacture of and trade in controlled substances 
with a view to facilitating the availability of those 
 substances for medical and scientific purposes while 
 preventing their diversion into illicit channels. The Board 
also engages with the countries visited in dialogue on 
national mechanisms for preventing and addressing illicit 
manufacture, trafficking and abuse of narcotic drugs and 
psychotropic substances.
260. Based on the results of carrying out those 
 treaty-monitoring functions, the Board adopts recom-
mendations that are communicated confidentially to the 
Governments in question. These recommendations pro-
pose measures aimed at improving compliance of national 
drug control systems with the international drug control 
conventions. 
261. During the period under review, the Board under-
took missions to Austria, Chile, Côte d’Ivoire, the Democratic 
People’s Republic of Korea, Jamaica, Jordan, Kosovo,69 
Madagascar, Mauritania, Montenegro, New Zealand, 
Norway, Paraguay, Sri Lanka, Trinidad and Tobago, Ukraine 
and Uzbekistan. Additional missions have been accepted in 
principle by the Governments of the Bahamas, Brunei 
Darussalam, Colombia, Dominica, Eswatini, Greece, 
Kyrgyzstan, the Niger, the Philippines, Tajikistan, Thailand 
and Yemen, but plans for those missions have not yet been 
finalized. In addition, the Board has contacted the 
Governments of Belize, Cameroon, Cyprus, Djibouti, the 
Gambia, Grenada, Guinea, Japan, Kazakhstan, Kuwait, 
Maldives, Mali, North Macedonia, Rwanda, Saint Lucia, 
South Sudan, Suriname and the United States.
262. In the cases of the United States and the Philippines, 
the Board has invited their representatives to attend the 
126th session of the Board, to take place in October–
November 2019, for consultations. At the time of finaliz-
ing the present report, the Board has received confirmation 
that the Government of the United States will be send-
ing a delegation to attend the Board’s session to be held 
in February 2020. In the case of the Philippines, the Board 
has not received formal acceptance of the invitation from 
the Government. In the case of the Bahamas, the mis-
sion, which was initially scheduled to take place in 
September 2019, could not take place due to the emer-
gency situation in the country caused by a hurricane.
(a) Austria
263. The Board conducted a mission to Austria in June 
2019 to discuss the country’s efforts to implement its 
national drug policy and respond to the health needs of 
the country’s drug users. With the objective of discussing 
national developments, the Board undertook a mission to 
review the drug control policies and obtain examples of 
69 References to Kosovo shall be understood to be in the context of 
Security Council resolution 1244 (1999).
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Austrian experiences in the areas of prevention and 
treatment.
264. Since the previous Board mission to Austria in 
2001, Austria has provided updates on developments in 
national drug control and coordination and new early 
warning measures. The Board took note of the positive 
effects of implementation of the policy called “therapy not 
punishment” on fulfilling the aims of the international 
drug control conventions through well-designed thera-
peutic treatment options. 
265. The Board welcomes the commitment of Austria 
to sharing information and experiences at the inter-
national level and recognizes that Austria has given high 
priority to providing drug-related treatment and health 
responses in outpatient and inpatient centres. The  mission 
also served to strengthen channels of communication 
between the Board and the Government of Austria. 
(b) Côte d’Ivoire
266. In April 2019, the Board undertook a mission to 
Côte d’Ivoire to discuss developments related to the coun-
try’s implementation of the three international drug con-
trol treaties since the Board’s previous mission in 1998.
267. In recent years, Côte d’Ivoire has seen a surge in 
the trafficking and abuse of tramadol, an opioid analge-
sic not under international control. Cannabis remains a 
major drug of abuse and is trafficked into the country, 
while trafficking in cocaine appears to have reduced. 
While it is believed that drug use is a major problem for 
Côte d’Ivoire, a lack of data makes it difficult to deter-
mine the extent that drugs are abused among the 
population.
268. The Board notes that Côte d’Ivoire has a well- 
established institutional framework for drug control and 
that legislative and policy reforms are under way with the 
aim of ensuring proportionate responses to drug offences, 
improving drug treatment services and strengthening 
drug use prevention programmes.
(c) Chile
269. An INCB mission visited Chile in March 2019. The 
objective of the mission was to review the drug control 
situation in Chile and the implementation of the three 
international drug control conventions, to which Chile is 
a party, including reporting to, and cooperation with, 
INCB in accordance with the conventions. The mission 
also discussed the actions taken by the Government to 
counter drug trafficking, to prevent drug abuse and to 
provide treatment and rehabilitation services for 
drug- dependent persons. 
270. The Government of Chile described the measures 
aimed at the prevention, treatment, rehabilitation and 
social reintegration of drug users, as well as its supply 
reduction efforts to address the trafficking of cocaine and 
cannabis and chemical precursors across its borders with 
Bolivia (the Plurinational State of) and Peru.
271. The Board noted the developments with respect to 
the cultivation of cannabis for medical purposes in Chile, 
as well as the increase in the non-medical use of cannabis, 
in particular among young people. The Government of 
Chile has initiated a programme of drug and/or alcohol 
treatment courts for first offenders who have committed 
minor offences and who, if they are recognized as 
drug-dependent, have their penal proceedings suspended 
and are referred to a drug and/or alcohol treatment court 
so that they can be assisted in the recovery process. 
(d) Democratic People’s Republic of Korea
272. In September 2019, the Board conducted a mission 
to the Democratic People’s Republic of Korea to discuss 
the drug control situation in the country and progress 
made in the implementation of the three international 
drug control conventions to which the country became a 
party in 2007. A previous INCB mission visited the coun-
try in 2006, the year before it acceded to the treaties. 
273. The reported consumption of narcotic drugs and 
psychotropic substances for medical purposes in the 
country is low, and the Government recognizes the 
importance of ensuring adequate access to medicines for 
the population and the contribution of such access to a 
functioning health system. According to the Government, 
illicit use of drugs is said to be almost non-existent in the 
country, but epidemiological studies, drug use assess-
ments or surveys and other information on this phenom-
enon are not available.
274. The Board noted that national drug control legis-
lation which gives effect to the provisions of the interna-
tional drug control treaties has been continuously updated 
over the years to ensure that effective control is exercised 
over narcotic drugs, psychotropic substances and precur-
sors that are needed for medical, scientific and other legit-
imate purposes and that scheduling decisions of the 
Commission on Narcotic Drugs are implemented at the 
national level in a timely manner.
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(e) Jamaica
275. An INCB mission visited Jamaica in November 
2018. The objective of the mission was to review the drug 
control situation in Jamaica and the implementation of 
the three international drug control conventions to which 
the country is a party and compliance with their require-
ments. Also, the mission reviewed the efforts of the 
Government to combat drug trafficking and drug-related 
criminal activities, as well as the actions to prevent drug 
abuse and to ensure access to treatment and rehabilita-
tion services for drug-dependent persons. 
276. The Board noted the legislative amendment that 
modifies penalties for the possession of cannabis in spec-
ified small quantities and the smoking of cannabis in 
specified circumstances (including religious use), and 
establishes a scheme of licences and permits and grants 
other authorizations for medical, therapeutic or scientific 
purposes. The Board reiterated to the Government of 
Jamaica that possession and cultivation of cannabis for 
personal therapeutic or medical purposes by households 
in Jamaica is inconsistent with the provisions of the 1961 
Convention, especially taking into account the inherent 
difficulties for the Government of restricting cultivation, 
distribution and use for medical purposes and the inher-
ent risk of diversion posed by personal possession and 
cultivation.
277. The Board was informed of the efforts made by 
Jamaica to address the trafficking of cannabis from 
Jamaica to North America and the transit through its ter-
ritory of cocaine trafficked from South America to North 
America and other illicit markets. 
(f ) Jordan
278. In October 2019, the Board undertook a mission 
to Jordan with the objective of discussing the country’s 
implementation of the three international drug control 
conventions and examining policy developments since 
the last mission of the Board in 2009. 
279. Jordan has, in recent years, seen an increase in sei-
zures on its territory. While considered to be mainly a 
transit country, it has been facing a number of domestic 
drug-related challenges in the light of the wider political 
situation of the region. Illicit drug use is thought to be 
moderate. However, its exact extent is difficult to mea-
sure given the limited drug prevalence data available. 
280. The Board notes the new legislative framework in 
the field of drug control and acknowledges the 
Government’s efforts in the area of drug use prevention. 
The Board further welcomes efforts to tackle drug 
trafficking, in particular the interdiction efforts under-
taken by law enforcement and customs authorities. During 
the mission, information regarding the country’s drug 
treatment and rehabilitation programmes was discussed.
(g) Kosovo
281. In June 2019, the Board undertook a mission to 
Pristina, Kosovo, to review the drug control situation with 
a view to facilitating access to controlled substances while 
preventing their diversion. The previous mission to 
Kosovo took place in 2002.
282. Kosovo is located on the so-called “Balkan route”, 
one of the major routes for the trafficking of opiates orig-
inating in Afghanistan to destination markets in Western 
and Central Europe. In recent years, Kosovo has seen a 
decline in trafficking of opiates through its territory, while 
trafficking and abuse of cannabis seem to have been on 
the rise. The most frequently abused drugs in Kosovo are 
cannabis, cocaine and heroin, but due to the lack of any 
recent studies or surveys on drug abuse, there are no reli-
able data on the true extent of the drug abuse in Kosovo. 
283. The Board notes the efforts of Kosovo in imple-
mentation of its drug control policy, including through 
adoption of the strategy against narcotics of Kosovo and 
action plan for the period of 2018–2022, which focus on 
the reduction of demand for and the supply of controlled 
substances, the promotion of cooperation and coordina-
tion across Kosovo, and the strengthening of supervision 
and monitoring mechanisms for drug control. Kosovo 
also adopted drug control legislation and regulations 
aimed at regulating the licit supply of controlled sub-
stances while preventing their diversion. 
(h) Madagascar
284. In September 2019, the Board conducted a mission 
to Madagascar with the purpose of discussing challenges 
related to the implementation of the international drug 
control conventions that have been encountered since the 
last INCB mission to the country in 2004.
285. The drug control situation in Madagascar poses 
several challenges owing to limited resources, geograph-
ical facts and demographic realities. As one of the larg-
est island nations in the world, law enforcement agencies 
of Madagascar are confronted with the difficulty of 
patrolling the country’s nearly 5,000 km of coastline with 
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limited resources. The country’s population, half of which 
is below the age of 20, also requires a drug policy that 
emphasizes education and prevention. The availability of 
narcotic drugs and psychotropic substances for medical 
purposes in the country is among the lowest in the region.
286. The Board notes the efforts deployed by the 
Government of Madagascar in seeking to address drug traf-
ficking through law enforcement and border control activ-
ities and increased regional cooperation. The Board also 
notes the Government’s efforts to coordinate stakeholder 
action in the area of drug control through the work of the 
country’s interministerial commission for coordi nating the 
fight against drugs, which includes non- governmental 
organizations and community-based organizations.
(i) Mauritania
287. In April 2019, the Board conducted a mission to 
Mauritania with the purpose of discussing challenges 
related to the implementation of the international drug 
control conventions since the last INCB mission to the 
country in 2004.
288. The strategic geographical position of Mauritania 
at the crossroads between continents, its vast territory and 
coastline and its proximity to areas affected by political 
instability have led to the country being increasingly tar-
geted by trafficking syndicates. While the prevalence of 
drug use is thought to be limited, epidemiological data 
are lacking. Prevention initiatives and access to treatment 
remain limited, and access to controlled narcotic drugs 
and psychotropic substances is low.
289. The Board notes the efforts deployed by the 
Mauritanian authorities to effectively address drug traf-
ficking by strengthening the country’s law enforcement 
and border control activities and its cooperation with 
neighbouring States. The Board also notes the prelimi-
nary efforts currently under way in Mauritania to develop 
effective prevention programmes and treatment strategies 
and to re-evaluate the country’s legitimate consumption 
needs for narcotic drugs and psychotropic substances. 
(j) Montenegro
290. In April 2019, the Board carried out a mission to 
Montenegro to review the drug control situation in the 
country and to discuss with the Government of 
Montenegro its implementation of the three international 
drug control conventions, to which the country is party. 
It was the first mission of the Board to Montenegro, 
which became independent in 2006.
291. The mission held consultations with the Minister 
of Health and senior officials of various ministries and 
governmental bodies and met with representatives of civil 
society. 
292. The country faces the challenge of preventing the 
trafficking of narcotic drugs, in particular cannabis and 
heroin, through its territory to countries in Western 
Europe. The Board notes the efforts being made by the 
Government of Montenegro in addressing drug traffick-
ing, in particular in the context of progress towards enter-
ing the European Union.
293. The Board notes the efforts by the Government to 
implement the Strategy of Montenegro for the Prevention 
of Drug Abuse for the period 2013–2020 and the sup-
porting Action Plan for the period 2019–2020. 
(k) New Zealand
294. In September 2019, the Board undertook a  mission 
to New Zealand to discuss developments related to the 
country’s implementation of the three international drug 
control treaties since the Board’s previous mission in 1996.
295. In recent years, New Zealand has seen a surge in 
the trafficking of methamphetamine, in particular from 
East and South-East Asia, which has also led to a surge 
in the abuse of the drug. The country was confronted 
with a major health crisis several years ago, when there 
were several dozen deaths linked to the proliferation of 
new psychoactive substances, but interventions on the 
part of the Government has brought the situation under 
control. The country also faces the growing challenge of 
trafficking in cocaine, which reaches the country after 
being trafficked through the Pacific islands.
296. The Board notes that New Zealand has a robust 
and well-established institutional framework for drug 
control and has taken significant measures to address the 
drug problem, with major reforms recently being under-
taken in the health and law enforcement sectors to reduce 
harms related to illicit drug consumption. In addition, the 
Board notes that the Government is making significant 
efforts to ensure the availability of programmes and ser-
vices to address drug abuse within indigenous commu-
nities in New Zealand, which are disproportionally 
affected by the harms of drug abuse.
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(l) Norway
297. In May 2019, the Board undertook a mission to 
Norway to discuss the country’s implementation of the 
three international drug control conventions since the 
previous mission to the country, in 2001.
298. Norway continues to closely monitor its drug use 
situation and has had a low level of drug use in general. 
The relatively high number of deaths resulting from over-
dose, however, continues to be of great concern to the 
country’s authorities. The Government plans to transfer 
the responsibility for implementation policy on the ille-
gal use and possession of drugs from the justice sector to 
the health sector through drug policy reform, and to that 
end consultations were under way among authorities and 
stakeholders.
299. The Board acknowledges the commitment of 
Norway to dialogue on drug policy reform and welcomes 
the inclusive approach adopted by the Government in 
soliciting views from all stakeholders. It also notes the 
significant efforts devoted to monitoring the drug use sit-
uation and limiting the negative impacts associated with 
drug use.
(m) Paraguay
300. In December 2018, the Board undertook a mission 
to Paraguay with the objective of maintaining a direct 
dialogue with the Government on matters related to the 
implementation of the international drug control conven-
tions and reviewing legislative and administrative mea-
sures, as well as achievements in preventing drug abuse 
and combating drug trafficking, since the Board’s previ-
ous mission to the country in 2005.
301. Paraguay is targeted for use as a major trans-shipment 
hub for drug trafficking. Its geographical location, with 
the tri-border area, and the presence of criminal organi-
zations involved in trafficking and operating in the 
tri-border area exacerbates the use of Paraguay as transit 
country for the trafficking of coca products to drug abuse 
markets within the region and beyond.
302. The country also faces challenges associated with 
being the main source of illicitly produced cannabis in 
South America. While illicit cannabis cultivation is con-
centrated in the eastern part of the country and the can-
nabis is trafficked mainly to Argentina and Brazil, the 
number of hectares of that cultivation is not known 
because assessments based on a systematic and verifiable 
methodology are still required.
303. The Board acknowledges the commitment of the 
Government of Paraguay to dialogue on drug policy 
issues and notes that various legislative and regulatory 
reforms in the field of drug control are currently under 
way in Paraguay. 
(n) Sri Lanka
304. In March 2019, the Board undertook a mission to 
Sri Lanka with the objective of discussing developments 
related to the country’s implementation of the three inter-
national drug control conventions since the previous mis-
sion to the country in 2002.
305. Considerable progress has been achieved by Sri 
Lanka in the adoption and implementation of two pieces 
of new drug control legislation. The country has also 
made improvements in fulfilling its reporting obligations 
and becoming an active member in the regional and 
international arena. There continues to be a strong need 
to further strengthen the technical capabilities related to 
law enforcement and forensic science, especially in the 
light of growing drug trafficking activities in the 
country.
306. The Board acknowledges the challenges faced by 
Sri Lanka as a transit country and the considerable efforts 
deployed by the Government regarding supply reduction. 
However, it would also like to remind the Government 
to give due regard to the principle of proportionality in 
sentencing and the possibility offered by the conventions 
to provide, in cases where users of drugs have commit-
ted such offences, for measures of referral for treatment, 
education, aftercare, rehabilitation and social reintegra-
tion, either as an alternative to conviction and punish-
ment or in addition to conviction or punishment. 
Moreover, regarding the developments on capital punish-
ment in the country, the Board wishes to encourage all 
States that retain capital punishment for drug-related 
offences to commute death sentences that have already 
been handed down and to consider the abolition of the 
death penalty for drug-related offences.
(o) Trinidad and Tobago
307. In September 2019, the Board undertook a mis-
sion to Trinidad and Tobago to discuss issues related to 
the implementation of the three international drug con-
trol treaties, to which Trinidad and Tobago is a party. The 
previous mission to the country was conducted in 2002.
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308. Trinidad and Tobago, because of its proximity to 
major cocaine-manufacturing countries and its geograph-
ical location, is attractive for major drug trafficking oper-
ations, in particular trafficking of cocaine that originates 
in Colombia and is trafficked through the Bolivarian 
Republic of Venezuela for trans-shipment to other coun-
tries in the Caribbean, the United States and Europe. 
Drug-related incidents are also assumed to be one of the 
reasons for the high crime rate in the capital of Trinidad 
and Tobago. 
309. The Board noted the efforts and commitment of 
the Government of Trinidad and Tobago in regard to the 
national drug control policy issues. 
(p) Uzbekistan
310. In March 2019, the Board undertook its first ever 
mission to Uzbekistan to discuss the drug control situa-
tion in the country and the status of implementation of 
the three international drug control conventions, to which 
Uzbekistan is a party.
311. As a neighbouring country to Afghanistan, 
Uzbekistan continued to be a likely target for drug traf-
fickers seeking to smuggle opiates across the borders to 
destinations north and west of the country. At the same 
time, seizures of opiates declined over the last few years, 
and a shift from heroin abuse to the non-medical use of 
pharmaceutical opioids, in particular tramadol and 
codeine, as well as alcohol, was observed over the same 
period.
312. The Board took note of various drug control ini-
tiatives that were under way in the country, including 
draft legislation aimed at expanding and improving treat-
ment for drug users receiving treatment and plans to con-
duct a country-wide survey on drug abuse prevalence.
(q) Ukraine
313. A mission of the Board to Ukraine was conducted 
in September 2019. The purpose of the country visit was 
to have direct dialogue with the Government of Ukraine 
on matters relating to the implementation of the provi-
sions of the international drug control conventions. The 
last visit of the Board to Ukraine was in 2008. 
314. The mission provided an opportunity to discuss 
Ukraine’s experiences in implementing the drug treaties 
through national legislation and regulatory reforms, espe-
cially with respect to treatment and prevention. National 
health and education policies, as well as the role of sports 
in counteracting drug use among youth, were highlights 
of the prevention efforts of Ukraine.
315. The Board takes note of the commitment of 
Ukraine to working closely with the international com-
munity on developing effective state policies and institu-
tions in the sphere of drug control. Ukraine has placed 
significant emphasis on evaluating the trends of the 
national and regional situation relating to drug abuse and 
trafficking.
3.  Evaluation of the implementation 
by Governments of 
recommendations made by the 
Board following its country 
missions
316. The Board annually reviews developments in coun-
tries that hosted INCB missions two to three years pre-
viously. Governments are requested to apprise INCB of 
relevant developments in the country since the mission, 
including any legislative or policy actions taken to imple-
ment the Board’s post-mission recommendations. This 
annual review helps build on the momentum created by 
the missions. 
317. In 2019, the Board invited the Governments of 
Afghanistan, Argentina, Bolivia (the Plurinational State 
of), Israel, Myanmar, Oman, Senegal, South Africa, the 
State of Palestine and Viet Nam, to which missions were 
conducted in 2016, to report on drug policy related devel-
opments, in particular any that resulted from the Board’s 
mission recommendations.
318. The Board wishes to express its appreciation to the 
Governments of Argentina, Bolivia (the Plurinational 
State of), Myanmar, Senegal and South Africa for submit-
ting timely responses to the Board and renews its call to 
the Governments of Afghanistan, Israel, Oman, the State 
of Palestine and Viet Nam to provide the information 
requested.
(a) Argentina
319. The Board notes that the Government of Argentina 
has made major efforts to implement the recommenda-
tions of the Board following the mission in 2016. Since 
2016, there have been efforts to enact new legislation, 
which resulted in the establishment of the Federal Council 
of Precursor Chemicals, an advisory body of the 
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authority responsible for operation of the National 
Registry of Chemical Precursors. In November 2016, 
harsher penalties were established for the intentional 
diversion of precursor chemicals, and legislation was 
enacted to establish the tools to investigate, prevent and 
combat complex offences, incorporating the use of con-
trolled deliveries. As part of efforts to tackle drug 
trafficking by criminal groups, Argentina provided infor-
mation about activities taken to recover illicitly acquired 
assets, including termination of ownership. 
320. The Government of Argentina provided updates to 
the Board about the establishment of inter-agency task 
forces on drug trafficking, consisting of federal and provin-
cial forces. Other task forces were also formed, including 
the Joint Airport Interdiction Task Force, which operates 
within the framework of the Airport Communication 
Project funded by the European Union. Additional inter-
agency task forces include the Seaport Cooperation Project 
and the joint task force on laundering of the proceeds of 
drug-related crime, which operates in coordination with the 
Financial Information Unit of Argentina. 
321. The work undertaken by joint task forces has 
resulted in early warning data and intelligence about 
emerging drugs and new patterns of consumption and 
trade. Harmonization of data collection by the federal 
forces and the provincial police bodies has progressed, 
and procedures for the detection of shipments contain-
ing narcotic drugs and psychotropic substances have been 
improved. With respect to precursors, Argentina has 
instituted an early warning system to report on suspicious 
transactions involving precursor chemicals, with the 
country making full use of the tools of the Board in this 
respect, in particular PICS and IONICS. The Board has 
noted the results of the Safe Neighbourhoods Programme, 
which increased the seizures of cocaine base paste by 
more than 3,000 per cent and seizures of cocaine by 
181 per cent. Nationwide drug incineration events led to 
more than 180 tons of cocaine and cannabis and 90,000 
tablets being destroyed.
322. Argentina has informed the Board that it is actively 
strengthening its international, regional and cross-border 
cooperation. Cooperation agreements were signed 
between Argentina and Bolivia (the Plurinational State 
of), China, Israel, Germany, Paraguay, the Russian 
Federation and the United States. Argentina organized a 
seminar on combating money-laundering and the financ-
ing of terrorism jointly with the South American Working 
Group. In addition, the country hosted a high-level meet-
ing of the Cooperation Programme on Drugs Policies 
between the European Union and Latin American and 
Caribbean countries. In November 2018, Argentina was 
elected to chair CICAD of OAS and was elected to chair 
the CICAD Group of Experts on Chemical Substances 
and Pharmaceutical Products. 
323. With respect to addiction prevention, Argentina 
established the “Municipalities in Action” programme, 
which promotes the prevention and treatment of problem-
atic use of psychoactive substances in the municipal policy 
agenda. The “Argentina prevents” programme, which was 
launched in 2017, has funded at least 80 prevention proj-
ects implemented by civil society organizations. In socially 
disadvantaged areas, accessibility of treatment has improved, 
and treatment coverage has been expanded by more than 
375 per cent compared with 2015 through community care 
and support centres. A prevention programme has been 
introduced in every school in the country’s 23 provinces 
and Buenos Aires, with gender and sexual diversity being 
given due consideration in strategic planning concerning 
problematic consumption of illicit drugs. 
324. The Board acknowledges the effective cooperation 
of the Government of Argentina in fulfilling the coun-
try’s obligations under the international drug control trea-
ties, and notes that it will continue working closely with 
the Government of Argentina to facilitate the implemen-
tation of the recommendations of the Board following its 
mission to the country in 2016.
(b) Bolivia (Plurinational State of)
325. The Government of the Plurinational State of 
Bolivia provided information about drug-related develop-
ments in the country since the Board’s mission of October 
2016. In the past three years, the country has demon-
strated the will to address drug control matters that fol-
lowed re-accession in 2013 to the 1961 Convention as 
amended by developing regulations for the licit produc-
tion and consumption of coca bush and coca leaf, includ-
ing for cultural purposes. Coca leaf is used in the 
manufacture of food and medicinal products, including 
other industrial uses, such as natural wool dye. 
326. According to the Government’s update, the General 
Law on Coca (Act No. 906) was passed into law in 2017 
with a view to (a) shaping national policy on the cultural 
reaffirmation, production, movement, transport, sale, 
consumption, research, industrial use and the promotion 
of coca in its natural state; (b) establishing an institutional 
framework for regulation, control and monitoring; and 
(c) regulating administrative fees. The General Law on 
Coca and its implementing regulations establish mecha-
nisms to strengthen control of surplus crops, including 
through satellite monitoring of coca crops, the 
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establishment of authorized areas of coca production, reg-
istration and licensing procedures, and continuous con-
sultation with producers to raise awareness about the role 
of communities in controlling coca production. 
327. In 2017, the Law on the Fight against Illicit 
Trafficking in Controlled Substances was promulgated. 
The substantive regulations attached to that law provide 
new tools for criminal investigation including financial 
compensation for informants and the interception of 
communications related to offences involving controlled 
substances. In demonstration of the enhanced regional 
cooperation on drug trafficking, the Plurinational State of 
Bolivia established the Regional Centre for Anti-Narcotics 
Intelligence, a joint project with Argentina and Brazil. 
328. The Board notes the efforts of the Government to 
ensure that none of the coca crops produced within the 
scope of the treaty reservation are diverted for use in 
other activities. The Office of the Deputy Minister for 
Social Defence and Controlled Substances, through the 
Directorate General of the Special Force to Fight Drug 
Trafficking, conducts actions and operations by way of 
the Special Group for Coca Control, which detects inci-
dents of diversion of coca leaf in breach of the country’s 
General Law on Coca. In addition, the Ministry for Rural 
Development and Land and the Ministry of Productive 
Development and the Plural Economy issue regulations 
to ensure compliance with the quality standards for the 
industrial use of coca. 
329. Measures were adopted by the Plurinational State 
of Bolivia to develop and implement studies to determine 
the average coca leaf yield for the regions of Yungas and 
Trópico de Cochabamba and the northern provinces of 
La Paz. An inter-institutional technical committee com-
prising Government institutions and UNODC has been 
formed to carry out the study. The committee will coor-
dinate the activities necessary to study the coca yield in 
the country. European Union funding has been secured 
for the preparation and implementation of the study. 
330. The Board looks forward to continued cooperation 
with the Plurinational State of Bolivia and thanks the 
Government for its regular exchange of information with 
the Board.
(c) Myanmar
331. The Board undertook a mission to Myanmar in 
June 2016 and notes three years later that considerable 
progress has been achieved through new drug control leg-
islation and the conduct of a national drug use survey, 
with efforts ongoing to ensure adequate availability of 
opioids for medical purposes. The Government of 
Myanmar has supplemented its action plan for the elim-
ination of illicit drugs for the period 1999–2014 with a 
five-year action plan for the period 2015–2019. 
332. In 2018, Myanmar enacted the Narcotic Drugs and 
Psychotropic Substances Law, which amended the previ-
ous law of 1993 to provide better medical treatment 
opportunities in accordance with international standards. 
The amended law paves the way for moving to a more 
health-oriented approach to the prevention and treatment 
of drug use. The Central Committee for Drug Abuse 
Control adopted a new drug control policy which reflects 
the outcome document of the thirtieth special session of 
the General Assembly, on the world drug problem, held 
in 2016, and uses approaches designed to meet the 
Sustainable Development Goals. 
333. Drug law enforcement activities are being carried 
out in close cooperation between the Armed Forces, the 
Police Force and the Customs Department of Myanmar. 
The Drug Enforcement Division of the Police Force con-
ducted four special operations in 2018, including joint 
Myanmar-Thailand measures. Cross-border law enforce-
ment operations, with the cooperation of border liaison 
offices of China, the Lao People’s Democratic Republic 
and Thailand, have enhanced drug control efforts. 
Myanmar has also hosted the Safe Mekong Coordination 
Center and facilitated the sharing of experiences among 
countries of the Mekong region. Myanmar has also been 
actively tackling the illicit manufacture of and trafficking 
in amphetamine-type stimulants, including through 
cross-border drug law enforcement operations and infor-
mation exchange with China. The Board recognizes the 
continued challenges faced by Myanmar with respect to 
controlling and detecting precursors and equipment 
being used in the manufacture of illicit drugs. 
334. The Board takes note of the public-awareness mea-
sures and drug use prevention efforts of Myanmar, includ-
ing outreach to communities, schools and universities. 
Alternative development projects and drug eradication 
efforts were also carried out from 2012 to 2017, contrib-
uting to progress in the peace process. There have been 
benefits obtained from the cultivation of alternative crops, 
including avocado trees and coffee, such as the develop-
ment of infrastructure and livestock breeding. Several dis-
tricts now have access to clean drinking water and 
irrigation, and family incomes have also increased. The 
Board commends the efforts to implement these opium 
poppy substitution pilot programmes and prevention 
efforts, which have reportedly led to annual decreases in 
opium poppy cultivation and production. Additional 
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efforts are ongoing to ensure access and availability of con-
trolled substances for medical and research purposes. 
335. Concerning drug demand reduction, Myanmar 
reported that at the end of 2018, there were 55 methadone 
clinics across the country and more than 16,000 patients 
taking methadone every day. From January to September 
2018, there were a total of 5,490 new methadone patients. 
The rate of completion of six months of methadone main-
tenance therapy by patients is 70 per cent. The Myanmar 
National Strategic Plan on HIV and AIDS for the period 
2016–2020 has been operationalized at the subnational 
level and provides a road map for concrete strategies and 
steps to reach the populations most vulnerable to HIV 
transmission. A national strategic framework on health and 
drugs is being developed by the Ministry of Health and 
Sport, in coordination with the Ministry of Home Affairs 
and Ministry of Social Welfare, Relief and Resettlement. 
By the end of 2018, the Government reported that approx-
imately one third of the people who injected drugs had 
access to HIV prevention and measures aimed at minimiz-
ing the adverse public health and social consequences of 
drug abuse. There is a national goal to reach 90 per cent 
of people who inject drugs through HIV prevention, treat-
ment and health-care programmes. 
336. The Board looks forward to a continued dialogue 
with Myanmar about its comprehensive drug control 
efforts and any continued challenges faced by the coun-
try as it implements activities within the framework of 
the amended legislation and a health-oriented approach.
(d) Senegal
337. The Government of Senegal has provided informa-
tion to the Board about national drug control measures 
adopted since the Board’s mission in October 2016. 
Senegal has reported progress in creating a more effec-
tive legislative and regulatory drug control infrastructure. 
National measures have included the adoption of the 
National Strategic Plan for the period 2016–2020, which 
has been a key reference document for the country’s drug 
policy. Since 2018, additional financial resources have 
been allocated from the State budget for implementation 
of the National Strategic Plan.
338. The Board takes note of the efforts of Senegal to 
improve access to and availability of narcotics drugs and 
psychotropic substances for medical purposes, including 
the use of opioids for the treatment of pain, and to ensure 
their rational medical use. The Government of Senegal 
has held training workshops for cancer specialists and 
pharmacists responsible for managing morphine-based 
medicines with the support of the National Pharmaceutical 
Supplier and WHO. 
339. Efforts undertaken by the Government of Senegal 
in the area of drug abuse and treatment have included 
preparations for the establishment of a national monitor-
ing centre for drugs and addiction. The new centre would 
operate in addition to the Dakar addiction treatment cen-
tre, which dispenses methadone (for opioid substitution 
treatment) and is specialized in treating all addictions. 
Senegal has also held large-scale awareness-raising cam-
paigns during an annual national drug awareness and pre-
vention week. Awareness-raising activities are aimed at 
combating the stigmatization and marginalization of drug 
users. They are also intended to provide information about 
the availability of care and access to treatment centres and 
to reduce the risks associated with drug use by injection.
340. The Government of Senegal also reported on the 
intensification of its efforts to address drug trafficking and 
foster increased cooperation within the region. Specifically, 
a joint airport interdiction task force was established at 
the Blaise Diagne International Airport and a joint con-
tainer and vessel control unit was created at the 
Autonomous Port of Dakar. Those joint operational bod-
ies are composed of police, gendarmerie and customs offi-
cers. Capacity-building initiatives were also undertaken 
for law enforcement agencies, in particular the holding 
of training workshops on detection, investigations and 
inquiries. With regard to international cooperation, the 
Government of Senegal provided information about bilat-
eral agreements signed in the area of security that pro-
vide for joint investigations, the exchange of information 
and intelligence and the sharing of experiences and good 
practices, and also provided information on the holding 
of joint operations such as “Operation Open roads”, which 
was conducted in 2018 as part of an action plan on 
cross-border cooperation between the Gambia, Guinea-
Bissau and Senegal.
341. The Board encourages the Government of Senegal 
to continue its efforts to implement the provisions of the 
drug control conventions and looks forward to continued 
cooperation with the Government’s authorities on drug 
control matters.
(e) South Africa
342. The Government of South Africa has communi-
cated national drug control developments since the 
Board’s mission of October 2016. The country’s National 
Drug Master Plan has been renewed for the period 2018–
2022, with an implementation plan that seeks to reduce 
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supply and demand for drugs for non-medical use, 
increase measures aimed at minimizing the adverse pub-
lic health and social consequences of drug abuse, control 
drugs for medical use, and prevent new drugs from enter-
ing the illicit market. As part of efforts to improve coor-
dination among national drug control stakeholders, the 
country’s Department of Social Development provides 
technical support to the Central Drug Authority, which 
coordinates with the other government agencies in the 
field of combating substance abuse in South Africa. 
343. Through its National Department of Health, South 
Africa has adopted the health sector drug master plan for 
the period 2019–2023, in line with the National Drug 
Master Plan and the country’s Prevention of and Treatment 
for Substance Abuse Act of 2008. The health sector plan 
is aimed at enhancing drug control coordination in the 
health sector at the national, provincial and district lev-
els. The country’s Department of Health works in collab-
oration with the South African National AIDS Council 
and other stakeholders to develop and implement tar-
geted interventions for HIV-affected population groups. 
Data regarding the nature and extent of drug use among 
people affected by HIV are being collected through health 
surveys. 
344. The Government, through the South African Police 
Service, has adopted measures to ensure compliance with 
precursor pre-export notifications, including submission 
of data on precursors and new psychoactive substances, 
as well as participating in the international operational 
initiatives launched by INCB. The South African Narcotics 
Enforcement Bureau serves as the focal point for the sub-
mission of data to INCB and participation in operational 
actions, together with the Forensic Science Laboratory of 
the Police Service. 
345. As part of the efforts to understand the extent of 
drug use and the scope of available treatment, the 
National Department of Health has a system in place to 
monitor drug abuse in the country. That surveillance 
system is funded by the Department of Health and is 
part of the South African Medical Research Council. 
Data are also available through the South Africa 
Demographic and Health Survey and the South African 
National Health and Nutrition Examination Survey. The 
Government has also been supportive of the South 
African Community Epidemiology Network on Drug 
Use to monitor the trends of substance use in drug treat-
ment facilities. 
346. The Board welcomes the regular exchange of infor-
mation with South Africa and looks forward to contin-
ued cooperation with the authorities.
E.  Action taken by the Board to 
ensure the implementation of 
the international drug control 
treaties
1.  Action taken by the Board pursuant 
to article 14 of the Single 
Convention on Narcotic Drugs of 
1961 as amended by the 1972 
Protocol and article 19 of the 
Convention on Psychotropic 
Substances of 1971
347. Where the Board has objective reason to believe that 
the aims of the international drug control conventions are 
being seriously endangered by the failure of a party, State or 
territory to comply with the obligations contained in one of 
the conventions, the Board can invoke certain measures to 
facilitate compliance. These measures, consisting of a series 
of steps, are set out in article 14 of the 1961 Convention as 
amended, article 19 of the 1971 Convention and article 22 
of the 1988 Convention. Under these articles, the Board 
engages in a dialogue with the State or States in question 
with a view to facilitating compliance with the conventions 
when all other means have been unsuccessful.
348. Throughout its history, INCB has invoked article 
14 of the 1961 Convention and/or article 19 of the 1971 
Convention with respect to a number of States and has 
engaged in dialogue with the Governments of those States 
with a view to bringing about compliance with the con-
ventions. In such cases, the name of the State concerned 
is not publicly disclosed and related consultations with 
the Board are confidential, unless the Board decides to 
bring the situation to the attention of the parties, the 
Economic and Social Council or the Commission on 
Narcotic Drugs following its consultations with the 
Government in question. 
349. The present section includes a discussion on mea-
sures taken by the Board regarding Afghanistan because, 
in 2001, the Board determined that a serious situation 
existed that called for cooperative action at the interna-
tional level and with the authorities of any future govern-
ing body in Afghanistan, whether transitional or 
permanent, and decided to use its annual report to call 
the parties to the 1961 Convention as amended by the 
1972 Protocol, the Economic and Social Council and the 
Commission on Narcotic Drugs to the situation in 
Afghanistan, pursuant to article 14, paragraph 1 (d), of 
the 1961 Convention as amended.
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2.  Consultation with the Government 
of Afghanistan pursuant to article 
14 of the 1961 Single Convention on 
Narcotic Drugs as amended by the 
1972 Protocol
350. The Board and its secretariat have been in regular 
contact with the Government of Afghanistan throughout 
the period under review and have met with senior 
representatives of the Government on several occasions 
to discuss the most effective way of securing international 
assistance for the country following the Board’s invoca-
tion in May 2018 of article 14 bis of the 1961 Convention 
as amended, with the consent of the Government. In par-
ticular, in February 2019, the President of the Board and 
the Permanent Representative of Afghanistan to the 
United Nations (Vienna) met to discuss the drug control 
situation in the country, as well as matters pertaining to 
the implementation of the Board’s recommendations fol-
lowing its mission to Afghanistan in May 2016, and the 
actions to be undertaken under article 14 bis of the 1961 
Convention as amended. 
351. In March 2019, the President of the Board met 
with the delegation of Afghanistan to the sixty-second 
session of the Commission on Narcotic Drugs, led by the 
Deputy Foreign Minister for Political Affairs of 
Afghanistan, to discuss the needs and challenges of 
Afghanistan in drug control. 
United Nations action
352. On 15 March 2019, Security Council unanimously 
adopted resolution 2460 (2019), in which it decided to 
extend until September 2019 the mandate of UNAMA, 
recognized that the renewed mandate of UNAMA was in 
support of the country’s full assumption of ownership in 
the security, governance and development areas,  consistent 
with priorities outlined in the Transformation Decade 
(2015–2024). In the same resolution, the Council stressed 
the central importance of a comprehensive and inclusive 
Afghan-led and Afghan-owned political process towards 
a peaceful resolution of the conflict and a comprehensive 
political settlement and welcomed progress in that regard. 
In addition, the Council stressed the critical importance 
of a continued and appropriate presence of UNAMA and 
other United Nations agencies, funds and programmes in 
the provinces, based on a “One United Nations” approach 
and in close consultation and coordination with and in 
support of the priorities of the Afghan Government, in 
response to needs and with a view to security and includ-
ing the objective of overall United Nations effectiveness.
353. On 17 September 2019, the Security Council 
adopted resolution 2489 (2019) in which it decided to 
extend the mandate of UNAMA until 17 September 2020. 
In the same resolution the Council decided that the 
Special Representative of the Secretary-General for 
Afghanistan and Head of UNAMA would continue to 
lead and coordinate the international civilian efforts, in 
full cooperation with the Government of Afghanistan, 
focusing on priorities that included providing outreach 
and good offices to support, in close consultation with 
the Government of Afghanistan, the Afghan-led and 
Afghan-owned peace process.
Situation in Afghanistan
354. The security situation in Afghanistan continued to 
be highly volatile. In 2018, UNAMA recorded 22,478 
security incidents, a decrease of 5 per cent compared with 
the figure for 2017 (23,744 security incidents), which was 
the highest figure ever recorded. The southern and east-
ern parts of Afghanistan saw the largest number of secu-
rity incidents in 2018, accounting for 52 per cent of all 
security incidents in the country. The number of targeted 
killings and abductions increased by 9 per cent in 2018 
compared with the previous year, and the number of sui-
cide attacks increased by 5 per cent. UNAMA also 
recorded 13,805 armed clashes in 2018 (a decrease of 
10 per cent compared with the figure for 2017), which 
accounted for 61 per cent of all security-related incidents 
in the country. There were 1,352 airstrikes reported in 
2018, which is a substantial increase (42 per cent) 
 compared with the figure for 2017. 
355. Despite the intensification of peace talks in the first 
half of 2019, the Taliban announced the start of its offen-
sive in April 2019. Throughout 2018, the Taliban tempo-
rarily captured 21 district administrative centres. In April 
2019, the Taliban announced that, in the areas in 
Afghanistan under its control, it had temporarily pre-
vented ICRC and WHO from carrying out relief work 
and that it had revoked security guarantees for their staff. 
In September 2019, the Taliban announced that it had 
revoked its ban on ICRC in Afghanistan and that, in the 
areas under its control, it would guarantee security of 
ICRC staff providing humanitarian assistance.
356. Several Taliban-led attacks in September 2019 
caused substantial casualties among civilians in 
Afghanistan. Following an attack on 6 September, in 
which a United States soldier and 11 others were killed, 
the President of the United States announced the with-
drawal of the United States from negotiations with the 
Taliban. 
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357. In April 2019, a four-day Consultative Peace Loya 
Jirga was convened by the President of Afghanistan with 
the aim of discussing the framework for negotiations with 
the Taliban. The Loya Jirga brought together about 3,200 
elders, religious scholars and other prominent Afghans, 
representing all parts of Afghanistan and all ethnic groups 
in the country. However, many political figures and par-
ties, including the Chief Executive of Afghanistan, refused 
to participate in the four-day gathering, claiming that they 
had not been involved in any of the prior consultations.
358. After several months of delay, the electoral man-
agement bodies finalized the results of the 2018 parlia-
mentary elections, which led to the inauguration of a new 
parliament for the first time since 2011. On 29 May 2019, 
the Independent Election Commission announced that 
the presidential election would be held on 28 September 
2019.
359. Afghanistan undertook structural reforms that 
resulted in the merger of the Ministry of Counter 
Narcotics and the Ministry of the Interior in April 2019. 
360. In their meetings with the Board, representatives of 
the Afghan Government emphasized that the Government 
would continue to attach the highest importance to its 
drug control efforts, even though those efforts continued 
to be hampered by structural issues facing the country, 
such as armed insurgency and terrorist acts and security 
threats; limited alternative livelihood opportunities; and 
poor prevention, treatment and rehabilitation programmes 
due to limited resources. The representatives noted the 
grave consequences of drug abuse on the Afghan popula-
tion and the disproportionate impact of drug abuse on 
women, given their role as primary caregivers and given 
the lack of resources earmarked specifically for their treat-
ment, rehabilitation and social reintegration. 
361. In July 2019, UNODC issued Afghanistan Opium 
Survey 2018: Challenges to Sustainable Development, Peace 
and Security, which had been prepared in close collabo-
ration with the Ministry of Counter Narcotics of 
Afghanistan. According to the publication, in 2018, the 
total area under illicit opium poppy cultivation in 
Afghanistan was reduced by 20 per cent and, as a result, 
the amount of opium produced dropped by 29 per cent 
to an estimated 6,400 tons. These sharp decreases came 
after sustained lack of rain and snow during the 2017/18 
wet season. A severe drought affected crops in more than 
two thirds of Afghanistan, devastating the agricultural 
sector, and incomes reportedly fell by about a half in 
severely affected areas. The gross value of the Afghan opi-
ate economy fell by two thirds, from between $4.1 billion 
and $6.6 billion in 2017 to between $1.2 billion and 
$2.2 billion in 2018. However, the opiate economy still 
accounted for 6–11 per cent of the country’s gross domes-
tic product and exceeded the value of its officially 
recorded licit exports of goods and services.
362. In the meantime, international partners of 
Afghanistan, including UNODC, continued to provide 
assistance in the area of drug control. Under a joint ini-
tiative of the Ministry of Agriculture, Irrigation and 
Livestock, the Ministry of Counter Narcotics and 
UNODC, a two-day conference on the role of agricultural 
extension in the promotion of alternative development in 
Afghanistan was held in Kabul in October 2018. About 
150 agricultural workers attended the event, which show-
cased agricultural products and technological advances in 
the private sector and provided marketing opportunities 
for crop and livestock products. A one-day national con-
ference focusing on investment in the development of the 
pine nut trade as an alternative development initiative was 
held in Kabul in January 2019. 
Cooperation with the 
international community
363. At the Thirteenth Triangular Initiative Senior 
Officials Meeting, held in Islamabad in December 2018 
with the support of UNODC, the drug control authori-
ties of Afghanistan, Iran (Islamic Republic of) and 
Pakistan discussed ways to improve regional drug control 
cooperation. The senior officials agreed on conducting 
joint activities, including joint patrolling operations, intel-
ligence-led drug interdiction operations and controlled 
delivery operations.
364. Afghanistan continued to pursue regional and 
international cooperation under the Heart of Asia – 
Istanbul Process. Under this platform, a regional techni-
cal group meeting on culture and education was held in 
Tehran in August 2018, a meeting on counter-terrorism 
was held in Kabul in September 2018, a meeting on trade 
and commerce was held in New Delhi in October 2018, 
a meeting on counter-narcotics was held in Moscow in 
October 2018 and a meeting of senior officials was held 
in Ankara in June 2019.
365. The President of Afghanistan attended a meeting of 
the Council of Heads of State of the member States of 
SCO held in Bishkek in June 2019. At that meeting, rep-
resentatives of member States of SCO reaffirmed their 
intention to step up joint efforts to combat drug traffick-
ing, including under the three international drug control 
conventions and other related legal instruments. They also 
reaffirmed their determination to ensure regional security 
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and stability and expressed their support for the work 
being carried out by the Government and people of 
Afghanistan, with the assistance of the international com-
munity, that was aimed at restoring peace and ensuring 
the sustained development of the country. They expressed 
their willingness to facilitate a political settlement under 
the guidance of the people of Afghanistan and with their 
involvement on a bilateral basis and within the framework 
of the contact group on Afghanistan of SCO.
Conclusions
366. Afghanistan continued to face complex challenges 
to its security and peacebuilding efforts. While between 
January and September 2019, there was an intensification 
of peace talks, including those facilitated by the interna-
tional community, as well as the intra-Afghan peace dia-
logue, the conflict continued, resulting in numerous 
casualties among the civilian population. The negotiation 
efforts led by the United States seem to have come to a 
standstill following a spate of Taliban-led attacks in 
September 2019. 
367. Despite the sharp drop in the total area under 
illicit opium poppy cultivation and the estimated amount 
of opium produced in Afghanistan in 2018, which were 
mainly attributable to severe drought, the opiate econ-
omy continued to be substantial, even exceeding the 
value of the country’s licit exports of goods and services. 
The Government continued to express its commitment 
to tackling the drug situation in the country, while 
underlining the need for continued regional and inter-
national cooperation and assistance in the area of drug 
control. 
368. The Board is committed to continuing its consul-
tations with the Government of Afghanistan, in particu-
lar, with a view to effectively implementing article 14 bis 
of the 1961 Convention as amended. In this regard, the 
Board will continue to engage with the Government of 
Afghanistan, the competent United Nations organs and 
specialized agencies, in order to facilitate the delivery of 
assistance to Afghanistan in addressing drug control chal-
lenges in the country and to ensure that sustainable devel-
opment is an essential component of drug control in the 
country.
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Chapter III.
Analysis of the world situation
A. Global issues
1.  Respect for human rights in the 
elaboration and implementation of 
drug control policy
369. Over the current reporting period, the Board has 
noted with great concern continued reports of grave 
human rights violations purportedly perpetrated in fur-
therance of national drug control policies. The Board is 
compelled to remind all States parties to the international 
drug control conventions that the primary objective of 
these instruments is to safeguard the health and welfare 
of humanity and to recall that the goal of protecting the 
welfare of humanity must be understood to include 
respect for human rights.
370. The Board therefore wishes to reiterate in the clear-
est possible terms that in order to comply with their legal 
obligations under the international drug control conven-
tions, States parties must adopt and pursue drug control 
policies in compliance with internationally recognized 
human rights which, as described in the Universal 
Declaration on Human Rights,70 are both inherent and 
inalienable.
371. Ensuring the consistency of drug control policies 
and programmes with human rights obligations means 
accepting that the drug control treaties are not in conflict 
with human rights. Rather, the three international drug 
control conventions ought to be read within the interna-
tional human rights framework, including the protection 
70 General Assembly resolution 217 A (III).
of fundamental freedoms and due process rights, stem-
ming from the inherent dignity of all people. Compliance 
with the drug conventions can therefore lead to the direct 
and positive fulfilment of human rights, especially the 
realization of our universal right to health, which includes 
access to treatment. Current approaches to drug use need 
to avoid the pathway that easily leads from stigmatizing 
and alienating drug users to violating their fundamental 
rights to humane treatment and care. Non-consensual 
drug treatment programmes should be replaced, and the 
inequality of access to treatment that women and minority 
groups face needs to be addressed and remedied.
372. The human rights challenges inherent in respond-
ing effectively to widespread drug abuse and drug-related 
crimes are exacerbated when States try to justify dispro-
portionately repressive and punitive measures. Protecting 
the rights and dignity of individuals suspected of having 
committed drug-related offences may at times seem 
counter-intuitive, but drug control policies that protect 
all human rights principles and standards have proved to 
be the most effective and sustainable. A human rights-
based approach to address the spread of problematic drug 
use specifically requires proportionate criminal justice 
responses for drug-related offences, including when they 
are allegedly committed by people who use drugs, and 
ending extrajudicial responses, which cannot be justified 
in any circumstances.
373. International cooperation in the field of drug con-
trol could be enhanced through increased respect for the 
binding and cross-cutting nature of international human 
rights. No State is exempt from human rights norms and 
principles when interpreting the drug control conven-
tions. From this perspective, the Board has consistently 
recommended to States that human rights norms should 
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form an integral part of their drug-related strategies and 
policies. Together, States and civil society can embrace 
the core objectives of the international drug control trea-
ties by designing drug policies that are harmonious with 
the human rights conventions and fully promote the 
health and welfare of humankind.
2.  Linkages between the international 
drug control conventions and the 
Sustainable Development Goals
374. The international drug control system was elabo-
rated by Member States to act on their concern for the 
health and welfare of humankind. It is founded primar-
ily on three conventions: the Single Convention on 
Narcotic Drugs of 1961 as amended by the 1972 Protocol, 
the Convention on Psychotropic Substances of 1971 and 
the United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988. At 
the most recent special session of the General Assembly 
on the world drug problem, held in 2016, Member States 
underscored that, together with other relevant interna-
tional instruments, those conventions constitute the cor-
nerstone of the international drug control system. 
375. Fundamentally, the international drug control con-
ventions are based on the principle that the medical use of 
narcotic drugs and psychotropic substances is indispens-
able for the relief of pain and suffering and that accord-
ingly their availability should not be unduly restricted. At 
the same time, Governments have the responsibility to pre-
vent drug abuse and diversion, including of substances 
controlled by the conventions. As a source of international 
law, the conventions are to be interpreted in good faith and 
in the light of that objective. 
376. On 1 January 2016, the 17 Sustainable Development 
Goals contained in the 2030 Agenda for Sustainable 
Development,71 adopted by the General Assembly in 
September 2015, came into force. The Sustainable 
Development Goals, which build on and supersede the 
Millennium Development Goals of the period 2000–2015, 
are aimed at ending all forms of poverty. Over the next 
15 years, these new universal goals are to guide countries 
in mobilizing efforts to develop strategies for economic 
growth by addressing a range of social needs including 
education, health, social protection and employment, 
while tackling climate change and promoting environmen-
tal protection and sustainable development. The Sustainable 
Development Goals are consistent with the three 
71 General Assembly resolution 70/1.
international drug control conventions as the Goals foster 
coordinated action and shared responsibility to address 
the world drug problem. At the thirtieth special session 
of the General Assembly, on the world drug problem, held 
in 2016, Member States noted that efforts to achieve the 
Goals and to effectively address the world drug problem 
were complementary and mutually reinforcing. 
377. Drug-related issues and challenges are vast, and 
currently there are great disparities in health and welfare 
in different regions of the globe. These challenges include 
the limited access to pain medication, including opioid 
analgesics and medicines used for substitution therapy, as 
well as the medication required for the treatment of men-
tal illnesses. In many parts of the world, prevention ini-
tiatives are lacking, treatment and rehabilitation services 
to people with drug use disorders are inexistent or poor, 
and mechanisms to eliminate stigma and foster social 
reintegration have yet to be established.
378. The conventions establish a system of administra-
tive controls regulating production, manufacture, import 
and export of substances under international control 
allowing States to estimate their domestic requirements 
and ensure that adequate amounts of medicines are avail-
able to their populations. Similarly, the conventions 
require States to give special attention to and take all 
practicable measures for the prevention of abuse of drugs 
and for the early identification, treatment, education, 
aftercare, rehabilitation and social reintegration of the 
persons involved. Despite their clarity, these provisions 
have to a large extent not been widely and sufficiently 
implemented by States. 
379. The Board therefore welcomes Sustainable 
Development Goal 3, which is to ensure healthy lives and 
promote well-being for all at all ages. Achieving that Goal 
entails, inter alia, access to high-quality essential health-
care services and access to safe, effective, high-quality and 
affordable essential medicines; ending the epidemic of 
AIDS; and strengthening the prevention and treatment of 
substance abuse, including narcotic drug abuse. Sustainable 
Development Goal 3 and its associated targets demonstrate 
the awareness of the global community in that regard. 
380. However, the world drug problem encompasses 
more than the health aspect. Illicit crop cultivation and 
drug trafficking perpetuate poverty, corruption, violence 
and criminality. In many parts of the world, human rights 
violations in the name of drug control, extrajudicial 
responses to drug-related criminality, the stigmatization of 
people with drug use disorders, disproportionate punish-
ment and the general lack of rule of law continue to hin-
der efforts to successfully address drug-related challenges. 
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381. The conventions oblige States to establish certain 
types of conduct as punishable offences, and they also 
require States to implement responses to drug-related 
crime that are proportionate. The conventions further 
provide States with the possibility of applying alternative 
measures to conviction, punishment and incarceration, 
including education, rehabilitation or social reintegration. 
They contain provisions on international cooperation in 
criminal matters and mutual legal assistance. 
382. In the Sustainable Development Goals, the inter-
national community undertook to promote peaceful and 
inclusive societies and provide access to justice for all 
(Goal 16), to reduce inequality within and among coun-
tries (Goal 10) and to make cities and human settlements 
inclusive, safe, resilient and sustainable (Goal 11). In that 
regard, the Board reiterates its call on States to counter 
drug trafficking and related violence while ensuring that 
responses to drug-related criminal conduct are propor-
tional and founded upon respect for human rights and 
dignity, in line with the three international drug control 
conventions and the rule of law. 
383. The adoption of the international drug control con-
ventions was based on the understanding among the 
international community that the challenges posed by the 
world drug problem required a coordinated response by 
States. Reflecting this, the conventions are today among 
the most widely ratified international instruments in exis-
tence. Addressing the world drug problem remains a 
common and shared responsibility and requires joint 
action. In this regard, international platforms and net-
works for dialogue, information-sharing and debate 
among States are crucial. The Commission on Narcotic 
Drugs acts as the principal policymaking body of the 
United Nations with prime responsibility for drug con-
trol matters. The Board calls on Governments to use the 
Commission as a forum for accessing and providing 
knowledge and experiences on drug-related successes and 
challenges and to support the international community 
in addressing the world drug problem in a comprehen-
sive and collaborative manner. 
384. As with other international treaties, the choice of 
policy, legislative and administrative measures to imple-
ment the conventions is left to the discretion of States 
parties. The Board will continue to urge Governments to 
take concrete action to guide their policymakers, institu-
tions and people to work towards full implementation of 
the conventions, guided by the key objective of promot-
ing health and welfare in harmony with human rights 
standards and norms and the rule of law. It is the action 
taken by Governments at the national level, founded on 
international law, that will determine whether global 
agreements and partnerships such as the 2030 Agenda for 
Sustainable Development will be achieved. 
3.  Reducing the negative consequences 
of drug use through effective public 
health policies
385. Managing pervasive and complex drug abuse risks 
requires adopting strategies that not only are scientifically 
proven to be effective but also avoid unintended negative 
consequences. The effects of epidemic-level drug abuse 
and addiction rates can be countered through balanced 
public health policies and practices that aim to provide 
all necessary treatment and recovery services and prevent 
the initiation of illicit drug use. Ending the devastation 
for individuals, families and entire communities caused 
by drug abuse primarily entails reducing demand and 
curbing supply, focusing efforts on treatment, education, 
aftercare, rehabilitation and social reintegration.
386. The Board has written extensively about measures 
that aim to minimize the adverse public health and social 
consequences of drug abuse as forming a tertiary preven-
tion strategy for demand reduction purposes that can play 
a part in comprehensive drug demand reduction. This 
long-standing vision of INCB with respect to reducing 
negative drug-related consequences is consistent with the 
outcome document of the thirtieth special session of the 
General Assembly, on the world drug problem, held in 
2016, in which Heads of State and Government invited 
relevant national authorities to consider such effective 
measures, including appropriate medication-assisted ther-
apy programmes.
387. In many States, drug control policy focuses exclu-
sively on the demand reduction and supply reduction 
aspects of drug control and does not include measures to 
curtail the adverse consequences associated with sub-
stance abuse and addiction. While demand reduction and 
supply reduction constitute two fundamental pillars of 
drug control policy, the Board also encourages States to 
take a balanced approach to countering drug use and 
dependence through the adoption of measures intended 
to reduce the associated negative public health conse-
quences. The Board notes that in some States, limited 
resources have resulted in civil society and community- 
based groups taking the lead in the delivery of these 
services.
388. Drug control policies, in order to be consistent 
with the international treaties, should be evidence-based 
and should not lead to the promotion of substance abuse 
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or facilitate trafficking or other illicit activities and thereby 
violate the treaties and the obligation to combat drug 
trafficking. In the past, the Board has expressed its sup-
port for strategies which met that threshold, including 
needle exchange programmes, opioid agonist therapies, 
psychosocial counselling and the use of drug consump-
tion rooms, as long as they were part of an integrated 
approach for referral and improved access for under-
served populations to treatment and support services.
389. The Board acknowledges the need for initiatives 
and measures aimed at minimizing the negative conse-
quences of drug abuse based on reliable and proven sci-
entific data and encourages the exchange of good practices 
through greater dialogue between relevant stakeholders, 
including Governments, civil society groups, public health 
authorities and law enforcement authorities.
4.  Exempted preparations under the 
Convention on Psychotropic 
Substances of 1971
390. Since the 1990s, INCB has noted an overall increase 
in the quantity of psychotropic substances used in the 
manufacture of preparations exempted pursuant to 
article 3 of the 1971 Convention (see figure XVII). 
According to INCB records, during this time, nearly 1,000 
pharmaceutical preparations containing psychotropic 
substances under control were considered for exemption 
from certain control measures. In recent years, the Board 
has noted with concern the lack of clarity surrounding 
article 3 of the 1971 Convention and the control mea-
sures that countries are still required to apply in the case 
of an exempted preparation.
391. The 1971 Convention defines a preparation of a psy-
chotropic substance as any solution or mixture, in what-
ever physical state, containing one or more psychotropic 
substances or one or more psychotropic substances in dos-
age form.72 According to article 3, paragraph 1, of the 1971 
Convention, if a preparation is not exempted, it is subject 
to the same measures of control as the psychotropic sub-
stance that it contains, and if it contains more than one 
such substance, the control measures of the most strictly 
controlled of those substances are applicable. 
392. Furthermore, under article 3, paragraph 2, States 
parties are permitted to exempt a preparation that contains 
72 According to the Commentary on the Convention on Psychotropic 
Substances, dosage form refers to a measured small quantity of a psycho-
tropic drug or combination of psychotropic drugs in whatever form 
(tablet, ampoule or powder) ready for consumption.
a psychotropic substance included in Schedule II, III or IV 
from international control measures under certain condi-
tions. While article 3 of the 1971 Convention provides the 
opportunity to reduce the regulatory requirements and 
measures of control that competent national authorities 
need to apply, the use of that article must be warranted in 
order to ensure that the exemptions from certain control 
measures do not pose a public health risk or encourage 
illicit activity. 
393. To warrant an exemption, the preparation must be 
compounded in a way that it presents no risk or negligible 
risk of abuse or of a public health problem and cannot 
be recovered by readily applicable means in a large 
enough quantity as to pose a risk. In determining whether 
this latter condition holds, the expense and technical dif-
ficulty of recovering the psychotropic substance from the 
preparation should be considered.73
394. While a country can decide to exempt a prepara-
tion from certain measures of control under the 1971 
Convention, article 3, paragraph 3, outlines the control 
measures that must be applied regardless. Those mea-
sures of control are provided in the following articles of 
the Convention: (a) article 8 (licences), as it applies to 
manufacture; (b) article 11 (records), as it applies to 
exempted preparations; (c) article 13 (prohibition of and 
restrictions on export and import); (d) article 15 (inspec-
tion), as it applies to manufacture; (e) article 16 (reports 
to be furnished by the parties), as it applies to exempted 
73 Commentary on the Convention on Psychotropic Substances, p. 116.
Figure XVII. Reported use of psychotropic 
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preparations; and (f) article 22 (penal provisions), to the 
extent necessary for the repression of acts contrary to laws 
or regulations adopted pursuant to the stated obligations.
395. Commission on Narcotic Drugs resolution 1 
(S-VIII) of 1984 provides further control measures from 
which preparations should not be exempted. In particu-
lar, the resolution states that exempted preparations 
should not be exempted from the requirements of article 
12 on provisions relating to international trade. More spe-
cifically, international trade in exempted preparations 
shall still require separate import and export authoriza-
tions and post-export declarations. 
396. If a country wishes to exempt a preparation from 
control measures, it must submit a notification to the 
Secretary-General with the trade names of the intended 
exempted preparation, as well as the name of the sub-
stance as listed in the schedules of the Convention or the 
international non-proprietary name if the former is not 
available. The notification must include a description of 
the composition of the preparation including the chemi-
cal structure and the formulae of all its ingredients, list 
the control measures from which the preparation is 
exempted, and confirm the control measures mentioned 
in article 3, paragraph 3, that would continue to apply.
397. Upon receipt of such notification, the Secretary-
General will transmit the notification to the other parties 
to the Convention, WHO and the International Narcotics 
Control Board. If a party or WHO receives information 
regarding an exempted preparation which in its opinion 
warrants the termination, in part or in whole, of the 
exemption, it will notify the Secretary-General, providing 
the information in support of the notification. The 
Secretary-General, will transmit such information to the 
parties and the Commission. WHO shall communicate to 
the Commission an assessment of the preparation in regard 
to the risk of abuse and potential recoverability, with a rec-
ommendation of the control measures, if any, from which 
the preparation should cease to be exempted.
398. Taking into account the assessment provided by 
WHO on medical and scientific matters, and considering 
the economic, social, legal, administrative and other fac-
tors it may consider relevant, the Commission may decide 
to terminate the exemption from any or all control mea-
sures. Any decision made by the Commission will be 
communicated by the Secretary-General to all parties. All 
parties must take measures to eliminate the exemption 
from the control measure or measures within 180 days 
of that notification from the Secretary-General. 
399. Between 2010 and 2018, 66 different psychotropic 
substances under international control were reported in 
the manufacture of exempted preparations in 22 countries. 
In 2018 alone, 34 psychotropic substances under interna-
tional control were reported to the Board as being used 
in the manufacture of exempted preparations in a com-
bination of 11 countries (see figures XVIII and XIX).
Figure XVIII. Number of psychotropic substances reported for use in the manufacture of 
exempted preparations 
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Figure XIX. Countries reporting the manufacture of exempted preparations on form P 
400. Phenobarbital is by far the most commonly used 
substance in the manufacture of exempted preparations, 
with tens of thousands of kilograms of the substance 
being used each year for exempted preparations (see 
table). Exempted preparations containing phenobarbital 
tend to be medications used for mild pain and sedation. 
Aside from phenobarbital, over the last five years, 
butalbital, oxazepam, zolpidem and diazepam have been 
the most reported substances used in the manufacture of 
exempted preparations.74
74 According to information furnished to the Board by Governments 
pursuant to the 1971 Convention and resolutions of the Commission on 
Narcotic Drugs and the Economic and Social Council, as maintained in 
the database of the INCB International Drug Control System.
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Substance 2014 2015 2016 2017 2018
Phenobarbital 26 923 18 975 20 224 23 331 20 850
Butalbital 3 292 12 095 8 296 5 090 15 814
Oxazepam 3 081 3 128 2 390 2 455 2 718
Zolpidem 1 626 1 216 2 191 2 036 1 700
Barbital 826 1 060 482 548 1 394
Diazepam 2 053 1 361 1 885 1 914 1 235
Amfepramone 579 581 691 862 862
Temazepam 414 464 754 207 663
Prazepam 676 416 312 520 312
Bromazepam 525 373 461 346 290
Table Quantity of psychotropic substances reported for use in the manufacture of exempted 
preparations, 2014–2018, in descending order (kg) 
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401. The Board calls upon Governments to ensure that 
all aspects of article 3 of the Convention on Psychotropic 
Substances of 1971 are correctly implemented if they 
wish to exempt a preparation from certain measures of 
control. The Board also reminds Governments that they 
are still obligated to uphold certain measures of control 
even in cases where a preparation has been exempted, 
such as in reporting annual data and provisions relat-
ing to international trade. Ensuring that all provisions of 
the 1971 Convention are upheld is imperative for elimi-
nating the possibility of diversion to illicit channels while 
allowing for countries to benefit from the flexibility that 
the Convention provides in cases where an exemption is 
warranted.
5.  Non-medical use of synthetic 
opioids
402. The world is currently in the midst of a global syn-
thetic opioids crisis. New data suggest that the problem 
is greater than was previously known, with current esti-
mates indicating that more than 53 million people, or 
1.1 per cent of the general population aged 15–64, abused 
opioids in the past year, of whom almost 30 million had 
reportedly used opiates such as heroin and opium. 
Although global estimates specifically for non-medical 
use of synthetic opioids are not available, the large 
increase in users has been attributed to increases in the 
non-medical use of synthetic opioids.
403. While non-medical use of synthetic opioids is 
reported in many countries, the crisis manifests itself in 
different forms from region to region. In some high-income 
countries such as Canada and the United States, synthetic 
opioids such as hydrocodone, oxycodone and fentanyl are 
widely and readily available, and their aggressive market-
ing and subsequent over-prescription has contributed to 
increases in dependency. In several countries in Europe, 
there are also indications of an increased non-medical use 
of synthetic opioids, with methadone, buprenorphine and 
fentanyl being reported as the main pharmaceutical opi-
oids misused. Past-year abuse of opioids in Australia is 
also higher than the estimated global average, with the 
non-medical use of pharmaceutical opioids being the 
main concern.
404. The Board has noted for years that the non-medical 
use of tramadol, an opioid analgesic not under interna-
tional control, is a significant and growing problem in 
several countries, in particular in West and North Africa, 
the Near and Middle East and South Asia. In Nigeria, 
the National Survey on Drug Use and Health, collecting 
data for 2017, found that 4.7 per cent of the general 
population aged 15–64 reported past-year non-medical 
use of prescription opioids, most commonly tramadol. 
In India, the national drug use survey found that nearly 
1 per cent of the general population engaged in 
non-medical use of pharmaceutical opioids in 2017. 
Non-medical use of high-concentration tramadol tablets 
continues to be reported throughout Egypt, the State of 
Palestine and the United Arab Emirates (see also sect. 
A.9 below on tramadol). 
405. The rate of global drug overdose deaths has been 
steadily increasing since 2000. In particular, it is estimated 
that 66 per cent of deaths attributed to drug use disor-
ders were related to opioids. Increases in drug-related 
deaths are in part due to the emergence and abuse of illic-
itly manufactured fentanyl and fentanyl analogues in 
North America. 
406. Globally, newly emerging fentanyls accounted for 
19 of the 22 new synthetic opioids identified in 2017. The 
largest share of those are from North America, where the 
United States Centers for Disease Control and Prevention 
estimated that overdoses in the United States alone 
increased to more than 70,000 in 2017 and that 47,600 
of those overdoses were opioid-related. In Canada, the 
rate of opioid-related deaths rose to 12.0 per 100,000 pop-
ulation in 2018; the percentage of accidental apparent 
opioid-related deaths that involved fentanyl or fentanyl 
analogues was 73 per cent in 2018.
407. While overdose death rates worldwide are cur-
rently far lower than in Canada and the United States, 
indications of the potential for increasing abuse of syn-
thetic opioids have been reported in other regions. In 
Europe, 9,400 overdose deaths were reported in 2017, 
with opioids accounting for between 80 and 90 per cent 
of drug-related deaths. States members of the European 
Union have reported increases in the amount of synthetic 
opioids in their illicit drug markets. Of a total of 38 new 
psychoactive substances detected since 2009, 28 were 
fentanyls. 
408. In Australia, by 2016, reported deaths caused by 
opioid overdose had nearly doubled since 2007, rising 
from 3.8 to 6.6 deaths per 100,000. While the increase is 
attributed mostly to pharmaceutical opioids, including as 
used in combination with heroin, overdose deaths due to 
synthetic opioids such as fentanyl increased more than 
tenfold over the same period. 
409. There are indications that the situation may be sta-
bilizing in some regions. In the United States, where pre-
scription practices have become more stringent, drug 
overdose deaths declined by about 5 per cent from 
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December 2017 to December 2018, to about 68,000 
deaths, due in part to decreases in overdose deaths related 
to prescription opioids (e.g., oxycodone). Following tra-
madol control changes in India in mid-2018, experts in 
Ghana and Nigeria noted a significant decline in large 
border and port seizures of tramadol, decreases in grey 
market availability and a corresponding increase in the 
price of tramadol tablets in the illicit market. The 
Government of China implemented group scheduling of 
all fentanyl-related substances effective May 2019, ensur-
ing class-wide control, inter alia, of all manufacture and 
export.
410. The Board, in its annual report for 2017, identified 
and reiterated the risks associated with long-term opioid 
use and the consumption of opioid analgesics. The Board 
once again encourages Governments to work together 
with public health officials, pharmacists and physicians, 
manufacturers and distributors, consumer protection 
associations and law enforcement agencies to promote 
public education about the risks associated with prescrip-
tion drugs and adopt appropriate measures to decrease 
their abuse and potential to cause dependence.
6.  Abuse of codeine-based cough 
syrups
411. The 1961 Convention as amended by the 1972 
Protocol allows for certain preparations of narcotic drugs 
(including codeine) which are included in Schedule III of 
the Convention to be exempted from some provisions 
when compounded with one or more other ingredients 
and containing not more than 100 milligrams of the drug 
per dosage unit and with a concentration of not more 
than 2.5 per cent in undivided preparations.
412. These preparations, in particular those containing 
codeine, are widely used for medical purposes for the 
treatment of cough. Since 2000, of the total amount of 
morphine utilized globally, the majority (88 per cent, on 
average) was converted into other narcotic drugs (mostly 
codeine), and almost all of the codeine manufactured 
(89 per cent) was used to manufacture cough medication. 
In 2010, over 255 tons of codeine were used for prepara-
tions listed in Schedule III. This amount has gradually 
increased, reaching over 291 tons in 2016, but decreased 
to 240 tons in 2017. 
413. Codeine syrups are easy to purchase as over-the-
counter medicine in many countries. They are relatively 
cheap and are perceived to have low risk of negative 
health consequences (e.g., dependence and overdose) in 
comparison with other drugs. 
414. The abuse of cough syrups has been a common 
occurrence in some countries for many years. More 
recently, there have been reports of the misuse of prepa-
rations containing codeine that are listed in Schedule III 
in Bangladesh, Hong Kong, China, India, Japan and the 
United States.
415. In the United States, the abuse of cough syrups 
containing codeine has been recently popularized through 
the use of videos posted on social media illustrating the 
process of preparation of the so-called “purple drank” 
(purple is the typical colour of the cough syrups), a mix 
of cough syrup with alcohol or soft drinks. This phenom-
enon expanded to other regions and has been described 
as an epidemic in Nigeria and other countries in West 
Africa. In Thailand, cough syrups have sometimes been 
used to prepare “cocktails”, made by boiling kratom leaves 
and mixing the resulting liquid with cough syrup, ice and 
soft drinks. 
416. In its annual report for 2008,75 the Board, while 
recognizing that cough syrups containing narcotic drugs 
were an effective medication for many patients and 
important in medical practice and health care, expressed 
concern about the fact that cough syrups were also known 
to be abused in several countries. The Board recom-
mended that the Governments of countries experiencing 
abuse of cough syrups consider the introduction of 
stricter control and supervision of the channels of distri-
bution of cough syrups containing narcotic drugs. The 
Board also recommended using programmes for drug 
abuse prevention to increase awareness of the risks asso-
ciated with inappropriate use of cough syrups.
417. To address the negative health and social conse-
quences of misuse of cough syrups containing codeine, a 
number of health authorities have introduced control 
measures to avoid diversion, recommended the use of 
cough suppressant preparations not containing codeine, 
discouraged the use of cough syrups containing codeine 
for children below a certain age and/or have required a 
prescription for the purchase of such preparations. These 
actions are in line with article 39 of the 1961 Convention 
as amended, which enables countries to adopt stricter 
control measures than those provided in the Convention 
and in particular requiring that preparations in Schedule 
III or drugs in Schedule II be subject to all or some of 
the measures of control applicable to Schedule I sub-
stances if it is deemed to be necessary or desirable for the 
protection of public health and welfare.
75 E/INCB/2008/1.
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418. The Board reiterates its call on Governments that 
are affected by the abuse of preparations containing 
codeine to make use of the possibility given by the 1961 
Convention as amended for the introduction of stricter 
control measures and to implement appropriate preven-
tion and treatment interventions focusing specifically 
on this problem. 
7.  Activities to address trafficking 
through international post, express 
mail and express courier services
419. As a response to the shift from the shipping of con-
trolled substances in comparatively large amounts to 
small shipments of new psychoactive substances not 
under international control, the Board launched Project 
Ion in 2013 and its IONICS platform for the global real-
time exchange of information. In order to address the 
problem of non-medical synthetic opioids, in particular 
illicitly manufactured fentanyls, the Board began activi-
ties under its OPIOIDS project in 2017. The OPIOIDS 
project has focused on developing partnerships between 
Governments, international organizations and the private 
sector as an effective means of preventing the manufac-
ture, marketing, movement and monetization of non- 
medical76 synthetic opioids.
420. Numerous non-medical synthetic opioids have 
emerged on global markets, and some such as fentanyl 
analogues are particularly dangerous substances when 
abused due to their high potency even in extremely small 
doses. Vendors use the open Internet, the darknet and 
social media sites to market a wide range of fentanyls, 
with purchases made using online financial services or 
cryptocurrencies. Purchases are shipped among the bil-
lions of letters and express parcels shipped around the 
world every year using international mail and express 
courier services. Because of the high potency of the sub-
stances, the transport of fentanyls in trace amounts makes 
detection and interdiction extremely challenging. Postal, 
express mail and express courier service staff and customs 
officers unwittingly handle these potentially dangerous 
substances, raising concerns over safety due to possible 
contamination and harm due to unintentional exposure.
421. In April 2018, the Board, recognizing the need to 
partner with other international agencies at the front-
line of trafficking, entered into a cooperative agreement 
with the Universal Postal Union (UPU). The agreement 
76 The term “non-medical” is used to refer to synthetic opioids and 
their products that are made specifically for illicit markets.
effectively responded to challenges posed by dangerous 
substances by promoting technical assistance and the 
provision of training designed to increase cooperation 
against trafficking and improve the ability to detect and 
safely seize these substances. INCB and UPU share 
information and alerts which allow for the improved 
profiling of high-risk shipments and increase the chances 
of officers identifying and interdicting shipments. 
422. Through its partnership with UPU and the World 
Customs Organization (WCO), INCB Project Ion and the 
OPIOIDS project trained 160 postal security and customs 
officers from over 80 Governments in 2019 on informa-
tion exchange, interdiction and intelligence-sharing on 
dangerous substances trafficked through the postal and 
express courier services. Experts provided materials and 
instruction on safe handling, interdiction and communi-
cation methods for working with suspected fentanyls. 
423. INCB convened two international meetings of the 
expert group on trafficking in synthetic opioids through 
postal and courier services, held in April 2018 and 
September 2019. The meetings brought together postal, 
customs and law enforcement experts from numerous 
affected countries and international partners including 
INTERPOL, the Oceania Customs Organization, UPU, 
UNODC and WCO. The meetings were also attended by 
representatives of the private express mail and courier 
industry, in order to share information, experiences and 
ways for future cooperation to stem the flow of synthetic 
opioids through the express post and courier systems.
424. In January 2019, the OPIOIDS project initiated a 
time-bound global intelligence gathering operation, 
Operation Fast Forward, targeting sources and 
re-distribution points for the trafficking of non-medical 
fentanyl, fentanyl analogues and related synthetic opi-
oids through the international post, express mail and 
courier services. Operation Fast Forward, involving 81 
officers from 45 countries and two international organi-
zations, resulted in the communication, through the 
Board’s IONICS secure communication platform, of 
more than 50 seizure events involving a total of nearly 
30 kg of seized fentanyl, fentanyl analogues and related 
pre- precursors. The special operation also produced for 
government investigators intelligence that identified 
pre-precursors, sources and modi operandi, as well as 
previously unknown trafficking routes.
425. The sanctity of the seal is a principle which pro-
tects the privacy of communications by post, and many 
Governments do not allow the inspection of international 
mail, thus making the consignment of potent fentanyls in 
small, lightweight amounts in letter-class envelopes 
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difficult to detect and interdict. Governments are encour-
aged to make use of risk-profiling approaches, informa-
tion-exchange tools, such as the INCB IONICS platform, 
intelligence packages and alerts, in order to increase the 
likelihood of interdiction of substances trafficked 
through international post, express mail and express 
courier services.
426. The Board’s significant expansion of activities 
under Project Ion and the OPIOIDS project resulted in 
the growth of the intelligence-sharing capacity of the 
IONICS system, the nomination of government postal 
security officers to increase the global focal points net-
work, and expanded training in the field that resulted in 
a 93 per cent increase since 2017 in seizure events as well 
as intelligence on trafficked dangerous substances.
8.  Methamphetamine trafficking and 
abuse
427. Over almost three decades, INCB, in its mandated 
role as a quasi-judicial body monitoring the compliance 
of States with the international drug control conventions, 
has observed the global expansion of illicit markets for 
amphetamine-type stimulants, in particular methamphet-
amine. Year after year during that period, and notwith-
standing the focus of the international community on 
various drugs, including new psychoactive substances 
and, most recently, non-medical synthetic opioids, more 
and more countries and regions have set new records in 
the amounts of methamphetamine seized by their law 
enforcement agencies. At the same time, the ever-growing 
worldwide abuse of this drug has fuelled a threat to the 
health and welfare of people.
428. UNODC estimates that, in 2017, roughly 0.6 per 
cent of the global population aged 15–64 (that is, about 
29 million people) had used amphetamine and metham-
phetamine in the past year. There are indications of an 
increase in the use of methamphetamine, in particular in 
East and South-East Asia and North America. While the 
lack of sufficient good-quality data based on household 
surveys makes it difficult to estimate the prevalence of 
methamphetamine use globally, data on illicit supply 
reported to UNODC show an increase of 50 per cent in 
the last decade in the number of countries reporting sei-
zures of methamphetamine.
429. The regions which have been traditionally most 
affected by methamphetamine trafficking and abuse are 
North America, East and South-East Asia and Oceania, 
specifically Australia and New Zealand. In Europe, the 
illicit manufacture and use of methamphetamine had long 
been a localized issue in parts of central Europe, but there 
is now evidence of large-scale illicit methamphetamine 
manufacture elsewhere in Europe. Since 2011, illicit 
methamphetamine manufacture has also been docu-
mented in West Africa, specifically Nigeria. Unlike in the 
past, there are now also indications of large-scale inter-
regional trafficking of methamphetamine, with seizures 
of unprecedented size being made en route from North 
America to Australia. 
430. The most significant increases have been observed 
in East and South-East Asia, where, according to UNODC, 
methamphetamine seizures have increased eightfold 
between 2007 and 2017, accounting, with 83 tons, for 
45 per cent of global methamphetamine seizures, and 
reaching a record high level in 2018. Data received indi-
cate that Thailand alone accounted for more than half of 
the methamphetamine seized in the region in 2018. 
Available data also indicate a geographical shift of illicit 
manufacturing to areas outside of government control, 
for example, north-eastern parts of Myanmar.
431. At the same time, the region is seeing a shift from 
low-purity methamphetamine tablets (“yaba”) to high-purity 
crystalline methamphetamine. In some countries in the 
region, crystalline methamphetamine users now account 
for a major share of people receiving treatment for drug 
use. Annual prevalence rates reported from household sur-
veys conducted in Thailand show an increase from a low 
of 0.1 per cent of the population aged 12–65 in 2008 to 
0.2 per cent in 2011, before rising rapidly to 0.9 per cent 
by 2016. The number of crystalline methamphetamine 
users has also started to increase. Proportions of people in 
treatment for the abuse of methamphetamine (in tablet and 
crystalline form) exceeding 50 per cent of all drug-related 
treatment in East and South-East Asia in 2017 were 
reported for Brunei Darussalam, Cambodia, Japan, the Lao 
People’s Democratic Republic, Malaysia, the Philippines, 
the Republic of Korea, Singapore and Thailand. 
432. The Board is also concerned about recent indica-
tions of growing illicit methamphetamine manufacture 
and trafficking in Afghanistan. With more than 650 kg 
seized in the first six months of 2019, the amount of 
methamphetamine seized represented a tenfold increase 
compared to the same period of 2018. Furthermore, the 
Islamic Republic of Iran witnessed an increase of some 
25 per cent in methamphetamine seizures in 2018, to a 
total of 2.9 tons, compared with 2017. Countries in West 
Asia have also reported increasing levels of methamphet-
amine abuse.
433. INCB has continuously expressed its concern about 
these developments and has noted in particular the 
ChaPTER III. aNalysIs Of ThE wORld sITuaTION  65
apparent mismatch between the large amounts of meth-
amphetamine end-product seized and the comparatively 
low number and limited volume of methamphetamine 
precursors seized in comparison, especially in East and 
South-East Asia. Substances, such as ephedrine and pseu-
doephedrine, that for years had been the most used in 
known methamphetamine-manufacturing methods in 
some regions are no longer the only precursors of con-
cern. There is limited yet growing evidence of the use of 
P-2-P-based manufacturing methods in regions where this 
was not previously common. To complicate matters fur-
ther, P-2-P itself is often manufactured illicitly from 
pre-precursors, including non-scheduled “designer pre-
cursors” made specifically to circumvent existing regula-
tions. As law enforcement experience with those chemicals 
is limited in most regions, information about changes in 
manufacturing trends is often only identified through the 
forensic analysis of seized methamphetamine. Those issues 
are addressed in the report of the Board for 2019 on the 
implementation of article 12 of the 1988 Convention.
434. The Board wishes to highlight that much remains 
to be done to enable a more effective response to the 
ongoing methamphetamine crisis. In addition to mea-
sures to prevent the initiation of methamphetamine use 
and treatment, the Board believes that no discernible 
change in this worrying trend will be achieved without 
adequate attention being given to ensuring control over 
methamphetamine precursors and the exchange of related 
intelligence information. The Board has put a range of 
tools at the disposal of Governments to help to close 
existing gaps in knowledge, intelligence and operational 
responses to precursor trafficking and diversion from 
legitimate trade. These tools include the Board’s PICS, the 
PEN Online system and the two initiatives of the Board 
focusing on precursors used in the illicit manufacture of 
synthetic drugs and on chemicals related to the illicit 
manufacture of cocaine and heroin, namely Project Prism 
and Project Cohesion, respectively.
435. The Board urges Governments to make full use of 
the relevant tools available and to keep the Board abreast 
of their efforts, successes and challenges. Only with the 
best available data and understanding of the issues can 
the international community live up to its common and 
shared responsibility in facing the world drug problem.
9.  Tramadol abuse and trafficking in 
Africa and Asia
436. Trafficking of illicitly manufactured, falsified or 
substandard preparations containing tramadol, an opioid 
analgesic not under international control, has become a 
significant problem, as tablets containing high-potency 
dosages exceeding 200 mg are often seized. Since 2013, 
the Board has repeatedly identified non-medical use of 
tramadol as a significant and growing problem in many 
countries, particularly in parts of West and North Africa, 
the Near and Middle East and South Asia. Tramadol may 
in high doses produce euphoria for the user. 
437. Such falsified, substandard or illicitly manufactured 
tramadol tablets are the most often reported synthetic opi-
oids seized, with a record 125 tons interdicted globally in 
2017, the majority of which were seized in Africa, in par-
ticular in Egypt and Nigeria. According to the WCO Illicit 
Trade Report 2017, the Central African Republic, the 
Democratic Republic of the Congo, Mali and Togo all 
reported that border seizures of synthetic opioids were 
exclusively of tramadol, and 75 per cent of drug seizures 
reported in Cameroon and the Niger were of tramadol. 
Intelligence communicated through IONICS indicated that 
there were large seizures of synthetic opioids, in particular 
high-potency tablets containing tramadol.
438. Tramadol abuse in Ghana became a national issue 
in 2016, when intelligence gathered across the country 
indicated the seizure of significant quantities of high-potency 
tramadol tablets with a non-medical concentration of 
120 mg or greater, and more than 527,000 tablets were 
seized in 2017. Tramadol abuse and seizures have also been 
reported in Benin, Chad, Côte d’Ivoire, Guinea, Libya, 
Senegal, Sierra Leone and the Sudan. Illicit tramadol sales 
have previously been associated with the funding of vio-
lent extremist groups operating in parts of Africa.
439. The first comprehensive drug use survey con-
ducted in Nigeria, in 2017, found that 4.7 per cent of the 
general population aged 15–64 reported past-year 
non-medical opioid use, predominantly in the form of 
tramadol. One in five high-risk drug users injects drugs 
(0.1 per cent of the population), and the most common 
drugs injected were pharmaceutical opioids such as tra-
madol, codeine and morphine.
440. In Egypt, the third most populous country in 
Africa, 3 per cent of adults self-reported past-year 
non-medical use of tramadol in 2016, and 0.74 per cent 
of students aged 15–19 reported non-medical use of tra-
madol. The misuse of tramadol was also reflected in treat-
ment data, as tramadol users accounted for 68 per cent 
of persons admitted to treatment. 
441. Demand for tramadol in Africa is exacerbated by 
lax regulatory and border controls, which have allowed 
trafficked or unregulated imports of tramadol originating 
in India.
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442. India is a significant source of trafficked, falsified, 
substandard or illicitly manufactured products branded 
and marketed as tramadol that are seized worldwide. As 
part of the efforts by India to reduce such incidents, the 
Government scheduled tramadol under the Narcotic 
Drugs and Psychotropic Substances Act, 1985, effective 
August 2018. As noted above, following the changes in 
control measures in India, experts in Ghana and Nigeria 
noted a significant decline in large seizures of tramadol 
and a corresponding increase in prices for tramadol tab-
lets in the illicit market. 
443. In Africa, where substantial non-medical market 
demand currently exists, a demand could be created for 
a replacement product with brand recognition. A similar 
phenomenon was observed in North America, where 
reduced availability of diverted oxycodone tablets has 
been linked to the emergence of illicitly manufactured 
tablets branded as oxycodone but containing fentanyls. 
The supply of such tablets by organized criminal groups 
subsequently filled part of the large market demand in 
North America. 
444. Furthermore, there have been reports of the emer-
gence of illicitly manufactured tablets that contain trama-
dol as well as fentanyls. In North America, there have 
been reports of seizures of tramadol mixed with fentanyls. 
Governments should therefore remain vigilant to the 
possibility of such a development occurring in other 
regions and communicate without delay through 
IONICS the details of tramadol seizures, in particular 
any seizure suspected of containing fentanyls. 
B. Africa
Record seizures among several countries in west africa 
indicate that the subregion remains a major trans- 
shipment hub for trafficking in cocaine from Central and 
south america to Europe.
Nigeria published its first-ever national study on drug 
use, reporting a past-year drug use prevalence rate of 
14.4 per cent in the country.
1. Major developments
445. Africa continues to confront numerous challenges 
posed by both the trafficking of drugs and the abuse of 
drugs. Record seizures from several countries in West 
Africa indicate that the trafficking of cocaine from Central 
and South America to Europe remains high, although 
insufficient data are available to determine the rate of 
growth. Trafficking of heroin is increasing among African 
countries bordering the Indian Ocean, while the illicit 
cultivation of cannabis remains a problem for countries 
throughout the region. Although the data are limited, it 
can be seen that trafficking in illicitly manufactured tra-
madol remains high and that tramadol is becoming a 
major substance of abuse, mostly in North, West and 
Central Africa. In addition, despite the newly available 
prevalence data from some countries, major gaps in the 
data remain and continue to impede efforts to determine 
the full extent of drug abuse in Africa.
446. According to a special report of the Secretary-
General (S/2018/1086), the drug trafficking situation in 
Guinea-Bissau has begun to show modest improvement, 
although significant challenges remain. In that regard, 
Security Council resolution 2458 (2019), aimed at 
strengthening the international response to the political 
situation in Guinea-Bissau, contains provisions on com-
bating drug trafficking in the country.
447. In January 2019, the Government of Nigeria, with 
the support of the European Union and UNODC, 
released its first-ever National Survey on Drug Use and 
Health, for 2018. This first comprehensive survey on 
drug use conducted in the country collects data from 
38,850 households and 9,344 high-risk drug users across 
Nigeria.
2. Regional cooperation
448. At the thirty-second Ordinary Session of the 
Assembly of the African Union, held in February 2019, 
Heads of State and Government of States members of the 
African Union formally adopted the Treaty for the 
Establishment of the African Medicines Agency. Once it 
has been ratified by 15 member States, the Agency will 
serve as the continental regulatory body for standardiz-
ing and strengthening regulatory systems across Africa, 
in order to ensure access to safe, effective, high-quality 
and affordable medicines and medical products.
449. The African Union and the Indian Council of 
Medical Research signed a memorandum of understand-
ing in March 2019 establishing a framework to formal-
ize cooperation between India and Africa in the health 
sector, including the facilitation of trade in pharmaceu-
ticals, as well as support for the manufacture of drugs 
and medicines in Africa, including those under interna-
tional control.
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450. In July 2019, heads of navies, coast guards and gen-
darmeries from Burkina Faso, Côte d’Ivoire, Ghana, 
Guinea, Liberia and Sierra Leone signed a memorandum 
of understanding for joint maritime operations in the 
maritime zone of the Economic Community of West 
African States. The memorandum of understanding is 
aimed at improving the response of the subregion to 
piracy and criminal activity in the Gulf of Guinea and 
ensuring security within the exclusive economic zones of 
these countries.
451. Seychelles received a mission from the European 
Union Action against Drugs and Organised Crime project 
in March 2019 to assess the drug situation in the country. 
The aim of the mission, the first of its kind in Seychelles, 
was to determine how the country could strengthen its 
efforts against drug trafficking, in particular trafficking in 
heroin, and improve drug demand reduction efforts in 
Seychelles.
452. The third Ordinary Session of the Specialized 
Technical Committee on Health, Population and Drug 
Control was held by the African Union Commission 
from 29 July to 2 August 2019. During the ministerial 
segment of the session, ministers from African Union 
member States reviewed and adopted the Plan of Action 
on Drug Control and Crime Prevention (2019–2023) of 
the African Union.
3.  National legislation, policy and 
action
453. Egypt has amended its national drug control law, 
stiffening penalties for drug trafficking in the country 
and placing additional substances under national con-
trol. The amendment includes penalization for traffick-
ing in synthetic cannabinoids that is equal to that for 
other narcotic drugs and extends the existing applica-
tion of capital punishment for drug trafficking to traf-
ficking in synthetic drugs.
454. Although the determination of sanctions applica-
ble to drug-related crime remains the prerogative of 
States parties to the conventions, INCB reiterates its posi-
tion on the issue of capital punishment for drug-related 
offences and encourages States that retain capital punish-
ment for drug-related offences to consider the abolition 
of the death penalty for that category of offence.
455. A special report of the Secretary-General 
(S/2018/1086), published in December 2018, containing 
an assessment of UNIOGBIS, highlighted that modest 
progress had been made in Guinea-Bissau to counter drug 
trafficking and transnational organized crime. However, it 
noted that officials in the Government of Guinea-Bissau 
acknowledged that the scope of drug trafficking remained 
a problem and that some military and security officials 
were involved in drug trafficking. The report also indi-
cated that powerful implicated parties in the country that 
did not want effective State institutions would hinder 
UNIOGBIS and other United Nations entities in their 
efforts to counter drug trafficking in the country.
456. Pursuant to the above-mentioned report, the 
Security Council, in its resolution 2458 (2019), reiterated 
its concern at the threat to peace and stability posed by 
drug trafficking and related transnational organized crime 
in Guinea-Bissau. The Council stressed that long-term 
political and economic stability in the country was not 
possible without combating drug trafficking, called upon 
the authorities of Guinea-Bissau to continue to improve 
efforts to deal with trafficking in drugs and called upon 
the international community, regional organizations and 
the United Nations system to increase support to the 
country to address the problem.
457. In connection with the report of the Secretary-
General and Security Council resolution on Guinea-
Bissau, in early November 2019, the Peace and Security 
Council of the African Union issued a communiqué 
regarding the deteriorating political and situation in 
Guinea-Bissau. The Peace and Security Council noted 
with concern the increase in drug-related crimes in the 
country and their major impact on the general political 
and security situation, including hindering efforts to con-
duct new elections.
458. The Gambia has developed and launched its first-
ever National Drug Control Strategy, for the period 
2019–2023. The Strategy will guide the policy and oper-
ational approaches taken by the country to counter drug 
trafficking.
459. In December 2018, Nigeria established the 
Presidential Advisory Committee for the Elimination of 
Drug Abuse to address all aspects of drug control in the 
country. The Committee comprises high-level officials 
from several departments of the Government and repre-
sentatives of civil society organizations and is charged with 
providing the President of Nigeria with sustainable recom-
mendations for addressing the country’s drug problems.
460. The Parliament of Kenya approved an amendment 
to the country’s drug control law whereby it significantly 
increased the penalties and fines for trafficking in nar-
cotic drugs and psychotropic substances. The amendment 
sets out additional penalties for any law enforcement 
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officer who aids or abets any offence under the drug con-
trol law.
461. Health authorities in Morocco launched the national 
multisectoral strategy for the prevention and control of 
non-communicable diseases for the period 2019–2029. The 
strategy, which covers many non-communicable health 
conditions, contains several measures to monitor and 
address health consequences related to drug use in the 
country and advocates for health-centred approaches to 
assist persons who abuse drugs.
462. On 23 May 2019, South Africa issued a notice 
updating the schedules of its Medicines and Related 
Substances Act of 1965, moving CBD from schedule 7 of 
the Act, the highest level of control, to schedule 4, which 
will allow for preparations containing CBD to be made 
available on prescription. In addition to the rescheduling, 
the Government indicated that CBD-based products that 
contain a maximum daily dose of 20 mg of CBD and that 
are produced from raw cannabis material containing no 
more than 0.001 per cent of THC and no more than 
0.0075 per cent of CBD would not be controlled after 12 
months following the issuing of the notice. That allows 
the purchase of CBD products below those established 
thresholds without any prescription. 
463. Following amendments to its Dangerous Drugs Act 
in 2018, Zimbabwe now permits the cultivation of can-
nabis for medical purposes. The amendment establishes 
the regulatory framework for the cultivation of cannabis, 
including provisions to ensure the security of cultivation 
areas and the quality of cannabis products.
464. In September 2019, Mauritius launched the new 
National Drug Control Master Plan for the period 2019–
2023. The Master Plan establishes four strategic pillars to 
address drug control issues in Mauritius: drug supply 
reduction; drug demand reduction; harm reduction; and 
coordination, monitoring and evaluation.
4.  Cultivation, production, 
manufacture and trafficking
465. Africa remains a major transit region for drug traf-
ficking, as well as a growing illicit market for drugs. 
Trafficking in cocaine remains a major problem, as sev-
eral countries in West Africa reported record seizures of 
the drug, taken from vessels that had departed from 
Central and South America and were bound for North 
Africa and Europe. Trafficking in heroin is also a grow-
ing problem in countries on the coast of the Indian 
Ocean. Trafficking of tramadol, an opioid analgesic not 
under international control, remains a major problem for 
parts of Africa, and tramadol is becoming one of the most 
trafficked and abused drugs, in particular in North, West 
and Central Africa. Cannabis continues to be one of the 
most trafficked drugs in the region. Although most of the 
trafficking appears to take place within the region, some 
North African countries reported the trafficking of can-
nabis herb and resins into Europe.
466. The largest-ever seizure of cocaine in Cabo Verde 
occurred in January 2019, when the Judicial Police 
seized over 9.5 tons of cocaine from a vessel that had 
departed from Panama. The authorities of Cabo Verde 
also seized over 2.2 tons of cocaine from a ship in 
August 2019, during a joint interdiction operation led 
by the national Coast Guard.
467. Another record seizure of cocaine occurred in 
March 2019 when authorities of Guinea-Bissau seized 
789 kg of the drug as part of Operation Carapau, which 
was led by the Transnational Crime Unit and the Judicial 
Police of Guinea-Bissau. That seizure was the largest ever 
made by authorities in the country. Similarly, in July 2019, 
the authorities of Senegal carried out a record seizure of 
cocaine during a three-day operation that detected 1 ton 
of the drug hidden on ships in the port of Dakar.
468. For 2018, data provided by countries in the region 
indicate that trafficking in cocaine is proliferating. The 
Kenyan authorities reported seizing 2.2 tons of cocaine 
that year, more than 90 per cent of which was trafficked 
by air. Major seizures in 2018 were also reported by 
Morocco, Algeria and Angola, which seized 1.7 tons, 
672 kg and nearly 500 kg, respectively. Côte d’Ivoire, 
Ghana, Mozambique, the Niger, Nigeria and South Africa 
all reported seizing quantities of cocaine ranging from a 
few kilograms to 155 kg.
469. The trafficking of tramadol continues to pose a chal-
lenge in the region, in particular among countries in North, 
West and Central Africa. Nigeria reported major seizures 
in late 2018, including more than 581 million high-dosage 
tramadol tablets seized in a two-day operation. In addi-
tion, the country reported seizing a total of some 22.5 tons 
of tramadol in 2018. Morocco reported the seizure of more 
than 45 million tablets of tramadol in 2018, while Senegal 
also reported seizures of the drug. Reported seizures sug-
gest that trafficking of the synthetic opioid in the region 
remains a major problem among countries in the Sahel 
and the Maghreb.
470. According to the UNODC World Drug Report 
2019, trafficking in heroin via Africa appears to have 
increased, with seizures rising from less than 0.5 tons in 
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2013 to almost 1.5 tons in 2017. In 2018, overall seizures 
of heroin in Africa have continued to rise, with Kenya 
alone reporting 1.5 tons seized that year. Trends derived 
from available data on heroin seizures suggest that traf-
ficking in heroin via Africa, in particular in countries on 
the Indian Ocean coast, is continuing to grow.
471. Major seizures of heroin were reported by Egypt, 
Mauritius and the United Republic of Tanzania for 2018, 
exceeding the quantities seized in 2017. The 1.5 tons of 
heroin seized by Kenya in 2018 represents more than a 
tenfold increase from 2017, when the country reported 
the seizure of 112 kg. Smaller seizures of heroin in 2018 
were also reported by Côte d’Ivoire, Madagascar, 
Mozambique and Seychelles.
472. While the illicit cultivation of cannabis occurs in 
many African countries, the trend of past years contin-
ued, as Morocco and Nigeria again reported the largest 
seizures of cannabis and cannabis resin in the region. 
Morocco reported the seizure in 2018 of nearly 72 tons 
of cannabis resin, as well as of 252 tons of majoun, a 
consumable product consisting mostly of cannabis but 
that can also include other drugs, along with poppy 
seeds and other foodstuff. In June 2019, Moroccan 
authorities reported the seizure of 12 tons of cannabis 
and 800 kg of cannabis resin. Another operation carried 
out two weeks later led to the seizure of 600 kg of can-
nabis found in sewage pipes in Taghbalt.
473. During 2018, at least 16 countries from all regions 
of Africa reported seizures of cannabis herb, resins and 
plants. Major seizures of at least several tons were reported 
by Angola, Côte d’Ivoire, Eswatini, Ghana, Kenya, the 
Niger, Senegal and Zambia. Nigeria reported the seizure 
in 2018 of more than 270 tons of cannabis herb, the larg-
est amount since 2015. Algeria reported the seizure of 
nearly 32 tons of cannabis resin. An analysis of reports 
available from countries in the region indicates that most 
of the illicit cultivation of cannabis herb is destined for 
country-level or subregional markets, even though signif-
icant amounts of cannabis resins and herb destined for 
European markets are trafficked through North Africa 
and, most often, thereon through Spain.
474. With regard to the trafficking of other drugs, sev-
eral countries reported seizures of amphetamine-type 
stimulants. In 2018, Nigeria and South Africa seized a 
few hundred kilograms each of methamphetamine, 
while Morocco reported the seizure of more than a mil-
lion MDMA tablets. Some seizures of khat were 
reported by a few countries, while only South Africa 
reported any seizures of ketamine, a sedative not con-
trolled internationally.
5. Prevention and treatment
475. The lack of information and prevalence data con-
tinues to be an impediment to determining the extent of 
drug use in Africa. It also hinders Governments and the 
international community as they seek to respond effec-
tively by means of evidence-based drug use prevention 
and treatment programmes. Nonetheless, it can be seen 
from the information available that trends in drug use in 
the region do not appear to be improving, as some coun-
tries report drug use rates for some drugs that are higher 
than the global prevalence rate. Cannabis continues to be 
the main drug of abuse, and tramadol, an opioid analge-
sic not under international control, is also a major drug 
of abuse in some parts of Africa.
476. The Board calls upon all States to provide regu-
larly to the Board and other relevant international orga-
nizations data on drug use prevalence and any official 
information regarding their efforts to prevent the use of 
drugs and provide treatment services to drug users.
477. The 2018 National Survey on Drug Use and Health, 
produced by the Government of Nigeria with support 
from the European Union and UNODC and released in 
January 2019, is the first-ever comprehensive survey of 
drug use conducted in the country. It analyses data col-
lected from 38,850 households and 9,344 high-risk drug 
users. The report found that, among persons aged 15–64 
years, the past-year prevalence rate for non-medical drug 
use (not including tobacco and alcohol) was 14.4 per cent. 
The report also found that cannabis was the most com-
monly used drug, with an estimated 10.8 per cent of the 
population (approximately 10.6 million people) having 
used cannabis in the previous year. Opioids, heroin and 
pharmaceutical preparations (tramadol, codeine and 
morphine) are the next most abused substances, with a 
prevalence rate of 6.0 per cent (approximately 4.6 million 
people). In addition, polydrug use was very common, as 
nearly 95 per cent of high-risk users and almost half of 
other users reported having consumed more than one 
drug in the previous year.
478. In addition to providing detailed data on the drug 
use situation in Nigeria, the National Survey also outlines 
the challenges and the policy approaches needed to 
address the drug use problem in the country. In partic-
ular, the data reported in the National Survey will be used 
to develop a new national drug master plan for the period 
2020–2024. Furthermore, the National Survey under-
scores the need for affordable and accessible scientific 
evidence-based treatment in Nigeria, noting the gender 
disparities in access to treatment and the need to address 
the problem of stigmatization of people who use drugs. 
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The National Survey also stresses that there is a need to 
ensure the availability of pain medications in the coun-
try, while also preventing diversions from licit trade and 
countering trafficking in opioids.
479. In Kenya, the National Authority for the Campaign 
against Alcohol and Drug Abuse and the Kenya Institute 
for Public Policy Research and Analysis released in June 
2019 a survey entitled Status of Drugs and Substance 
Abuse among Primary School Pupils in Kenya. The survey 
was conducted among 3,307 randomly selected students 
between 10 and 14 years of age from 177 primary schools 
across the country. The survey found that among respon-
dents, the average median age of onset of at least one sub-
stance of abuse was 11 years, while the lowest reported 
age of onset was 4 years. The survey also found that 
20.2 per cent of primary school pupils had used at least 
one drug or substance of abuse (including alcohol or 
tobacco) in their lifetime and 1.2 per cent had used can-
nabis in their lifetime. It also found that students were 
more likely to abuse drugs if one or both parents had 
used drugs or some other substance. The report found 
that alcohol, tobacco and prescription drugs were the sub-
stances that were most available to students to abuse.
C. Americas
Central America and the Caribbean
The largest single seizure of cocaine ever recorded in 
Central america and the Caribbean took place in 
El salvador, where authorities seized more than 13,779 kg 
of cocaine trafficked by sea. The seized cocaine had orig-
inated in Colombia and Ecuador, destined for cocaine 
markets in North america.
although the amount and the quality of information 
regarding drug abuse patterns in Central america and 
the Caribbean have improved in recent years, a more 
systematic collection of drug abuse patterns and trends 
is needed.
1. Major developments
480. Central America and the Caribbean continue to be 
exploited by local gangs and international organized 
criminal groups which use the subregion as a transit area 
and trans-shipment route for illicit drugs originating in 
South America and destined for consumer markets in 
North America and Europe. As cocaine trafficking 
remains the most lucrative source of income for orga-
nized criminal groups in the subregion, the intensified 
competition in that trafficking has increased the level of 
violence in a subregion considered to be among the most 
violent in the world. According to the UNODC “Global 
study on homicide 2019: executive summary”, firearms 
are involved in homicides in the Americas far more often 
than in other parts of the world.
481. Most of the cocaine consumed in the United States 
and Canada is trafficked through Central America. The 
Caribbean coast of Central America is particularly vul-
nerable to drug trafficking because of its remoteness, lim-
ited infrastructure, the lack of government presence and 
weak law enforcement institutions.
482. Reported levels of consumption of opioids for pain 
relief and of psychotropic substances for the treatment of 
mental health and neurological conditions continue to be 
low in most countries in Central America, and some 
countries face a further decline in their already low lev-
els of availability.
483. Illicit drug use, in particular of cannabis, appears 
to be growing in all countries in the subregion. According 
to the CICAD Report on Drug Use in the Americas 2019, 
the highest prevalence rate of cannabis use among the 
general population in 2018 was that reported by Jamaica, 
at 15.5 per cent, followed by Barbados, at almost 
8 per cent, and the lowest prevalence rates were reported 
by the Dominican Republic and Panama, which both 
reported a past-year prevalence below 1 per cent. Key 
problems in Central America and the Caribbean continue 
to be the design and implementation of effective preven-
tion, treatment and rehabilitation programmes through-
out the subregion, the need to address the chronic lack 
of capacity for the collection of drug-related data and the 
lack of centralized agencies mandated to assess that infor-
mation. Although the amount and the quality of infor-
mation regarding drug abuse patterns in the subregion 
have improved, as seen by the number of national drug 
use surveys published in the past few years, more research 
on consumption patterns and trends is needed to tailor 
treatment initiatives to meet local needs. 
2. Regional cooperation
484. In January 2019, drug control officials from 
El Salvador, Guatemala and Honduras participated in a 
seminar held in Vienna as part of the INCB Learning 
project. INCB Learning is the Board’s global initiative to 
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strengthen the capacity of Governments in the regulatory 
control and monitoring of the licit trade in narcotic 
drugs, psychotropic substances and precursor chemicals. 
The training seminar contributed to improved monitor-
ing and reporting capacities of participating national 
authorities, in order to ensure that controlled substances 
are adequately available for medical purposes while at the 
same time preventing their diversion into illicit channels, 
abuse or trafficking. 
485. In April 2019, UNODC and the Ministry of Public 
Security of Panama held the first Regional Conference 
against Drug Trafficking Networks, which took place in 
Panama City. The objective of the conference was to 
exchange best practices among law enforcement officials 
of countries in the subregion affected by production, 
trafficking and consumption of drugs.
486. In April 2019, UNODC held a workshop on inter-
national judicial cooperation for the detection of illicit 
drug trafficking and organized crime, with the participa-
tion of judges and prosecutors of participating countries.
487. In June 2019, CICAD published the reports of the 
seventh evaluation round of the Multilateral Evaluation 
Mechanism for countries in Central America and the 
Caribbean. The reports assess the progress made by coun-
tries in the implementation of the objectives and priori-
ties established in the CICAD Hemispheric Plan of Action 
on Drugs for the period 2016–2020.
3.  National legislation, policy and 
action
488. In Nicaragua, the National Council against Organized 
Crime was restructured in 2018 to increase coordination 
between law enforcement entities and enhance the effec-
tiveness of the measures taken against criminal organiza-
tions, including drug trafficking organizations. The policies, 
action plans and measures being taken by the Government 
and the efforts being made to control trafficking and abuse 
of illicit drugs are set out in the National Anti-Drug 
Strategy for the period 2018–2021. 
489. In El Salvador, enforcement of drug control activ-
ities continued in accordance with the goals established 
in the national drug strategy for the period 2016–2021. 
In April 2019, 21 officials from ministries and law 
enforcement and drug control bodies of El Salvador par-
ticipated in a seminar on control of drug trafficking and 
chemical precursors, which took place in San Salvador, 
hosted by the National Anti-Drug Commission. Also in 
San Salvador, in August 2019, the personnel of the Joint 
Task Force on Airport Interdiction received training on 
the detection of suspicious passenger profiles linked to 
drug trafficking. 
490. In Jamaica, the Cannabis Licensing Appeal Tribunal 
became operational in April 2019 following the publica-
tion of its rules and regulations in the Jamaica Gazette. 
The Appeal Tribunal was established to receive petitions 
from persons and entities that wish to appeal any decision 
by the Cannabis Licensing Authority of Jamaica to deny, 
revoke or suspend a licence or permit issued in accordance 
with the Dangerous Drugs Act. Regulations to establish a 
comprehensive licensing regime to regulate the import 
into and export from Jamaica of cannabis for medical and 
scientific purposes have been drafted and are currently 
under review by authorities and are consolidated in the 
Dangerous Drugs (Cannabis Import and Export Licensing) 
Regulations, 2019. 
491. In Guatemala, the plenary of the Commission 
against Addictions and Illicit Drug Trafficking approved 
the National Policy on Addictions and Illicit Drug 
Trafficking for the period 2019–2030 at its second regu-
lar session of the year, in June 2019. The new policy cov-
ers four thematic areas: strengthening institutions, 
demand reduction, supply reduction, and development 
and human rights. 
4.  Cultivation, production, 
manufacture and trafficking
492. In Central America, the largest quantities of 
cocaine seizures were reported by Costa Rica, El Salvador 
and Panama. Seizures reported by countries of the 
Caribbean accounted for just 1 per cent of the total quan-
tity of cocaine seized worldwide, and that total amount 
for the Caribbean consisted mostly of the great amount 
seized in the Dominican Republic. In Belize, in 2018, law 
enforcement authorities reported the seizure of more than 
990 kg of cocaine from an aircraft carrying illicit drugs.
493. The largest seizure of cocaine ever recorded in 
Central America and the Caribbean took place in 
El Salvador in 2018, when more than 13,779 kg of 
cocaine was seized. The seized cocaine had originated 
in Colombia (90 per cent) and Ecuador (10 per cent) 
and been trafficked by sea, destined for cocaine markets 
in the United States. The second most seized substance 
in El Salvador in 2018 was cannabis herb, of which 
almost 1,253 kg was seized.
494. In 2018, the Government of Guatemala reported 
cocaine seizures totalling more than 16,823 kg, of which 
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the largest monthly seizure totals were those for November 
(3,214 kg) and December (5,338 kg).
495. In 2019, the security situation in Haiti further dete-
riorated as a result of the persistent political crisis, which 
led to a continued deterioration of the economic situa-
tion and an increase in criminal activity, including drug 
trafficking. Law enforcement agencies continue to suffer 
from a chronic shortage of the resources required to 
ensure the adequate functioning of those agencies. The 
national police conducted 37 operations against gangs in 
2019, including 10 operations conducted with support 
from the United Nations Mission for Justice Support in 
Haiti. The number of reported homicides in Haiti in the 
first half of 2019 was double that of the previous year, 
with 523 homicide cases in the first half of 2019 com-
pared with 274 in the same six-month period in 2018. 
496. According to the UNODC World Drug Report 2019, 
outdoor cultivation of cannabis in Central America has 
been reported by Costa Rica, Honduras and Panama. Small 
quantities of heroin available in Central America and the 
Caribbean continue to arrive from Colombia, for local con-
sumption in a relatively small market and for onward traf-
ficking to markets in North America and Europe.
497. In recent years, criminal organizations that traffic 
narcotics have used various areas of Honduras and 
Guatemala as a transit area, which has contributed to the 
increase in the trafficking of drugs to North America. In 
the case of Honduras, these activities are concentrated in 
the Mosquitia rainforest, which is used for landing air-
craft loaded with illegal cargo from Colombia and 
Venezuela (Bolivarian Republic of). According to statis-
tics of UNODC, Honduras has become the country with 
the highest levels of violence in the world, with the mur-
der rate reported for 2012 reaching a peak of 92 homi-
cides per 100,000 people in the country. A significant 
proportion of the homicides committed in Honduras are 
drug- related. Domestic violence associated with drug use 
has increased as a result of the development of domestic 
microtrafficking networks controlled by street gangs, 
known as maras or pandillas, which commit crimes and 
are thought to finance their activities largely through the 
trafficking of drugs. The two main such street gangs are 
Mara Salvatrucha 13 (MS-13) and Calle 18. Violence, 
poverty and corruption are by far the main causes of 
social problems. Several legislative initiatives have been 
proposed over the past few years to reduce drug traffick-
ing and improve the transparency and effectiveness of the 
judicial system and the security forces.
498. In the case of Guatemala, the hidden landing strips 
are mainly in the departments of Petén, Izabal, Retalhuleu, 
Escuintla, Quiché and Alta Verapaz, most of which are 
provinces bordering Mexico or near the border. Those 
landing strips cause environmental destruction primarily 
because of the deforestation required to build them, with 
the greatest damage in the Department of Petén, which 
contains the largest tropical rainforest in Central America 
and is home to the Maya Biosphere Reserve. 
499. Laboratories manufacturing fentanyl and its ana-
logues have been found in the Dominican Republic in 
recent years, as reported in the UNODC World Drug 
Report 2019.
5. Prevention and treatment
500. According to the CICAD Report on Drug Use in 
the Americas 2019, among countries of the Caribbean, the 
highest rate of past-year cannabis use among the general 
population in 2018 was that reported by Jamaica at 
15.5 per cent, followed by Barbados at almost 8 per cent. 
The lowest rates were reported by the Dominican Republic 
and Panama, which had the lowest past-year prevalence 
rate of those reported: below 1 per cent. In the Bahamas, 
Barbados and Jamaica, past-year use of cannabis was 
found to be higher among those aged 35–64 than among 
those aged 12–17. In Central America, Belize stands out 
with a rate of more than 15 per cent, and past-year use 
in Costa Rica is close to 10 per cent. The lowest levels of 
use in the subregion were those reported by Panama and 
Honduras, both below 5 per cent.
501. Misuse of psychotropic substances was found to be 
higher among women than among men in nearly every 
country in Central America and the Caribbean, accord-
ing to the CICAD Report on Drug Use in the Americas 
2019. In Costa Rica and Honduras, for example, the prev-
alence of non-prescription use of tranquillizers by female 
secondary school students is almost double that of their 
male counterparts.
502. In 2019, the Government of El Salvador published 
the results of its national report on the drug situation for 
2018. That survey collected data from individuals aged 
12–65 on patterns of abuse of controlled substances. 
Results show an increase in the prevalence of past-year 
use of cannabis and psychoactive substances. 
503. Use of “ecstasy” in Central America remains lower 
than the global average, with an estimated prevalence of 
past-year use of 0.2 per cent, equivalent to roughly 100,000 
users in Central America in 2017. According to the CICAD 
Report on Drug Use in the Americas 2019, past-year use of 
“ecstasy” in Belize among those aged 12–65 was reported 
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to be 0.5 per cent and in Costa Rica to be 0.2 per cent, 
among the highest in Central America. Guatemala and 
El Salvador are the only countries of Central America that 
reported amphetamine use among secondary school stu-
dents. Those two countries had a lifetime prevalence of 
0.8 per cent and 0.7 per cent, respectively. The only two 
countries of the Caribbean to report the prevalence of past-
year use of “ecstasy” among the general population were 
Barbados, at 0.3 per cent, and the Dominican Republic, at 
0.2 per cent.
504. According to the UNODC World Drug Report 
2019, in 2017, cannabis was the drug with the highest 
prevalence of past-year use in both the Caribbean (at 
3.6 per cent) and Central America (at 2.9 per cent). After 
cannabis, the drug with the next highest prevalence rate 
in Central America was cocaine (0.66 per cent), followed 
by amphetamines and prescription stimulants (0.21 per 
cent) and “ecstasy” (0.17 per cent). The overall prevalence 
of past-year use of amphetamines in countries in Central 
America continued to be low in 2017, at about 0.2 per 
cent of the population aged 15–64. In the Caribbean, the 
drug of greatest use is cannabis, followed by amphet-
amines and prescription stimulants (0.87 per cent), 
cocaine (0.62 per cent) and “ecstasy” (0.23 per cent). 
505. Over the past decade, a total of 14 countries and 
territories in Latin America and the Caribbean have 
reported 178 different new psychoactive substances 
belonging to diverse chemical groups. In 2017 alone, 61 
different new psychoactive substances were reported to 
UNODC by nine countries in Latin America and the 
Caribbean, reflecting the diversity of the new psycho-
active substances market. Hallucinogenic drugs make up 
the largest category in terms of the number of substances 
reported, followed by stimulants.
North America
The opioids crisis continues to destroy lives, families and 
communities in North america.
measures to decriminalize or legalize cannabis are pro-
liferating in North america, and cannabis initiation and 
consumption are increasing.
1. Major developments
506. The opioids crisis in North America continues to be 
a matter of concern, despite the slight drop in the overall 
number of drug overdose deaths (based on preliminary 
data) reported for the United States for the year 2018. 
While deaths linked to synthetic opioids, such as fentanyl, 
continued to rise in 2018, deaths linked to semi-synthetic 
opioids, such as oxycodone, declined. Collective efforts to 
address the contamination and mixing of illicit drugs with 
synthetic opioids were stepped up in 2019, including 
through widespread community outreach and the distri-
bution of overdose-reversing drugs. Stopping opioid abuse 
and seizing illicitly manufactured fentanyls are important 
public health and safety objectives in all countries in this 
region.
507. The increases in cocaine manufacture and surges 
in methamphetamine manufacture and trafficking have 
had negative effects in countries in North America, 
including an apparent increase in the use of methamphet-
amine in Canada. 
508. The devastating effects on communities of poly-
drug use and inadequate treatment options continue to 
be felt throughout the United States. 
509. Cannabis legalization and decriminalization con-
tinue to spread in North America; and the effects of 
increased cannabis use on the health of the population – 
especially youth – are being actively studied and addressed 
by national authorities.
2. Regional cooperation
510. The three countries in North America – Canada, 
Mexico and the United States – have expanded their col-
lective efforts to address the complex threats of traffick-
ing in and the abuse of drugs, especially opioids. Those 
three countries are trying to reduce the illicit supply of 
heroin, methamphetamine and fentanyls through joint 
investigative efforts and the destruction of clandestine 
laboratories. Shared priorities among those countries 
include the close monitoring of cannabis trafficking fol-
lowing the introduction of legalization measures. 
511. Supply reduction efforts and the sharing of good 
practices in the prevention and treatment of drug abuse 
are discussed by officials from all countries in the region 
in the annual meetings of the North American Dialogue 
on Drug Policy. This forum promotes enhanced regional 
cooperation on the opioid crisis and helps facilitate coor-
dinated responses to the increasing number of deaths 
related to the abuse of opioids. Mexico and the 
United States also came together to strengthen their col-
laboration at the second meeting of the working group 
on transnational criminal organizations, held in Cartagena, 
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Colombia, in June 2019. Those two countries work with 
Colombia, the third member of the working group, on 
the development of joint strategies to dismantle Colombian 
drug trafficking organizations and Mexican drug cartels.
512. Regional security and strategic cooperation efforts 
have been boosted through effective bilateral law enforce-
ment initiatives, involving Mexico and the United States, 
and public campaigns for secure borders. The United States 
noted in its National Drug Control Strategy that Mexico 
was increasing its opium poppy eradication efforts. 
Bilateral drug control and security cooperation between 
the two countries was also affected by political statements 
and rhetoric about the use of the south-western border 
of the United States as a corridor for drug smuggling, 
such as the presidential proclamation on declaring a 
national emergency concerning the southern border of 
the United States, signed by the United States President 
on 15 February 2019, and indications by the United States 
that tariffs would be imposed on Mexican goods if the 
rates of drug trafficking did not decrease. Subsequently, 
the United States Government began construction of 
enhanced border security facilities and barriers to block 
land routes used for smuggling drugs from Mexico into 
the United States. 
3.  National legislation, policy and 
action
513. In January 2019, the United States Office of 
National Drug Control Policy released the National Drug 
Control Strategy, the top priority of which is the opioid 
crisis. The Strategy calls for government efforts to focus 
on addressing the increased availability of and trafficking 
in synthetic drugs. The emerging crisis of cocaine avail-
ability and use in the United States, as well as illicit heroin 
and methamphetamine manufacture in Mexico, are 
described as major challenges that United States agencies 
should deal with by expanding their efforts in detecting 
and monitoring air and sea routes used for drug 
trafficking.
514. Mexico released its National Development Plan 
2019–2024, which had been approved by its Chamber of 
Deputies in June 2019 and will be used to prepare legisla-
tion in line with the Sustainable Development Goals. In 
the section on reformulating the fight against drugs, the 
Plan includes a proposal to decriminalize prohibited drugs 
and shift priorities through drug policy reform based on 
expanding treatment for drug addiction. According to the 
Plan, the State will renounce its claim to combat drug 
addiction by banning addictive substances and instead will 
dedicate its resources to the treatment of drug-dependent 
persons through programmes offering clinical follow-up 
and the provision of prescriptions, as part of personalized 
detoxification treatment under medical supervision. In line 
with this new approach focusing on treatment, the national 
drug policy will be based on public health, prevention and 
reduction of drug-related harm, as well as deterrence of 
illicit drug production, trafficking and distribution, and 
will be carried out according to the national public secu-
rity strategy. 
515. In a statement made in March 2019 at the 
sixty-second session of the Commission on Narcotic 
Drugs, the representative of Mexico called for the focus 
to be on not only criminal justice matters, but also social 
issues, including strengthening the culture of prevention, 
public health and the rights of victims and vulnerable 
groups. The launch of the country’s new addiction strat-
egy, “Together for peace”, provided a plan focused on 
protecting children and adolescents while avoiding the 
stigmatization, criminalization and discrimination of 
substance users, including by viewing the issue through 
a gender and a human rights lens. The strategy is based 
on four pillars: education, well-being, culture and 
communication. 
516. In Mexico, the Senate held public hearings from 
August to November 2019 on the design of plans to legal-
ize and regulate the non-medical use of cannabis. 
According to a website created to provide information 
about the hearings, the purpose is to approach cannabis 
regulation in a transparent manner and along lines sim-
ilar to the changes in cannabis policy and legislation in 
countries such as Canada and Uruguay.
517. In Canada, after the Cannabis Act came into force 
in 2018, Health Canada, as part of its Substance Use and 
Addictions Program, initiated projects to educate the 
public and raise awareness about cannabis. The initiatives 
included campaigns to raise awareness about the health 
effects of cannabis use during pregnancy and social media 
messages informing Canadians between the ages of 13 
and 24 about the risks of drug-impaired driving. Bill C-93 
was passed by the Parliament of Canada in June 2019, 
allowing Canadians who had been previously convicted 
of simple cannabis possession to apply for a pardon and 
to reduce barriers to their reintegration by making avail-
able to them job opportunities, educational programmes 
and housing.
518. In June 2019, the Government of Canada announced 
amendments to the cannabis regulations to regulate the 
production and sale of edible cannabis products, cannabis 
extracts and topical applications. The amendments, which 
entered into force in October 2019, represent an attempt 
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to displace the country’s illicit market for cannabis prod-
ucts, while establishing regulatory measures to address 
health risks and promote safeguards. The regulations on 
cannabis production call for packaging to be child-resistant 
and plain, in order to make the packages less appealing to 
youth. In addition, each package of edible cannabis must 
not contain more than 10 mg of THC.
519. In the United States, as from 1 January 2020, the 
State of Illinois will allow the non-medical sale and use 
of cannabis for adults over the age of 21, with designated 
possession limits. The Illinois General Assembly passed 
the Cannabis Regulation and Taxation Act, which was 
signed into law on 25 June 2019 by the Governor of 
Illinois. In the State of New York, lawmakers agreed to 
further decriminalize the possession of cannabis, treating 
the possession of up to 2 ounces (56.7 grams) of canna-
bis as a civil violation instead of a crime. In July 2019, 
the State of Hawaii passed legislation to decriminalize the 
possession of up to 3 grams of cannabis. In all three states, 
there will be retroactive expungement of criminal records 
for past eligible cannabis convictions, with Illinois includ-
ing social equity and community development compo-
nents in its programme. 
520. In the United States, the Agriculture Improvement 
Act of 2018, signed into law in December 2018, amends 
the Controlled Substances Act to remove from Schedule 
I hemp, defined as cannabis with a delta-9-THC concen-
tration of not more than 0.3 per cent. Under federal law, 
CBD continues to be controlled under Schedule I. The 
removal of hemp from Schedule I is a reclassification of 
cannabis and will place hemp agricultural products under 
regulation of the Department of Agriculture.
521. Two cities in the United States have decriminalized 
the use and possession of mushrooms containing psilo-
cybin: Oakland, California, and Denver, Colorado. The 
hallucinogenic compound is controlled under Schedule I 
of the 1971 Convention. The ordinance in Denver was 
supported by 50.5 per cent of voters; it calls for city offi-
cials to deprioritize criminal penalties for the personal 
use and possession of psilocybin mushrooms by persons 
over the age of 21. In Oakland, a vote for decriminaliza-
tion of the substance was taken by the city council. At 
the national level, psilocybin is a substance controlled 
under Schedule I of the Controlled Substances Act. 
Psilocybin also remains controlled under Schedule I of 
both the California Uniform Controlled Substances Act 
and the Uniform Controlled Substances Act of 2013 of 
Colorado. Since criminal law in the United States is a fed-
eral and state responsibility and not a municipal respon-
sibility, the practical effect of those cities’ actions will be 
limited to how this substance is treated by municipal 
police officials. Possession and use of psilocybin will 
remain a criminal offence in both jurisdictions.
522. As part of national efforts to combat the opioid 
crisis, the United States Department of Justice reached an 
agreement in 2019 with a consumer goods company, 
according to which the company agreed to pay $1.4 billion 
to resolve potential criminal and civil liability related to the 
marketing of Suboxone, a drug used for the treatment of 
opioid addiction, which had resulted in false claims to the 
Government. The conduct by a subsidiary company was 
alleged to include the prescription of opioids to more 
patients than allowed by law, at high doses and in a care-
less manner. The State of Oklahoma also reached a historic 
settlement with a pharmaceutical company for its role in 
aggressively marketing OxyContin and fuelling the opioid 
crisis. There are numerous lawsuits pending in the United 
States that involve manufacturers of prescription opioids, 
as attempts are being made to impose legal penalties on 
those responsible for the large number of deaths (nearly 
218,000) from overdoses related to prescription opioids in 
that country in the period 1999–2017. In August 2019, a 
judge in the State of Oklahoma ordered a large pharma-
ceutical company to pay $572 million for its role in fuel-
ling the opioid crisis.
523. In May 2019, the Government of Canada took a 
proactive approach to addressing the proliferation of 
chemicals that share a similar chemical structure with a 
controlled chemical through amendments to its Precursor 
Control Regulations. Three precursors of fentanyl and 
fentanyl analogues, including their derivatives and ana-
logues and salts of derivatives and analogues, were placed 
under national control. At the same time, the scope of 
control was extended in a similar manner for several pre-
cursors already listed in the relevant schedules of the 
Controlled Drugs and Substances Act of Canada.
4.  Cultivation, production, 
manufacture and trafficking
524. Online drug trafficking through anonymous net-
works is fuelling the drug abuse and overdose crises in 
North America. Cryptocurrencies have been identified as 
a major challenge to agencies involved in combating ano-
nymity, preventing the use of virtual currency for money- 
laundering and prosecuting drug trafficking. In the 
United States, illegal online drug sales are being countered 
through multi-agency and government-wide efforts. The 
Department of Justice, for example, created the Joint 
Criminal Opioid and Darknet Enforcement team, which, 
with the cooperation of multiple federal agencies and local 
law enforcement partners, has shut down 50 darknet 
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accounts and led to 61 arrests as part of Operation SaboTor. 
In March 2019, there were 30 ongoing investigations in 
Canada that involved online drug trafficking. Coordinated 
and undercover law enforcement efforts have led to the 
infiltration of darknet networks and the arrest of 
vendors. 
525. The availability of and demand for cocaine have 
increased in Canada and the United States. According to 
the 2018 National Drug Threat Assessment, prepared by 
the Drug Enforcement Administration of the United 
States, the increase in illicit coca bush cultivation in 
Colombia has led to a re-emerging cocaine threat. In June 
2019, United States Customs and Border Protection and 
Homeland Security Investigations seized nearly 20 tons 
of cocaine, with a street value of about $1.3 billion, on 
board a shipping vessel in Philadelphia. It was the larg-
est cocaine seizure in the history of United States Customs 
and Border Protection.
526. Heroin continues to be readily available through-
out the United States, and the number of organized crim-
inal groups in Canada involved in the illicit market for 
heroin has increased substantially in the past year. 
According to the United States Office of National Drug 
Policy, Mexico continues to be the primary supplier of 
heroin to the United States. In 2019, there were multiple 
large-scale operations in the United States to combat 
heroin trafficking. In the first quarter of 2019, Mexican 
authorities reported 16 cases involving the detection of 
fentanyl, including cases involving the stopping of ship-
ments of fentanyl in tablet form sent to the United States 
via courier companies. 
527. Substantial intelligence about the drug trafficking 
activities carried out by the Sinaloa cartel – an organized 
crime syndicate based in Mexico – was released as evi-
dence in 2019 during the trial of one of its principal oper-
ators. A kingpin of major drug trafficking operations, 
responsible for smuggling massive amounts of cocaine, 
heroin, methamphetamine and cannabis into Canada and 
the United States since 1984, was found guilty. Key evi-
dence released during the trial was the result of multiple 
investigations and close partnership involving the 
Governments of Mexico and the United States.
528. Law enforcement operations throughout the 
United States have been targeting networks for the illicit 
supply and distribution of synthetic opioids. For the past 
year, Operation Synthetic Opioid Surge of the Department 
of Justice has provided a turning point in efforts to 
counter synthetic opioids, targeting local areas with a 
high rate of fatal overdoses. At the beginning of 2019, 
United States Customs and Border Protection officers 
seized nearly $4.6 million worth of fentanyl and meth-
amphetamine in the State of Arizona. The seizure 
included about 115 kg of fentanyl, making it the largest 
seizure of fentanyl in the history of United States Customs 
and Border Protection. 
529. Canadian authorities have been instrumental in 
extraditing suspects and procuring evidence during 
United States cross-border investigations of cases involv-
ing trafficking in fentanyl. Canada reported that in the 
period 2017–2018, there were 16,180 drug seizures at its 
border, including 438 seizures of opioids. That was sup-
ported by the expansion of authority in 2017 that allowed 
Canadian border officers to inspect mail of any weight 
that was suspected of containing illegal drugs, particu-
larly fentanyls. Prior to that, special permission was 
required for the inspection of mail weighing less than 
30 grams. At the global level, many countries still do not 
authorize the inspection of international mail of any 
weight, allowing multiple shipments of small envelopes 
containing pure fentanyl or other drugs to either slip 
through border control or be disposed of without open-
ing or further investigation.
530. In the United States, the number of fentanyl traf-
ficking offenders has increased by more than 4,700 per 
cent since 2014. According to the United States Sentencing 
Commission, the average sentence for fentanyl trafficking 
offenders was 74 months in 2018, compared with 66 
months in 2016. Throughout the region, questions have 
been raised about how to determine the most appropri-
ate sentences in fentanyl trafficking cases involving death. 
531. In the United States, differences in the price of can-
nabis in various states appear to be heightening the risks 
of interstate trafficking. In California, the Governor 
announced the redeployment of National Guard troops in 
2019, in part to enhance law enforcement efforts to counter 
illegal and unlicensed cannabis farms and shops. According 
to the Governor, there are major concerns about the 
increase in non-regulated cannabis and the cartels that are 
not participating in the regulated cannabis market and are 
growing cannabis plants illegally on public lands. The use 
of commercial aircraft for trafficking in cannabis may also 
be increasing, possibly as a result of the legalization of can-
nabis in certain states and the rise in the interstate trans-
port of cannabis by consumers. In Canada, there are also 
considerable differences in the price of cannabis among the 
provinces, and there are reports indicating that users could 
pay substantially more for cannabis on the licit market than 
on the illicit market. Statistics Canada has been collecting 
anonymous submissions from different parts of the coun-
try about the price users pay for dried cannabis, as well as 
estimates about the prevalence of cannabis use. 
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532. The illicit manufacture of and trafficking in meth-
amphetamine and synthetic drugs are increasing in 
Canada and the United States, as organized criminal 
groups are involved in trafficking in a variety of drugs 
and engaged in money-laundering proceeds derived from 
drug trafficking. According to information received by the 
Board from the United States, methamphetamine, both 
as a solid (crystal) and as a liquid, continues to be smug-
gled into the United States, where it is then crystallized 
in conversion laboratories. From October 2018 to June 
2019, over 21 tons of methamphetamine were seized by 
United States Customs and Border Protection. The num-
ber of new psychoactive substances continues to grow and 
experimentation with unregulated substances poses a sig-
nificant challenge for national authorities, with Canada 
reporting that methamphetamine trafficking and manu-
facture are central to many of its investigations of orga-
nized crime and polydrug trafficking. Efforts are being 
strengthened throughout North America to regulate and 
prohibit the importation, possession and sale of devices 
and equipment known to be used in the illicit manufac-
ture of controlled substances, such as tabletting machines.
533. In Mexico, the National Centre for Planning, 
Analysis and Information for Combating Crime (CENAPI) 
will ensure that drug control policy and drug abuse pre-
vention strategies and programmes, including the 
drug-profiling programme, are based on scientific evi-
dence. The objective of the profiling programme is to be 
able to recognize the chemical characteristics of fentan-
yls, heroin, methamphetamine and cocaine, facilitating 
the identification of the composition of samples, includ-
ing the concentration, cutting agents and adulterants, 
thereby determining substances not under international 
control, production modalities and new control models. 
534. A detailed analysis of the control of precursors and 
chemicals frequently used in the illicit manufacture of nar-
cotic drugs and psychotropic substances in the region can 
be found in the report of the Board for 2019 on the imple-
mentation of article 12 of the 1988 Convention. 
5. Prevention and treatment
535. The rise in methamphetamine use throughout 
North America has become a major public health con-
cern. In some parts of the region, methamphetamine 
addiction is an emerging threat that poses new preven-
tion and treatment challenges, such as methamphetamine 
abuse co-occurring with the abuse of opioids or cocaine. 
The Government of Canada, for example, has noted that 
problematic use of methamphetamine in some provinces 
and in underserved communities is an emerging threat 
that requires early detection and intervention, including 
the development of new models of care. In May 2019, 
under the Canadian Integrated Response to Organized 
Crime, a national social media campaign was started to 
inform Canadians about the role that outlaw motorcycle 
gangs play in drug trafficking and the illicit activities of 
organized crime. According to the Royal Canadian 
Mounted Police, such gangs have extensive illicit distri-
bution networks that appear to be connected with over 
half of all organized criminal groups in Canada.
536. The United States has indicated in its National 
Drug Control Strategy that there is a need to expand 
treatment capacity in the country and to encourage peo-
ple who require treatment for drug addiction to seek 
care. In 2017, of the 20.7 million Americans in need of 
treatment and recovery services, only 4 million received 
any kind of treatment and only 2.5 million received 
treatment at a specialized facility. Moreover, the num-
ber of patients receiving medication-assisted treatment 
for opioid addiction at health centres funded by the 
Health Resources and Services Administration increased 
by 142 per cent in the period 2016–2018, and the num-
ber of patients receiving buprenorphine, a substance 
commonly used in medication-assisted treatment, has 
increased by 28 per cent since 2017.
537. The United States has been a leader in providing 
support for international partners in programmes for the 
prevention of drug abuse and the treatment of drug- 
dependent persons. The Board encourages the United States 
to undertake programmes at the national level that will 
close its treatment gap, including by providing opioid 
substitution treatment options to all members of its pop-
ulation who are in need of and can benefit from such 
options.
538. As part of efforts in the United States to stem pub-
lic health problems related to the opioid crisis, the 
National Institutes of Health is supporting research on 
quality addiction treatment for opioid use disorder in 
criminal justice settings. The needs of treatment and 
related services in a wide range of criminal justice set-
tings, including the need to increase the availability of 
medication-assisted treatment, will be addressed by ini-
tiatives such as the Justice Community Opioid Innovation 
Network. Public health and safety interventions have also 
been initiated in response to the increased number of 
overdose deaths involving cocaine, attributable primarily 
to the co-involvement of synthetic opioids. The United 
States Department of Health and Human Services has 
introduced initiatives during the past year to help 
Americans affected by the opioid crisis. For example, ini-
tiatives such as the Integrated Care for Kids Model and 
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the Maternal Opioid Misuse Model of the Center for 
Medicare and Medicaid Innovation have been designed 
to improve care delivery for vulnerable beneficiaries, par-
ticularly those affected by the opioid crisis. The initiatives 
also seek to improve the quality of care and reduce expen-
ditures for beneficiaries. 
539. Canada and the United States are actively imple-
menting projects to ensure the safe supply of prescription 
opioids, while preventing overdoses by encouraging dis-
posal of all unused prescription medicines. According to 
the Government of Canada, about 11 lives were lost each 
day due to opioid overdoses in 2017, and there will be 
over 4,000 opioid-related deaths in Canada in 2019. The 
national budget for 2019 and additional funding will pro-
vide more than 100 million Canadian dollars to support 
access to safe supplies of prescription opioids, increase 
access to the overdose-reversing drug naloxone, mitigate 
the effects of the illicit supply of drugs and address the 
growing use of methamphetamines. The approval by the 
United States Food and Drug Administration of new pre-
scription opioids, such as Dsuvia, which is 10 times more 
potent than fentanyl, has met with calls for strong eval-
uation of the risks of their diversion and abuse.
540. The National Center for Health Statistics of the 
United States, in its fact sheet of February 2019, states 
that deaths from drug overdose are an increasing public 
health burden in the United States, with the age-adjusted 
rate of death from drug overdose in 2017 9.6 per cent 
higher than in 2016, and that the rate of death from drug 
overdose involving synthetic opioids other than metha-
done increased on average by 71 per cent each year in 
the period 2013–2017. In 2017, there were 70,237 drug 
overdose deaths.
541. In 2019, the Correctional Service of Canada opened 
an overdose prevention site in a federal prison in the 
Province of Alberta, where inmates can safely consume 
their own self-supplied substances, purportedly without 
access to a needle-syringe programme.
542. In Mexico, the National Commission against 
Addictions has indicated that the national priority is pro-
tecting children and adolescents from drug use, as well 
as training families and teachers on drug abuse preven-
tion. The Commission’s 2019 report on the situation with 
regard to drug use in Mexico focuses on demand reduc-
tion, as prevalence of the use of any drug in the past year 
was reported to be 2.9 per cent and lifetime prevalence 
was reported to be 10.3 per cent. According to that report, 
in 2018, there were 92,479 cases of treatment for illicit 
drug users, including for 11,840 women and 32,615 users 
of amphetamine-type stimulants. 
543. In 2019, a report was published by the National 
Institute of Psychiatry of Mexico which examines the 
prevalence of heroin consumption in treatment centres in 
the border cities of Tijuana, San Luis Río Colorado and 
Ciudad Juárez. The results of the study show that over 
56 per cent of respondents self-reported that they injected 
only heroin, more than 32 per cent used heroin with crys-
talline methamphetamine, and 5.4 per cent used heroin 
with cocaine. Most respondents had not used and were 
unfamiliar with fentanyl. This is the first study to deter-
mine how heroin use in Mexican border cities close to 
the United States is closely linked to the risk of fatal and 
non-fatal overdoses. It also highlighted the rates of HIV 
and hepatitis C among the heroin users.
544. The Government of Canada announced in 2019 
substantial funding to increase understanding of the 
impact of the opioid crisis and substance-related harm on 
indigenous communities, which have been disproportion-
ately affected. The goals of the new projects are centred 
on filling gaps in data, determining how prevention and 
treatment needs are being addressed and assessing the 
effects of the opioid crisis on First Nations, Métis and 
Inuit communities, based on culturally appropriate evi-
dence and approaches. 
545. Throughout North America, cannabis is becoming 
more widely available and the prevalence of cannabis 
abuse is increasing. According to the National Institute 
on Drug Abuse, an estimated 3 million people in the 
United States tried cannabis for the first time in 2017. In 
August 2019, the Surgeon General of the United States 
issued an advisory urging youth and pregnant women not 
to consume cannabis. According to the Surgeon General, 
“no amount” of cannabis during pregnancy or adoles-
cence is known to be safe.  The advisory includes data 
from the 2018 National Survey on Drug Use and Health 
showing that cannabis continues to be the most widely 
used drug, and its frequent use by youth and young adults 
is apparently associated with risks for opioid use, heavy 
alcohol use and major depressive episodes. The Surgeon 
General’s advisory also states that while CBD is not intox-
icating and does not lead to addiction, its long-term 
effects are largely unknown and most CBD products are 
untested and of uncertain purity. 
546. Statistics Canada reported in the National 
Cannabis Survey that 18 per cent of Canadians 15 years 
and older reported having used cannabis in the past 
three months. The number of first-time users of canna-
bis in 2019 was nearly double the estimated number of 
first-time users in 2018, when non-medical cannabis was 
not yet legal. An estimated 47 per cent of cannabis users 
– 2.5 million Canadians – obtained cannabis from legal 
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sources in the first three months of 2019, compared with 
23 per cent in the same period in 2018. 
547. In the context of cannabis legalization, additional 
research and studies are being conducted to better under-
stand the public health implications of cannabis con-
sumption. The Canadian Centre on Substance Use and 
Addiction and the Canadian Institutes of Health Research 
have formed a partnership to support and fund research 
on and the evaluation of cannabis policies.
548. The Board wishes to reiterate that article 4 (c) of 
the 1961 Convention as amended by the 1972 Protocol 
clearly limits to medical and scientific purposes the pro-
duction, manufacture, export, import, distribution of, 
trade in and use and possession of controlled narcotic 
drugs and that legalization measures or regulations that 
permit the non-medical use of any controlled substance, 
including cannabis, are in contravention of the legal 
obligations incumbent upon States parties to that 
Convention. The Board calls upon all States to respect 
their international legal obligations in the elaboration 
of their national drug control policies. 
South America
despite the negligible 1.2 per cent decline in illicit coca 
bush cultivation from 171,000 ha in 2017 to 169,000 ha 
in 2018, the potential manufacture of cocaine hydro- 
ch loride in Colombia increased by 5.9 per cent, from 
1,058  tons in 2017 to 1,120 tons in 2018.
1. Major developments
549. South America is responsible for the total global 
illicit production of coca leaf, cocaine base paste and 
cocaine hydrochloride. The region also illicitly produces 
cannabis for use within the countries of the region and 
for trafficking to destinations outside the region, and, to 
a much lesser extent, is the site of illicit cultivation of 
opium poppy. The problems linked to the illicit produc-
tion of, trafficking in and use of drugs have continued to 
negatively affect the quality of life of the population in 
the region by generating insecurity and violence. These 
drug-related problems can undermine governance, cause 
institutional weakness, promote corruption and money- 
laundering and generate diverse forms of social exclusion 
in some countries in the region.
550. According to Latin American Economic Outlook 
2018, which analyses economic and social development 
issues, 33 per cent of world homicides occur in Latin 
America and the Caribbean, making it one of the most 
violent regions in the world. According to the UNODC 
Global Study on Homicide 2019, firearms are involved in 
homicides in the Americas far more often than in other 
parts of the world. In Brazil, Colombia and Venezuela 
(Bolivarian Republic of), the homicide rate exceeds the 
regional average of 22 per 100,000.
551. One of the main objectives of CICAD is to 
develop strategies to strengthen implementation of the 
commitments made at the thirtieth special session of the 
General Assembly, on the world drug problem, held in 
2016. Regional policymakers, while maintaining a global 
vision, advocate that the strategies and goals of the coun-
tries of South America for combating the drug problem 
should be based on the local realities and be focused, 
among other things, on strengthening public health and 
human security and implementing measures to fight 
corruption.
552. The total area under illicit coca bush cultivation in 
South America has steadily increased from 120,600 ha in 
2013 to an all-time record 245,000 ha in 2017. The esti-
mated global illicit manufacture of cocaine also reached 
an all-time record of 1,976 tons in 2017, mainly driven 
by the increases in cocaine manufacture in Colombia.
553. In 2018, the area under illicit coca bush cultivation 
in the Plurinational State of Bolivia decreased by 6 per 
cent, to 23,100 ha. In Colombia, it decreased slightly, by 
1.2 per cent, to a total of 169,000 ha. Owing to the lack 
of data on illicit coca bush cultivation in Peru in 2018, 
the total area under illicit coca bush cultivation in South 
America in 2018 could not be estimated at the time of 
finalization of the annual report of the Board for 2019 
(1 November 2019). 
554. The CICAD Report on Drug Use in the Americas 
2019 provides an overview of drug use in the Western 
Hemisphere based on data submitted by 33 States mem-
bers of OAS. The report underlines the early age of onset 
of drug use, in particular cannabis, among young people. 
In 2019, CICAD also issued a guide on standardized indi-
cators for national drug information networks in Latin 
America that provides a model set of indicators for coun-
tries that want to standardize how they organize, collect 
and communicate information related to drugs and med-
icines for their national drug information networks.
555. Improving the capacities in epidemiological 
research and information systems has continued to be a 
challenge in the region. The lack of up-to-date data on 
the prevalence of drug abuse for some countries makes 
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regional and global analysis of the magnitude of the drug 
abuse problem a difficult task. In that context, regional 
experts on demand reduction expressed support for the 
development and enhancement of early warning systems 
in the States members of CICAD and for the develop-
ment of a regional early warning system for the Americas, 
which has been initiated by OAS.
2. Regional cooperation
556. CICAD continues to be the primary conduit of the 
strong regional cooperation in South America. The 
long-standing cooperation between CICAD and EMCDDA 
has enabled countries in the Americas and Europe to effec-
tively utilize available resources, improve data collection 
and analysis, develop and promote methods for data com-
parison and enhance the dissemination of information. 
Recently, CICAD held high-level consultations with the 
Presidency of the Council of Europe’s Pompidou Group on 
several issues, including the proposed launch of a joint 
activity on successful prevention models.
557. In the framework of the XI Summit of the Police 
Community of the Americas on the theme “The road to 
institutionalization”, an initial group of five countries 
(Argentina, Bolivia (Plurinational State of), Brazil, 
Ecuador and Panama) signed, in Buenos Aires in August 
2018, the first agreement of the Police Community of the 
Americas on police cooperation against organized crime, 
aimed at strengthening capabilities for international 
cooperation.
3.  National legislation, policy and 
action
558. The Board notes the efforts of the countries of 
South America to address the growing threat of micro-
trafficking in the region. For example, to improve the 
quality of life of its citizens, the Government of Argentina 
implemented under its “Safe neighbourhood” programme 
activities designed to identify criminal organizations 
involved in microtrafficking and to reduce the number of 
homicides. The authorities of Chile continued to imple-
ment the “Study without drugs” programme, aimed at 
reducing the availability of drugs in the areas around 
schools. In Colombia, experts were considering alterna-
tive strategies to counter microtrafficking of drugs in the 
country, including interventions in and around schools, 
the use of undercover agents and the demolition of build-
ings being used as drug warehouses. In July 2019, the 
Government of the Bolivarian Republic of Venezuela 
approved the national anti-drug strategy for the period 
2019–2025, focusing on the general public, in particular 
children and adolescents. One of the key goals of that 
strategy is the development of programmes that address 
the risk of microtrafficking in public and school settings 
and thus contribute to the prevention of drug abuse and 
promote international cooperation.
559. The countries of South America do not currently 
have any specific regional legal instrument, such as an 
instrument of OAS, that would allow countries of the 
region to act together in response to all potentially dan-
gerous new psychoactive substances. Although some 
countries in Latin America and the Caribbean have made 
progress in improving their national mechanisms for 
monitoring new psychoactive substances, there are signif-
icant differences between the monitoring mechanisms in 
Latin America and the Caribbean and those developed in 
the United States and Canada.
560. To respond to the emergence of new psychoactive 
substances, the Government of Argentina adopted decree 
560/2019, which introduces generic scheduling to com-
plement the current system of individual substance 
listing.
561. In November 2018, the Plurinational State of 
Bolivia became the eighth country of Latin America and 
the Caribbean to participate in the CRIMJUST project 
implemented in the framework of the European Union’s 
Cocaine Route Programme, which focuses on enhancing 
cooperation in criminal investigations and criminal jus-
tice in countries of Latin America and the Caribbean and 
West Africa. In 2019, the Plurinational State of Bolivia 
inaugurated a port control unit in La Paz which will help 
the country to counter drug trafficking. 
562. In 2019, as part of a recent restructuring at the 
ministerial level, the Government of Brazil established 
SENAPRED, which is linked to the newly created Ministry 
of Citizenship. Under the new institutional structure, the 
National Secretariat for Drug Policies of Brazil is respon-
sible for managing drug policies related to supply reduc-
tion and countering the illicit manufacture of and 
trafficking in drugs, while SENAPRED is responsible for 
the management of public policies on drugs related to 
care, prevention and social reintegration.
563. In 2019, the Government of Brazil proposed to the 
Congress a new law establishing enhanced measures 
against corruption and organized and violent crime, 
which is expected to contribute to countering drug traf-
ficking. The Government was also considering the estab-
lishment of a specialized agency to maximize the recovery 
of illicit proceeds through the sale of seized assets.
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564. The report for 2018 of the Observatory on Drug 
Trafficking in Chile, among other things, drew attention 
to the upsurge in cannabis of Colombian origin, known 
as “creepy”, which was replacing cannabis of Paraguayan 
origin, as corroborated by the increasing number of sei-
zures of that strain of cannabis. The report also pointed 
out the increased seizures of MDMA (“ecstasy”), which 
recently have accounted for 80 per cent of all seizures of 
synthetic drugs in Chile, compared with the scarce sei-
zures of the drug in 2010.
565. In December 2018, the Government of Colombia 
approved a comprehensive drug policy called “Future 
route”. With active international cooperation, “Future 
route” will focus on major aspects of the drug problem 
in the country, including illicit crop cultivation, drug sup-
ply and drug use, organized crime and money- laundering. 
The policy will be jointly implemented by more than 15 
relevant governmental entities, including those forming 
part of the National Council on Narcotic Drugs.
566. In May 2019, the Government of Colombia adopted 
law 1955, which promulgated the National Development 
Plan for the period 2018–2022, entitled “Pact for Colombia, 
pact for equity”. An integral part of the National 
Development Plan is the document entitled “Bases of the 
National Development Plan 2018–2022: Pact for Colombia, 
pact for equity”. A key objective of the Pact is the imple-
mentation of a comprehensive drug control policy.
567. In May 2019, the Ministry of Health of Ecuador 
presented the National Agreement 2030 for the preven-
tion of addiction and use of drugs. Agreement 2030 is 
aimed at developing comprehensive prevention and treat-
ment interventions in the framework of balanced drug 
control strategies. Activities carried out under Agreement 
2030 will focus on the national information system; the 
socioeconomic phenomenon of drugs; intervention strat-
egies and the treatment of drug use; and the coordinated 
implementation of prevention and control strategies in 
the community.
568. On 27 December 2017, the Government of 
Paraguay enacted Law No. 6007 to regulate the legal 
framework governing the production and use of canna-
bis and its derivatives for medical and scientific purposes. 
The law establishes the National Programme for the Study 
of and Medical and Scientific Research on the Medicinal 
Use of the Cannabis Plant and its Derivatives and pro-
motes medical and scientific research on the medical and 
therapeutic use of cannabis for the treatment of human 
diseases and conditions. Decree No. 9303 of 6 August 
2018 established the requirements for registration, in the 
national register of users, of products derived from 
cannabis, restricting it to patients in treatment, including 
those participating in a research programme.
569. In Peru, the medicinal and therapeutic use of can-
nabis and its derivatives is regulated through law No. 
30681, which provides for the informed use, research, pro-
duction, import and marketing of cannabis and its deriv-
atives, exclusively for medicinal and therapeutic purposes. 
In February 2019, the Government of Peru published 
Supreme Decree No. 005-2019-SA, which ensures access 
to cannabis for more than 7,000 people who require the 
substance to treat their specific health problems.
4.  Cultivation, production, 
manufacture and trafficking
570. In the Plurinational State of Bolivia, coca bush 
cultivation rose from 20,200 ha in 2015 to 24,500 ha in 
2017. In 2018, the total area under illicit coca bush cul-
tivation in the country decreased to 23,100 ha, 6 per 
cent less than in 2017. A total of 11,200 ha of coca bush 
were eradicated in 2018, 54 per cent more than in 2017, 
when 7,200 ha were eradicated. Over the past 10 years, 
an average of about 4,400 illicit cocaine laboratories per 
year were dismantled in the Plurinational State of 
Bolivia; in 2018, a total of 1,004 illicit cocaine laborato-
ries were dismantled, about 2,200 laboratories fewer 
than in 2017. Almost all dismantled clandestine labora-
tories were located in the departments of Cochabamba 
and Santa Cruz. While the number of dismantled illicit 
cocaine laboratories significantly decreased in 2018, 
compared with 2017, the number of dismantled illicit 
cocaine crystallization laboratories increased by 33 per 
cent, and the number of laboratories used for the recy-
cling of chemicals used in the illicit manufacture of 
cocaine increased by 45 per cent.
571. The area under illicit coca bush cultivation in 
Colombia declined from 99,000 ha in 2007 to 48,000 ha 
in 2013. Since 2013, the area of cultivation has been grow-
ing, reaching a peak of 171,000 ha in 2017, with an aver-
age year-on-year increase of 38 per cent over that 
four-year period. In 2018, the total area under illicit coca 
bush cultivation in Colombia decreased to 169,000 ha, a 
1.2 per cent decrease. However, the potential illicit man-
ufacture of cocaine hydrochloride – as estimated accord-
ing to a new UNODC methodology for estimating that 
potential illicit manufacture that has been in use since 
2017 – was found to have increased in 2018, by 5.9 per 
cent: from an estimated 1,058 tons of cocaine hydrochlo-
ride in 2017 to 1,120 tons in 2018. That increase in the 
potential illicit manufacture can be attributed in part to 
reported higher yields of coca leaves per hectare. 
82  INCB REPORT 2019
572. The minor decrease in illicit coca bush cultivation 
in Colombia in 2018 could be attributed in part to the 
gradual increase in eradication of illicit coca bush in the 
country, reaching 60,000 ha in 2018, up from the low level 
of 2016 (17,600 ha). That effort included the increased par-
ticipation of farming families in the National Comprehensive 
Plan for the Substitution of Illicit Crops, the aim of which 
is to replace the coca bush crops with a profitable legal 
crop, supported by a voluntary eradication process. The 
number of families participating in that substitution pro-
gramme increased from about 54,000 families in 2017 to 
99,100 families in 2018.
573. Over the period 2010–2012, an average of 138,000 ha 
of illicit coca bush cultivation per year were eradicated in 
Colombia, manually or by aerial spraying. In that period, 
aerial spraying of glyphosate on coca crops accounted for 
about three quarters of all eradication.
574. In the period 2013–2017, the total area eradicated 
per year decreased, to an average of about 51,000 ha per 
year. That significant drop in eradicated area could be 
attributed in part to a decision of the National Council 
on Narcotic Drugs in May 2015, to suspend, for consti-
tutional and sanitary reasons, the aerial spraying of 
glyphosate from aircraft. Since 2017, Colombia has imple-
mented eradication programmes involving the terrestrial 
spraying of coca bush using glyphosate, at lower concen-
trations. In 2018 and 2019, in line with the quinquennial 
plan for the period 2018–2023 and the Government’s 
“white paper” for the eradication of illicit crops, the 
Government’s strategy to address illicit coca bush culti-
vation continued to be based on the suspension of the 
aerial spraying of coca bush crops, increased goals for 
manual eradication, the implementation of the national 
illicit crop substitution plan and the promotion of com-
prehensive action targeting the different links of the drug 
trafficking chain.
575. A number of other factors, in particular economic 
and security factors, also appear to have played a role in 
the increased coca bush cultivation and declining area of 
eradication in Colombia over the past few years. Those 
factors include the growing unemployment in some parts 
of Colombia, owing to the decreased exports of agricul-
tural products from Colombia to the market of the 
Bolivarian Republic of Venezuela, increased cultivation of 
coca bush by people who, following the collapse of the 
price of gold, stopped illegal gold mining, and the deval-
uation of the Colombian currency. The increased involve-
ment of Mexican cartels and the growing involvement of 
former members of paramilitary organizations in orga-
nized crime might have also contributed to the increased 
coca bush cultivation and drug trafficking. 
576. In 2018, about 60,000 ha of coca bush cultivation 
were eradicated in Colombia, representing roughly a 15 per 
cent increase compared with the area eradicated in 2017. 
In 2019, in pursuit of its goal to reduce the area under 
illicit coca bush cultivation to a maximum of 90,000 ha by 
2023, the Government of Colombia planned to eradicate 
100,000 ha of illicit crop cultivation through a combina-
tion of forced eradication and crop substitution.
577. In Peru, the area of illicit coca bush cultivation 
declined each year from 2011 to 2015, from 62,500 ha in 
2011 to 40,300 ha in 2015. In 2017, the total area of illicit 
coca bush cultivation increased for the second year in a 
row, reaching 49,900 ha, an area 14 per cent larger than 
in 2016 (43,900 ha). The Board is concerned that the 
recent negative trend of increasing coca bush cultivation 
might put at risk the successful model of integral and sus-
tainable alternative development in the country.
578. In recent years, organized criminal groups traf-
ficked large amounts of illicit drugs from Colombia, 
through the Bolivarian Republic of Venezuela, to Europe 
and the United States. The organized criminal groups 
control this trafficking, in particular the trafficking of 
cocaine through Central America to the United States, 
through the control of sea ports and using illegal flights 
of light aircraft. There are indications that in the Bolivarian 
Republic of Venezuela the criminal groups have suc-
ceeded in infiltrating government security forces, form-
ing an informal network known as the “Cartel of the 
Suns” to facilitate the passage of illicit drugs into and out 
the country. 
579. Trafficking in drugs, in particular cocaine hydro-
chloride, by sea from ports in Chile to Europe has fur-
ther increased, putting Chile, together with Brazil and 
Colombia, among the three key countries of departure 
for cocaine seized in Valencia and Algeciras, Spain, an 
important entry point of cocaine shipments to Europe.
580. According to the 2018 report of the National 
Anti-Drug Secretariat of Paraguay, the country contin-
ues to be a significant illicit producer of cannabis, as the 
area of illicit cannabis cultivation in Paraguay is esti-
mated to be 6,000 ha. Owing to the permeability of its 
borders in some areas, the territory of Paraguay contin-
ued to be used to traffic cocaine from Bolivia 
(Plurinational State of), Colombia and Peru to destina-
tions in Argentina, Brazil and Europe.
581. Law enforcement authorities of Paraguay contin-
ued to eradicate illicit cannabis crops and counter 
cross-border cocaine and cannabis trafficking, in cooper-
ation with police authorities of Brazil. The Government 
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of Paraguay also made efforts to replicate its arrange-
ments with its Brazilian counterparts with the Governments 
of Argentina and Bolivia (Plurinational State of) through 
mutual cooperation to eradicate cannabis under cultiva-
tion and to interdict cannabis and cocaine trafficking, and 
through the exchange of information.
582. In 2018, among the countries that reported sei-
zures of cannabis herb exceeding 200 tons were Brazil 
(268.1 tons), Colombia (264.3 tons) and Argentina 
(256.2 tons). Significant amounts of the drug were also 
seized in Peru (22 tons), Chile (16.8 tons), the 
Plurinational State of Bolivia (8.6 tons), the Bolivarian 
Republic of Venezuela (7.1 tons) and Uruguay (2.5 tons). 
Most of these countries also reported seizures of can-
nabis plant. For example, the Plurinational State of 
Bolivia seized over 231 tons of cannabis plant and Peru 
seized more than 1.7 million plants. In the Plurinational 
State of Bolivia, the illicit cultivation of cannabis 
increased, resulting in the drug becoming easily avail-
able at a low cost.
583. In 2018, seizures of significant amounts of cocaine 
hydrochloride were reported by Bolivia (Plurinational 
State of) (18.1 tons), Chile (3.7 tons), Colombia 
(414.5 tons), Peru (19.5 tons), Uruguay (0.6 tons) and 
Venezuela (Bolivarian Republic of) (35.5 tons). From 
Colombia, the drug continues to be smuggled primar-
ily by sea, with traffickers making use of “go-fast” boats, 
submersible and semi-submersible vessels, unmanned 
undersea vehicles and buoys with satellite-location 
devices on them. 
584. In addition to cocaine hydrochloride, traffickers 
also smuggle coca base from Colombia for further pro-
cessing outside the country, as corroborated by the sei-
zures of the substance as it entered international waters, 
as well as seizures of the substance effected in other coun-
tries in the region. For example, sizeable amounts of coca 
base and coca paste have been seized in Argentina, Brazil, 
Chile and Uruguay. In 2018, a total of 33 illicit medium- 
sized cocaine laboratories were dismantled in the 
Bolivarian Republic of Venezuela, close to the country’s 
border with Colombia.
585. In addition to seizures of plant-based drugs, a 
number of countries reported seizures of synthetic 
drugs. For example, in 2018, Chilean authorities seized 
more than 840,000 doses of synthetic drugs, including 
amphetamine, methamphetamine and “ecstasy”. This 
was about 500,000 doses of synthetic drugs more than 
what was seized in 2017 (an increase of almost 150 per 
cent). Increased demand for synthetic drugs was also 
reported by Uruguay. 
5. Prevention and treatment
586. There have continued to be changes in the legal 
and regulatory status of cannabis throughout the 
Americas. According to OAS, decriminalization of can-
nabis for non-medical and medical purposes might have 
contributed to increased access to the drug for adults. The 
information available from those countries that have pro-
duced recent epidemiological data, including Argentina 
and Chile, indicate that most have experienced an increase 
in the prevalence of cannabis use. According to the 
CICAD Report on Drug Use in the Americas 2019, while 
past-year use of cannabis herb among the general popu-
lation in Argentina (2017) and Uruguay (2014) was under 
10 per cent, in Chile (2016) it was 14.5 per cent. The low-
est prevalence rates reported in the region were those of 
Ecuador (2014) and Paraguay (2003), which had past-
year prevalence rates of use of the drug below 1 per cent. 
The first survey on drug use among university students 
in Chile, published in May 2019, indicates that over 
70 per cent of the university students in the country had 
been offered cannabis in the past 12 months. In some 
countries, cannabis use appears as early as the eighth 
grade. Experts of OAS advocate giving greater priority to 
prevention programmes and interventions that delay the 
age of onset of drug use.
587. About half the countries in the Americas were 
shown to have increases in cocaine use among the gen-
eral population. The use of cocaine base paste, which had 
previously been confined to cocaine-manufacturing coun-
tries, has spread to countries farther south in the region. 
According to the UNODC World Drug Report 2019, the 
provision of treatment for which cocaine is the primary 
drug of abuse continues to be widely seen in Latin 
America. 
588. According to UNODC, the annual prevalence rate 
of non-medical use of opioids in South America in 2017 
was estimated to be 0.2 per cent. In Chile, the past-year 
prevalence of non-medical use of pharmaceutical opioids 
increased fourfold, from 0.3 per cent in 2012 to 1.2 per 
cent in 2016.
589. While drug use has historically been regarded as a 
phenomenon of male use, according to the CICAD Report 
on Drug Use in the Americas 2019, recent data show that 
females in some countries are now using certain drugs 
either at the same rate, or at higher rates, than males. In 
every population group in nearly every country in the 
Americas, misuse of tranquilizer pharmaceuticals is 
higher among females.
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D. Asia
East and South-East Asia
The expansion of illicit manufacture, trafficking and use 
of synthetic drugs, in particular methamphetamine, con-
tinued to be of major concern for East and south-East 
asia.
1. Major developments
590. The expansion of illicit manufacture, trafficking 
and use of synthetic drugs, in particular methamphet-
amine, continued to be of great concern in most coun-
tries of East and South-East Asia. Effective border 
management and control over precursor chemicals have 
become particularly important for countering this phe-
nomenon, given that the chemical industry has a substan-
tial presence in the region and the increasingly improved 
infrastructure has further enhanced connectivity among 
countries.
591. In a region that has historically adopted drug con-
trol policies that relied heavily on deterrence through 
severe penal sanctions and compulsory treatment, some 
Governments are reviewing their drug policies, adopting 
proportionate sanctions for minor drug-related offences 
and a health-based approach to addressing drug use. 
592. In 2019, the Republic of Korea and Thailand legal-
ized the cultivation and use of cannabis for medical 
purposes. 
593. Most countries continue to lack comprehensive 
drug use prevalence data and evidence-based drug treat-
ment protocols. Greater attention should be given and 
more resources devoted to demand reduction, treatment 
and social reintegration in order to improve quality of 
life, help reduce the burden on the health-care system 
and remove the stigmatization of drug use.
2. Regional cooperation
594. Various meetings to enhance regional cooperation 
took place in 2019. The 42nd and 43rd meetings of the 
Heads of National Drug Law Enforcement Agencies, Asia 
and the Pacific, took place in October 2018 and October 
2019, respectively. In April 2019, ministers and high-level 
officials of the ASEAN region gathered in Bangkok for a 
meeting entitled “Synchronizing trade and security plans 
in support of ASEAN 2025”. Providing a platform for 
decision-makers to discuss challenges stemming from the 
closer regional integration, the meeting paved the way for 
a common ASEAN border management strategy, to be 
presented in Bangkok before the end of 2019.
595. Signatories to the Mekong Memorandum of 
Understanding on drug control (Cambodia, China, the 
Lao People’s Democratic Republic, Myanmar, Thailand 
and Viet Nam and UNODC) agreed to a draft subregional 
action plan to guide activities to be conducted under the 
Memorandum of Understanding in the period 2019–
2021. The Mekong Memorandum of Understanding is an 
agreement between the signatory countries to work 
together and provide a platform to address the threat of 
illicit production, trafficking and use of drugs in the 
Mekong region. According to UNODC, the 11th version 
of the subregional action plan was expected to be 
endorsed during the ministerial meeting of the Mekong 
Memorandum of Understanding, to take place on 
15 November 2019.
3.  National legislation, policy and 
action
596. A number of legislative and policy changes took 
place in 2018 and 2019, relating to, among other things, 
legislative changes regarding the use of cannabis for med-
ical purposes, the application of the death penalty for 
drug-related crimes, extrajudicial responses to suspected 
drug-related acts, the national scheduling of substances 
not under international control and partnerships promot-
ing alternative development.
597. On 19 February 2019, Thailand became the first 
country in South-East Asia to legalize the use of canna-
bis for medical purposes. Under the Narcotics Act (No. 7) 
B.E. 2562, State enterprises, scientific institutions and fac-
ulties of pharmacy in public and private universities that 
have obtained a licence from the licensing authority can 
cultivate, produce, manufacture, import, export and pos-
sess cannabis for medical purposes. The Food and Drug 
Administration is the national agency mandated to con-
trol the cultivation of cannabis for medical and scientific 
purposes. Patients with certain serious debilitating dis-
eases or indications who cannot be treated satisfactorily 
using an approved medical product can obtain cannabis 
through the country’s special access programme by first 
consulting their doctor and then applying to the Food 
and Drug Administration. The Narcotics Act also legal-
ized, in some administrative regions, the licensed medi-
cal use of kratom (Mitragyna speciosa), a plant-based 
psychoactive substance not under international control 
that had been banned in the country since 1943, although 
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reportedly it had long been used by rural populations for 
its stimulant and analgesic properties.
598. The Republic of Korea, at the end of 2018, became 
the first country in East Asia to legalize the use of can-
nabis for medical purposes. Since 12 March 2019, patients 
have been able to import cannabis products after receiv-
ing authorization from the Ministry of Food and Drug 
Safety. To obtain authorization, individuals are required 
to submit to the Ministry their medical records and a 
note from a physician stating that there is a lack of alter-
native treatment.
599. On 15 March 2018, the Government of Malaysia 
amended section 39B of the Dangerous Drugs Act 1952 
to remove the mandatory death penalty for those con-
victed of drug trafficking and replaced it with a discre-
tionary power of the court to commute death sentences 
to life imprisonment and not less than 15 strokes of the 
cane if certain conditions are met. One such condition is 
that the court is satisfied beyond a reasonable doubt that 
the accused assisted the enforcement agencies of Malaysia 
in disrupting further drug trafficking in or outside the 
country. The other conditions allowing the commutation 
of death sentences are the following: if there was no evi-
dence that at the time of arrest the individual was buy-
ing or selling a substance categorized as a dangerous drug, 
if there was no involvement of an agent provocateur (e.g., 
an undercover agent), and if the accused individual’s 
involvement is restricted to transporting, carrying, send-
ing or delivering a dangerous drug.
600. The Philippines officially withdrew from the 
International Criminal Court on 17 March 2019, after 
the Court had decided to conduct a preliminary inquiry 
into accusations that the President of the Philippines and 
other officials of the country had committed crimes 
within the Court’s jurisdiction in carrying out the coun-
try’s drug control policies. 
601. Following reports of human rights violations over 
the previous three years in the Philippines, the Human 
Rights Council adopted its resolution 41/2, in which it 
took note of the allegations of the killing of thousands of 
people allegedly involved in drug-related activities and/
or offences. In its resolution, the Council called on the 
Government of the Philippines to cooperate with the 
Office of the United Nations High Commissioner for 
Human Rights and requested the High Commissioner to 
prepare a comprehensive report on the situation of human 
rights in the country. 
602. The Board reminds all Governments that extraju-
dicial action, purportedly taken in pursuit of drug 
control objectives, is fundamentally contrary to the pro-
visions and objectives of the three international drug con-
trol conventions, as well as to human rights instruments 
to which all countries are bound. All drug control actions 
should be undertaken in full respect of the rule of law 
and due process of law.
603. The Misuse of Drugs (Amendment) Act of Singapore, 
aimed at strengthening drug control and rehabilitation, 
came into effect on 1 April 2019. The amendment crimi-
nalizes behaviour that facilitates or promotes drug use, 
such as introducing a person to a drug trafficker or pro-
viding drug-related information to someone who intends 
to carry out those activities. The amendment also crimi-
nalizes the act of exposing children to drugs or allowing 
them to consume drugs. Further, the use of drug detection 
methods, in particular hair analysis and saliva screening, 
was expanded through the amendment. In addition, the 
Government increased the maximum detention period for 
a drug user in a drug rehabilitation centre from three to 
four years and the maximum duration of post-release 
supervision from two to five years. The Board discourages 
the use of compulsory detention for rehabilitation of 
people affected by drug use and calls on Governments in 
the region to implement voluntary, evidence-based treat-
ment services with due respect for patients’ rights.
604. Effective 1 May 2019, the Central Narcotics Bureau 
of Singapore rescheduled five new psychoactive sub-
stances77 from the Fifth Schedule of the Misuse of Drugs 
Act to the First Schedule of the Act. The substance lis-
dexamfetamine (l-lysine-d-amfetamine) was also added 
to the First Schedule. The rescheduling of these new 
psycho active substances means that trafficking, manufac-
ture, import, export, possession or consumption of these 
substances will constitute an offence and will result in a 
minimum of five years’ imprisonment and five strokes of 
the cane. In addition, the Central Narcotics Bureau listed 
two new psychoactive substances78 in the Fifth Schedule, 
which will allow them to be seized so that circulation can 
be restricted while further research and consultations are 
conducted.
605. To further strengthen its drug control system, the 
Government of China decided to schedule as a class-wide 
group all fentanyl-related substances on the national 
77 Adamantyl-CHMINACA, 3,4-dichloromethylphenidate (3,4-
DCMP) and its dichloro positional isomers in the phenyl ring, 5-fluoro-
CUMYL-PICA and its phenylpropyl isomers and their respective fluoro 
positional isomers in the pentyl group, 5-fluoro-SDB-005 and its fluoro 
positional isomers in the pentyl group, and SDB-005.
78 5-Fluoro-CUMYL-PeGACLONE and its phenylpropyl isomers 
and their respective fluoro positional isomers in the pentyl group and 
CUMYL-PeGACLONE and its phenylpropyl isomers.
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control list, effective as of 1 May 2019. The National 
Narcotics Control Commission of China clarified the 
legal definition of “fentanyl-related” and emphasized that 
the definition would be scientifically determined on the 
basis of the chemical structure of the substance in ques-
tion. The Commission stated that if, at a later stage, any 
of the affected substances were found to have legitimate 
pharmaceutical, industrial, scientific, research or other 
legal use, they would be treated accordingly.
606. Over the course of 2018, the Government of 
Thailand has continued to promote and implement its 
alternative development programme, both within the 
country and through various international partnerships, 
by providing assistance in community development, agri-
cultural knowledge, techniques and marketing strategies. 
Working closely with the Government of Myanmar, 
Thailand has been expanding such aid and activities to 
further drug-affected areas in Myanmar. In addition, in 
January 2019, the drug authorities of Thailand and the 
Lao People’s Democratic Republic agreed to promote a 
pilot project in Borikhamxay Province of the Lao People’s 
Democratic Republic. 
4.  Cultivation, production, 
manufacture and trafficking
607. According to UNODC, the amount of metham-
phetamine seized in the region increased eightfold 
between 2007 and 2017 and reached a record high level 
in 2018. Data received indicated that Thailand alone 
accounted for more than half of the methamphetamine 
seized in the region in 2018.
608. Preliminary data for 2019, in particular the data 
for methamphetamine tablets, indicated a geographical 
shift in the manufacture and trafficking from China to 
other countries in the region. Targeted law enforcement 
in China seems to have pushed organized criminals to 
move their illicit methamphetamine manufacture to 
neighbouring countries including Myanmar, contributing 
to the slight reduction in methamphetamine seizures in 
China but also to increases in Myanmar and its neigh-
bouring countries.
609. With the continuing growth of illicit methamphet-
amine manufacture in Myanmar, the Lao People’s 
Democratic Republic has become an important transit 
country for methamphetamine destined for other coun-
tries in the Mekong region. In 2018, more than 21 million 
methamphetamine tablets and 1.8 tons of crystalline 
methamphetamine were seized in the Lao People’s 
Democratic Republic, compared with an annual average 
of less than 100 kg of crystalline methamphetamine 
between 2013 and 2017. In comparison, authorities in 
Indonesia seized over 8 tons of crystalline methamphet-
amine in 2018, by far the largest seizure ever reported in 
that country.
610. While the wholesale and street prices of illicit 
methamphetamine in Thailand fell in 2018 to their low-
est levels in the past decade, UNODC estimated the illicit 
methamphetamine market in East and South-East Asia to 
be worth up to approximately $45 billion annually. Japan 
and the Republic of Korea accounted for almost one fifth 
of that estimated value, mainly because of the significantly 
higher wholesale and retail prices in those countries.
611. The illicit manufacture, trafficking and use of 
heroin, which is reported as the second most frequently 
trafficked drug in South-East Asia, continued to pose 
challenges for most countries in the region.
612. Most illicit manufacture of heroin in the region 
takes place in northern Myanmar. The area under illicit 
opium poppy cultivation in that country in 2018 was esti-
mated at 37,300 ha, down from its recent peak of approx-
imately 60,000 ha in 2014. Compared with 2017, there 
has been a reduction in illicit cultivation in almost all 
regions of the country, with considerable decreases in 
Shan and Kachin States (the two main producer states).
613. However, heroin seizures have moved in the oppo-
site direction: total seizures of heroin in Myanmar, 
Thailand and Viet Nam increased in 2018, with Viet Nam 
being a major destination. Viet Nam accounted for more 
than one third of all heroin seized in South-East Asia 
from 2013 to 2018. Malaysia also reported an increasing 
amount of heroin being trafficked through its territory 
with the final destination of Australia.
614. In their latest national report, authorities of China 
expressed concern at the continuous increase in cocaine 
seizures in 2018 and the considerable rise of cannabis being 
trafficked into the country by post. Similarly, up to 170 
cases of attempted smuggling of drugs through the postal 
system were detected in Indonesia in 2018. Trafficking by 
sea has been identified as an increasingly popular modus 
operandi among large-scale drug traffickers.
615. Substantial quantities of precursor chemicals have 
been diverted from the region’s sizeable chemical indus-
try and trafficked for the manufacture of methamphet-
amine, as the region has an increasingly lucrative illicit 
market for synthetic drugs. Limited forensic data suggest 
that ephedrine and pseudoephedrine remained the main 
precursor chemicals used for the illicit manufacture of 
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methamphetamine, although there is also growing use of 
P-2-P. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances can be found in the report 
of the Board for 2019 on the implementation of article 
12 of the 1988 Convention.
616. Countries of East and South-East Asia continued 
to account for most of the ketamine seized worldwide. 
The latest data from UNODC indicated that more than 
90 per cent of the ketamine seized worldwide between 
2013 and 2017 had been seized in Asia, and most of that 
had been seized in East and South-East Asia.
617. With respect to ketamine, which is not under 
international control, the latest data indicate a displace-
ment of some ketamine manufacture from China to other 
countries in the region. While ketamine seizures declined 
in China, including Hong Kong, China, after 2015, sei-
zures in Myanmar and Thailand have increased signifi-
cantly since 2017.
5. Prevention and treatment
618. The region continued to lack systematic and quan-
titative information on drug use. Although data are lim-
ited, some regional studies suggest that cannabis is the 
most commonly used illicit drug in the region. The 
Philippines reported the highest prevalence of past-year 
cannabis use in 2016, a rate of 1.64 per cent for respon-
dents aged 15–64, and Japan reported that the prevalence 
of past-year cannabis use increased to 1.4 per cent in 
2017, with an estimated total of 1.33 million cannabis 
users in the country.
619. Qualitative information provided to UNODC indi-
cated that methamphetamine was the main drug of con-
cern for treatment admissions, and other recent data 
pointed to high rates of annual prevalence of use of the 
substance (between 0.5 and 1.1 per cent).
620. Data from the Global Burden of Disease Study 
2017, as cited in the UNODC World Drug Report 2019, 
show that the region has a much bigger health loss (in 
terms of years of healthy life lost) compared with other 
world regions, mainly as a result of the number of peo-
ple who inject drugs (28 per cent of the global total) and 
alarming rates of blood-borne illnesses among people 
who inject drugs. 
621. Authorities of China estimated there were 2.5 mil-
lion drug users in the country in 2018, slightly less than 
the year before. Methamphetamine remained the primary 
drug of use (1.35 million, or 56 per cent of the total), fol-
lowed by heroin (an estimated 890,000, or 37 per cent) and 
ketamine (an estimated 63,000, or 2.6 per cent). The num-
ber of cannabis users in 2018 was reported to have reached 
24,000, an increase of 25 per cent over the previous year.
622. The total number of reported drug users in Hong 
Kong, China, dropped to 2,033 in the first quarter of 
2019, slightly less than in the previous year. Heroin 
remained the primary drug of use (1,056 users), followed 
by methamphetamine (435 users). 
623. Authorities of Singapore remained concerned at the 
increase in the number of drug users in 2018 (around 3,500 
users), a considerable proportion of which were new drug 
users under the age of 30. Methamphetamine remained the 
primary drug of use (75 per cent of drug users). 
624. According to the official report of Cambodia, there 
were over 20,000 drug users in the country in 2018 that 
were seeking or receiving some form of treatment through 
a private or public health system or drug centre. 
Authorities of Malaysia reported that in 2018 an esti-
mated 25,000 drug users were receiving treatment or in 
rehabilitation with the National Anti-Drugs Agency, 
slightly fewer than the previous year, mainly because 
there was a smaller number of new users. The total num-
ber of crystalline methamphetamine users, however, 
increased to over 16,000 users in 2018, and users of 
amphetamine-type stimulants more than doubled, to over 
1,000 users. In Indonesia, over 7,500 users of metham-
phetamine were receiving treatment in 2018, compared 
with roughly 2,000 users of cannabis. 
South Asia
seizures of methamphetamine tablets are increasing at 
an alarming rate in the region, in particular in Bangladesh.
New legislation in Bangladesh extended the death pen-
alty to the possession of 200 grams of methampheta-
mine. sri lanka expressed the intention to reinstate the 
death penalty for drug-related offences.
1. Major developments
625. Drug trafficking is widespread throughout South 
Asia, particularly in the border areas of the subregion. 
Trafficking in heroin, cannabis, methamphetamine and 
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pharmaceutical preparations containing narcotics and 
psychotropic substances pose major challenges in South 
Asia. The trends observed show that synthetic drugs are 
now replacing the natural and semi-synthetic drugs that 
have been abused for decades. The rapid advance of 
Internet availability and information and communica-
tions technology infrastructure has fostered Internet-
driven drug trafficking, illustrated by recently reported 
seizures of drugs sent through postal services. 
626. The proximity of South Asia to three major drug- 
producing and drug-trafficking countries (Afghanistan, the 
Lao People’s Democratic Republic and Myanmar) contin-
ued to pose a challenge for drug control in the subregion. 
Furthermore, the coastal States of South Asia are vulnera-
ble to maritime drug trafficking as a result of their expo-
sure to trafficking routes across the India Ocean.
2. Regional cooperation
627. In response to the trafficking of opiates from 
Afghanistan, heads of law enforcement agencies of South 
Asia, from Bangladesh, Bhutan, India, Maldives, Nepal 
and Sri Lanka, met in Chandigarh, India, in October 
2018. The key themes of the meeting included how to use 
existing bilateral and regional cooperation mechanisms 
between countries to better control drug trafficking.
628. A meeting of the Paris Pact initiative’s expert 
working group on detecting and blocking financial flows 
linked to illicit traffic in opiates originating in Afghanistan 
was held in New Delhi on 27 and 28 June 2019. 
Representatives of financial intelligence services, counter- 
narcotics agencies and customs authorities of 15 coun-
tries participated in the meeting, as well as six international 
organizations and UNODC, and deliberated on new 
trends and challenges related to illicit financial flows and 
trafficking of opiates. Participants highlighted the need to 
unite their efforts in developing information exchange 
and best practices on methods for identifying shadow 
financial transactions.
3.  National legislation, policy and 
action
629. In Bangladesh, the Narcotics Control Act 2018, 
which is an amendment to the Narcotics Control Act 
1990, came into force in December 2018. The new Act 
repeals the existing law relating to drug control, drug sup-
ply and demand reduction, the prevention of abuse and 
the smuggling of drugs, treatment and rehabilitation for 
drug users and related matters. Under the Act of 2018, the 
application of the death penalty or life imprisonment in 
Bangladesh has been expanded to include the production, 
possession, distribution and trafficking of methamphet-
amine or its principal ingredient amphetamine, which has 
been moved to the category of class A under the Act.
630. At a meeting held in Sri Lanka in March 2019, on 
drug trafficking and abuse prevention programmes, the 
President of Sri Lanka announced that a process for rein-
stating the death penalty was under way. In his speech, 
the President commended the current, strengthened law 
and regulations for combating illegal drugs and announced 
the decision to impose the death penalty for drug smug-
gling, which, if carried out, would be the first time the 
death penalty has been imposed since 1976. On 26 June 
2019, the President signed death warrants for four peo-
ple who have been convicted of drug-related offences. On 
29 October 2019, prior to the finalization of the present 
report, it was reported that the Supreme Court of Sri 
Lanka had further extended, until 9 December 2019, the 
interim order staying the implementation of the death 
penalty for prisoners sentenced to death for drug offences. 
The Board continues to encourage all States that retain 
the death penalty for drug-related offences to consider 
abolishing the death sentence for those offences.
631. In line with the international drug control conven-
tions and the existing national legislation and policies, 
India adopted the National Action Plan for Drug Demand 
Reduction for the period 2018–2023 to address drug and 
substance abuse. The National Action Plan employs a 
multi-pronged strategy involving the education, 
de-addiction and rehabilitation of affected individuals and 
their families to address the issue and focus on preventive 
education, awareness-raising, counselling, treatment and 
the rehabilitation of drug-dependent users, in addition to 
training and capacity-building for service providers 
through collaborative efforts between the Government 
and non-governmental organizations. 
4.  Cultivation, production, 
manufacture and trafficking
632. Illicit cultivation of cannabis continued to be a 
challenge for law enforcement agencies in South Asia, in 
particular in India. An analysis of data from 2010 to 2017 
shows that India is among those countries worldwide 
with the greatest extent of illicit cannabis cultivation and 
amount of production. Indian drug enforcement author-
ities eradicated 1,980 ha of illicit cannabis cultivation in 
2018, which was substantially less than the 3,446 ha of 
eradication in 2017. The estimated area of illicit cannabis 
cultivation in Sri Lanka in 2018 was 500 ha, similar to 
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the amount in the previous year. Bhutan reported that 
100,000 cannabis plants taken from 12 cultivation sites 
were destroyed in 2017.
633. Total cannabis herb seizures in South Asia 
declined to 336 tons in 2018, compared with 434 tons 
in 2017. In 2018, the largest total quantity of cannabis 
herb seized by a country in South Asia was that of India 
(266.5 tons or 79 per cent of the subregion’s total sei-
zures), followed by Bangladesh (60.3 tons or 18 per cent). 
Bhutan, Nepal and Sri Lanka accounted for the remain-
ing 3 per cent of cannabis herb seizures (9.1 tons). 
Cannabis resin seizures in South Asia increased in 2018 
to 5.2 tons from 3.2 tons in 2017. India and Nepal con-
fiscated almost 100 per cent (5.2 tons) of the total can-
nabis resin seized in the region.
634. India is the only country in the subregion that has 
consistently reported eradication of illicit opium poppy 
cultivation. India has increased its illicit opium poppy 
eradication over four consecutive years beginning in 2015 
(1,400 ha in 2015, 2,635 ha in 2016, 3,076 ha in 2017 and 
3,508 ha in 2018). In addition, the country seized a con-
siderable quantity of poppy straw in 2018 (16 tons). That 
amount was 70 per cent greater than the amount of poppy 
straw seized in 2017 (9 tons).
635. The amount of opium seized in India increased to 
4.1 tons in 2018, up from 2.6 tons in 2017. Opium sei-
zures followed an upward trend starting in 2015 (1.7 tons 
in 2015, 2.3 tons in 2016, 2.6 tons in 2017 and 4.1 tons 
in 2018). Overall, the increasing trend in both the 
amount of illicit opium and poppy straw seized and the 
area eradicated underline the severity of the problem in 
the country. 
636. South Asia, in particular Sri Lanka, has experi-
enced an increase in seizures of heroin due to the grow-
ing use of the southern route by drug traffickers. Most of 
the heroin that is smuggled through the so-called “south-
ern route” to reach South Asia (from Afghanistan to 
Pakistan and then to South Asia) is of Afghan origin and 
has the final destination of North America. In Sri Lanka, 
heroin seizures continued to increase in 2018, reaching 
732 kg, compared with 315 kg in 2017. However, heroin 
seizures in the region decreased to 2.4 tons in 2018 from 
2.9 tons in 2017. India seized the largest amount (1.2 tons), 
followed by Sri Lanka (0.7 tons) and Bangladesh 
(0.45 tons) accounting for 99 per cent of the total sei-
zures in the subregion.
637. South Asia reported record low cocaine seizures of 
59.5 kg in 2018, which is less than in the past four years 
(309 kg of seizures in 2017, 1.6 tons in 2016, 124.7 kg in 
2015 and 327.9 kg in 2014). The amount of seizures of 
this drug fluctuated from year to year, as shown in the 
reported data of all countries in the subregion.
638. Codeine-based preparations, particularly Phensedyl, 
continued to be seized in the region. In Bangladesh, 
Phensedyl seizures declined to 715,529 ampoules in 2018, 
compared with seizures of 720,843 ampoules in 2017. India 
also reported, through the monthly drug reports of the 
Narcotics Control Bureau, that the country’s authorities 
seized more than 51,821 bottles of Phensedyl in 2018. Drug 
traffickers now tend to smuggle pharmaceutical drugs 
rather than illicitly manufactured drugs such as hashish 
and heroin because of the more lenient penalties imposed 
for the smuggling of controlled pharmaceutical drugs.
639. South Asia is being targeted by transnational orga-
nized criminal groups in Myanmar that manufacture and 
traffic methamphetamine in both crystalline and tablet 
form into the subregion. Methamphetamine is the most 
prevalent substance of abuse among the amphetamine- 
type stimulants in South Asia. South Asia accounted for 
1 per cent of the total seizures of methamphetamine at 
the global level. 
640. In Bangladesh, methamphetamine seizures con-
tinued to increase, as 53 million tablets were seized in 
2018, compared with 40 million tablets in 2017, an 
increase mainly due to a nationwide anti-drug operation 
undertaken by the Government. Methamphetamine was 
smuggled into Bangladesh from East and South-East 
Asia, predominantly from Myanmar. Sri Lanka seized 
147.83 kg of methamphetamine in the first quarter of 
2019. The Department of Narcotics Control of Bangladesh 
raided a clandestine drug laboratory and confiscated, for 
the first time, crystalline methamphetamine and MDMA, 
in February 2019. 
641. In India, seizures of amphetamine-type stimu-
lants peaked again in 2018, at 931 kg. The highest total 
annual seizures of amphetamine-type stimulants in India 
was in 2016, when there was a record 1.7 tons of seizures, 
before falling sharply to 95 kg in 2017. Seizures of meth-
aqualone in the country decreased to 99 kg in 2018, com-
pared with 124 kg in 2017. The highest single seizure of 
methaqualone, on 25 June 2018, was of 30 kg, which was 
destined for the United States. Buprenorphine also con-
tinued to be seized in India in both injectable and tablet 
forms.
642. In Bangladesh, the quantity of buprenorphine 
seized in 2018 (128,708 ampoules) was 18 per cent higher 
than in 2017 (109,063 ampoules). Total seizures of 
buprenorphine in Nepal also increased significantly in 
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2018, to 58,963 tablets, up from 31,567 tablets in 2017. 
Nepal seized 66,430 tablets of diazepam in 2018, which 
was more than the quantity seized in 2017 (49,304 tab-
lets). Bhutan seized 3,947 tablets of nitrazepam in 2018.
643. The diversion of controlled precursors, in partic-
ular ephedrine and pseudoephedrine, from licit to illicit 
channels has continued in India. According to the 
Narcotics Control Bureau of India, 1.8 tons of pseudo-
ephedrine were confiscated in Noida, India, in a single 
seizure conducted on 11 May 2019. This was the largest 
seizure on record in the country. There continued to be 
reports of seizures of pharmaceutical preparations con-
taining ephedrine and pseudoephedrine trafficked from 
India to Myanmar for the purpose of precursor extraction.
644. There was an exceptionally large total quantity of 
acetic anhydride seizures (8,998 litres) in India in 2018. 
That amount was substantially higher than the total sei-
zures of acetic anhydride in the four previous years 
(23 litres in 2017, 2,464 litres in 2016, 4 litres in 2015 and 
93 litres in 2014). Of the total seizures of acetic anhy-
dride in 2018, 8,937 litres were confiscated in a single sei-
zure effected in Noida and New Delhi on 20 October 
2018. The chemical was destined for a consignee in 
Afghanistan. A comprehensive review of the situation 
with respect to the control of precursors and chemicals 
frequently used in the illicit manufacture of narcotic 
drugs and psychotropic substances in the region can be 
found in the report of the Board for 2019 on the imple-
mentation of article 12 of the 1988 Convention.
645. Globally, most of the tramadol, which is not an 
internationally controlled substance, that was seized from 
2013 to 2017 was reported to have originated in India. 
Available data indicate that the tramadol being used for 
non-medical purposes in Africa is illicitly manufactured 
in South Asia. Further, India was the source of 87 per 
cent of the tramadol seized in Ghana in 2017. Available 
data suggest that in recent years India has emerged as the 
centre of manufacturing of tramadol destined for clan-
destine markets. However, in April 2018 India placed tra-
madol among the nationally controlled substances under 
its Narcotic Drugs and Psychotropic Substances Act of 
1985. Control under the Act gives more powers to law 
enforcement authorities and, in particular, enables author-
ities to enter the premises of tramadol laboratories and 
prosecute those who are engaging in the unauthorized 
manufacture of tramadol.
646. Bangladesh is also closely monitoring substances 
that are not under control internationally such as ket-
amine, nalbuphine and tramadol, among which ketamine 
is under control at the national level. In Bhutan, Spasmo 
Proxyvon Plus, which contains tramadol, is the most 
common trafficked non-controlled substance. In 2018, 
68,685 capsules of Spasmo Proxyvon Plus were seized in 
Bhutan, a significant decline from the seizure of 130,316 
capsules in 2017.
5. Prevention and treatment
647. According to the UNODC World Drug Report 
2019, 1.8 per cent of the adult population of South Asia, 
or 19 million people, are past-year users of opioids, thus 
comprising 35 per cent of the estimated number of past-
year opioid users worldwide. Drug abuse prevalence stud-
ies have been lacking in the region for the past few years. 
However, India and Sri Lanka have conducted surveys to 
assess the prevalence of drug abuse in their respective 
countries. The Board commends such initiatives and 
encourages countries to allocate adequate resources to 
drug abuse prevention and treatment and to conduct 
prevalence studies to inform the adoption of evidence- 
based public health policies.
648. A national survey on the extent and pattern of sub-
stance use in India was conducted between December 
2017 and October 2018. According to the resulting report, 
Magnitude of Substance Use in India 2019, cannabis and 
opioids are the most frequently abused substances in the 
country, after alcohol, with rates of past-year use of 
2.8 per cent and 2.1 per cent respectively among the pop-
ulation aged 10–75. Heroin was reported to be the most 
commonly used opioid in India, with a 1.1 per cent prev-
alence rate, followed by pharmaceutical opioids, with a 
prevalence rate close to 1 per cent among the population 
aged 10–75. The survey also indicated that existing treat-
ment programmes in India, which are heavily focused on 
inpatient treatment, are inadequate given the large num-
ber of people affected by substance abuse. The report 
indicated the need to enhance treatment services in out-
patient clinics, which need resources to meet require-
ments in the areas of human resources, infrastructure and 
supply of medicine.
649. In Sri Lanka, according to the report National 
Prevalence Survey on Drug Use 2019, cannabis was the 
most commonly abused drug in 2017/18, with a preva-
lence rate of 1.9 per cent (301,898 people) followed by 
heroin, for which the prevalence rate was 1.2 per cent 
among the population aged 14 and older (92,540 people). 
The misuse of pharmaceutical tablets has increased. Based 
on the statistics on treatment admissions provided by the 
Government, the number of drug-addicted people seek-
ing treatment in 2018 was greater than in the previous 
three years; however, only 7 per cent of drug users in 
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Sri Lanka have been admitted to treatment and rehabili-
tation centres. Psychotropic substances such as diazepam 
and other substances that are not under control (trama-
dol, pregabalin and gabapentin) are abused to a lesser 
extent in the country.
650. According to the Annual Drug Report of Bangladesh 
for 2017, drug abuse is becoming a national concern in the 
country. Methamphetamine tablets (“yaba”) are now 
abused to a greater extent in Bangladesh. People seeking 
treatment for abuse of methamphetamine made up 35.5 per 
cent of all patients seeking treatment for drug abuse in 
2017, an increase of 12 per cent from the previous year. 
According to the data from treatment services, the num-
ber of patients seeking treatment for Phensedyl addiction 
is decreasing, as those affected by drug use disorders are 
shifting to abuse of “yaba” because it can be more easily 
obtained. Drug-using populations are also consuming a 
combination of different pharmaceutical drugs (for exam-
ple, buprenorphine and diazepam).
West Asia
In 2018, afghanistan continued to be the country where 
the vast majority of the world’s illicit opium poppy culti-
vation and opium production took place.
The middle East and south-west asia are the subregions 
with the highest annual prevalence of opiate use (opium, 
morphine and heroin) globally, at 1.6 per cent of the 
population.
1. Major developments
651. Afghanistan remained the country of origin of 
nearly all opiates seized in Europe, Central Asia and 
Africa.79 It was the country responsible for the vast major-
ity of the world’s illicit opium poppy cultivation and 
opium production in 2018. The country also continued 
to be one of the major sources of cannabis resin world-
wide. Furthermore, Afghanistan continued to experience 
an increase in trafficking of synthetic drugs on its terri-
tory. While recognizing the efforts of the Government of 
Afghanistan to address those challenges through its 
National Drugs Control Strategy and the National Drug 
Action Plan, the Board reiterates the need to prioritize 
measures to address the illicit drug economy in the 
79 The subregion of Central Asia as referred to in this report com-
prises Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan.
country, which should be part of the overall effort to build 
peace, establish security and achieve sustainable develop-
ment in the country. Moreover, the global community, in 
the context of global and shared responsibility, needs to 
be part of this process through comprehensive, multi-
faceted and concerted local, national, regional and inter-
national assistance efforts.
652. The Balkan route, which passes through the Islamic 
Republic of Iran, Turkey and the Balkan countries on the 
way to destination markets in Western and Central 
Europe, remained the main route for the trafficking of 
opiates originating in Afghanistan. In recent years, sev-
eral branches of the Balkan route have gained promi-
nence, including the branches transiting the Syrian Arab 
Republic and Iraq and the countries of the Southern 
Caucasus. 
653. The manufacture and trafficking of counterfeit 
“captagon”80 continued to seriously affect the countries of 
the Middle East, which not only are destination markets 
for those drugs but are also increasingly becoming a 
source of counterfeit “captagon”. The subregion also con-
tinues to witness trafficking in, and abuse of, tramadol, a 
synthetic opioid not under international control. Political 
instability and unresolved conflicts, poverty and the lack 
of economic opportunities in some parts of the subregion 
have contributed to increased trafficking in tramadol and 
“captagon”. 
654. The emergence of a growing number of new psycho-
active substances continued to be reported by almost every 
country of Central Asia. Proximity to several countries 
with developed markets for synthetic drugs, such as China, 
Iran (Islamic Republic of) and the Russian Federation, has 
increased the potential market for new psychoactive sub-
stances in the Central Asian subregion. 
2. Regional cooperation
655. Through a decision of the Council of Heads of 
State of SCO of 10 June 2018, the Organization approved 
its Anti-Drug Strategy for the period 2018–2023 and the 
programme of action to implement the Anti-Drug 
Strategy, as well as the SCO Concept to Prevent the Abuse 
of Narcotic Drugs and Psychotropic Substances. The 
80 “Captagon” was originally the official trade name of a pharmaceutical 
preparation containing fenethylline, a synthetic stimulant. As encountered 
in seizures across West Asia today and as referred to in the present report, 
“captagon” is a counterfeit drug compressed into tablets that are similar 
only in appearance to the original trademarked Captagon. The active 
ingredient in counterfeit “captagon” is amphetamine, which is typically cut 
with multiple adulterants, such as caffeine and other substances.
92  INCB REPORT 2019
Strategy is aimed at stepping up multilateral cooperation 
to prevent and combat drug-related threats affecting SCO 
member States.
656. At an expert group meeting of the Afghanistan-
Kyrgyzstan-Tajikistan (AKT) Initiative held in Bishkek on 
28 and 29 November 2018, representatives of law enforce-
ment agencies and Ministries of Foreign Affairs of those 
three countries reviewed the current situation on coun-
tering narcotics in their respective countries and dis-
cussed the role of their drug liaison officers in planning 
and conducting joint counter-narcotics operations. 
Participating experts adopted a draft memorandum of 
understanding on the placement of drug liaison officers 
and the standard operating procedures for their activities, 
which is to be signed at the next ministerial meeting of 
the countries of the AKT Initiative.
657. At the thirteenth senior officials’ meeting of the 
Triangular Initiative, held in Islamabad on 12 and 
13 December 2018, counter-narcotics authorities of 
Afghanistan, Iran (Islamic Republic of) and Pakistan dis-
cussed means of strengthening cooperation to combat traf-
ficking in Afghan opiates. At the meeting, the three parties 
agreed to strengthen their border liaison offices and to plan 
and conduct more joint patrolling and intelligence-led 
interdiction operations. They also expressed interest in uti-
lizing one another’s counter- narcotics training academies 
with a view to sharing knowledge and strengthening 
coordination.
658. With a view to addressing the channels of entry 
and illegal distribution of new psychoactive substances 
and other synthetic drugs, opioids and cannabis, a joint 
multilateral counter-narcotics operation, Operation 
Kanal-Centre, was conducted by the States members of 
the Collective Security Treaty Organization, namely 
Armenia, Belarus, Kazakhstan, Kyrgyzstan, the Russian 
Federation and Tajikistan, from 26 February to 1 March 
2019. The operation was hosted by CARICC. 
Representatives of competent national authorities of 
China, France, Iran (Islamic Republic of), Italy, Mongolia, 
Turkey, the United Kingdom and the United States, as 
well as the Commonwealth of Independent States, the 
Eurasian Group on Combating Money Laundering and 
Financing of Terrorism, INTERPOL, OSCE, SCO and 
UNODC, also took part in the operation as observers. 
The operation resulted in seizures of more than 11.4 tons 
of various drugs, including more than 8.8 tons of opium, 
more than 1.8 tons of cannabis resin, more than 220 kg 
of heroin, almost 127 kg of cannabis and more than 
205 kg of synthetic drugs; the arrest of 579 individuals; 
and the dismantling of one illegal laboratory manufac-
turing synthetic drugs.
659. On 2 and 3 May 2019, the 11th Review Meeting of 
the Memorandum of Understanding on Subregional Drug 
Control Cooperation was held in Tashkent. High-level offi-
cials, including the Ministers of Foreign Affairs of the 
Russian Federation, Tajikistan and Uzbekistan, the Deputy 
Ministers of Foreign Affairs of Azerbaijan, Kazakhstan and 
Kyrgyzstan, the Deputy Minister of Internal Affairs of 
Turkmenistan, the Chief Executive Officer of the Aga Khan 
Development Network and the Secretary-General of SCO, 
as well as high-level international partners and donors such 
as UNODC, the United States, the European Union and 
OSCE, attended the event. The parties to the Memorandum 
of Understanding agreed on common strategic priorities 
and targets in order for the region to address emerging 
drug-related threats and related criminal behaviour, includ-
ing illicit financial flows and the financing of terrorism, 
trafficking in precursors and new psychoactive substances, 
the darknet, health and development, as set out in a min-
isterial declaration reiterating the parties’ commitment to 
strengthening multilateral cooperation within the frame-
work of the Memorandum of Understanding.
3.  National regulation, policy and 
action
660. In December 2018, the Ministry of Agriculture, 
Irrigation and Livestock of Afghanistan launched the first 
call centre for farmers as part of its alternative develop-
ment activities under the National Drug Action Plan. The 
service, which provides free advice and information to 
farmers, is intended to establish contacts between local 
farmers and agricultural experts of the Ministry. The 
Government of Afghanistan continued to implement 
measures to mainstream the economic empowerment of 
women in the alternative livelihood sector. Ten small and 
medium-sized enterprises led by women participated in 
a jobs fair and exhibition held to celebrate International 
Women’s Day on 8 March 2019 in Kabul, at which over 
80 companies and organizations exhibited alternative 
development products.
661. Following a presidential decree which came into 
effect in April 2019, the Ministry of Counter-Narcotics of 
Afghanistan was dissolved. Several joint committees were 
established to complete the restructuring process. The 
resources, responsibilities and activities of the Ministry 
of Counter-Narcotics were transferred to the Ministry of 
Interior Affairs, the Ministry of Agriculture, Irrigation 
and Livestock and the Ministry of Public Health.
662. To promptly respond to the worsening situation 
with the illicit drug market, in December 2018 Kazakhstan 
adopted a law amending some legislative acts related to 
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controlling trade in narcotic drugs, psychotropic sub-
stances and their analogues and precursors. The law pro-
vides for the elaboration of mechanisms instituting State 
control over trade in new psychoactive substances and 
scheduling their analogues, and it empowers the 
Government to approve (a) the list of narcotic drugs, 
psycho tropic substances and precursors subject to control 
in Kazakhstan; and (b) the aggregate table establishing 
threshold quantities of narcotic drugs and psychotropic 
substances and their analogues and precursors for classi-
fying the gravity of offences involving those substances.
663. Kazakhstan reported that there was an increasing 
use of the Internet, instant messaging services and 
e-wallets to trade illicitly in new psychoactive sub-
stances. In 2018, the law enforcement agencies of 
Kazakhstan detected 4,700 websites retailing illicit drugs 
(compared with 430 websites in 2017) that were blocked 
by the Ministry of Information and Communications 
upon notification by the Ministry of Internal Affairs. 
Over 2,540 graffiti inscriptions advertising websites that 
distribute illicit substances were removed throughout 
the country.
664. In February 2019, the federal Cabinet of Pakistan 
approved the National Anti-Narcotics Policy of 2019, 
which had been formulated by the Ministry of Narcotics 
Control in consultation with federal and provincial stake-
holders. The policy was designed to strengthen the efforts 
of Pakistan in the area of anti-drug trafficking operations. 
The policy provides for stronger enforcement measures, 
increased international cooperation and more effective 
drug demand reduction strategies.
665. In January 2019, the first drug treatment and reha-
bilitation centre in the State of Palestine was opened, in 
Bethlehem, as a result of the joint efforts of the Ministry 
of Health of the State of Palestine and UNODC to develop 
a comprehensive system for drug dependence treatment 
and care in the State of Palestine. The centre will benefit 
from the UNODC-developed Treatnet package, which 
provides comprehensive expert guidance and advice in 
the areas of drug use prevention, treatment, rehabilitation 
and social reintegration.
666. Operation “Black poppy”, an annual anti-drug law 
enforcement operation, was conducted in Uzbekistan from 
1 May to 30 June and from 1 August to 30 September 2018. 
As a result, 904 cases of illicit cultivation were detected 
(compared with 895 cases in 2017), and 2,644 square 
meters of illicit drug cultivation were destroyed (compared 
with 3,306 square metres in 2017). That illicit cultivation 
that was eradicated included 385 cases of illicit cultivation 
of opium poppy (compared with 277 cases in 2017) on a 
total area of 1,381 square meters (compared with 
1,757 square metres in 2017) and 519 cases of cannabis 
cultivation (compared with 618 cases in 2017) on a total 
area of 1,263 square meters (compared with 1,503 square 
metres in 2017).
667. On 22 October 2018, Uzbekistan adopted amend-
ments to its drug-related legislation, which stipulated 
criminal and administrative sanctions for illicit trade in 
analogues of narcotic drugs and the illegal sale of med-
icines outside pharmacies. Furthermore, amendments 
were introduced to improve procedures for the import, 
export and transit through the territory of Uzbekistan of 
narcotic drugs, psychotropic substances and precursors 
through the scheduling of synthetic cannabinoids, tra-
madol, nalbuphine preparations, zopiclone and baclofen, 
all of which have been associated with many cases of 
abuse.
4. Cultivation, production, 
manufacture and trafficking
668. Afghanistan was the country of origin of nearly all 
opiates seized in Europe, Central Asia and Africa in the 
period 2013–2017. Afghanistan accounted for 100 per 
cent of all mentions of “country of origin” for opiates 
seized in Central Asia, 96 per cent of mentions of coun-
try of origin for opiates seized in Europe and 84 per cent 
of mentions for opiates seized in Africa in that period.
669. UNODC confirmed that Afghanistan remained the 
country responsible for the vast majority of the world’s 
illicit opium poppy cultivation and opium production in 
2018. The area under cultivation in Afghanistan amounted 
to 263,000 ha in 2018, the equivalent of 76 per cent of 
the estimated total area devoted to illicit opium poppy 
cultivation worldwide (346,000 ha). As a result of the very 
high levels of production in previous years, opium prices 
in Afghanistan dropped in the period 2016–2018. Opium 
production on such a massive scale continues to pose 
substantial challenges for Afghanistan, the neighbouring 
countries through which the drugs transit and the coun-
tries that serve as destination markets. Impacts include 
the further deterioration of the drug-related and security 
situation in Afghanistan and the potential for increased 
consumption and associated negative developments in 
transit and consuming countries.
670. The Balkan route, running through the Islamic 
Republic of Iran, Turkey and the Balkan countries towards 
destination markets in Western and Central Europe, con-
tinued to be the main path for the trafficking of opiates 
originating in Afghanistan. In recent years, a new branch 
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of the Balkan route involving the Syrian Arab Republic 
and Iraq has gained importance.
671. In addition, seizures in Azerbaijan and the Russian 
Federation suggest that heroin and other opiate products 
may be entering the Russian Federation through a variant 
of the Balkan route that runs along the border between 
Azerbaijan and the Russian Federation. From Afghanistan, 
that sub-branch of the Balkan route transits the Islamic 
Republic of Iran and the Southern Caucasus, notably 
Azerbaijan, from where it goes northwards into the 
Russian Federation, or, transiting Georgia, it crosses the 
Black Sea to Ukraine and the European Union. That route 
has also been reported by the authorities of the Russian 
Federation, who noted that part of the opiates originat-
ing in Afghanistan were being trafficked into its territory 
through the Islamic Republic of Iran and Azerbaijan, by 
means of a possible extension of the Balkan route.
672. This extension of the Balkan route running 
through the Southern Caucasus was initially detected 
following three large seizures of heroin (totalling 
1.7 tons) made by the countries of the Southern 
Caucasus in 2014. Heroin seizures in the Southern 
Caucasus decreased sharply the following year, in 2015 
(83 kg seized), but there were later surges in heroin sei-
zures in 2016 (1.2 tons seized, mainly by Azerbaijan) 
and in 2018 (1.26 tons seized by Azerbaijan).
673. The so-called “southern route” continued to be 
used for the trafficking of opiates to Europe by means of 
shipments from Iran (Islamic Republic of) and Pakistan 
by air or sea, either directly or transiting through Gulf 
countries and East Africa. Most of the morphine and 
heroin seized in 2018 in the Islamic Republic of Iran 
entered the country from Pakistan. Seizures of opium and 
heroin in the Islamic Republic of Iran in 2018 saw an 
increase compared with 2017 levels, as 643.6 tons of 
opium was seized in 2018 compared with 630.5 tons 
seized in 2017, and 25.4 tons of heroin seized in 2018 
compared with 23.7 tons seized in 2017.
674. In addition, opiates and other illicit substances con-
tinue to be trafficked from Afghanistan to India and other 
countries in South Asia, destined for markets in Europe 
and, to a lesser extent, North America. Air routes were 
increasingly being used to smuggle heroin and other illicit 
substances from Afghanistan. Although the substances 
were mainly bound for New Delhi, there have been sev-
eral attempts to traffic Afghan opiates to Dubai, United 
Arab Emirates and Jeddah, Saudi Arabia. In the period 
from November 2018 to June 2019, the airport interdic-
tion unit at Hamid Karzai International Airport seized 
150 kg of heroin, 17 kg of methamphetamine and 16 kg 
of cannabis resin, along with substantial amounts of cash, 
and the unit arrested 154 suspected traffickers. During the 
same period, a similar unit at Kandahar International 
Airport seized 93 kg of heroin and 1 kg of methamphet-
amine and arrested 150 suspected traffickers.
675. According to UNODC, as in years past, the vast 
majority of opiates seized worldwide were seized in the 
countries of the Middle East and Afghanistan, Iran 
(Islamic Republic of) and Pakistan. In 2017, that group 
of countries accounted for 79 per cent of global opiates 
seized as expressed in common heroin equivalents, in 
particular opium (97 per cent of global opium seizures) 
and morphine (99 per cent of global morphine seizures). 
Moreover, the quantities of morphine and heroin seized 
in those countries continued to increase in the period 
2016–2017 as a consequence of a combination of the 
marked increases in Afghan opiate production during 
that period and the ongoing law enforcement operations 
in those countries. 
676. In 2017, the largest quantities of opiates (as 
expressed in heroin equivalent) continued to be seized in 
the Islamic Republic of Iran, which accounted for 39 per 
cent of the global total, followed by Afghanistan (26 per 
cent), Pakistan (14 per cent) and Turkey (7 per cent).
677. States of Central Asia located along the so-called 
“northern route” continued to be used for opiates traf-
ficked from Afghanistan to the Russian Federation and 
elsewhere in Europe. The main modes of transportation 
used in trafficking heroin from Central Asia into the 
Russian Federation remain road, rail and air traffic. 
According to UNODC, seizures in the region indicate 
that opiates are primarily trafficked from Afghanistan into 
Tajikistan and, to a lesser extent, Uzbekistan and 
Turkmenistan, and then on to Kazakhstan. The largest 
quantities of opiates seized in the region were being traf-
ficked by land routes from Tajikistan to Kyrgyzstan, then 
to Kazakhstan and into the Russian Federation. Heroin is 
also occasionally trafficked into the Russian Federation 
by air from States of Central Asia, but this mode of trans-
portation is less common than is trafficking overland.
678. Seizure data for the period 2014–2018 suggest that 
opiate trafficking along the northern route has been 
steadily declining. In 2018, heroin seizures amounted to 
58.61 kg in Kazakhstan, 73.57 kg in Kyrgyzstan, 282.18 kg 
in Tajikistan and 20.60 kg in Uzbekistan. Tajikistan 
accounted for most of the opiates seized in Central Asia. 
According to law enforcement agencies in Central Asia, 
opiate trafficking from the region to the Russian Federation 
continued to decrease, which Central Asian authorities 
attribute to successful law enforcement operations. At the 
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same time, further studies are needed to analyse data on 
average purity, prices and daily consumption of heroin, 
estimated number of opiate users and trafficking meth-
ods, in order to accurately determine the extent of opi-
ate flows through the northern route.
679. Opium seizures in the countries of Central Asia 
remained stable at approximately 2.2 tons per year over the 
period 2014–2018, which may indicate that there is a con-
tinuing demand for opium. In 2018, Kazakhstan seized 
6.96 kg of opium, Kyrgyzstan seized 5.42 kg, Tajikistan 
seized 1,606.79 kg, and Uzbekistan seized 254.70 kg. 
Although not fully indicative of actual prevalence of use, 
the number of registered opium users in the countries of 
Central Asia decreased by 33 per cent from 2014 to 2018. 
According to information provided by the Drug Control 
Agency of Tajikistan, the 33 per cent growth in opium sei-
zures in Tajikistan in 2018 was related to the increase in 
cultivation of opium poppy in Afghanistan.
680. There are no indications or reports that opium is 
being processed into heroin in Central Asia. Opium 
poppy cultivation and opium production in Central Asia 
continue to be minimal, since, according to Central Asian 
national law enforcement agencies, over 99 per cent of 
the opiates in the subregion originate in Afghanistan, and 
there are no production facilities located in the subregion. 
Therefore, all opiates transiting Central Asia are thought 
to be either processed in Afghanistan or remain in the 
form of opium and are later processed elsewhere.
681. Afghanistan continues to be one of the major 
sources of cannabis resin worldwide. Afghanistan was 
reported as being the source of 20 per cent of all can-
nabis resin reported seized worldwide in the period 
2013–2017, in particular for seizures reported in Central 
Asia, the Southern Caucasus and Europe. Other coun-
tries reported as source countries were Lebanon (6 per 
cent) and Pakistan (6 per cent). Cannabis resin from 
Lebanon is mainly destined for markets in the Middle 
East and to a lesser extent markets in Western and 
Central Europe.
682. The Islamic Republic of Iran reported Afghanistan 
as the main source of cannabis resin found on its mar-
ket. According to UNODC, in 2017, about 90 per cent of 
cannabis resin entered the Islamic Republic of Iran via 
Pakistan and 10 per cent entered directly from Afghanistan. 
Most of the cannabis resin was trafficked by land and 
some was trafficked by sea from Pakistan. In 2017, about 
55 per cent of the cannabis resin smuggled out of the 
Islamic Republic of Iran was destined for countries on 
the Arabian Peninsula and 25 per cent was destined for 
Turkey and the Southern Caucasus.
683. The quantity of cannabis seized in Afghanistan 
decreased by 90 per cent from 2016 to 2017. Iran (Islamic 
Republic of) and Pakistan also reported a decrease in can-
nabis seizures, of 6 per cent and 22 per cent, respectively. 
Similar trends were also observed in countries of the 
Middle East, which taken as a whole reported a 53 per 
cent reduction in cannabis seizures. 
684. According to UNODC, the law enforcement agen-
cies of countries of Central Asia reported seizures of more 
than 20 tons of cannabis and more than 2 tons of canna-
bis resin in 2018. Since information on seizures of canna-
bis and cannabis resin of Afghan origin is limited, it is 
difficult to estimate the exact scale of trafficking of these 
substances via the northern route. The share of cannabis 
resin seizures that were made in Tajikistan in 2018 was 
54 per cent of total cannabis resin seizures in Central 
Asia, which may indicate a large demand in countries 
along the northern route for cannabis-based drugs orig-
inating in Afghanistan. In 2018, as in the previous year, 
the share of cannabis and cannabis resin seizures in the 
total volume of seized drugs was highest in Kazakhstan, 
Kyrgyzstan and Tajikistan, while in Turkmenistan and 
Uzbekistan the bulk of seized drugs were opiates.
685. There continued to be small-scale illicit cannabis 
cultivation and large areas of wild cannabis growth in 
Central Asia. Cannabis is mainly illicitly produced for 
domestic consumption, with a smaller portion trafficked 
to markets in Europe and the Russian Federation.
686. Seizures of cannabis in the countries of the 
Southern Caucasus continued to increase over the period 
2014–2018, while seizures of cannabis resin in that same 
period continued to decline. Those statistical trends are 
based mostly on the statistics on drug seizures reported 
by Azerbaijan.
687. An increase in trafficking of cocaine by air (includ-
ing by use of “mules” and parcels) was reported in 
Lebanon. The most important cocaine seizures at the air-
ports were those reported by Lebanese authorities in 
August 2018, when authorities at the Beirut Rafic Hariri 
International Airport seized more than 60 kg of cocaine 
that had been hidden inside personal care items imported 
from Brazil. More recently, in June 2019, Lebanese 
Customs seized 10.5 kg of cocaine at the Beirut Rafic 
Hariri International Airport on a flight that had departed 
from Brazil.
688. Afghanistan continued to witness an increase in 
trafficking of synthetic drugs on its territory. The amount 
of methamphetamine seized continued to increase, with 
657 kg seized in the first six months of 2019 compared 
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with 61 kg seized during the same period of 2018 (rep-
resenting an almost tenfold increase). In 2018, a total of 
182 kg of methamphetamine were seized in Afghanistan, 
while in 2017 total seizures for that substance amounted 
to 121 kg. Afghanistan also seized 35,763 MDMA tablets 
in the first six months of 2019, compared with 24,587 
tablets in the entire year of 2018, and 2,322 tablets in 
2017.
689. Continuing the trend reported in the previous year, 
the Islamic Republic of Iran witnessed an increase of 
approximately 25 per cent in methamphetamine seizures 
in 2018, a total of 2.9 tons, compared with 2.3 tons in 2017. 
In 2018, law enforcement authorities of the Islamic 
Republic of Iran dismantled 133 laboratories for manufac-
turing amphetamine-type stimulants in the country. 
690. Manufacture and trafficking of counterfeit “capta-
gon” continued to seriously affect drug control efforts in 
the Middle East, especially given the continued political 
instability in many parts of the subregion. There are indi-
cations of the existence of clandestine laboratories man-
ufacturing counterfeit “captagon” in the subregion, in 
particular in Lebanon and the Syrian Arab Republic, for 
domestic consumption as well as for illicit markets in 
Saudi Arabia and several other Gulf States. Some of those 
“captagon” tablets were also smuggled into Turkey or 
smuggled from the Syrian Arab Republic to Lebanon for 
onward trafficking to various countries in the Middle 
East. Iran (Islamic Republic of) and Jordan have also been 
identified by other countries in the subregion as possible 
countries of origin of amphetamine shipments.
691. While there are only limited official data available on 
trafficking of counterfeit “captagon”, certain notable seizures 
covered by the media may provide an indication of the 
extent of trafficking in the subregion. In June-July 2019, 
authorities of Greece seized three containers containing 
substantial amounts of “captagon” (5.25 tons, in the form 
of 33 million tablets) worth an estimated $660 million, 
which was believed to have been shipped from the Syrian 
Arab Republic. Earlier, in December 2018, authorities of 
Greece detained a Syrian-flagged freight ship in the 
Mediterranean carrying about 3 million “captagon” tablets, 
believed to be destined for Libya. In two separate attempts 
to smuggle “captagon” from the territory of Lebanon, 
Lebanese authorities seized 142 kg of “captagon” from a 
refrigerated truck in April 2019 in an operation coordinated 
with the authorities of Saudi Arabia, and seized 10 kg at 
the Beirut Rafic Hariri International Airport in May 2019. 
Approximately 250,000 “captagon” tablets were seized at the 
Istanbul Atatürk Airport in March 2019, from a passenger 
on a flight bound for Saudi Arabia. In May 2019, Dubai 
Customs of the United Arab Emirates seized 5.7 million 
“captagon” tablets that were hidden in a foodstuff container, 
bringing the total amount seized by Dubai Customs to 
about 11 million “captagon” tablets in the first five months 
of 2019. There have also been several reports of seizures of 
substantial amounts of “captagon” tablets by the authorities 
of Jordan, Saudi Arabia and the Syrian Arab Republic.
692. Central Asian countries continued to experience 
trafficking in psychotropic substances on their territories 
even though the amount of trafficking continued to be at 
lower levels than for other types of drugs. In particular, 
Kazakhstan seized 9.7 kg of psychotropic substances, 
including 2.6 kg of MDMA, compared with the 12.2 kg 
of psychotropic substances it seized in 2017, which had 
included 2 kg of MDMA. Kyrgyzstan seized 21 kg of 
psycho tropic substances in 2018, which included small 
amounts of methamphetamine and MDMA, compared 
with almost no officially reported seizures of such sub-
stances in 2017. Tajikistan seized 1.8 kg of psychotropic 
substances in 2018, compared with 7.6 kg in 2017. 
Countries in the region also continue to face the prob-
lem of a lack of comprehensive data collection and foren-
sic analysis with respect to such substances.
693. Large quantities of precursors are needed for 
opium processing in Afghanistan, and those precursors 
cannot easily be trafficked across the multiple mountain-
ous borders and so must be transported on established 
roads and by railway. In 2018, the most widely seized 
precursor in Central Asia was hydrochloric acid, fol-
lowed by acetic anhydride and potassium permanganate. 
The largest total quantity of hydrochloric acid and sul-
phuric acid seized in 2018 was that seized in Kyrgyzstan, 
where authorities seized a total of 3.2 tons of those 
precursors.
694. According to information provided by CARICC, in 
the period 2014–2018, only Tajikistan and Uzbekistan 
reported seizures of acetic anhydride (Uzbekistan in 2017 
and Tajikistan in 2018). Tajikistan reported five seizures 
of precursors totalling 284 kg, including three seizures of 
acetic anhydride that totalled 266.5 kg. Afghanistan was 
suspected of being the country of destination for one of 
these seizures. According to CARICC, there is no evi-
dence that any other seized substance was bound for 
Afghanistan. Uzbekistan seized 20 litres of acetic 
anhydride in 2017. Uzbekistan also reported seizures of 
0.8 kg of potassium permanganate in 2018.
695. The position of Azerbaijan and Georgia along the 
opiate trafficking route means that their territories are 
also attractive as a route for trafficking in precursors, in 
particular acetic anhydride, which is used to manufacture 
heroin. Law enforcement authorities of Georgia seized 
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5 tons and 9.8 tons of acetic anhydride, respectively, in 
two operations conducted in February and April 2018 at 
the port of Poti, Georgia, on the Black Sea; they were the 
largest seizures of precursors in the country’s history. The 
chemicals were destined for Afghanistan. According to 
UNODC, Azerbaijan reported only on seizures of potas-
sium permanganate: 20.8 kg seized in 2017 and 5.5 kg 
seized in 2018. In 2017, less than 50 grams of ephedrine 
was seized in the entire Southern Caucasus, and all of it 
was seized in Georgia.
696. In 2018, law enforcement authorities of Afghanistan 
dismantled 33 heroin-manufacturing laboratories, com-
pared with the dismantlement of 50 heroin-manufacturing 
laboratories and 3 methamphetamine-manufacturing lab-
oratories in 2017. One methamphetamine-manufacturing 
laboratory was dismantled in the first six months of 2019.
697. There continues to be limited information available 
on trafficking and abuse of new psychoactive substances 
in most countries of West Asia due to the lack of moni-
toring and analysis capacities in those countries. The 
Board reiterates that although the countries of West Asia 
continue to adopt the necessary legislation and take the 
necessary steps to improve their law enforcement and 
forensic capabilities in order to counter new psychoactive 
substances, there is a strong need for a comprehensive 
regional approach to address the challenge. 
698. The emergence of a growing number of new 
psycho active substances continued to be reported by 
almost every country in Central Asia, which may suggest 
that the region is linked to international trafficking of both 
amphetamine-type stimulants and new psychoactive sub-
stances beyond the subregion. The Ministry of Internal 
Affairs of Kyrgyzstan reported an increase in total sei-
zures of new psychoactive substances from 338 grams in 
2017 to 18,928 grams in 2018. Uzbekistan reported a 
decrease in new psychoactive substance seizures, from 
362 grams in 2017 to 166 grams in 2018.
699. There is limited information available on trafficking 
in new psychoactive substances in the Southern Caucasus. 
Although Azerbaijan reported an increase in seizures of 
psychotropic substances in 2018 (1,545.4 kg of powdered 
substances and 1,615 tablets) compared with 2017 (0.4 kg 
of powdered substances and 1,918 tablets), no information 
was reported on seizures of new psychoactive substances 
in the country. Georgia reported on the emergence of and 
increase in trafficking in new psychoactive substances, as 
it seized 6.5 kg of new psychoactive substances in 2018, 
while in 2017 it seized 1.5 kg. Police in Armenia reported 
on the seizure of 27 grams of new psychoactive substances 
in 2018, compared with 1.1 kg in 2017.
700. Countries in the Middle East continued to be 
affected by trafficking in and abuse of tramadol, a syn-
thetic opioid not under international control. During the 
reporting period, there were several media reports on sei-
zures of tramadol in the subregion, including in Iraq, 
Jordan, Kuwait, the State of Palestine and the United Arab 
Emirates. The countries of the subregion need to effec-
tively prevent illicit manufacture and trafficking of trama-
dol while ensuring sufficient supply of this substance for 
medical needs. The countries of the subregion would ben-
efit from more effective international law enforcement 
and criminal justice cooperation.
5. Prevention and treatment
701. The Board notes with concern that in some coun-
tries of the region access to treatment for drug depen-
dence is possible only upon registration as a drug user, 
that registration as a drug user brings with it various lim-
itations on that individual’s career prospects, ability to 
travel and enjoyment of other rights, and that the pros-
pect of having such limitations imposed is often a disin-
centive to seeking treatment. In many cases, registration 
as a drug user also results in serious social stigmatization 
that impedes recovery and social reintegration. 
702. In addition, most countries in West Asia have dif-
ficulties finding the resources for conducting comprehen-
sive and regular drug abuse studies and surveys, which 
hinders efforts to fully grasp the true extent of drug use 
and dependency in the subregion. Countries still lack the 
test and reference samples needed to carry out effective 
drug testing and analysis. 
703. UNODC estimated that the Middle East and South-
West Asia were the subregions with the highest past-year 
prevalence of opiate use (opium, morphine and heroin), 
at 1.6 per cent of the population in each subregion. South-
West Asia was the subregion with the highest prevalence 
of HIV among people who inject drugs, 2.3 times the 
global average, and South-West Asia also had a higher 
than average proportion of injecting drug users.
704. Over the past decade, there has been a decline in 
the number of registered opiate users in Central Asia, 
which may be a result, at least in part, of the overall 
reduction in trafficking of those substances along the 
northern route. In 2018, there were 43,511 registered drug 
users in Central Asia, excluding Turkmenistan, for which 
no data were available. Of that total, 51 per cent were 
opiate users, of whom 86 per cent were heroin users and 
14 per cent were opium users. Injecting drug users 
accounted for 56 per cent of registered drug users. Data 
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disaggregated by gender showed that 5 per cent of all 
drug users registered in 2018 were female drug users. 
UNODC estimated that the full scope of opiate use in 
Central Asia and the Southern Caucasus was likely much 
larger than what was suggested by the number of regis-
tered users, as the prevalence of use of opiates in those 
subregions combined was estimated to be 0.9 per cent.
705. In Azerbaijan, there were 30,131 registered drug 
users in treatment centres in 2017. Injecting remained the 
most frequently used method of administering opiates 
(70 per cent of users). Of those who registered as drug 
users in 2017, about 2 per cent were women. 
706. Countries of Central Asia and the Southern Caucasus 
continued to witness an overall decline in injecting drug 
use, an increase in the prevalence of cannabinoid abuse, 
and an increase in abuse of psychoactive medicines as part 
of polydrug use. It should be noted that alcohol addiction 
remained more prevalent than illicit drug addiction. The 
most used types of stimulants in Central Asia and the 
Southern Caucasus, in order of greatest prevalence, are 
amphetamine, methamphetamine and “ecstasy”.
707. According to UNODC, the proportion of the pop-
ulation aged 15–64 who inject drugs remains relatively 
high in Central Asia and the Southern Caucasus, with 
rates that are 3.4 times the global average (i.e., more than 
triple). UNAIDS found that in Eastern Europe and 
Central Asia, people who inject drugs accounted for more 
than one third (39 per cent) of new HIV infections in 
2017. Other research found that in Central Asia, approx-
imately one in five people held in prison have injected 
drugs at least once while incarcerated.
708. Opioid consumption patterns in the countries of 
South-West Asia remain diverse. UNODC found that in 
Afghanistan, nearly 70 per cent of opioid users reported 
using opium and there was also significant abuse of 
heroin and pharmaceutical opioids. In the Islamic 
Republic of Iran, nearly 90 per cent of opioid users 
reported using opium or the condensed extract of 
smoked opium ashes. In Pakistan, according to the most 
recently available data, for 2012, excluding polydrug use 
among opioid users, of the estimated 2.7 million opioid 
users, 1.6 million also reported the non-medical use of 
pharmaceutical opioids, whereas over 1 million people 
were estimated to be regular opiate users, of whom the 
majority were heroin users (860,000) while one third 
were opium users (320,000). While the use of opiates 
(heroin and opium) was much higher among men than 
among women in Pakistan, almost equal percentages of 
men and women in that country reported the non-med-
ical use of pharmaceutical opioids.
E. Europe
Record amounts of high-purity cocaine seized, together 
with the increasing prevalence of cocaine use among 
adults, suggest that cocaine use is on the rise in Europe.
The discussion of different approaches to regulating can-
nabis has figured prominently in the policy debate on 
drug control across Europe.
1. Major developments
709. A recent surge in the availability of high-purity 
cocaine across Europe, now also including Eastern 
European countries that had been targeted to a lesser 
extent in the past, appears to have made the drug an 
affordable commodity and the preferred stimulant for 
many drug users in the region. Record seizures of cocaine 
in several European countries in 2018 and 2019 may also 
indicate an increasing trend in cocaine trafficking, with 
European overseas territories increasingly being used as 
transit points, according to EMCDDA.
710. An increasing number of European countries 
were in the process of exploring regulatory approaches 
to the cultivation of cannabis for medical purposes 
during the reporting period, or had already set up can-
nabis agencies and instituted medical cannabis pro-
grammes by 2019. In a few countries, there were 
indications of steps being taken towards legalization of 
the non-medical use of cannabis at the national level. 
However, the majority of European countries allow can-
nabis to be used only for medical and scientific pur-
poses, in keeping with their obligations under the 1961 
Convention as amended by the 1972 Protocol, while 
many continue not to permit medical uses of the sub-
stance at all. An EMCDDA paper entitled “Developments 
in the European cannabis market”, published in 2019, 
presents the diverse range of cannabis-based products 
available in Europe and highlights the complexity of reg-
ulatory frameworks necessary to manage their appropri-
ate distribution.
711. The Russian Federation, in July 2019, passed leg-
islation authorizing the cultivation on its territory of 
opium poppy plants (Papaver somniferum) for the pur-
pose of extracting alkaloids. More specifically, the new 
law allows for the cultivation of varieties of opium poppy 
rich in morphine, thebaine and codeine and the process-
ing of poppy straw for the purpose of manufacturing 
pharmaceutical or veterinary preparations containing 
these opiates. 
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2. Regional cooperation
712. A number of well-established regional cooperation 
frameworks and intergovernmental organizations of var-
ied composition and geographical scope, such as the 
European Union, EMCDDA, the Pompidou Group of the 
Council of Europe, OSCE, Europol, the European Border 
and Coast Guard Agency (Frontex), and others have con-
tinued to act as the primary vehicles for regional coop-
eration in Europe. In addition, a multitude of multilateral 
law enforcement operations involving several European 
countries were undertaken, many of which resulted in 
considerable drug seizures. 
713. In an effort to evaluate the effectiveness of European 
precursor control legislation, the European Commission 
conducted an in-depth review of the implementation and 
functioning of four legislative documents, which reflect 
the exclusive competence of the European Union to reg-
ulate the trade in chemicals in all of its member States. 
The last phase of the process, which started in 2017, 
involved a public consultation that concluded in November 
2018. The results of the evaluation and any necessary 
amendments to existing European Union regulations 
were expected to be published in the last quarter of 2019.
714. In November 2018, the Pompidou Group of the 
Council of Europe adopted its new work programme for 
the period 2019–2022. Its three thematic priorities are 
centred on good governance; international drug policy 
development for 2019 and beyond, with particular focus 
on contributing to the achievement of the Sustainable 
Development Goals; and new psychoactive substances. A 
new element under the good governance pillar is aimed 
at reducing drug-related stigmas in order to remove some 
of the barriers to drug users’ access to health care and 
social services. 
715. In December 2018, new formal cooperation agree-
ments were signed between EMCDDA and two European 
agencies, the European Chemicals Agency and the 
European Food Safety Authority, in the context of the 
European Union early warning system to respond to new 
psychoactive substances. Existing agreements between 
EMCDDA and Europol, the European Centre for Disease 
Prevention and Control and the European Medicines 
Agency were updated at the same time. 
716. In July 2019, the Thirteenth Meeting of Heads of 
National Drug Law Enforcement Agencies, Europe, was 
held in Lisbon, bringing together some 70 participants 
from 24 Member States and 7 organizations. The recom-
mendations addressed a range of issues. In one of the rec-
ommendations, it was recommended that Governments 
should consider the use of artificial intelligence in 
analysis, profiling, cross-checking information and other 
investigative efforts with a view to adapting to the chang-
ing criminal environment.
3.  National legislation, policy and 
action
717. On 3 July 2019, the Russian Federation passed a 
federal law permitting on its territory the cultivation of 
the opium poppy plant (Papaver somniferum) for the pro-
duction of poppy straw. More specifically, the law allows 
for the cultivation of varieties of opium poppy rich in 
morphine, thebaine and codeine and the processing of 
poppy straw for the purpose of manufacturing pharma-
ceutical or veterinary preparations containing those opi-
ates. According to government authorities, the rationale 
for this step was to satisfy domestic demand for life-saving 
medications containing opiates. In addition, the law pro-
vides a legal basis for the cultivation of opium poppy to 
produce poppy seeds for culinary purposes.
718. Belgium paved the way for the creation of a national 
cannabis agency by providing a legal basis for the estab-
lishment of a cannabis office within its Federal Agency for 
Medicines and Health Products. A bill passed in April 
2019 requires further executing regulations in order for 
the cannabis office to become operational and start over-
seeing the cultivation of cannabis for medicinal purposes. 
Similarly, Croatia (in April 2019) and Malta (in April 
2018) permitted cultivation of cannabis for medical pur-
poses. In Portugal, where cultivation of cannabis for 
medicinal purposes had been authorized since 1994, leg-
islation was passed in July 2018 and additional implement-
ing regulations were adopted in January 2019 regarding 
the prescription, use and dispensation of cannabis for 
medical use through pharmacies, thereby achieving con-
trol of the full production chain from cultivation to dis-
tribution. The Board wishes to remind all States that have 
established medical cannabis programmes or that are 
considering doing so of the control measures set forth 
in articles 28 and 23 of the 1961 Convention as amended 
by the 1972 Protocol.
719. Short of permitting the cultivation of cannabis for 
medicinal purposes, many European countries for the first 
time allowed the use of cannabis-based medicinal products 
or were in the process of creating the necessary legal 
framework to do so during the reporting period. Following 
the approval of its National Agency for Medicines and 
Health Products Safety in July 2019, France was in the pro-
cess of devising the regulatory framework for an experi-
ment on the use of cannabis-based medicinal products to 
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treat certain medical conditions under strictly defined 
conditions. The experiment was expected to be launched 
in 2020. With effect from 1 November 2018, the United 
Kingdom introduced legislative changes providing a defi-
nition of the type of products falling within the category 
of “cannabis-based products for medicinal use” and per-
mitting their prescription by registered specialist doctors 
based on clinical need, not limiting prescriptions to any 
particular medical condition. Raw cannabis (whether 
plant or resin) was unaffected by the change and 
remained a class B drug under the Misuse of Drugs Act 
of 1971. 
720. In the course of 2019, the Netherlands has taken 
steps to introduce a pilot programme for the production 
and commercial distribution of cannabis for non-medical 
purposes, referred to as the “closed cannabis supply chain 
experiment”. Under the programme, the cultivation and 
wholesale supply of cannabis to so-called “coffee shops” 
was expected to be legalized in up to 10 municipalities 
for a trial period of four years, followed by an evaluation 
of the “experiment” and its effects on public health, pub-
lic order, safety and crime. As of August 2019, 10 munic-
ipalities (not including the 4 largest ones: Amsterdam, 
Rotterdam, The Hague and Utrecht) had been selected 
from among some two dozen that had expressed an inter-
est in participating in the programme. As of 1 November 
2019, the legislation necessary to enable the official 
“preparation phase” of the experiment to be launched in 
2020, commencing with a public tender to select a lim-
ited number of local producers, had been partially 
approved in January 2019. Municipalities not selected to 
participate in the trial will continue to enforce the appli-
cable national laws, which generally prohibit the cultiva-
tion, distribution and use of cannabis, with the option of 
tolerating (i.e., not enforcing the prohibition of) the sale 
and purchase of small amounts for personal use in “coffee 
shops” under certain conditions.
721. In late 2018, Luxembourg announced its intention 
to legalize the cultivation, distribution, possession and use 
of cannabis for recreational purposes within five years. An 
interministerial task force was reported to be in the pro-
cess of drafting a corresponding legislative proposal. The 
use of (imported) cannabis for medical purposes, pre-
scribed by specially trained medical professionals and dis-
tributed exclusively through hospital pharmacies, was 
permitted in August 2018 for a trial period of two years.
722. The Board wishes to remind all parties to the 
1961 Convention as amended by the 1972 Protocol that 
article 4 (c) of that Convention limits exclusively to 
medical and scientific purposes the production, manu-
facture, export, import and distribution of, trade in and 
use and possession of drugs and that any measures 
allowing for the non-medical use of cannabis are in vio-
lation of the legal obligations incumbent upon parties 
to the Convention.
723. A number of countries in the region amended their 
national laws to subject new psychoactive substances and 
other substances of concern to national control in 2018 
and 2019. Those countries included Germany (new sub-
stance groups were added and existing ones were amended 
or enlarged in its generic schedules under the New 
Psychoactive Substances Act, which entered into force in 
2016), the Russian Federation (47 new psychoactive sub-
stances scheduled at the national level), Serbia (15 sub-
stances scheduled, including tramadol), Spain (6 new 
psychoactive substances scheduled) and Sweden (36 new 
psychoactive substances scheduled, 15 as narcotic drugs 
and 21 as goods endangering health). Malta brought its 
laws in line with European Parliament and Council of the 
European Union directive 2017/2103, which defines new 
psychoactive substances as substances in pure form or in 
a preparation that are not covered by the 1961 Convention 
as amended by the 1972 Protocol or by the 1971 
Convention but may pose health or social risks similar 
to those posed by the substances covered by those 
Conventions. The United Kingdom also classified prega-
balin and gabapentin as class C drugs under the Misuse 
of Drugs Act of 1971 with effect from 1 April 2019.
724. Since February 2019, Croatia has applied a generic 
approach to controlling new psychoactive substances at 
the national level, targeting groups of substances and 
chemical compounds rather than individual substances. 
Poland also introduced generic definitions for four groups 
of new psychoactive substances that now fall under the 
act counteracting drug addiction and State sanitary 
inspection as a result of a comprehensive amendment 
passed in August 2018. The groups include derivatives of 
fentanyl, cathinone and 2-phenylethylamine, as well as 
synthetic cannabinoids. The amendment also redefined 
new psychoactive substances, putting them on a par with 
narcotic drugs and psychoactive substances and thereby 
attaching criminal sanctions to their use and possession; 
previously, sanctions had been administrative in nature 
for that category of substances.
725. In 2018, the United Kingdom conducted a man-
dated review of its Psychoactive Substances Act 2016, cov-
ering the first 30 months since the Act had entered into 
force, with a view to assessing whether its aims were being 
achieved. The results of the review were published in 
November 2018. The review found that open retail sale 
of new psychoactive substances had been largely elimi-
nated in the wake of the entry into force of the Act and 
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that there had been a significant drop in their use in the 
general population, particularly among youth, with an 
associated reduction in health-related harms. At the same 
time, the Act was found not to have had any significant 
impact on the emergence of new psychoactive substances 
or on their online sale, neither through the clear web nor 
through the darknet, and it appeared that street dealers 
had replaced retail shops as the main source of supply for 
users.
726. The Russian Federation placed seven precursors 
under national control in 2018, including the interna-
tionally controlled fentanyl precursor N-phenethyl-4-
piperidone (NPP) and six precursors not under 
international control. 4-Anilino-N-phenethylpiperidine 
(ANPP), another internationally controlled precursor of 
fentanyl, was moved from catalogue I to catalogue IV 
of the relevant national schedules in 2018. In February 
2019, the requirements regarding thresholds for precur-
sors of fentanyl under catalogue I of the relevant national 
schedules were removed and five more substances were 
added to that catalogue.
727. In addition to amending its existing legislation on 
psychotropic substances and precursors (in July 2018 and 
April 2019), Serbia adopted in 2019 a comprehensive set 
of by-laws concerning procedures related to precursor 
control, including by-laws on licensing, import and export 
authorizations, and statements concerning the end user 
of a traded precursor. 
728. Since 1 January 2019, French customs authorities 
have been entitled to request and be provided with data 
stored and processed by hosting and Internet service pro-
viders, as well as telecommunication operators, in order 
to ascertain whether, according to the Customs Code of 
that country, a drug offence may have been committed.
729. Spain finalized its first plan of action for the period 
2018–2020 under the national strategy on addictions cov-
ering the period 2017–2024. Social reintegration features 
prominently as one of the areas to be strengthened in the 
context of the comprehensive care approach adopted in 
the national strategy. In January 2019, Croatia published 
a comprehensive report on the implementation of activ-
ities undertaken under its National Strategy on Combating 
Drug Abuse for the period 2012–2017 and the two three-
year action plans covering that period. The report con-
tains detailed statistics and findings on the drug abuse 
situation in the country during that period. 
730. In the United Kingdom, a prison drug strategy was 
published in April 2019; it builds on the 2017 Drug 
Strategy, published by the Home Office. According to the 
prison drug strategy, the number of incidents where 
drugs were found in prisons increased by 23 per cent in 
the period 2017/18 compared with the previous 12-month 
period. The prison drug strategy mirrors the three objec-
tives of the 2017 drug strategy: restricting supply, reduc-
ing demand and building recovery. The prison drug 
strategy is not time-bound, it focuses on improving 
capacity in five areas, it comes with a catalogue of con-
tinually updated good practice guidance for prison gov-
ernors and staff and it requires prisons at the national 
and subnational levels to implement their own tailored 
drug strategies by September 2019.
731. The Russian Federation passed new legislation on 
palliative care in March 2019. The law is to provide 
improved access for terminally ill patients to pain relief 
medications, in particular preparations containing nar-
cotic drugs and psychotropic substances, alongside other 
support services.
732. In March 2019, Greece became the most recent 
European country to provide a legal framework for “drug 
consumption rooms” or supervised drug use areas to 
operate on its territory. To access such areas, which are 
to be authorized by the Ministry of Health, and to make 
use of the care and services provided in those areas, inclu-
sion in the government-maintained register of recipients 
of such services will be a prerequisite. “Drug consump-
tion rooms” are already operating, on a trial or perma-
nent basis, in Belgium, Denmark, France, Germany, 
Luxembourg, the Netherlands, Norway, Portugal, Spain 
and Switzerland, while a legal basis for their operation 
exists in Ireland (since 2017), and governmental initia-
tives seeking to introduce supervised drug injection facil-
ities are under way in several other European countries, 
including Finland and Iceland.
733. In line with its earlier observations on the oper-
ation of “drug consumption rooms” in different coun-
tries, the Board wishes to reiterate that the ultimate 
objective of such measures is to reduce the adverse con-
sequences of drug abuse without condoning or encour-
aging drug trafficking. Accordingly, any such facility 
must provide, or refer recipients of its services to, treat-
ment, rehabilitation and social reintegration services. 
4.  Cultivation, production, 
manufacture and trafficking
734. Drug trafficking trends and patterns generally 
remained stable in Europe, with minor changes observed 
in relation to individual substances. Cannabis (including 
both herb and resin) remained the most frequently seized 
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drug and the substance seized in the highest quantities in 
2017 in the member States of the European Union. However, 
the figures for cannabis herb almost doubled in 2017 com-
pared with the figures for 2016 (210 tons were seized in 
2017 compared with nearly 124 tons in 2016 in about the 
same number of seizures as in 2017), while the figures for 
cannabis resin remained relatively stable, both in terms of 
the number of seizures and the quantities seized (466 tons 
were seized in 2017 compared with some 424 tons in 2016). 
Italy alone accounted for some 43 per cent of the total 
amount of cannabis herb seized in the European Union in 
2017 (more than 90 tons); it was followed by Spain (about 
34.5 tons). At the same time, Spain accounted for almost 
72 per cent of the total amount of cannabis resin seized in 
the European Union member States (almost 335 tons); that 
country was followed by France, where a significantly 
smaller amount of that drug was seized (some 67 tons). 
735. Cannabis was also the most frequently encoun-
tered drug in both drug possession and supply offences 
reported in the European Union in 2017, with 75 per cent 
of an estimated total of 1.2 million cases involving the 
use or possession of cannabis and 57 per cent of an esti-
mated 230,000 cases involving the supply of cannabis.
736. The amount of heroin seized in Europe has also 
been stable for a number of years. Illicit heroin manufac-
turing sites discovered in recent years in Bulgaria, 
Czechia, the Netherlands and Spain, in combination with 
higher amounts of opium and morphine seized, indicate 
that some manufacturing of heroin from morphine may 
be taking place closer to European consumer markets. Of 
all the European Union member States, the Netherlands 
seized the highest quantity of heroin in 2017 (1.1 tons), 
representing about a fifth of all heroin seized within the 
European Union that year; that country was followed by 
the United Kingdom (844 kg) and Bulgaria (698 kg).
737. Opioids other than heroin (including prescription 
opioids such as methadone, buprenorphine, tramadol, fen-
tanyl derivatives, codeine, dihydrocodeine and oxycodone, 
as well as opium and morphine) were seized in markedly 
increased quantities in 2017, although those seizures 
accounted for a small share of the total quantity of seized 
opioids. Seized amounts of tramadol and fentanyl deriva-
tives increased in 2017 for the second year in a row.
738. Record seizures of cocaine were reported in 2018 
and 2019 in several countries, including Belgium (a total 
of 53 tons seized in 2018, up from nearly 45 tons in 2017), 
France (individual seizures of about a ton and a half in 
2018, as well as in 2019) and Germany (4.5 tons in a sin-
gle seizure in 2019, representing the largest single seizure 
of cocaine ever made in the country). Since at least 2011, 
the same four countries – Belgium, France, the Netherlands 
and Spain – have seized the highest amounts of cocaine 
in the European Union. In 2017, the total amount of 
cocaine seized in the European Union was more than 
140.4 tons, the highest amount ever recorded (almost 
double the amount seized in the previous year (70.8 tons)). 
739. Cocaine trafficking has recently been linked to the 
activities of numerous organized criminal groups from 
Colombia, Morocco, Spain and the Balkan countries, 
most of which are operating out of major European ports. 
An EMCDDA trendspotter study entitled “Recent changes 
in Europe’s cocaine market”, published in 2018, found that 
European overseas territories such as French Guiana and 
the French West Indies (Guadeloupe, Martinique, Saint 
Martin and Saint-Barthélemy) are increasingly being used 
as transit areas between producing countries in South 
America and the European mainland. In addition, accord-
ing to the study, traffickers are making increased use of 
online drug markets to manage low-volume cocaine sales 
and are supplying the drug directly to consumers. 
740. Europe continues to be a major source of the 
world’s supply of amphetamine-type stimulants, includ-
ing amphetamine, methamphetamine and MDMA, and a 
significant share of the manufacture of such stimulants 
takes place in Belgium and the Netherlands.
741. Greek authorities effected the largest seizure of 
“captagon” (amphetamine) pills ever recorded in Europe 
in June–July 2019 in the port of Piraeus: some 33 million 
“captagon” pills – more than five tons of tablets. According 
to government sources, the shipment, concealed in three 
containers carrying medium-density fibreboard, origi-
nated in the port of Latakia, in the Syrian Arab Republic, 
and the suspected destination was China.
742. Within the European Union, 55 new psychoactive 
substances emerged and were reported through the early 
warning system of the European Union in the course of 
2018; that represents an average of about one new sub-
stance per week. According to EMCDDA, the emergence 
of new psychoactive substances appeared to have slowed 
down in the European Union since the period 2013–2014. 
However, a considerable number of substances identified 
in earlier years have remained. New synthetic opioids 
(including fentanyl derivatives) continued to play a limited 
role in the European drug market, while the number, type 
and availability of benzodiazepines not under international 
control appeared to have increased in the past few years. 
743. Seizures of precursors and pre-precursors (includ-
ing both scheduled and non-scheduled substances that can 
be easily converted to internationally controlled precursors, 
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usually through a simple chemical synthesis step), espe-
cially those used in the manufacture of amphetamine-type 
stimulants such as methamphetamine or MDMA 
(“ecstasy”), continued to be effected in large quantities in 
European countries during the reporting period. A fully 
equipped illicit drug laboratory, including several tons of 
precursor chemicals used in the large-scale manufacture of 
crystalline methamphetamine, was discovered in Belgium, 
and a “floating” illicit methamphetamine laboratory was 
discovered in the Netherlands (an unprecedented occur-
rence in that country) on board a large cargo ship, where 
more than 300 litres of methamphetamine oil and 
drug-manufacturing equipment were seized.
744. At the same time, there has been a significant 
increase in seizures of acetic anhydride (a key substance 
frequently used in the illicit manufacture of heroin) in 
Europe in the past two years, along with an increase in 
the detection of sites using that precursor for illicit heroin 
manufacture.
745. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2019 on the implementa-
tion of article 12 of the 1988 Convention.
5. Prevention and treatment
746. Overall, the situation with respect to the preva-
lence of drug abuse within the European Union remained 
largely unchanged in 2018 compared with the previous 
year. Based on 2017 data, EMCDDA estimated that about 
29 per cent of the adult population, or some 96 million 
adults, had used illicit drugs at least once during their 
lives, while five years earlier about a quarter of the adult 
population in the European Union (over 80 million 
adults) was estimated to have used such drugs at least 
once. Data on the prevalence of drug use are generally 
available and of high quality in many parts of Europe.
747. In 2018, cannabis continued to be the most com-
monly used illicit drug in European Union member 
States, its prevalence having remained five times higher 
than that of other drugs for at least the past four years, 
with a number of countries having reported increased use 
of cannabis among youth.
748. Among stimulants, cocaine continued to be the 
most commonly used illicit drug, albeit more prevalent in 
countries in Southern and Western Europe, while, based 
on 2017 data, EMCDDA reported growing evidence of a 
potential increase in the injection of stimulants, including 
cocaine, amphetamines and synthetic cathinones. The find-
ings of the largest European wastewater analysis project 
focusing on stimulants and covering some 70 cities and 
towns in 2018 showed that patterns of use varied signifi-
cantly in the region by type of drug, timing and location 
of use. For example, cocaine and MDMA (“ecstasy”) use 
appeared higher in large cities than in smaller urban areas, 
and the highest levels of those drugs and amphetamine 
(so-called “party drugs”) were detected in the wastewater 
during the weekend; furthermore, the highest levels of 
MDMA and cocaine appeared in the wastewater of cities 
in countries in Western Europe (MDMA in cities in 
Belgium, Germany and the Netherlands and cocaine in 
cities in Belgium, the Netherlands, Spain and the United 
Kingdom), while the highest levels of amphetamine were 
concentrated in the wastewater of cities in countries in 
Northern and Eastern Europe. 
749. In 2017, Europe was the region with the second 
highest prevalence of opiate use in the world (0.59 per 
cent, second to Asia with 0.72 per cent). Heroin has also 
remained the most commonly used opioid in European 
Union member States, although the abuse of other syn-
thetic opioids such as fentanyl, methadone and buprenor-
phine appears to be on the rise. In Estonia, fentanyl has 
overtaken heroin as the primary opioid reported as the 
basis for seeking specialized treatment; and in Finland, 
the majority of opioid users sought treatment primarily 
for the use of buprenorphine. In fact, 22 per cent of all 
persons seeking treatment for opioid-related health issues 
in the European Union now cite as their primary drug 
opioids other than heroin (including codeine, morphine, 
tramadol and oxycodone, in addition to the above-named 
substances). 
750. In June 2019, OECD published a report entitled 
“Addressing problematic opioid use in OECD countries”. 
The report found that the average number of opioid- related 
deaths among the 25 OECD members for which data 
were available had increased by 20 per cent in the period 
2011–2016. Although that average includes data for the 
United States, where the opioid crisis has hit the hardest 
in recent years, the report also found a pronounced rise 
in opioid-related deaths in many areas in Europe, includ-
ing (in decreasing order, from the most to the least pro-
nounced rise) Sweden, the United Kingdom (England and 
Wales), Lithuania, Norway and Ireland. The data include 
deaths associated with the abuse of heroin and other opi-
oids, as well as the abuse of prescription opioids. Overall, 
deaths associated with fentanyl and its analogues were 
likely to have been underestimated according to the 
EMCDDA report entitled “Drug-related deaths and mor-
tality in Europe”. With regard to general drug-induced 
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mortality, Estonia and Sweden reported the highest death 
rates in Europe in 2017 (130 and 92 deaths per million 
inhabitants aged 15–64, respectively).
751. According to official statistics released in July 2019, 
the United Kingdom (Scotland) recorded an increase of 
27 per cent in drug-related deaths in 2018 compared with 
the year before, the highest number of drug-related deaths 
since the recording of such deaths began (i.e., since 1996) 
and more than double the number recorded in 2008. Of 
the 1,187 drug-related deaths registered in 2018 in 
Scotland, most (i.e., about two thirds) were among the 
age group 35–44 (37 per cent) and the age group 45–54 
(29 per cent), and 72 per cent of the deceased were male. 
In 86 per cent of all drug-related deaths, one or more 
opiates or opioids (including heroin/morphine and meth-
adone) were involved. Benzodiazepines were implicated 
in, or potentially contributed to, 67 per cent of the cases 
recorded, indicating a high proportion of polydrug use. 
In Scotland, the drug-death rate (relative to the number 
of people aged 15–64) was found to be higher than that 
reported for all European Union member States and (per 
head of population) appeared to be almost three times 
that of the United Kingdom as a whole.
752. In absolute terms, Europe is also the region with 
the second highest prevalence of “ecstasy” use, with an 
estimated 4 million users (second to Asia, with an esti-
mated 11.5 million users, and followed by the Americas, 
with an estimated 3.5 million). 
753. Several countries have undertaken comprehensive 
efforts to further improve their datasets and provide a 
detailed picture of the drug use situation during the 
reporting period. In Poland, the National Bureau for 
Drug Prevention conducted or commissioned more than 
a dozen studies in the course of 2018 and 2019 to exam-
ine different aspects of drug use patterns among various 
population groups in the country. Apart from collecting 
national samples for prevalence studies involving differ-
ent target groups, including substance abuse among 
youth, needle-and-syringe clients, in schools and in 
prison settings, numerous data collection efforts were 
dedicated to better understanding the specific threat 
posed by new psychoactive substances. In the same 
period, Belgium conducted Health Interview Survey 
2018, studying the general condition of health of its pop-
ulation and identifying main health issues, including drug 
use, as well as factors and behaviours that might be deter-
minant in this regard. The results were published in 
October 2019.
754. A variety of drug abuse prevention efforts were ini-
tiated or ongoing in many European countries in 2018 and 
2019. In Serbia, for example, the Ministerial Commission 
for the Prevention of Drug Use launched a six-month 
awareness-raising campaign that ended in February 2019 
and saw the participation in interactive forums of over 
31,000 students, more than 5,400 teachers and some 1,500 
parents, as well as health professionals, social workers, 
judges, prosecutors, police officers and other relevant 
stakeholders, to increase understanding of the harmful 
effects of drug use on young people. The forums followed 
a methodology developed by the Ministerial Commission, 
comprised of seven ministers whose work programme also 
is aimed at strengthening young people’s self-confidence, 
resilience and their capacity to resist in the face of 
drug- using peers, and identifying meaningful alternatives 
to drug use. In Italy, among the numerous prevention 
activities undertaken during the reporting period, two 
areas of focus were the prevention of road accidents caused 
by driving under the influence of drugs and alcohol and a 
more responsible use of the Internet by minors to limit 
exposure to dangerous psychoactive substances.
F. Oceania
drug trafficking through the Pacific islands en route to 
australia and New Zealand is of increasing concern and 
poses a security and public health challenge to the coun-
tries of the region.
1. Major developments
755. Drug trafficking through the Pacific islands en 
route to Australia and New Zealand is of increasing con-
cern. The low level of adherence to the three international 
drug control treaties coupled with the unique geography 
of the region renders the Pacific islands vulnerable to 
drug trafficking and drug-related organized crime. In 
addition to large seizures seen in the Pacific islands of 
drugs that were destined for Australia and to a lesser 
extent New Zealand, domestic seizures of smaller quan-
tities and observations in the region appear to indicate 
growing levels of drug abuse in some Pacific island States. 
756. There were increasing concerns about trafficking 
in drugs such as methamphetamine in the Pacific islands, 
as noted by the Regional Policy Consultations of the 
Pacific Islands Forum, which identified trafficking as an 
emerging issue to be covered by the Forum in 2019. The 
Regional Security Declaration (the “Boe Declaration”) 
endorsed by Forum Leaders at the Forty-Ninth Pacific 
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Island Forum held in Nauru from 3 to 6 September 2018 
recognized an increasingly complex regional security 
environment driven by multifaceted security challenges. 
In the Forum communiqué, Forum Leaders welcomed 
the decision by the Government of Australia to work with 
regional security agencies to establish the Pacific Fusion 
Centre to strengthen information-sharing and maritime 
domain awareness to inform responses to threats such as 
drug trafficking and transnational crimes. The Pacific 
Fusion Centre was to build on existing security architec-
ture, including the Pacific Transnational Crime 
Coordination Centre.
757. The Board reiterates its concern that many of the 
non-parties to the three international drug control con-
ventions are located in Oceania.81 The Board remains 
engaged with the countries of the region to support their 
steps towards treaty adherence and implementation and 
welcomed the accession of Palau to the 1988 Convention. 
The Board urges those States that are not yet party to all 
three drug control conventions to take steps towards 
accession as a matter of priority. In addition, the Board 
calls on countries and international and regional organi-
zations that provide support to the non-parties in the 
region to aid the efforts of the non-parties to accede to 
the treaties as a matter of priority. 
2. Regional cooperation
758. The Transnational, Serious and Organized Crime 
Pacific Taskforce was launched by the law enforcement 
agencies of Australia, Fiji, New Zealand and Tonga in 
February 2019. The goals of the Taskforce are to (a) 
enhance the sharing of information between participants 
through the established Pacific Transnational Crime 
Network, the Pacific Transnational Crime Coordination 
Centre and transnational crime units; (b) investigate and 
disrupt transnational serious and organized crime enti-
ties operating from, through or impacting the participant 
countries; (c) target organized crime entities or syndicates 
utilizing small craft to move illicit drugs and facilitate 
other organized criminal activity; (d) demonstrate the 
commitment of participants to effective multinational 
cooperation and effectiveness in combating transnational 
organized crime; and (e) strengthen cooperation to con-
duct expanded investigations on transnational organized 
criminal groups.
81 Seven of the 10 States yet to accede to the 1961 Convention are in 
Oceania: Cook Islands, Kiribati, Nauru, Niue, Samoa, Tuvalu and 
Vanuatu. Eight of the 13 States not party to the 1971 Convention are in 
Oceania: Cook Islands, Kiribati, Nauru, Niue, Samoa, Solomon Islands, 
Tuvalu and Vanuatu. Four of the 7 non-parties to the 1988 Convention 
are in Oceania: Kiribati, Papua New Guinea, Solomon Islands and Tuvalu. 
759. The twenty-first annual conference of the Oceania 
Customs Organization took place in May 2019 in Saipan, 
Northern Mariana Islands, attended by 21 member cus-
toms administrations and representatives of international 
and regional organizations, including the Pacific Islands 
Chiefs of Police. Topics discussed at the conference 
included trade facilitation, revenue mobilization, border 
security and digital capacity. The INCB secretariat partic-
ipated in the conference to highlight challenges in 
addressing trafficking in synthetic drugs and related sub-
stances to and through the small island States of the 
region. In particular, the Board’s secretariat provided 
information on the trafficking of fentanyl-related sub-
stances by means of international mail and express cou-
rier services, and demonstrated the use of the Board’s 
IONICS system. In 2019, the Board signed a memoran-
dum of understanding with the Oceania Customs 
Organization to facilitate cooperation in countering 
trafficking in narcotic drugs, psychotropic substances, 
new psychoactive substances and precursor chemicals. 
760. The 2019 PICP conference, on “Preventing drug 
harm within our communities”, was held in American 
Samoa in August 2019, at which a draft PICP strategic 
plan was presented. At a meeting of the PICP Executive 
Leadership Team held in Sydney in early 2019, the Pacific 
Transnational Crime Network gave a presentation on 
crime trends across the Pacific, focusing on illicit drugs, 
human trafficking and gang movements.
761. At the meeting of the Pacific Island Law Officers’ 
Network held in the Cook Islands in October 2018, the 
PICP Secretariat gave a presentation on current activities 
and the Pacific Methamphetamine Action Plan. According 
to the PICP Secretariat, the Network had completed an 
analysis of legislation on methamphetamine in the Pacific 
island region. A Pacific Transnational Crime Network 
Team Leaders’ Meeting held in Fiji in September 2018 
included a workshop to identify actions to support the 
Pacific Methamphetamine Action Plan. 
3.  National legislation, policy and 
action
762. In August 2019, Palau acceded to the 1988 
Convention, a development which was welcomed by the 
Board. In an executive order issued in April 2019, the 
President of Palau referred, inter alia, to the growing inci-
dence of drug trafficking. The executive order stated that 
the policy of the Government was to strengthen border 
security, and it set out measures to secure ports of entry 
and prevent the entry of foreign nationals intending to 
commit any form of transnational crime. 
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763. In Tonga in June 2019, representatives of 
Government, churches and young people participated in 
a two-day meeting to discuss and review the draft first 
national illicit drugs policy. The five-year policy aims at 
building a safe, healthy and resilient Tonga through effec-
tive prevention and enhanced enforcement and by pro-
gressively reducing harm, and was approved by the 
Tongan Cabinet in October 2019. The policy had six stra-
tegic areas of focus: supply reduction and alternative devel-
opment; demand and harm reduction; improved 
coordination and control; international and regional coop-
eration; improving data collection, analysis and 
information- sharing; and compliance with human rights. 
Also in 2019, the Tonga Police announced that a drug task 
force had been initiated. 
764. In Samoa, participants doing training on the 
Universal Treatment Curriculum for Substance Use 
Disorders completed a training course on basic counsel-
ling skills for addiction professionals as a step towards 
their certification as alcohol and drug addiction counsel-
lors. The training was facilitated through the Colombo 
Plan in partnership with the Government of Samoa, with 
funding from the United States State Department Bureau 
of International Narcotics and Law Enforcement Affairs.
765. The Misuse of Drugs (Medicinal Cannabis) 
Amendment Act 2018 came into effect in New Zealand 
in December 2018. As a result, people with terminal ill-
nesses have an exemption and statutory defence for pos-
sessing and using cannabis, and CBD is no longer a 
controlled drug at the national level. Within a year of 
coming into effect, the Minister of Health must recom-
mend regulations establishing standards for medicinal 
cannabis products, and those regulations will be a key 
element of the medical cannabis programme to be estab-
lished. In 2019, the drug legislation of New Zealand was 
amended, inter alia, to reaffirm the existing discretion in 
prosecuting for possession and use, with the specification 
that when considering whether a prosecution is required 
in the public interest, in addition to any other relevant 
matters, consideration should be given to whether a 
health-centred or therapeutic approach would be more 
beneficial to the public interest, and to make it possible 
to issue temporary drug orders for emerging and poten-
tially harmful substances of abuse.
766. In September 2019, the Legislative Assembly of the 
Australian Capital Territory, a self-governing territory 
within the Australian federal system of government, 
adopted legislation which, once in force, will create excep-
tions to existing criminal offences for persons over the 
age of 18 for the following: possession of up to 50 grams 
of cannabis for non-medical purposes; and cultivation of 
up to two cannabis plants (with a maximum of four plants 
per household). The Board remains engaged in dialogue 
with the Government of Australia with a view to ensur-
ing the full implementation by Australia of its interna-
tional legal obligations under the international drug 
control legal framework. The Government of New 
Zealand announced that on the occasion of the general 
election in 2020 a referendum would be held on the legal-
ization and regulation of cannabis. The Board remains 
engaged in dialogue with the Government of New 
Zealand, including through its mission to the country 
held in September 2019. The Board recalls that the 1961 
Convention as amended, to which Australia and New 
Zealand are parties, requires States parties to limit the use 
of narcotic drugs exclusively to medical and scientific 
purposes. 
767. Noting plans in the region to permit the cultiva-
tion of cannabis for medical and scientific purposes, the 
Board reminds Governments of the need to respect the 
requirements of the 1961 Convention as amended and 
that controls must be in place to ensure that material is 
not diverted to the illicit market. The Board also notes 
that, according to the terms of the 1961 Convention as 
amended, the overproduction of cannabis for medical and 
scientific purposes should be avoided and currently, as 
reported to the Board, this supply is being met through 
existing licit sources.
768. In New Zealand, in December 2018, a report was 
released containing the findings of a government enquiry 
into mental health and addiction, with recommendations 
covering, inter alia, prevention, treatment and rehabilita-
tion, regulation, and responses to possession of drugs for 
personal use. In response, the Government announced a 
number of related initiatives in connection with its 2019 
budget, focusing on mental health and addiction support. 
The initiatives announced included the expansion of 
access to primary mental health and addiction support, 
enhancement of specialist drug services, a new acute drug 
harm response discretionary fund, establishment of a 
drug early warning system, and addiction training focus-
ing on communities experiencing harm from synthetic 
drugs.
769. In September 2019, the final report of the review 
of the Narcotic Drugs Act 1967 was submitted to the 
Parliament of Australia. The report contains 26 recom-
mendations to improve the regulatory framework for the 
cultivation, production and manufacture of medicinal 
cannabis in Australia. The recommendations were 
accepted by the Government and would be implemented 
through a two-stage process commencing as of the end 
of 2019.
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770. Efforts continued in Australia to address the illicit 
supply of methamphetamine. For example, in February 
2019, a specialist multi-agency team was established in 
the State of South Australia, led by the South Australia 
Police and comprising members of agencies such as the 
Australian Federal Police, the Australian Border Force 
and the Australian Criminal Intelligence Commission. 
The Western Australia Police Force started use of its 
“meth enforcement vans”, which were equipped with 
forensic testing facilities, drug detection devices and spe-
cialist communications equipment, and were used to 
counter trafficking of methamphetamine on state 
highways. 
771. In Australia, following a public consultation on 
prescription opioids in 2018, an Opioid Regulatory 
Advisory Group was established to provide independent, 
expert advice. As a result of the Group’s advice, for exam-
ple, smaller pack sizes would be introduced for immedi-
ate-release prescription opioid products, specific warnings 
for health professionals and consumers would be required 
for all prescription opioids, and consumers were being 
encouraged to return unwanted opioids for destruction.
4.  Cultivation, production, 
manufacture and trafficking
772. Large quantities of drugs, mainly cocaine and 
methamphetamine, continue to be seized in the island 
States of the region. For example, a record seizure of 
500 kg of cocaine was made on a yacht in Honiara, 
Solomon Islands, in September 2018, as a result of a joint 
investigation with Australian authorities. A seizure of 
6.7 kg of methamphetamine, 625.29 grams of cannabis 
and 107.29 grams of cannabis oil was made in Tonga in 
April 2019, detected in a shipment sent from the United 
States. Also in April 2019, approximately 3 kg of meth-
amphetamine were seized in a drug operation in Tonga. 
A number of seizures of smaller quantities of metham-
phetamine were also reported in Tonga in the past year, 
indicating the possibility of abuse of methamphetamine 
in the country. Cooperation between law enforcement 
authorities in Fiji and New Zealand resulted in seizures 
of methamphetamine that was alleged to have been 
trafficked from the United States to New Zealand, as well 
as the seizure of 39 kg of cocaine in Fiji.
773. A varying trend is observed in the quantity of 
methamphetamine seized in Oceania: following an 
upward trend in seizure quantities over the period 2009–
2014 and a subsequent decline over the period 2014–
2016, there was an increase again in 2017. Australia and 
New Zealand accounted for 93 per cent and 7 per cent, 
respectively, of the quantity of methamphetamine seized 
in the region in the period 2013–2017. A ninefold increase 
in the quantity of “ecstasy” seized in the period 2013–
2017 was reported in Oceania, which accounted for one 
fifth of the quantity of “ecstasy” seized worldwide in that 
period.
774. The amount of amphetamine-type stimulants 
(excluding MDMA), predominantly methamphetamine, 
detected at the Australian border (2.95 tons) increased by 
61 per cent from 2016/17 to 2017/18, and the amount of 
MDMA detected at the border increased by 59.6 per cent 
over that period, to 1.42 tons in 2017/18. Over the same 
period, total seizures of amphetamine-type stimulants 
(including MDMA) in Australia increased by 48 per cent 
to 11.2 tons.
775. A change in the pattern of methamphetamine traf-
ficking into Australia has been seen in recent years. In 
2015, China and Hong Kong, China, were the two main 
embarkation points for methamphetamine trafficked to 
Australia. By 2017, the United States had become the 
most important embarkation point, followed by Thailand 
and Malaysia. In 2017/18, the United States continued to 
be the primary embarkation point for amphetamine-type 
stimulants (excluding MDMA) detected at the Australian 
border. In January 2019, cooperation between the author-
ities of Australia and the United States led to the seizure 
in the United States of a record quantity of more than 
1.7 tons of methamphetamine destined for Australia. In 
June 2019, in Australia, a record onshore seizure of almost 
1.6 tons of methamphetamine, concealed in a consign-
ment originating in Thailand, was announced.
776. In 2017, Canada and to a lesser extent the United 
States were reported for the first time as being main coun-
tries of departure for methamphetamine found in New 
Zealand, followed by Hong Kong, China; China; and 
Mexico. In New Zealand, over 2018 and 2019, police in 
Wellington targeted organized criminal groups involved 
in the distribution of methamphetamine. 
777. The number of clandestine laboratories detected in 
Australia continued to decrease, with 432 detected clan-
destine laboratories in 2017/18, compared with 463 the 
previous year, and with methamphetamine being the 
main drug manufactured. The clandestine laboratories 
detected continued to be primarily user-based (i.e., man-
ufacture for own use) and located in residential areas, but 
the proportion of such laboratories has decreased by a 
third since 2011/12, while the proportion of other small-
scale laboratories has doubled, and the proportion that 
are medium-sized laboratories has more than doubled. 
While almost half of the detected laboratories (46.2 per 
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cent) were illicitly producing amphetamines, predomi-
nantly from the precursors ephedrine and pseudoephed-
rine, a record 22 clandestine laboratories manufacturing 
GHB/GBL were detected (compared with 11 the previous 
year), and 20 laboratories were illicitly manufacturing 
MDMA, the largest number in the past decade and more 
than double the number in the previous year (8 labora-
tories manufacturing MDMA detected). A fluctuating 
trend was seen in the detection of clandestine laborato-
ries in New Zealand, rising from 45 detections in 2015 
to 745 in 2016 but then falling to 79 detections in 2017. 
778. Significant amounts of the methamphetamine pre-
cursors ephedrine and pseudoephedrine were seized in 
Australia and New Zealand in the period 2013–2017, 
while only small amounts of the amphetamine precursors 
1-phenyl-2-propanone (P-2-P) and phenylacetic acid 
were seized in the region. The amount of precursors for 
the manufacture of amphetamine-type stimulants (exclud-
ing MDMA) detected at the Australian border more than 
doubled from the past year, reaching a record level of 
4.9 tons in 2017/18. Over the same period, the amount 
of precursors of MDMA detected at the border decreased 
significantly, from 10 kg to 5 grams in 2017/18, consist-
ing of a single seizure. 
779. The quantity of heroin and morphine seized in 
the region continued to decrease in 2017, falling to the 
lowest level since 2009. More than 90 per cent of the total 
amount of heroin and morphine seized in Oceania was 
seized in Australia. The amount of heroin detected at the 
Australian border decreased by 5.7 per cent from the pre-
vious year, to 190.1 kg in 2017/18. Most of the heroin 
seized in Australia originated in South-East Asia, but an 
increase was observed in the proportion of seized heroin 
originating in South-West Asia. 
780. Owing to a spike in seizures in Australia, the total 
quantity of cocaine seized in Oceania increased by 94 per 
cent from 2016 to 2017, and accounted for 0.3 per cent 
of the quantity of cocaine seized globally in 2017. Of the 
cocaine seized in Oceania over the period 2013–2017, 
98 per cent was seized in Australia; during that period, 
seizures of cocaine in Australia quadrupled, from 1 ton 
to 4.1 tons. Seizures of cocaine at the Australian border 
were relatively stable over the past year, declining by 
16.5 per cent, from a record 1.1 tons in 2016/17 to 0.9 tons 
in 2017/18; seizures of cocaine in the country decreased 
by 57.4 per cent, to 1.97 tons, nevertheless still the second 
highest seizure total on record. While Colombia remained 
the primary source of cocaine analysed, the proportion 
of cocaine originating in Peru increased, returning to a 
level similar to that of 2015. Over the period 2013–2017, 
the quantity of cocaine seized in New Zealand also 
increased, from 0.2 kg to 108 kg. In August 2018, a record 
seizure of approximately 190 kg of cocaine, destined for 
Australia, was made at the New Zealand border follow-
ing a joint investigation with Australian authorities.
781. Increases in cannabis seizures were reported in 
2017 in Oceania, although those seizures accounted for 
less than 1 per cent of total worldwide seizures of canna-
bis herb and cannabis resin. A 10-year record amount 
(580.2 kg) of cannabis was detected at the Australian bor-
der in 2017/18 (compared with 102.5 kg in 2016/17), the 
greatest proportion of which was cannabis oil. The 
amount of cannabis seized within Australia increased for 
the third consecutive year, to 8.656 tons in 2017/18, from 
7.55 tons in 2016/17. 
782. The analysis of wastewater monitoring data in 
Australia indicated that the total seizures (by weight) of 
amphetamines, MDMA, heroin and cocaine in 2017/8 
were the equivalent of 51.4 per cent, 175.0 per cent, 
30.5 per cent and 47.9 per cent of the estimated consump-
tion of those respective substances in the country for that 
period.
783. According to UNODC, countries in Oceania 
reported minimal seizures of fentanyl and its analogues. 
The number of detections of new psychoactive sub-
stances at the Australian border decreased by 29.0 per 
cent from 2016/17 to 2017/18 (687 detections). By 
weight, amphetamine- type substances accounted for 
46.5 per cent of the new psychoactive substances analysed, 
followed by cathinone-type substances (38.1 per cent) and 
tryptamine- type substances (9.3 per cent). 
5. Prevention and treatment
784. According to UNODC, the prevalence of past-year 
drug use among adults in Oceania (statistics for Australia 
and New Zealand only) is 11.0 per cent for cannabis, 
3.28 per cent for opioids (including opiates and pharma-
ceutical opioids), 0.16 per cent for opiates, 2.2 per cent 
for cocaine, 1.34 per cent for amphetamines and phar-
maceutical stimulants, and 2.17 per cent for “ecstasy”. In 
the Federated States of Micronesia, the prevalence of past-
year abuse of cannabis is 17.2 per cent, and past-year 
abuse of amphetamines and pharmaceutical stimulants is 
1.58 per cent. No comprehensive data on the level of drug 
abuse exist for the remainder of the region. The Board 
encourages the regional and international organizations 
that provide assistance to the Pacific island States to 
extend their support to the collection of data on the 
extent of the drug problem in order to facilitate the adop-
tion of targeted and evidence-based drug policies. 
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785. The National Wastewater Drug Monitoring 
Programme of Australia, with coverage of 54 per cent of 
the country’s population, shows that methamphetamine 
consumption continues to exceed consumption of all 
other illicit drug types and pharmaceuticals, and the 
population-weighted average consumption of metham-
phetamine increased from 2016 to 2018. Estimated 
MDMA consumption was low compared with other sub-
stances that were tested for, and the population-weighted 
average consumption decreased from 2016 to 2018. 
Oxycodone and fentanyl had elevated consumption lev-
els at several test sites, and fentanyl consumption was 
increasing in several areas. Estimated heroin consump-
tion decreased at the test sites from 2017 to 2018, while 
the estimated consumption of cocaine increased. 
Authorities report that both supply and demand indica-
tors suggest an expanding cocaine market in the coun-
try. Among people who inject drugs, increasing use of 
methamphetamine has been reported, now surpassing 
heroin as the drug most frequently injected.
786. According to the 2017 Australian Secondary 
Students Alcohol and Drug Survey, 2 per cent of respon-
dents, aged 12–17, reported having ever used metham-
phetamine, and 1 per cent reported past-month use of 
the substance. Lifetime prevalence of cannabis use 
increased from 16 per cent in 2014 to 17 per cent in 2017; 
and past-month use had increased from 7 per cent to 
8 per cent. For “ecstasy”, reported lifetime use increased 
from 3 per cent in 2014 to 5 per cent in 2017, and 
reported past-month use increased over the same period, 
from 1 per cent to 2 per cent. For heroin abuse, both life-
time and past-month prevalence were reported to be 
1 per cent. Cocaine abuse remained stable, with lifetime 
prevalence of 2.0 per cent and past-month use at 1.0 per 
cent. Past-month use of hallucinogens (specified in the 
survey as LSD or “magic mushrooms”) remained stable 
at 1.0 per cent, while lifetime use increased, from 3 per 
cent in 2014 to 4 per cent in 2017. The lifetime preva-
lence of synthetic cannabis decreased, from 2.3 per cent 
to 2.0 per cent. 
787. The number of amphetamines-related treatment 
episodes in Australia increased by about 84 per cent 
between 2013/14 and 2017/18. Cocaine-related episodes 
increased by 160 per cent, while the number of 
heroin- related treatment episodes decreased by about 
8 per cent, and morphine cases decreased by 40 per cent. 
Over the past decade, treatment episodes for amphet-
amines increased by over 300 per cent, and the number 
of heroin treatment episodes decreased by 22 per cent. In 
2017/18, the most common principal drugs of concern 
leading clients to seek treatment were amphetamines, 
cannabis and heroin.
788. The proportion of police detainees in Australia 
testing positive for methamphetamine decreased from 
51.3 per cent in 2016/17 to 45.6 per cent in 2017/18, 
which is still significantly higher than in 2008/09 (15.8 per 
cent). Cannabis remained a commonly used drug among 
detainees, but its prevalence steadily declined from 57 per 
cent in 2008/09 to 46 per cent in 2017/18. The propor-
tion of detainees testing positive for MDMA also 
decreased, from 2 per cent in 2016/17 to 0.8 per cent in 
2017/18. A decrease was also seen in the proportion of 
detainees testing positive for heroin, from 7.3 per cent in 
2016/17 to 6.4 per cent in 2017/18. For cocaine, the pro-
portion of detainees testing positive increased from 
1.8 per cent in 2016/17 to 2.1 per cent in 2017/18.
789. The New Zealand Health Survey for 2017/18 found 
that among adults, the past-year prevalence of abuse of 
cannabis and amphetamines was 11.9 per cent and 
0.8 per cent, respectively. Because of changes in the sur-
vey methodology, comparison with previous surveys was 
not possible. 
790. The first findings of the New Zealand national 
wastewater testing programme, which covers about 80 per 
cent of the population and which tests for the presence 
of methamphetamine, cocaine, heroin, MDMA and fen-
tanyl, were released in April 2019. Preliminary results for 
the period from November 2018 to January 2019 show 
that methamphetamine is the most commonly detected 
illicit drug nationwide, with an estimated average total 
national consumption of 16 kg per week. According to 
UNODC, wastewater analysis indicated a 350 per cent 
increase in the quantity of MDMA consumed in 2017 in 
New Zealand, surpassing in December 2017 the level of 
consumption of methamphetamine. In the light of those 
findings and the increasing quantities of MDMA seized 
over the period 2015–2017, demand for MDMA and 
“ecstasy”-type substances appears to have been increasing 
rapidly in the country.
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Chapter IV. 
Recommendations to Governments, the 
United Nations and other relevant international 
and national organizations
791. Following its review of the implementation of the 
international drug control conventions, the Board would 
like to present to Governments and relevant international 
and regional organizations its main conclusions and rec-
ommendations as follows.
Improving drug use prevention and 
treatment services for young people
792. Article 38 of the 1961 Convention as amended 
underscores the importance of measures to prevent and 
treat drug dependence. In addition, the need to address 
drug dependence, in particular among young people, has 
been the subject of numerous resolutions and declarations 
of the Commission on Narcotic Drugs, the Economic and 
Social Council and the General Assembly in its special 
sessions on the world drug problem held in 1998 and 
2016. Drug use and associated health consequences are 
greatest among young people, in particular those aged 
18–25. Cannabis is a drug widely used by young people. 
Although many who initiate use of psychoactive sub-
stances later discontinue use, those who are most vulner-
able because of physiological, social, emotional and 
developmental factors may progress to the use of multiple 
substances, as well as an increased frequency of use. 
Research shows that those who initiate substance use 
early are most at risk of becoming dependent. 
793. Furthermore, primary prevention measures that 
protect people, in particular children and youth, from drug 
use are among the key operational objectives of the recom-
mendations on drug demand reduction contained in the 
outcome document of the thirtieth special session of the 
General Assembly. There is also a fundamental protection 
aspect of the Convention on the Rights of the Child, as 
reflected in article 33 of that Convention. The International 
Standards on Drug Use Prevention, published by UNODC 
in 2013 and later jointly revised by UNODC and WHO in 
2018, summarize the scientific evidence on the effective-
ness of drug use prevention efforts. They were followed by 
the International Standards for the Treatment of Drug Use 
Disorders, published by UNODC and WHO in 2017. In a 
number of documents and resolutions, including the out-
come document of the thirtieth special session of the 
General Assembly, Governments have recognized those 
two sets of international standards as useful tools to pro-
mote evidence-based prevention and treatment. The Board 
would like to draw the attention of Governments to the 
importance of considering the scientific evidence summa-
rized in those two sets of international standards when 
implementing programmes for the prevention of drug use 
and treatment of drug dependence among youth.
Recommendation 1: The Board urges all Governments to:
(a)  Develop national systems for the collection of 
data on drug use; 
(b)  Develop capacity-building in the field of drug use 
prevention and treatment;
(c)  Implement evidence-based prevention pro-
grammes for young people using a wide range of 
interventions in the family, in school and in the 
community;
(d)  Promote early detection and interventions;
(e)  Implement multisectoral evidence-based preven-
tion programmes not only for drug use but also 
for other problematic behaviours;
(f)  Implement specific interventions to prevent the 
progression to substance use disorders;
(g)  Promote evidence-based treatment programmes 
specifically tailored for young people, taking into 
consideration the recommendations on the treat-
ment of drug dependence contained in chapter I 
of the annual report of the Board for 2017. 
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794. For additional recommendations and more details 
of proposed action, please refer to the section entitled 
“Implications for policy development worldwide: conclu-
sions and recommendations”, contained in chapter I of 
the present report.
Cannabis
795. The Board notes with concern the legalization of 
cannabis for non-medical and non-scientific purposes in 
several jurisdictions and that other jurisdictions are con-
sidering taking similar action. The Board reiterates that 
the 1961 Convention as amended, the 1971 Convention 
and the 1988 Convention limit the use of all controlled 
substances to medical and scientific purposes.
796. The developments in a few countries that have 
legalized or permitted the use of cannabis for non-medical 
purposes or that have tolerated its legalization at the sub-
national level are undermining the universal adherence 
to the three international drug control conventions and 
the commitment to their goals and objectives, as was reaf-
firmed by Member States at the thirtieth special session 
of the General Assembly on the world drug problem, held 
in 2016, and as expressed in the 2019 Ministerial 
Declaration on Strengthening Our Actions at the National, 
Regional and International Levels to Accelerate the 
Implementation of Our Joint Commitments to Address 
and Counter the World Drug Problem.
Recommendation 2: Recalling the health and welfare 
objectives of the three international drug control con-
ventions, the Board reiterates that the conventions limit 
the use of controlled narcotic drugs and psychotropic 
substances, of which cannabis is one, exclusively to med-
ical and scientific purposes. The Board calls upon the 
Governments of countries in which the use of cannabis 
or cannabis derivatives for non-medical purposes has 
been permitted, nationally or at the subnational level, 
to take steps to bring the entirety of their territories 
back into compliance with the legal obligations incum-
bent upon States parties to the international drug con-
trol conventions.
797. Over the past several years, some States parties have 
taken steps to control and regulate the sale of cannabis for 
neither medical nor scientific purposes. The Board’s review 
of this issue of convention compliance has included engage-
ment with individual States parties, statements in inter-
governmental forums, and publication of the Board’s views 
in its annual reports. At all times, the Board has endeav-
oured to fulfil its mandate, as expressed in the three inter-
national drug control conventions, including under 
article 9, paragraphs 4 and 5, of the 1961 Convention as 
amended. In particular, consistent with article 9, the Board 
has sought to facilitate effective national action to attain 
the aims of the 1961 Convention and to limit the cultiva-
tion, production, manufacture and use of drugs to an ade-
quate amount required for medical and scientific purposes, 
ensure their availability for such purposes and prevent the 
illicit cultivation, production and manufacture of, illicit 
trafficking in and use of drugs.
798. Responding to changes in the regulation of canna-
bis in some countries, the Board has engaged with States 
parties individually, considering their specific circum-
stances, and has reflected on the individual approaches 
and programmes of each State party. Notwithstanding the 
variations in each State party’s approach to cannabis, the 
Board has identified inconsistencies in their compliance 
with their obligations under the Conventions. As a result 
of this ongoing dialogue on the topic of cannabis regula-
tion, the Board takes note of significant risks to the abil-
ities of individual States parties to implement certain 
elements of their Convention obligations. 
Recommendation 3: The Board therefore takes the oppor-
tunity of this annual report to draw the attention of the 
Commission on Narcotic Drugs to the need to address 
this issue, consistent with the three international drug 
control conventions and taking into account the outcome 
document of the thirtieth special session of the General 
Assembly, on the world drug problem, entitled “Our joint 
commitment to effectively addressing and countering the 
world drug problem”, and the 2019 Ministerial Declaration 
on Strengthening Our Actions at the National, Regional 
and International Levels to Accelerate the Implementation 
of Our Joint Commitments to Address and Counter the 
World Drug Problem.
International drug control conventions 
and human rights 
799. The fundamental goal of the international drug 
control conventions, to safeguard the health and welfare 
of humanity, includes the full enjoyment of human rights. 
State actions that violate human rights in the name of 
drug control policy are inconsistent with the international 
drug control conventions. Extrajudicial responses to sus-
pected drug-related activities cannot be justified under 
international law, including under the international drug 
control conventions. 
800. In addressing suspected drug-related crime, States 
should be proportionate in their responses and in their 
treatment of suspected offenders. According to the 
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principle of proportionality, the penalties handed down 
should reflect the gravity of the offence and the degree 
of responsibility of the suspected offender. In cases of 
lesser gravity, or in which the alleged crime has been 
committed by a person who uses drugs, States are not 
legally required by the international drug control conven-
tions to impose criminal sanctions, including imprison-
ment, but may provide for treatment and rehabilitation 
measures as an alternative to conviction or punishment, 
or in addition thereto. 
Recommendation 4: The Board appeals to all States par-
ties to pursue drug control policies that respect and pro-
tect all human rights and are consistent with international 
human rights instruments. Drug abuse and drug-related 
activities cannot be lawfully addressed without ensur-
ing the protection of human rights and compliance with 
the international drug control conventions.
Recommendation 5: The Board reiterates that in address-
ing drug-related criminality, States must continue to 
apply the principle of proportionality as a guiding prin-
ciple in the determination and application of criminal 
sanctions. 
Recommendation 6: Although the determination of 
sanctions applicable to drug-related crime remains the 
prerogative of States parties to the conventions, the 
Board reiterates its position on the issue of capital pun-
ishment for drug-related offences and urges States that 
retain capital punishment for drug-related offences to 
consider the abolition of the death penalty for that cat-
egory of offence.
Recommendation 7: The Board recalls that States parties 
to the conventions are required to give special attention 
to and take all practicable measures for the prevention, 
treatment, rehabilitation and social reintegration of per-
sons affected by drug use disorders. The Board reiter-
ates that respecting the right of people affected by drug 
use disorders to health and treatment services will con-
tribute to reducing the stigma and discrimination asso-
ciated with those disorders.
Universal adherence to the international 
drug control conventions
801. The three international drug control conventions 
embody the international consensus on requirements for 
the control of licit trade in narcotic drugs, psychotropic 
substances and precursor chemicals that can be diverted, 
and on the measures needed to facilitate access to and 
the availability of controlled substances for legitimate 
medical and scientific purposes. By becoming parties to 
the conventions, States demonstrate their common and 
shared responsibility for meeting those minimum require-
ments with a view to achieving the aim of the conven-
tions, which is the health and welfare of humankind. 
Recommendation 8: The Board reiterates that universal 
ratification of the drug control conventions is impera-
tive for strengthening the international licit drug con-
trol framework and for ensuring that traffickers do not 
target non-parties due to actual or perceived weaknesses 
in the scope of control of scheduled substances. 
Accordingly, the Board urges all States that have not yet 
become parties to one or more of these instruments to 
do so without delay and to take steps to ensure their 
full implementation within their national legal orders. 
Reducing the adverse public health and 
social consequences of drug abuse
802. An area in which the implementation of the inter-
national drug control conventions has not been fully real-
ized is the provision of prevention and treatment. The 
relevant provisions of the conventions do not mandate a 
specific approach, instead leaving it to States to determine 
which approaches are most suitable to their national cir-
cumstances. The lack of epidemiological data remains a 
barrier to the elaboration of evidence-based drug policy 
to support the development, formulation and provision 
of targeted and effective prevention and treatment inter-
ventions and to the optimization of resource utilization. 
In many parts of the world, prevention initiatives are 
inexistent or lacking, and the provision of treatment ser-
vices is inadequate, while there are only insufficient mech-
anisms to combat stigma and foster social reintegration.
803. The health and welfare of humankind is the corner-
stone of the international drug control framework and 
includes ensuring that persons affected by drug use dis-
orders receive services that are evidence-based to treat 
drug use and potential related harms.
Recommendation 9: The Board notes that measures 
aimed at minimizing the adverse public health and 
social consequences of drug abuse, when they are based 
on scientific data, can help manage the pervasive effects 
and complex risks of epidemic-level drug abuse. As 
they form part of a strategy for comprehensive drug 
demand reduction, States parties are encouraged to 
implement measures that can minimize the adverse 
public health and social consequences of drug abuse, 
including through appropriate medication-assisted 
therapy programmes.
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Availability and access to narcotic drugs 
and psychotropic substances
804. The cultivation of opium poppy for the production 
of opium and opiate raw material is a matter of major 
international importance in the context of drug control 
and public health. While recognizing the challenge posed 
by existing disparities in access to opioid analgesics, for 
several years the amount of opiate raw material available 
globally for the manufacture of narcotic drugs for medi-
cal purposes, including for pain management, has been 
more than sufficient to satisfy the current and anticipated 
levels of global demand as estimated by Governments, 
because both production and stocks are continuing to 
increase. 
805. At the same time, the lack of access to and availabil-
ity of controlled narcotic drugs and psychotropic sub-
stances for legitimate medical use continues to be a pressing 
public health problem in many regions of the world. In the 
20-year period 1997–2016, the manufacture of morphine 
increased considerably, but of the total amount of mor-
phine utilized globally, the majority (88 per cent, on aver-
age) was converted into codeine or into substances not 
covered by the 1961 Convention. Most of the codeine con-
verted from morphine (89 per cent) was used to manufac-
ture cough medication. The limited use of morphine and 
the difficulties in procuring it for pain management and 
relief are also related to the marketing of more expensive 
synthetic opioids that are used for the same indications as 
are opiates. Since 1997, the overall availability of opioid 
analgesics for consumption has more than tripled. 
Recommendation 10: The Board recommends that all 
States parties prevent the accumulation of stocks of 
poppy straw in excess of the quantities required for the 
normal conduct of business, taking into account the 
prevailing market conditions.
Recommendation 11: The Board recalls that the 1961 
Convention sets out a number of mandatory control 
measures for the licit cultivation of opium poppy and the 
production of opiate raw materials in order to ensure that 
they are limited to use for licit medical and scientific pur-
poses. Therefore, the Board urges countries that are con-
sidering or are intending to commence the licit cultivation 
of opium poppy for medical and scientific purposes to 
consider the importance of the principle of non-
proliferation. This objective is emphasized in the relevant 
resolutions of the Economic and Social Council and the 
Commission on Narcotic Drugs on the supply of and 
demand for opiates, in which the Council and the 
Commission urged all Governments to cooperate in pre-
venting the proliferation of sources of production of 
opiate raw materials and urged all Governments of coun-
tries in which opium poppy was not being cultivated for 
the licit production of opiate raw materials to refrain, in 
the spirit of collective responsibility, from engaging in the 
commercial cultivation of opium poppy. 
Recommendation 12: The Board urges countries to 
develop mechanisms to ensure that the pharmaceutical 
industry produces and makes available medicines con-
taining controlled substances, such as opioid analgesics, 
specifically morphine, that are affordable, and enforce 
the regulation of the pharmaceutical industry to deal 
with promotional and informational campaigns for pre-
scribing and using high-cost formulations, including 
with respect to costly synthetic opioids. 
806. Article 3 of the 1971 Convention allows countries 
to exempt certain preparations containing psychotropic 
substances from some measures of control. Such exemp-
tions allow countries to facilitate easier access to some 
medicines containing internationally controlled psycho-
tropic substances. However, the Board notes that in some 
jurisdictions that have chosen to exempt preparations 
containing psychotropics from some measures of control, 
certain provisions of article 3 are not correctly or fully 
implemented.
Recommendation 13: The Board calls upon Governments 
to ensure that all aspects of article 3 of the 1971 
Convention are correctly implemented if they wish to 
exempt a preparation from certain measures of control. 
The Board would also like to remind countries that they 
are still obligated to uphold certain measures of control 
even in cases where a preparation has been exempted, 
such as the requirement to report annual data and apply 
provisions relating to international trade.
807. Diversion from licit domestic channels remains a 
major source of psychotropic substances used for illicit 
purposes; however, the Board continues to receive from 
Governments only a limited number of reports on their 
interdiction efforts. In addition, the Board stresses that 
while diversions from international trade are rare, 
Governments should remain vigilant to attempts by traf-
fickers to divert psychotropic substances from the licit 
international market.
Recommendation 14: The Board encourages all 
Governments to provide to the Board regular and timely 
reports on diversions or attempted diversions of psycho-
tropic substances from licit trade.
808. The Board notes with appreciation that an increas-
ing number of countries have been submitting data on 
the consumption of psychotropic substances, pursuant to 
Commission on Narcotic Drugs resolution 54/6. Aware 
of the difficulties faced by some Governments in this 
regard, the Board is prepared to assist Governments in 
finding the most appropriate method of collecting such 
data, as a first step towards assessing their availability.
Recommendation 15: The Board calls upon all 
Governments to report on the consumption of psycho-
tropic substances on an annual basis, given the essen-
tial role that reported data plays in the monitoring and 
evaluation of the availability of psychotropic substances 
for medical and scientific purposes.
Precursor chemicals
809. The proliferation of non-scheduled chemicals, 
including “designer precursors”, with no known legitimate 
use remains an issue of concern (an in-depth analysis of 
recent trends and developments can be found in the 
Board’s report on the implementation of article 12 of the 
1988 Convention). Often, these chemicals are available 
through online vendors and trading platforms. To assist 
Governments in preventing such chemicals from reach-
ing illicit laboratories, the Board, in 2019, conducted a 
number of awareness-raising activities both at the ses-
sions of the Commission on Narcotic Drugs and directly 
with Governments. It has also updated the limited inter-
national special surveillance list of non-scheduled chem-
icals to expand the concept of extended (“generic”) 
definitions for precursors and highlight those chemicals 
which do not have any known legitimate uses.
Recommendation 16: The Board calls on Governments to 
continue to identify approaches to proactively address the 
proliferation of non-scheduled chemicals used in illicit 
drug manufacture. To that end, Governments could 
explore ways and means of addressing series of chemical 
relatives and chemicals with no known legitimate uses 
and of facilitating the prosecution of relevant criminal 
cases. The Board encourages Governments to share suc-
cessful national approaches and actively engage relevant 
sectors of industry, as well as enforcing applicable regu-
lations to prevent the misuse of the Internet for the diver-
sion of non-scheduled chemicals into illicit channels. At 
a minimum, Governments should cooperate with each 
other and with INCB by generating and sharing action-
able intelligence for use in further investigations.
810. The Board has previously expressed concern about 
the risk that drug trafficking organizations might exploit 
the lack of effective government control over certain ter-
ritories in order to divert precursors. Other risks to 
effective precursor control identified by the Board include 
the competing incentives and interests of different 
national authorities, bureaucracy and an inadequate 
capacity to enforce existing legislation and regulations. 
The Board has also observed that competent national 
authorities, in the absence of clear national regulations, 
sometimes face difficulties in objecting to transactions 
even when those transactions are suspicious. 
Recommendation 17: The Board calls on Governments to 
review their domestic control mechanisms with a view 
to ensuring that manufacture, distribution and end uses 
of precursors are adequately monitored and that all 
diversions and attempted diversions are investigated to 
prevent future diversions using similar modi operandi. 
The Board also calls on Governments of exporting coun-
tries to remain vigilant and suspend exports until doubts 
about their legitimacy have been dispelled.
Article 13 of the United Nations 
Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic 
Substances of 1988 
811. The clandestine manufacture of narcotic drugs, 
psychotropic substances, new psychoactive substances 
and precursors is not possible without the input of chem-
icals, materials and equipment. While the control of 
chemicals has long been a focus of authorities worldwide 
pursuant to the provisions of article 12 of the 1988 
Convention, much less attention has been given to equip-
ment and materials and article 13 of the Convention, 
which provides a basis for international action and coop-
eration in such control efforts. To address the issue, in 
November 2019 the Board approved a set of guidelines 
for Governments wishing to embark on activities in the 
context of article 13.
Recommendation 18: The Board encourages Governments 
to increase the operational use of article 13 of the 1988 
Convention and take appropriate measures to prevent 
and investigate the diversion of equipment essential for 
the illicit manufacture of drugs and precursors.
Abuse of codeine-based cough syrups
812. The Board has previously recognized that cough 
syrups containing narcotic drugs, including codeine, are 
an effective medication for patients and an important part 
of many health systems. However, their abuse continues 
to pose a challenge in several jurisdictions.
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Recommendation 19: The Board calls on Governments 
that are affected by the abuse of preparations contain-
ing codeine in their jurisdictions to consider the intro-
duction of stricter control measures on such preparations 
as provided in the 1961 Convention as amended and to 
implement appropriate prevention and treatment inter-
ventions to address this challenge.
Non-medical use of opioids
813. While non-medical use of synthetic opioids has 
been reported at an unprecedented scale globally, the 
crisis manifests itself in different forms from region to 
region and involves both internationally scheduled sub-
stances such as fentanyl (and fentanyl analogues) and 
internationally non-scheduled substances such as trama-
dol. An estimated 66 per cent of the steadily increasing 
number of estimated global drug overdose deaths are 
related to opioids, and the overprescription of pharma-
ceutical opioids, as well as their illicit manufacture, has 
exacerbated the problem.
Recommendation 20: The Board calls upon all States to 
carefully review their prescription practices related to 
pharmaceutical opioids and to be vigilant about the 
increasing non-medical use of such substances in many 
regions. The Board also emphasizes the need for increased 
efforts to reduce trafficking in synthetic opioids and invites 
Governments to make full use of existing mechanisms and 
tools facilitating the prompt and secure sharing of infor-
mation in this regard, in particular the IONICS system.
Electronic tools and training
814. The Board recognizes the efforts of Governments 
that have implemented I2ES and the advantages it offers to 
national authorities by significantly alleviating the admin-
istrative burden of the import and export administration 
process while also being a useful tool to help prevent the 
diversion of internationally controlled substances.
815. Having noted the challenges faced by some 
Governments in the further implementation of I2ES, the 
Board, through its secretariat, will continue to reach out 
and assist Governments in overcoming barriers such as 
know-how at the operational level and commitment to 
using I2ES at the decision-making level in order to 
encourage the wider adoption of the system and greater 
user engagement. 
Recommendation 21: The Board continues to encourage 
all Governments that have not yet done so to utilize the 
I2ES system and support its rapid implementation. The 
Board also invites existing users of the platform to share 
their experiences and expertise with other Governments 
and INCB with the aim of encouraging other countries 
to register for I2ES and actively use it. Finally, the Board 
urges Member States to consider the provision of 
extrabudgetary resources to scale up efforts to increase 
the rate of adoption and expand the functionalities of 
the platform.
Specific countries and regions
816. The abuse of tramadol, a synthetic opioid not 
under international control, and trafficking in falsified or 
illicitly manufactured tramadol continues to negatively 
affect countries in the Middle East and Africa. In many 
jurisdictions, tramadol-related abuse has been reported 
to be greater than that of internationally controlled drugs.
Recommendation 22: The Board calls upon States to rec-
ognize the importance of the exchange of information, 
coordination and cooperation among those countries 
affected by the diversion and abuse of tramadol and by 
trafficking in falsified and illicitly manufactured forms 
of the substance.
817. The lack of official information and data regarding 
trafficking in drugs, the prevalence rates of drug use and 
drug use prevention and treatment efforts in Africa and 
Oceania remain a concern for the Board. The lack of such 
information hinders efforts by the international commu-
nity to fully assess the drug problem in those regions.
Recommendation 23: The Board calls upon all States to 
regularly provide to the Board and other relevant inter-
national organizations data on drug trafficking and drug 
use prevalence, as well as any information regarding leg-
islation, policies or other efforts on drug use prevention, 
treatment, rehabilitation and social reintegration in their 
territories.
(Signed)
Cornelis P. de Joncheere, President
(Signed)
Sevil Atasoy, Rapporteur
(Signed)
Andrés Finguerut, Secretary
Vienna, 15 November 2019
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Annex I
Regional and subregional groupings used  
in the report of the International Narcotics 
Control Board for 2019
The regional and subregional groupings used in the report of INCB for 2019, together with the States in each of those 
groupings, are listed below.
Africa
Algeria Liberia
Angola Libya
Benin Madagascar
Botswana Malawi
Burkina Faso Mali
Burundi Mauritania
Cameroon Mauritius
Cabo Verde Morocco
Central African Republic Mozambique
Chad Namibia
Comoros Niger
Congo Nigeria
Côte d’Ivoire Rwanda
Democratic Republic of the Congo Sao Tome and Principe
Djibouti Senegal
Egypt Seychelles
Equatorial Guinea Sierra Leone
Eritrea Somalia
Eswatini South Africa
Ethiopia South Sudan
Gabon Sudan
Gambia Togo
Ghana Tunisia
Guinea Uganda
Guinea-Bissau United Republic of Tanzania
Kenya Zambia
Lesotho Zimbabwe
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Central America and the Caribbean
Antigua and Barbuda Guatemala
Bahamas Haiti
Barbados Honduras
Belize Jamaica
Costa Rica Nicaragua
Cuba Panama
Dominica Saint Kitts and Nevis
Dominican Republic Saint Lucia
El Salvador Saint Vincent and the Grenadines
Grenada Trinidad and Tobago
North America
Canada United States of America
Mexico
South America
Argentina Guyana
Bolivia (Plurinational State of) Paraguay
Brazil Peru
Chile Suriname
Colombia Uruguay
Ecuador Venezuela (Bolivarian Republic of)
East and South-East Asia
Brunei Darussalam Mongolia
Cambodia Myanmar
China Philippines
Democratic People’s Republic of Korea Republic of Korea
Indonesia Singapore
Japan Thailand
Lao People’s Democratic Republic Timor-Leste
Malaysia Viet Nam
South Asia
Bangladesh Maldives
Bhutan Nepal
India Sri Lanka
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West Asia
Afghanistan Oman
Armenia Pakistan
Azerbaijan Qatar
Bahrain Saudi Arabia
Georgia State of Palestine
Iran (Islamic Republic of) Syrian Arab Republic
Iraq Tajikistan
Israel Turkey
Jordan Turkmenistan
Kazakhstan United Arab Emirates
Kuwait Uzbekistan
Kyrgyzstan Yemen
Lebanon
Europe
Eastern Europe
Belarus Russian Federation
Republic of Moldova Ukraine
South-Eastern Europe
Albania Montenegro
Bosnia and Herzegovina North Macedonia82
Bulgaria Romania 
Croatia Serbia
Western and Central Europe
Andorra Liechtenstein
Austria Lithuania
Belgium Luxembourg
Cyprus Malta
Czechia Monaco
Denmark Netherlands
Estonia Norway
Finland Poland
France Portugal
Germany San Marino
Greece Slovakia
Holy See Slovenia
Hungary Spain
Iceland Sweden 
Ireland Switzerland
Italy United Kingdom of Great Britain and Northern Ireland
Latvia
82 Since 14 February 2019, “North Macedonia” has replaced “the former Yugoslav Republic of Macedonia” as the short name used in the 
United Nations.
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Oceania
Australia Niue
Cook Islands Palau
Fiji Papua New Guinea
Kiribati Samoa
Marshall Islands Solomon Islands
Micronesia (Federated States of) Tonga
Nauru Tuvalu
New Zealand Vanuatu
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Annex II
Current membership of the International 
Narcotics Control Board
Munich Institute for Physical Biochemistry and Institute 
of Legal Medicine; Center of Human Genetics, Bremen 
University; Institute of Legal Medicine, Muenster 
University, Germany; United Nations Drug Laboratory, 
Vienna; Central Bureau of Investigation, New Delhi.
Member, special commission on preventing drug abuse, 
Office of the Prime Minister (since 2014). Founding edi-
tor, Turkish Journal of Legal Medicine (1982–1993). 
Member of the scientific board of the International 
Criminal Justice Review. Founding President, Turkish 
Society of Forensic Sciences; Honorary Member of the 
Mediterranean Academy of Forensic Sciences. Member of 
the International Society of Forensic Toxicology; the 
Indo-Pacific Association of Law, Medicine and Science; 
the International Association of Forensic Toxicologists; 
the American Academy of Forensic Sciences; the 
American Society of Crime Laboratory Directors; and the 
American Society of Criminology.
Member of INCB (2005–2010 and since 2017). Member 
(2006 and 2018) and Chair (2017) of the Committee on 
Finance and Administration. Member of the Standing 
Committee on Estimates (2007). Second Vice-President 
and Chair of the Standing Committee on Estimates 
(2006). Rapporteur (2007 and 2019). First Vice-President 
of the Board (2008). President of the Board (2009).
Cornelis P. de Joncheere
Born in 1954. National of the Netherlands. Currently 
Chair of the Netherlands Antibiotics Development 
Platform, Member of the Expert Advisory Group of the 
Sevil Atasoy
Born in 1949. National of Turkey. Professor of Biochemistry 
and Forensic Science, Vice-Rector and Director, Institute 
of Addiction and Forensic Science; Head, Department of 
Forensic Science; Director, Center for Violence and Crime 
Prevention, Uskudar University, Istanbul. Director, 
Institute of Forensic Science, Istanbul University (1988–
2010). Director, Department of Narcotics and Toxicology, 
Ministry of Justice of Turkey (1980–1993). Expert witness 
in civil and criminal courts (since 1980).
Bachelor of Science in Chemistry (1972), Master of 
Science in Biochemistry (1976), Doctor of Philosophy 
(PhD) in Biochemistry (1979), Istanbul University.
Lecturer in biochemistry, criminalistics and crime scene 
investigation (since 1982); supervisor of more than 50 
master’s and doctoral theses in the area of biochemistry 
and forensic science. Author of over 130 scientific papers, 
including papers on drug testing, drug chemistry, drug 
markets, drug-related and drug-induced crime, drug 
abuse prevention, clinical and forensic toxicology, crime 
scene investigation and DNA analysis.
Hubert H. Humphrey Fellow, United States of America 
Information Agency (1995–1996); Guest Scientist at the 
School of Public Health, Department of Forensic Science, 
University of California, Berkeley, and the Drug Abuse 
Research Center, University of California, Los Angeles; 
Department of Genetics, Stanford University; Department 
of Human Genetics, Emory University; California 
Criminalistics Institute; Federal Bureau of Investigation, 
Virginia; Crime Laboratories, Los Angeles Sheriff ’s 
Department, United States; Federal Criminal Police Office 
(BKA), Wiesbaden; Ludwig-Maximilian University, 
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Medicines Patent Pool in Geneva and a consultant to 
WHO on pharmaceutical policies.
Doctor of Pharmacy (PharmD) and Master of Science 
(MSc) in Pharmacy, University of Groningen and 
University of Amsterdam, the Netherlands (1975–1981); 
Master’s in Business Administration, University of San 
Diego, United States/San José, Costa Rica; Bachelor of 
Science (BSc). Pharmacy, cum Laude (Honorary student), 
University of Groningen, the Netherlands (1972–1975).
Previously held positions as Director, Department of 
Essential Medicines and Health Products at WHO in 
Geneva (2012–2016), which included work on access to 
controlled medicines, and the WHO Expert Committee 
on Drug Dependence; WHO Representative, Kyiv (2011–
2012); WHO Regional Adviser for Pharmaceuticals and 
Health Technologies, WHO Regional Office for Europe, 
Copenhagen (1996–2010); National Essential Drugs 
Programme Coordinator, Pan American Health 
Organization (PAHO)/WHO, Brazil (1994–1996); 
Pharmacist, Essential Drugs Projects Coordinator, 
PAHO/WHO, Costa Rica (1988–1993); Pharmaceutical 
expert, PAHO/WHO, Panama (1986–1988); 
Pharmaceutical supply expert in Yemen, Ministry of 
Foreign Affairs, Directorate for International 
Cooperation, the Netherlands (1982–1985); hospital and 
community pharmacy in Amsterdam, the Netherlands 
(1981–1982).
President of the WHO Europe Staff Association (2006–
2010); Member of the WHO Guidelines Review 
Committee (2007–2011); Member of the Royal Dutch 
Pharmaceutical Society; author and co-author of numer-
ous publications in the fields of pharmaceutical and 
health sciences.
Member of INCB (since 2017). Rapporteur (2017). Member 
of the Standing Committee on Estimates (2017–2018). 
Member of the Committee on Finance and Administration 
(2017–2018). President of the Board (2019).
Wei Hao 
Born in 1957. National of China. Professor of Psychiatry 
and Deputy Director of the Mental Health Institute, 
Central South University, Changsha, China. Director of 
WHO Collaborating Centre for Psychosocial Factors, 
Substance Abuse and Health. Currently serving as Chair, 
Education Committee of the Asian-Pacific Society for 
Alcohol and Addiction Research, and as President, 
Chinese Association of Drug Abuse Prevention and 
Treatment and Chinese Association of Addiction 
Medicine.
Bachelor of Medicine, Anhui Medical University; Master’s 
and Doctoral degrees in Psychiatry, Hunan Medical 
University.
Previously held positions as Scientist, Substance Abuse 
Department, WHO, Geneva (1999–2000); Medical 
Officer, Department of Mental Health and Substance 
Abuse, WHO, Western Pacific Region (2004–2005), and 
President, Chinese Psychiatrist Association (2008–2011). 
Currently holding membership of the Expert Advisory 
Panel on Drug Dependence and Alcohol Problems, WHO 
(since 2006); and member of the Working Group on the 
Classification of Substance Abuse for the eleventh 
revision of the International Classification of Diseases 
(ICD-11), WHO (since 2011).
Recipient of research support from various bodies at the 
national level (Ministry of Health, Ministry of Science 
and Technology, National Natural Science Foundation) 
and at the international level (WHO and the National 
Institute on Drug Abuse and the National Institute on 
Alcohol Abuse and Alcoholism of the United States). 
Coordinator of a series of WHO/China workshops on 
addictive behaviour. Member of the Expert Committee of 
the national project on mental health services in commu-
nities in China. Consultant for the development, 
implementation and evaluation of China’s mental health 
law, and for the development of the anti-drug law and 
regulations in China.
Published over 400 academic articles and 60 books on 
alcohol and drug dependence. Selected recent publica-
tions in peer-reviewed journals include the following: 
“Longitudinal surveys of prevalence rates and use pat-
terns of illicit drugs at selected high-prevalence areas in 
China from 1993 to 2000”, Addiction (2004); “Drug 
policy in China: progress and challenges”, Lancet (2014); 
“Alcohol and the sustainable development goals”, Lancet 
(2016); “Transition of China’s drug policy: problems in 
practice”, Addiction (2015); “Improving drug addiction 
treatment in China”, Addiction (2007); “Stigmatization of 
people with drug dependence in China: a community-
based study in Hunan province”, Drug Alcohol Dependence 
(2013); and “Drinking and drinking patterns and health 
status in the general population of five areas of China”, 
Alcohol & Alcoholism (2004); Textbook of Addictive 
Medicine: Theory and Practice (2016); and Textbook of 
Psychiatry (8th edition, 2018).
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Member of INCB (since 2015). Member of the Committee 
on Finance and Administration (2015–2016). Member of 
the Standing Committee on Estimates (since 2015). Vice-
Chair of the Standing Committee on Estimates (2016). 
Second Vice-President and Chair of the Standing 
Committee on Estimates (2018). First Vice-President of 
the Board (2017 and 2019).
David T. Johnson
Born in 1954. National of the United States. President, 
SwanJohnson LLC; retired diplomat. Bachelor’s degree in 
economics from Emory University; graduate of the 
National Defence College of Canada.
United States Foreign Service officer (1977–2011). 
Assistant Secretary for the Bureau of International 
Narcotics and Law Enforcement Affairs, United States 
Department of State (2007–2011). Deputy Chief of 
Mission (2005–2007) and Chargé d’affaires, a.i. (2003–
2005), United States Embassy, London. Afghan 
Coordinator for the United States (2002–2003). United 
States Ambassador to the Organization for Security and 
Cooperation in Europe (1998–2001). Deputy Press 
Secretary at the White House and Spokesman for the 
National Security Council (1995–1997). Deputy 
Spokesman at the State Department (1995) and Director 
of the State Department Press Office (1993–1995). United 
States Consul General, Vancouver (1990–1993). Assistant 
National Trust Examiner, Office of the Comptroller of the 
Currency, United States Treasury (1976–1977).
Member of INCB (since 2012). Member of the Committee 
on Finance and Administration (since 2012). Chair of the 
Committee on Finance and Administration (2014 and 
2018). Second Vice-President and Chair of the Standing 
Committee on Estimates (2019).
Galina Korchagina
Born in 1953. National of the Russian Federation. 
Professor, Deputy Director of the National Centre for 
Research on Drug Addiction (since 2010).
Graduate of the Leningrad Paediatric Medical Institute, 
Russian Federation (1976); doctor of medicine (2001). 
Thesis based on clinical and epidemiological research 
dealing with new ways of looking at management of drug 
abuse in a time of change. 
Previously held positions as paediatrician at the Central 
District Hospital of Gatchina, Leningrad region, and doc-
tor at a boarding school (1976–1979). Head of the 
Organizational and Policy Division, Leningrad Regional 
Drug Clinic (1981–1989); Lecturer, Leningrad Regional 
Medical Academy (1981–1989); Head Doctor, City Drug 
Clinic, St. Petersburg (1989–1994); Assistant Lecturer 
(1991–1996) and Professor (2000–2001), Department of 
Social Technologies, State Institute for Services and 
Economics; Assistant Lecturer (1994–2000), Associate 
Professor (2001–2002) and Professor (2002–2008), 
Department for Research on Drug Addiction, St. 
Petersburg Medical Academy of Postgraduate Studies; 
Chief Professor and Head of the Department for Medical 
Research and Healthy Lifestyles, Herzen State Pedagogical 
University of Russia (2000–2008); Professor, Department 
for Conflict Studies, Faculty of Philosophy, St. Petersburg 
State University (2004–2008).
Member of many associations and societies, including the 
Association of Psychiatrists and Drug Addiction Specialists 
of the Russian Federation and St. Petersburg, the Kettil 
Bruun Society for Social and Epidemiological Research 
on Alcohol, the International Council on Alcohol and 
Addictions and the International Society of Addiction 
Medicine. Head of the sociology of science aspects of 
medical and biological research section of the Research 
Council on the Sociology of Science and the Organization 
of Scientific Research, St. Petersburg Scientific Centre of 
the Russian Academy of Sciences (2002–2008). 
Author of more than 100 publications, including more 
than 70 works published in the Russian Federation, chap-
ters in monographs and several practical guides. Award 
for excellence in health protection from the Ministry of 
Health of the Union of Soviet Socialist Republics (1987). 
Consultant, Global Business Coalition on HIV/AIDS, 
Tuberculosis and Malaria (since 2006).
Expert on the epidemiology of drug addiction, Pompidou 
Group of the Council of Europe (1994–2003); participa-
tion in the WHO cocaine project (1993–1994) as leading 
researcher; WHO Healthy Cities project (1992–1998) as 
leading coordinator in St. Petersburg; WHO alcohol 
action plan, realization on the basis of the city treatment 
centre, St. Petersburg (1992–1998). Co-trainer, WHO 
programmes “Helping people change” (since 1992) and 
“Skills for change” (since 1995); and temporary adviser, 
WHO (1992–2008). Participant in meetings of the 
Commission on Narcotic Drugs (2002–2008).
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Member of INCB (2010–2015 and since 2017). Member 
(2018) and Vice-Chair of the Standing Committee on 
Estimates (2011–2012, 2017 and 2019). First Vice-
President of the Board (2013).
Bernard Leroy 
Born in 1948. National of France. Honorary Deputy 
Prosecutor General and Director of the International 
Institute of Research against Counterfeit Medicines.
Degrees in Law from the University of Caen, Institute of 
European Studies of Saarbrucken, Germany, and 
University Paris X. Graduate of the French National 
School for the Judiciary (1979).
Previously held positions of Deputy General Prosecutor, 
Versailles Court of Appeal (2010–2013). Senior Legal 
Adviser, UNODC (1990–2010). Adviser in charge of 
international, legislative and legal affairs in the French 
National Drug Coordination office (1988–1990). 
Investigating judge specializing in drug cases, Evry High 
Court (1979–1988). Head of the Legal Assistance 
Programme, UNODC, and Coordinator of the decentral-
ized team of legal experts, Bogotá, Tashkent and Bangkok 
(1990–2010). Leader of the legal assistance team assisting 
the Government of Afghanistan in the drafting process 
of the new drug control law, 2004. Co-author of the pre-
paratory study for the law introducing community ser-
vice sentencing as an alternative to imprisonment in 
France (1981). Co-founder of “Essonne Accueil”, a non-
governmental organization providing treatment services 
for drug addicts (1982). Member of the French delega-
tion for the final negotiations of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988. Chair of the study group 
on cocaine trafficking in Europe, Council of Europe 
(1989). Author of the report resulting in the first European 
political coordinating committee to combat drugs (1989). 
Chair of the World Bank and UNODC joint team (the 
Stolen Asset Recovery (StAR) Initiative) which organized 
the freezing and subsequent recovery in Switzerland of 
the assets stolen by the former dictator Jean-Claude 
Duvalier in Haiti (2008).
Organizer of the lifelong learning programme on com-
bating drug trafficking and addiction for members of the 
French judiciary, French National School for the Judiciary 
(1984–1994). Lecturer for medical graduates in psychia-
try in the field of forensic expertise and responsibility, 
Faculty of Medicine, Paris-Sud University (1983–1990). 
Lecturer in the field of social work, University of Paris 
13 (1984–1988). Lecturer for second-year Master’s courses 
in Security and Public International Law, Jean Moulin 
Lyon 3 University (2005–2013).
Member of the Executive Board of the international sec-
tion of the National Association of Drug Court 
Professionals (2006). External member of the Management 
Board of the French Monitoring Centre for Drugs and 
Drug Addiction (2013). Member of the committee of the 
Reynaud report (2013). Honours: Chevalier of the Legion 
of Honour.
Selected publications include “Le travail au profit de la 
communauté, substitut aux courtes peines d’emprisonne-
ment”, Revue de science criminelle et de droit comparé, 
No.  1 (Sirey, 1983); Drogues et drogués, École nationale 
de la magistrature, studies and research (1983); Étude 
comparative des législations et des pratiques judiciaires 
européennes face à la drogue (Commission of the European 
Communities, 1991); Ecstasy, Inserm Collective Expertise 
series (Editions Inserm, 1997); The International Drug 
Control System, in cooperation with Cherif Bassiouni and 
J. F. Thony, in International Criminal Law: Sources, 
Subjects and Contents (Martinus Nijhoff Publishers, 2007); 
Routledge Handbook of Transnational Criminal Law, 
Neil Boister and Robert Curie, eds. (Routledge, 2014).
Member of INCB (since 2015). Rapporteur (2015 and 
2018). Member of the Standing Committee on Estimates 
(2016). Member of the Committee on Finance and 
Administration (2019).
Raúl Martín del Campo Sánchez
Born in 1975. National of Mexico. Director General of 
the National Commission against Addictions (May 2013–
December 2016).
Bachelor’s Degree in Psychology; Honourable Mention, 
Autonomous University of Aguascalientes, 1998. Master’s 
Degree in Health Psychology, Faculty of Psychology, 
National Autonomous University of Mexico, with 
residency in Addictions, 2002. Specialization in Drug 
Dependence and Related Crisis Situations, Drug 
Dependence Treatment Centre, Health Institute of the 
State of Mexico, 2010. 
Director of Coordination of National Programmes against 
Addictions, Mexican Observatory on Tobacco, Alcohol 
and Drugs, National Commission against Addictions 
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(2012–2013); Director, Mexican Institute against 
Addictions (IMCA), State of Mexico (2007–2011); Head 
of the Indicator Monitoring Department, National 
Commission against Addictions (2003–2007); Head of the 
Psychology Unit (treatment of drug users), Drug Abuse 
Treatment Centre, Municipality of Aguascalientes (1999–
2000); residential therapist for drug users and psychiat-
ric patients, Addiction Treatment and Rehabilitation 
Centre (CAPRA) and Neuropsychiatric Centre of 
Aguascalientes (1999–2000); volunteer providing social 
services and support to the technical team, youth inte-
gration centres, Aguascalientes (1997–2000). 
Author and co-author of, and contributor to, numerous 
publications on drug abuse prevention, treatment, surveys 
and related subjects, including: National Survey on Drug 
Use Among Students, 2014 (INPRFM, National 
Commission against Addictions, Ministry of Health of 
Mexico, 2015); “Is the medical use of cannabis supported 
by science?” (National Commission against Addictions, 
National Centre for the Prevention and Control of 
Addictions, 2014); “The treatment model used by the 
‘Centros Nueva Vida’ addiction treatment centres and its 
relationship to primary health-care services” and 
“Addiction treatment based on models for the State of 
Mexico: cases in the study of risk factors and prevention 
through the Chimalli model”, Actualidades en adicciones 
2012, vol. II (National Commission against Addictions, 
2012); “Is alcohol an isolated problem in children and 
adolescents?”, in Actualidades en adicciones 2012, vol. IV 
(National Commission against Addictions, 2012); “Alcohol 
in primary care mental health clinics”, in Alcohol use dis­
order (World Organization of National Colleges, 
Academies and Academic Associations of General 
Practitioners/Family Physicians, 2010); State of Mexico 
Survey on Alcohol, Tobacco and Drug Use among Students 
(INPRFM, Mexican Institute against Addictions (IMCA), 
2009). 
Member of INCB (since 2016). Member of the Standing 
Committee on Estimates (since 2017). Member of the 
Committee on Finance and Administration (2019).
Richard P. Mattick 
Born in 1955. National of Australia. Honorary Professor 
of Drug and Alcohol Studies at the National Drug and 
Alcohol Research Centre, Faculty of Medicine, University 
of New South Wales; Professor of Brain Sciences, 
University of New South Wales; Principal Research Fellow 
awarded, Australian Government National Health and 
Medical Research Council (2013–2017 and 2019–2023), 
and endorsed and registered Clinical Psychologist.
Bachelor of Science (Psychology), Honours, Class 1, 
University of New South Wales, 1982; Master of 
Psychology (Clinical), University of New South Wales, 
1989; Doctor of Philosophy, University of New South 
Wales, 1988; and Certificate in Neuroanatomy, Anatomy, 
University of New South Wales, 1992.
Director of Research, Australian National Drug and 
Alcohol Research Centre (1995–2001), and Executive 
Director, Australian National Drug and Alcohol Research 
Centre, Faculty of Medicine, University of New South 
Wales (2001–2009). Member, Australian National Expert 
Advisory Committee on Illicit Drugs (2002–2004), 
Australian National Expert Advisory Group on Sustained 
Release Naltrexone (2002–2004), Monitoring Committee 
of the Medically Supervised Injecting Centre for the New 
South Wales Government Cabinet Office (2003–2004), 
Australian Ministerial Council on Drug Strategy Working 
Party on Performance and Image Enhancing Drugs 
(2003–2005), Australian Government Department of 
Health and Ageing Expert Advisory Committee on 
Cannabis and Health (2005–2006), New South Wales 
Expert Advisory Group on Drugs and Alcohol for the 
New South Wales Minister of Health (2004–2013), 
Australian National Council on Drugs advising the Prime 
Minister (2004–2010), WHO/UNODC Technical 
Guidelines Development Group on Pharmacotherapy of 
Opioid Dependence (2004–2008), Australian Research 
Alliance for Children and Youth (2005–2015).
Served on the editorial and executive boards of Drug and 
Alcohol Review (1994–2005), and as Deputy Editor (1995–
2000) and Executive Editor (2000–2005). Assistant Editor 
of the international peer-reviewed journal Addiction 
(1995–2005). Editor, Cochrane Review Group on Drugs 
and Alcohol (1998–2003). Authored over 300 books, 
chapters in edited volumes on substance abuse, addiction 
and treatment, and peer-reviewed academic journal 
articles on those subjects. Recent articles include 
“Buprenorphine maintenance versus placebo or metha-
done maintenance for opioid dependence”, “Young adult 
sequelae of adolescent cannabis use” and “The Pain and 
Opioids IN Treatment study: characteristics of a cohort 
using opioids to manage chronic non-cancer pain”. 
Recipient of academic and research support from the 
Australian Government Department of Health; the New 
South Wales Government Department of Health; the 
Australian National Drug Law Enforcement Research 
Fund; the Alcohol Education and Rehabilitation 
Foundation; UNODC; the National Institute on Drug 
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Abuse of the United States; the Australian Research 
Council; and the Australian Government National Health 
and Medical Research Council.
Member of INCB (since 2015). Member of the Standing 
Committee on Estimates (2015–2016).
Luis Alberto Otárola Peñaranda
Born in 1967. National of Peru. Lawyer. Postgraduate 
degree in Public Policy and Public Management from the 
Pontifical Catholic University of Peru.
Executive Director of the National Commission for 
Development and Life without Drugs (2014–2016). 
President of the Inter-American Drug Abuse Control 
Commission of OAS (November 2015–September 2016). 
Minister of Defence (2012), Deputy Minister of the 
Interior (2011), Deputy Minister of Defence (2003), 
Officer of the Peruvian State before the Inter-American 
Court of Human Rights (2001), Professor of Constitutional 
Law and Human Rights.
Author or co-author of the following works: Compendio 
sobre Tráfico Ilícito de Drogas y Desarrollo Alternativo 
(2015); La Constitución Explicada (2011); La Constitución 
de 1993: Estudio y Reforma a Quince Años de su Vigencia 
(2009); Modernización Democrática de las Fuerzas 
Armadas (2002); Parlamento y Ciudadanía (2001); La 
Constitución de 1993: Análisis Comparado (1999).
Order of Merit for Distinguished Services at the level of 
Grand Cross (decoration awarded by the Constitutional 
President of the Republic). Also received the Order of 
Ayacucho (highest distinction awarded by the Peruvian 
Army).
Presenter at the workshop entitled “Responding to the 
evolving drug challenge”, Deutsche Gesellschaft für 
Internationale Zusammenarbeit (GIZ), London (2015); 
presenter on alternative development at the Economic 
and Social Council, New York (2015); Head of the 
Peruvian delegation to the seventh meeting of the 
Peruvian-Colombian Joint Committee on Drugs (2014); 
Head of the Peruvian delegation to the Twenty-fourth 
Meeting of Heads of National Drug Law Enforcement 
Agencies, Latin America and the Caribbean (2014); 
speaker at the second Latin American Seminar on 
Democracy and Corruption, Montevideo (2014); Head of 
the Peruvian delegation to the eighth meeting of the 
Peruvian-Brazilian Joint Committee on Drugs (2014); 
speaker at the Latin American Seminar on Youth and 
Democratic Governance, Cartagena de Indias, Colombia 
(2012); speaker at the Latin American Seminar on Youth, 
Violence and Culture of Peace, Antigua, Guatemala 
(2009).
Member of INCB (since 2017). Member of the Standing 
Committee on Estimates (since 2017).
Jagjit Pavadia 
Born in 1954. National of India. Graduate in English 
Honours (1974), Dhaka University, LLB from Delhi 
University (1988), Master’s Diploma in Public 
Administration, Indian Institute of Public Administration 
(1996). Completed dissertation “Forfeiture of Property 
under the Narcotics Drugs and Psychotropic Substances 
Act, 1985” towards completion of Master’s Diploma. 
Held several senior positions in the Indian Revenue 
Service for 35 years in the Government of India, includ-
ing Narcotics Commissioner of India, Central Bureau of 
Narcotics (2006–2012); Commissioner, Legal Affairs 
(2001–2005); Chief Vigilance Officer, Power Finance 
Corporation (1996–2001); Customs Training Adviser 
Maldives, deputed by the Commonwealth Secretariat 
(1994–1995); Deputy Director, Narcotics Control Bureau 
(1990–1994); and retired as Chief Commissioner, Customs, 
Central Excise and Service Tax, Nagpur, in 2014.
Recipient of Presidential Appreciation Certificate for 
Specially Distinguished Record of Service on the occa-
sion of Republic Day (2005), published in the Gazette of 
India Extraordinary.
Member of the Indian delegation to the Commission on 
Narcotic Drugs, Vienna (2007–2012); introduced resolu-
tions 51/15 (2008) and 53/12 (2010), adopted by the 
Commission on Narcotic Drugs, and organized a side 
event on the margins of the Commission’s 2011 session, 
presenting issues involved in the illegal movement of 
opium poppy seeds to producing, importing and export-
ing countries. As representative of the competent national 
authority, attended Project Prism and Project Cohesion 
task force meetings (2006–2012), and coordinated and 
organized the Project Prism and Project Cohesion meet-
ing in New Delhi (2008). Participated in the Thirtieth 
Meeting of Heads of National Drug Law Enforcement 
Agencies, Asia and the Pacific, held in Bangkok (2006), 
and organized the Thirty-fifth Meeting of Heads of 
National Drug Law Enforcement Agencies, Asia and the 
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Pacific, held in Agra, India (2011). Member of the INCB 
advisory expert group on the scheduling of substances 
(2006), and member of the advisory group finalizing the 
INCB Guidelines for a Voluntary Code of Practice for the 
Chemical Industry (2008). Rapporteur of the forty-first 
session of the Subcommission on Illicit Drug Traffic and 
Related Matters in the Near and Middle East, held in 
Amman (2006); Chair of the forty-second session of the 
Subcommission, held in Accra, India (2007); organized 
the meeting of the Paris Pact Initiative Expert Working 
Group on Precursors, held in New Delhi (2011), and par-
ticipated in the International Drug Enforcement 
Conferences hosted by the United States Drug Enforcement 
Agency, held in Istanbul, Turkey (2008) and Cancún, 
Mexico (2011).
Member of INCB (since 2015). Second Vice-President 
and Chair of the Standing Committee on Estimates 
(2015 and 2017). Vice-Chair (2018) and Member (2019) 
of the Standing Committee on Estimates. Member 
(2016–2017) and Chair (2019) of the Committee on 
Finance and Administration. First Vice-President of the 
Board (2016).
Viroj Sumyai
Born in 1953. National of Thailand. Retired Assistant 
Secretary-General of the Food and Drug Administration, 
Ministry of Public Health of Thailand, and clinical phar-
macologist specializing in drug epidemiology. Professor, 
Mahidol University (since 2001).
Bachelor of Science degree in chemistry (1976), Chiang 
Mai University. Bachelor’s degree in pharmacy (1979), 
Manila Central University. Master’s degree in clinical 
pharmacology (1983), Chulalongkorn University. 
Apprenticeship in narcotic drugs epidemiology at St. 
George’s University of London (1989). Doctor of 
Philosophy, Health Policy and Administration (2009), 
National Institute of Administration. Member of the 
Pharmaceutical Association of Thailand. Member of the 
Pharmacological and Therapeutic Society of Thailand. 
Member of the Thai Society of Toxicology. Author of nine 
books in the field of drug prevention and control, includ-
ing Drugging Drinks: Handbook for Predatory Drugs 
Prevention and Déjà vu: A Complete Handbook for 
Clandestine Chemistry, Pharmacology and Epidemiology of 
LSD. Columnist, Food and Drug Administration Journal. 
Recipient, Prime Minister’s Award for Drug Education 
and Prevention (2005). 
Member of INCB (since 2010). Member (2010–2016 and 
2019) and Chair (2012, 2014 and 2016) of the Standing 
Committee on Estimates. Chair of the Committee on 
Finance and Administration (2011 and 2013). Second 
Vice-President of the Board (2012, 2014 and 2016). 
President of the Board (2017–2018).
Francisco E. Thoumi
Born in 1943. National of Colombia and the United 
States. Bachelor of Arts and Doctor of Philosophy in 
Economics. Senior Member of the Colombian Academy 
of Economic Sciences and Corresponding Member of the 
Royal Academy of Moral and Political Sciences (Spain).
Tinker Visiting Professor at the University of Texas, 
Professor at Rosario University and Universidad de Los 
Andes (Bogotá) and California State University, Chico. 
Worked for 15 years in the research departments of the 
World Bank and the Inter-American Development Bank. 
Founder and Director, Research and Monitoring Center 
on Drugs and Crime, Rosario University (August 2004–
December 2007); Research Coordinator, Global 
Programme against Money-Laundering, Proceeds of 
Crime and the Financing of Terrorism; Coordinator for 
the World Drug Report, UNODC (August 1999–September 
2000); Researcher, Comparative Study of Illegal Drugs in 
Six Countries, United Nations Research Institute for 
Social Development, Geneva (June 1991–December 
1992); Fellow, Woodrow Wilson International Center for 
Scholars (August 1996–July 1997); Research Coordinator, 
Research Programme on the Economic Impact of Illegal 
Drugs in the Andean Countries, United Nations 
Development Programme, Bogotá (November 1993–
January 1996).
Author of three books and co-author of one book on ille-
gal drugs in Colombia and the Andean region. Editor of 
three volumes and author of over 70 academic journal 
articles and book chapters on those subjects. Also 
authored one book, co-authored two books and published 
50 articles and book chapters on economic development, 
industrialization and international trade issues before 
focusing on drug issues. His work on drugs focuses on 
the political economy of illegal drugs and crime.
Member of the Friedrich Ebert Foundation Observatory 
of Organized Crime in Latin America and the Caribbean 
(since 2008) and the World Economic Forum’s Global 
Agenda Council on Organized Crime (2012–2014). 
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Member of INCB (since 2012). Rapporteur (2012). 
Member of the Committee on Finance and Administration 
(2014–2015 and 2018–2019). Member of the Standing 
Committee on Estimates (2013 and 2016–2018).
Jallal Toufiq 
Born in 1963. National of Morocco. Head of the National 
Centre for Drug Abuse Prevention and Research; Director 
of the Moroccan National Observatory on Drugs and 
Addictions; Director of the Ar-razi University Psychiatric 
Hospital and Professor of Psychiatry at the Rabat Faculty 
of Medicine.
Medical Doctor, Rabat Faculty of Medicine (1989); 
Diploma of Specialization in Psychiatry (1994); and lec-
turer at the Rabat Faculty of Medicine (since 1995). 
Undertook specialized training in Paris at the Sainte-
Anne Psychiatric Hospital and Marmottan Centre (1990–
1991); and at Johns Hopkins University as a National 
Institute on Drug Abuse research fellow and Clinical 
Observer (1994–1995). Conducted research at the 
University of Pittsburgh (1995); and gained Clinical Drug 
Research certificates at the Vienna School of Clinical 
Research (2001 and 2002).
Currently holding positions in Morocco as Head of the 
Harm Reduction Programme, National Centre for Drug 
Abuse Prevention and Research; teaching and residency 
training coordinator, Ar-razi Hospital; Director of the 
National Diploma Programme on Treatment and 
Prevention of Drug Abuse, Rabat Faculty of Medicine; 
Director of the National Diploma Programme on Child 
Psychiatry, Rabat Faculty of Medicine and Member of the 
Ministry of Health Commission on Drug Abuse.
At the international level, Representative of the 
Mediterranean Network (MedNET) for Morocco 
(MedNET/Pompidou Group/Council of Europe); former 
permanent correspondent of the Pompidou Group for 
Morocco (Council of Europe) on drug abuse prevention 
and research and former member of the Reference Group 
to the United Nations on HIV and Injecting Drug Use. 
Founding member and steering committee member, 
Middle East and North Africa Harm Reduction 
Association (MENAHRA); Director of Knowledge Hub 
Ar-razi for North Africa, MENAHRA; Member, Mentor 
International Scientific Advisory Network (drug abuse 
prevention in youth); former focal point/expert on pre-
vention, United Nations Office on Drug Control and 
Crime Prevention (local network for North Africa); 
founding member, MedNET (advisory group on AIDS 
and drug abuse policies) of the Council of Europe, and 
member of the Reference Group to the United Nations 
on HIV and Injecting Drug Use.
Held consultancy roles with the WHO Regional Office 
for the Eastern Mediterranean, UNODC and other inter-
national institutions, research fellowships and the 
National Institute on Drug Abuse of the United States. 
Published widely in the field of psychiatry, alcohol and 
drug abuse. 
Member of INCB (since 2015). Member of the Standing 
Committee on Estimates (2015). Member of the 
Committee on Finance and Administration (2016). First 
Vice-President of the Board (2018).
About the International Narcotics 
Control Board 
INCB is an independent and quasi-judicial control organ, 
established by treaty, for monitoring the implementation 
of the international drug control treaties. It had prede-
cessors under the former drug control treaties as far back 
as the time of the League of Nations.
Composition
INCB consists of 13 members who are elected by the 
Economic and Social Council and who serve in their per-
sonal capacity, not as government representatives. Three 
members with medical, pharmacological or pharmaceu-
tical experience are elected from a list of persons nomi-
nated by WHO and 10 members are elected from a list 
of persons nominated by Governments. Members of the 
Board are persons who, by their competence, impartial-
ity and disinterestedness, command general confidence. 
The Council, in consultation with INCB, makes all 
arrangements necessary to ensure the full technical inde-
pendence of the Board in carrying out its functions. INCB 
has a secretariat that assists it in the exercise of its treaty-
related functions. The INCB secretariat is an administra-
tive entity of UNODC, but it reports solely to the Board 
on matters of substance. INCB closely collaborates with 
UNODC in the framework of arrangements approved by 
the Council in its resolution 1991/48. INCB also cooper-
ates with other international bodies concerned with drug 
control, including not only the Council and its Commission 
on Narcotic Drugs, but also the relevant specialized agen-
cies of the United Nations, particularly WHO. It also 
cooperates with bodies outside the United Nations sys-
tem, especially INTERPOL and WCO.
Functions
The functions of INCB are laid down in the following 
treaties: Single Convention on Narcotic Drugs of 1961 as 
amended by the 1972 Protocol; Convention on 
Psychotropic Substances of 1971; and United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988. Broadly speaking, INCB 
deals with the following:
 (a) As regards the licit manufacture of, trade in and 
use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs 
are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels 
does not occur. INCB also monitors Governments’ con-
trol over chemicals used in the illicit manufacture of 
drugs and assists them in preventing the diversion of 
those chemicals into the illicit traffic;
 (b) As regards the illicit manufacture of, trafficking in 
and use of drugs, INCB identifies weaknesses in national 
and international control systems and contributes to cor-
recting such situations. INCB is also responsible for 
assessing chemicals used in the illicit manufacture of 
drugs, in order to determine whether they should be 
placed under international control.
In the discharge of its responsibilities, INCB:
 (a) Administers a system of estimates for narcotic 
drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs 
through a statistical returns system, with a view to assist-
ing Governments in achieving, inter alia, a balance 
between supply and demand;
 (b) Monitors and promotes measures taken by 
Governments to prevent the diversion of substances fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances and assesses such substances 
to determine whether there is a need for changes in the 
scope of control of Tables I and II of the 1988 Convention;
 (c) Analyses information provided by Governments, 
United Nations bodies, specialized agencies or other com-
petent international organizations, with a view to ensur-
ing that the provisions of the international drug control 
treaties are adequately carried out by Governments, and 
recommends remedial measures;
 (d) Maintains a permanent dialogue with Governments 
to assist them in complying with their obligations under 
the international drug control treaties and, to that end, 
recommends, where appropriate, technical or financial 
assistance to be provided.
INCB is called upon to ask for explanations in the event 
of apparent violations of the treaties, to propose appro-
priate remedial measures to Governments that are not 
fully applying the provisions of the treaties or are encoun-
tering difficulties in applying them and, where necessary, 
to assist Governments in overcoming such difficulties. If, 
however, INCB notes that the measures necessary to rem-
edy a serious situation have not been taken, it may call 
the matter to the attention of the parties concerned, the 
Commission on Narcotic Drugs and the Economic and 
Social Council. As a last resort, the treaties empower 
INCB to recommend to parties that they stop importing 
drugs from a defaulting country, exporting drugs to it or 
both. In all cases, INCB acts in close cooperation with 
Governments.
INCB assists national administrations in meeting their 
obligations under the conventions. To that end, it pro-
poses and participates in regional training seminars and 
programmes for drug control administrators.
Reports
The international drug control treaties require INCB to 
prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation world-
wide so that Governments are kept aware of 
existing and potential situations that may endanger the 
objectives of the international drug control treaties. INCB 
draws the attention of Governments to gaps and weak-
nesses in national control and in treaty compliance; it also 
makes suggestions and recommendations for improve-
ments at both the national and international levels. The 
annual report is based on information provided by 
Governments to INCB, United Nations entities and other 
organizations. It also uses information provided through 
other international organizations, such as INTERPOL 
and WCO, as well as regional organizations.
The annual report of INCB is supplemented by detailed 
technical reports. They contain data on the licit move-
ment of narcotic drugs and psychotropic substances 
required for medical and scientific purposes, together 
with an analysis of those data by INCB. Those data are 
required for the proper functioning of the system of con-
trol over the licit movement of narcotic drugs and psy-
chotropic substances, including preventing their diversion 
to illicit channels. Moreover, under the provisions of arti-
cle 12 of the 1988 Convention, INCB reports annually to 
the Commission on Narcotic Drugs on the implementa-
tion of that article. That report, which gives an account 
of the results of the monitoring of precursors and of the 
chemicals frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances, is also pub-
lished as a supplement to the annual report.
Since 1992, the first chapter of the annual report has 
been devoted to a specific drug control issue on which 
INCB presents its conclusions and recommendations in 
order to contribute to policy-related discussions and 
decisions in national, regional and international drug 
control. The following topics were covered in past annual 
reports:
1992:  Legalization of the non-medical use of drugs
1993:  The importance of demand reduction
1994:  Evaluation of the effectiveness of the international 
drug control treaties
1995:  Giving more priority to combating 
money-laundering
1996:  Drug abuse and the criminal justice system
1997:  Preventing drug abuse in an environment of illicit 
drug promotion
1998:  International control of drugs: past, present and 
future
1999:  Freedom from pain and suffering
2000:  Overconsumption of internationally controlled 
drugs
2001:  Globalization and new technologies: challenges to 
drug law enforcement in the twenty-first century
2002:  Illicit drugs and economic development
2003:  Drugs, crime and violence: the micro-level impact
2004:  Integration of supply and demand reduction 
strategies: moving beyond a balanced approach
2005:  Alternative development and legitimate 
livelihoods
2006:  Internationally controlled drugs and the unregu-
lated market
2007:  The principle of proportionality and drug-related 
offences
2008:  The international drug control conventions: 
history, achievements and challenges
2009: Primary prevention of drug abuse
2010: Drugs and corruption
2011:  Social cohesion, social disorganization and illegal 
drugs
2012:  Shared responsibility in international drug control 
2013: Economic consequences of drug abuse
2014:  Implementation of a comprehensive, integrated 
and balanced approach to addressing the world 
drug problem
2015:  The health and welfare of mankind: challenges and 
opportunities for the international control of drugs
2016: Women and drugs
2017:  Treatment, rehabilitation and social reintegration 
for drug use disorders: essential components of 
drug demand reduction
2018:  Cannabis and cannabinoids for medical, scientific 
and “recreational” use: risks and benefits
Chapter I of the report of the Board for 2019 is entitled 
“Improving drug use prevention and treatment services 
for young people”.
Chapter II presents an analysis of the operation of the 
international drug control system based primarily on 
information that Governments are required to submit 
directly to INCB in accordance with the international 
drug control treaties. Its focus is on the worldwide con-
trol of all licit activities related to narcotic drugs and psy-
chotropic substances, as well as chemicals used in the 
illicit manufacture of such drugs.
Chapter III presents global issues and some of the major 
developments in drug abuse and trafficking and measures 
by Governments to implement the international drug 
control treaties by addressing those problems.
Chapter IV presents the main recommendations addressed 
by INCB to Governments, UNODC, WHO and other 
relevant international and regional organizations.

 United Nations system and drug control organs and their secretariat
General Assembly
Economic and Social 
Council
INCB Commission onNarcotic Drugs
UNODCa/INCB secretariatb
Key:
Direct connection (administrative or constitutional)
Reporting, cooperating and advising relationship 
a United Nations Office on Drugs and Crime.
b The INCB secretariat reports on substantive matters to INCB only.
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The International Narcotics Control Board (INCB) is the independent monitoring body for the 
implementation of United Nations international drug control conventions. It was established in 
1968 in accordance with the Single Convention on Narcotic Drugs, 1961. It had predecessors 
under the former drug control treaties as far back as the time of the League of Nations.
Based on its activities, INCB publishes an annual report that is submitted to the United Nations 
Economic and Social Council through the Commission on Narcotic Drugs. The report provides a 
comprehensive survey of the drug control situation in various parts of the world. As an impartial 
body, INCB tries to identify and predict dangerous trends and suggests necessary measures to 
be taken.
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